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Prologue 
 
For many years I have been fascinated by the neuro(patho)physiology of high 
altitude, hypoxia and microgravity. This interest has led me to question 
some of the tenets that are currently taught as ‘fact’. At best, some appear 
oversimplifications. By way of example, I have questioned and explored the 
Monro-Kellie doctrine. This describes the skull as a closed box within which the 
addition of mass leads, after a period of compliance, to a rise in intracranial 
pressure (ICP). However, “mass” added in response to hypoxia largely 
represents that of blood (as cerebral blood flow changes). As a result, pressure 
changes dynamically.  
 
Some 60% of astronauts suffer space motion sickness (space adaptation 
syndrome), the development of which has been linked to rising intracranial 
pressure. My BSc project investigated the use of ultrasound to measure 
changes in transcranial distance as an index of intracranial pressure in 
astronauts.  Subsequently, I worked in Pre-Hospital Care (with HEMS, London’s 
Air Ambulance) before becoming a neurosurgeon- both situations in which 
changes in ICP can be matters of life and death. Meanwhile, a brief spell 
working for the Himalayan Rescue Service had allowed me to observe subjects 
with presumed raised ICP in response to the hypoxia of altitude.  
 
These experiences led me to first consider the key factors that regulate ICP. At 
that time, research was largely focussed on changes in arterial inflow, which 
rises substantially in response to hypoxia (just as it can in cases of cerebral 
trauma). However, I was struck by the similarity between the headaches 
described by my patients with venous hypertension, and those experienced by 
high-altitude mountaineers. I thus postulated that differences in venous efferent 
structure, or venous engorgement, might play an important role in regulating 
ICP when cerebral arterial inflow rises. I began to explore this concept further. 
Shortly after UCL’s Centre for Altitude, Space and Extreme Environment 
(CASE) was born, I became the lead for Neuroscience Research, allowing me 
to pursue this issue further. Expeditions with the Birmingham Medical Research 
Expeditionary Society (BMRES) to Ladakh, India were followed by a UCL pilot 
expedition to Cho Oyu, an 8201m peak in China, in 2006.  
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This thesis is the culmination of (or perhaps one major stop upon) this journey. 
The climb has been hard. But I hope you find the view as exciting and 
worthwhile as I do. 
 
 
 
 
 
 
Transcranial Ultrasound with NASA  
1994 
 
…and again on Everest  
2007 
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Brief (300 word) Abstract: 
 
This thesis studies the effect of hypoxia (at rest and during exercise) on the 
arterial and venous cerebral circulation, investigating the venous system role in 
high altitude headache.  
Methods: 1) Hypobaric hypoxic studies investigated 198 trekkers and 24 
Investigators to 5300m, 14 to 6400m and 8 to 8848m. 2) Normobaric hypoxic 
studies used Magnetic Resonance Imaging (MRI)) at sea-level.  Four domains 
were addressed: 
i. Arterial: Hypobaric hypoxia: (n=24) Transcranial Doppler (TCD) 
measured middle cerebral artery diameter (MCAD) and blood velocity 
(MCAv). Sea-Level normobaric hypoxia: (n=7) A hypoxicator (FiO2 = 
11%) for 3 hours with a 3Tesla MRI scan measured MCAD and MCAv. 
ii. Brain Oxygenation: Near Infrared Spectroscopy (NIRS) monitored 
Regional Brain Oxygenation (rSO2). 
iii. Venous: Retinal imaging at altitude and MRI at sea-level assessed 
the venous system. 
iv. Headache: A daily diary recorded headache burden.  
Results: Arterial: Hypobaric and normobaric hypoxia induced MCA dilatation. 
Mean (±(SEM)) MCAD increased in hypoxia (from 5.23(±0.23)mm (at 5300m) to 
9.34(±0.88)mm (at 7950m)(p<0.001) (TCD). At sea-level, (after 3 hours FiO2 = 
11%) MCAD increased from 3.04(±0.13)mm to 3.27(±0.13)mm (MRI). 
Brain Oxygenation: rSO2 decreased more than peripheral arterial saturation 
(SaO2), especially during exercise. The relative percentage reduction in resting 
SaO2 and rSO2 from 75m to 5300m was -22.23 ±0.56% and -30.61 ±1.28% 
(p<0.001) respectively.  
Venous: Hypoxia induced retinal and cerebral venous distension. Twenty-three 
of 24 subjects exhibited retinal venous distension (range 5 to 44%). Degree of 
distension correlated with headache (r = 0.553, p=0.005). Possession of a 
narrow transverse sinus strongly related to retinal and cerebral venous 
distension and headache.  
Headache: Headache Severity Index (HSI) (headache score x duration) 
correlated inversely to both lateral and third ventricular volumes summed (r = -
0.5, p = 0.005) and pericerebellar CSF volume (r = -0.56, p = 0.03).  
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Conclusions: Large cerebral arteries dilate and veins distend with hypoxia.  
This suggests an important influence of cerebral venous anatomy and 
physiology on headache, with implications for pathophysiological states and 
their management.  
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Full Abstract 
 
Aims 
In this thesis, I aim to investigate the effect of hypoxia on the arterial and 
venous cerebral circulation. I seeks to characterise the response of cerebral 
arterial calibre (as a regulator of flow) to hypoxia, to investigate changes in 
cerebral oxygenation both at rest and with exercise during systemic hypoxia 
and, uniquely, to investigate whether the venous system might have a role in 
the pathogenesis of high altitude headache.  
 
Methods 
The studies within this thesis fall into two categories. Hypobaric hypoxic 
studies were conducted as part of the Caudwell Xtreme Everest Expedition 
(CXE) of 2007, the partial pressure of inspired oxygen falling with ascent to 
altitude. This studied 198 trekkers and 24 Investigators in London (75m), 
Kathmandu (1300m), Namche Bazaar (3500m) and Everest Base Camp 
(5300m). Fourteen of the investigators were also studied in the Western Cwm 
(6400m), and 8 of these at the summit (8848m). Meanwhile, normobaric 
hypoxic studies (with Magnetic Resonance Imaging (MRI)) were performed at 
The National Hospital for Neurology and Neurosurgery, Queen Square, 
University College London.  Across these, four domains were addressed: 
v. Arterial Studies: Hypobaric hypoxic studies were performed using 
Transcranial Doppler (TCD) at rest on the 24 investigators. Right 
Middle Cerebral Artery Velocity (MCAv) and right Middle Cerebral 
Artery Diameter (MCAD) were measured at each altitude and cross 
sectional area and blood flow subsequently calculated. Sea-Level 
normobaric hypoxic studies (n=7) were performed using a 
hypoxicator (FiO2 = 11%) for 3 hours ending concurrently with a 
3Tesla Magnetic Resonance Imaging scan. Similarly MCAv and 
MCAD were measured using this technique. 
vi. Brain Oxygenation Studies: Regional Brain Oxygenation (rSO2) was 
monitored at rest and during exercise in both the CXE trekker and 
investigator groups using Near Infrared Spectroscopy (NIRS). Cluster 
analysis was performed to investigate if desaturation at sea level 
predicted desaturation at altitude. 
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vii. Venous Studies: The venous system was investigated dynamically 
with two types of study: Retinal Imaging: All CXE investigators had 
retinal imaging performed at sea level and again at Everest Base 
Camp with arterial and venous measurements made. Magnetic 
Resonance Imaging: Static (anthropomorphic) T1 MRIs and Dynamic 
(Susceptibility Weighted and Gadolinium Enhanced MR Venograms) 
were performed in a number of normobaric normoxic and hypoxic 
experiments. 
viii. Headache Assessment: Headache burden was monitored in CXE 
subjects by daily diary recording of headache score and duration to 
create a number of different scores including headache severity index. 
These domains were related to one another, in a manner determined a priori.  
 
Results 
Arterial Studies: Mean (±(SEM)) middle cerebral artery (MCA) diameter 
increased in hypoxia (from 5.23(±0.23)mm (at 5300m) to 6.66(±0.32)mm (at 
6400m) to 9.34(±0.88)mm at 7950m as measured using TCD (p<0.001). At sea 
level, after 3 hours of hypoxia (FiO2 = 11%) MCA increased from 
3.04(±0.13)mm to 3.27(±0.13)mm, when measured using MRI. At altitude this 
dilatation was found to increase estimated MCA flow (from 13.30(±0.97)ml/sec 
at 75m to 41.15(±8.5)ml/sec at 7950m (p<0.01)), which increased estimated 
oxygen delivery (from 2.47(±0.19)mlO2/sec to 6.98(±1.39)mlO2/sec (p<0.01)). 
Using MRI at sea-level it was found that dilatation increased estimated MCA 
flow (from 2.33(±0.33)mls/sec vs 3.23 (±0.48)mls/sec (p=0.01) and maintained 
oxygen delivery (0.44mls(±0.06)O2/sec vs 0.45(±0.07)mlsO2/sec p=0.58).     
Brain Oxygenation Studies: rSO2 decreased more rapidly relative to peripheral 
arterial saturation (SaO2), especially during exercise. The relative percentage 
reduction in resting SaO2 from 75m to 5300m was -22.23 ± 0.56%. The relative 
percentage reduction in resting rSO2 from 75m to 5300m was -30.61 ± 1.28% 
(paired t test p<0.001). During exercise at 5300m, relative SaO2 fell by 9.2 + 
0.59% between rest and VO2Max while relative rSO2 fell 15.6 +0.97% between 
rest and VO2Max (paired t-test p=0.002). Cluster analysis demonstrated that 
those who cerebrally desaturate during exercise at sea level desaturate more at 
altitude (p<0.05).  
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Venous Studies: Retinal and cerebral venous distension occurred in response 
to hypoxia. Twenty-three of 24 subjects exhibited retinal venous distension 
ranging from 5 to 44%. The degree of this distension correlated with ascent 
headache score (r = 0.553, p=0.005). A correlation was also demonstrated 
between peripheral saturation at 5300m and the change in venous retinal 
vessel diameter (r = -0.55, p = 0.005). Similarly, ETCO2 at 5300m also 
correlated with retinal venous vessel diameter (r =-0.4, p = 0.05) 
Similarly, transverse sinus morphology (the narrowing of one or both transverse 
sinuses) was strongly related to the degree of both retinal and cerebral venous 
distension and with headache burden. A hypoxic Magnetic Resonance 
Venogram study demonstrated that cerebral and retinal vein engorgement 
correlated (r = 0.598, p=0.05), and rose as Combined Conduit Score (CCS - a 
measure of venous outflow restriction) fell (r=-0.75, p<0.05). 
Headache Assessment: Headache Severity Index (HSI) was calculated as 
headache score multiplied by the duration of headache each day as a measure 
of headache burden at altitude. In addition to the venous relations above, HSI 
correlated inversely to both lateral and third ventricular volumes summed (r = -
0.5, p = 0.005) and pericerebellar CSF volume (r = -0.56, p = 0.03). HSI only 
related to rSO2 when preceded by an acute drop in FiO2 (increase in altitude).  
 
Conclusions 
An increase in cerebral arterial blood flow occurs in response to hypoxia, to 
which an increase in cerebral arterial diameter contributes. Until now, this had 
been thought to remain unchanged. Increased cerebral blood flow can lead to 
venous engorgement when outflow is compromised, and this correlates with 
headache. This suggests an important influence of cerebral venous anatomy 
and physiology on ICP regulation, with possible significant implications for 
pathophysiological states and their management.  
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Chapter 1: INTRODUCTION AND BACKGROUND 
 
See “The Brain at Altitude – The cerebral effects of ascent to high altitude” in 
Lancet Neurology (Wilson, Newman et al. 2009) for a shorter paper derived 
from this literature review, and “Direct measurement of intracranial pressure at 
high altitude and correlation of ventricular size with acute mountain sickness” in 
Neurosurgery  (Wilson and Milledge 2008) which reported the results of a 
preliminary investigation. 
 
1.1 Abstract 
 
Cellular hypoxia is the final common mechanism of brain injury, not just in 
asphyxia, but also in the diverse conditions in which cerebral perfusion is 
impaired directly (for instance, by embolic stroke) or indirectly (by raised 
intracranial pressure, such as that which occurs after head injury). Exposure to 
altitude (and thus hypobaric hypoxia) appears to offer a reproducible model for 
the study of cerebral cellular hypoxia in normal individuals. This chapter reviews 
the accepted understanding, at the time of this thesis commencement, of 
neurological clinical syndromes that occur upon such exposure, and the 
physiology, genetics and molecular mechanisms that underpin them. High 
Altitude Illness has been considered a spectrum of diseases and symptoms, 
from High Altitude Headache (HAH) through to Acute Mountain Sickness (AMS) 
and then High Altitude Cerebral (O)Edema (HACE). All represent clinical 
syndromes rather than defined illnesses: indeed, evidence for the existence of 
oedema in HACE is sparse. Most investigations of the aetiology of HAH (and 
HACE in particular) have, to date, focused on parameters that are relatively 
easy to study. These include arterial blood flow (measured using transcranial 
Doppler, TCD) and circulating or cellular “factors” (such as Hypoxia Inducible 
factor, HIF; Vascular Endothelial Derived Growth Factor, VEGF; and Nitric 
Oxide, NO). The venous system has received far less attention, largely because 
the tools to study it (in the field or laboratory) are far less well developed. In 
addition, because venous vessels lack muscle within their walls, they have 
been considered ‘mere passive conduits’ of no relevance to hypoxia. In this 
introduction, I shall demonstrate that the formation of retinal haemorrhages is 
associated with that of microhaemorrhages in the brain, and that both are 
caused by venous hypertension. This, and similarities with clinical syndromes of 
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venous hypertension, underpin my hypothesis that the venous system is 
involved in high altitude headache.    
 
1.2 Introduction 
 
With air travel providing easier mountain access, and increasing demand for 
adventurous holidays, millions of people now travel to altitude each year to ski, 
trek, climb and work (as soldiers, astronomers, miners and guides). 
Consequently, Acute Mountain Sickness (AMS) has become a common 
complaint in such travellers. As a result of differences in definition and ascent 
profiles between studies, the reported prevalence of AMS varies widely, but 
approximately half of trekkers ascending to 5000m are affected (Vardy and 
Judge 2006). In recent years, AMS and HACE have become occupational 
hazards for the workers on the Qinghai-Tibetan Railway with an overall 
incidence of 45-95% and 0.49% respectively (Wu, Ding et al. 2006; Wu, Ding et 
al. 2007) and for the rapidly expanding populations of native lowland Chinese in 
Tibet. An awareness of the presentations, pathogenesis and treatment of 
altitude-related illness is thus increasingly important to the medical profession.  
 
Existing reviews have described well the epidemiology and management of 
high altitude illness (Hackett and Roach 2001; Basnyat and Murdoch 2003). 
This chapter reviews the current understanding of neurological clinical 
syndromes and the underlying pathophysiological changes in cerebral perfusion 
and oedema formation that occur on ascent to altitude. It also explores the 
possible molecular and genetic mechanisms involved and the 
neuropsychological sequelae.  
 
Search Strategy and selection criteria:  
An extensive literature review of articles listed within PubMed from 1969 using 
MESH terms [Brain] and combinations of [Altitude], [Hypoxia], [Cerebral Blood 
Flow], [Acute Mountain Sickness], [High Altitude Cerebral (O)Edema] and 
[Neuropsychology] form the basis of this review. In addition, abstracts from 
recent international scientific meetings were considered. As requested for the 
Lancet Neurology review, priority was given to more recent publications, and 
especially to those published since 2005. 
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1.2.1 Clinical Relevance and Translation of Research 
 
The findings from this thesis can translate into the physiological changes that 
occur in some forms of brain injury. However, probably of greater translational 
significance are the cerebral physiological changes that occur with extreme 
systemic hypoxia to brain (and non-brain) injured patients in the critical care 
environment.  
 
The controlled study of restrictions in cerebral oxygenation resulting from brain 
injury is difficult because injuries vary by mechanism (e.g. gunshot, 
subarachnoid haemorrhage, ischemia) and location (e.g. frontal, parietal), and 
due to heterogeny in patient characteristics (such as age). Because most 
effects of short duration hypobaric hypoxia are reversible, the study of the brain 
at altitude offers a clean, repeatable, controlled, prospective, ethical model of 
brain responses to hypoxia with few confounding variables (Grocott, 
Montgomery et al. 2007). Whilst elements of the pathophysiology of hypoxic 
brain injury will differ from (for example) traumatic brain injury, there may well 
be more mechanisms in common than might be initially considered. Cellular 
hypoxia can be the result of failure in any stage of oxygen delivery to a tissue 
bed. Ischemia refers to lack of blood flow which itself results in tissue hypoxia 
although other mechanisms relating to the presence of coagulated blood and 
failure to remove waste products may be superimposed. Carbon monoxide and 
cyanide poisoning, and anoxia associated with cardiopulmonary arrest, all result 
in cerebral oedema, loss of grey-white differentiation and then selective 
damage starting with watershed areas and areas with high metabolic rate (such 
as the basal ganglia) (Varnell, Stimac et al. 1987; James 1988; Kasamo, 
Okuhata et al. 1993; Mills, Gunasekar et al. 1999). Traumatic brain injury and 
brain tumours often result in cerebral oedema that, if ICP rises, can compromise 
perfusion and, especially in trauma, cause subsequent ischaemic injury. Similar 
pathophysiological processes are thought to occur in HACE. Obstructive Sleep 
Apnoea with periodic breathing and COPD result in chronic hypoxia with 
intermittent exacerbations of acute hypoxia in a similar manner to the effects of 
altitude. 
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In the critical care environment, hypoxia is commonplace. Hypoxaemia can 
occur with hypoventilation, ventilation/perfusion mismatch, right-to-left shunting 
or limitation of diffusion across the alveolar-capillary membrane. Tissue (and 
cerebral) hypoxia may arise as a consequence of hypoxaemia or as a result of 
reduced oxygen delivery due to decreased cardiac output or decreased 
circulating haemoglobin concentration (anaemia). It may also occur with the 
systemic inflammatory response syndrome, with microcirculatory dysfunction or 
alterations in cellular and mitochondrial function (Brealey, Brand et al. 2002). 
Moreover, neuronal ischaemia is a common result of a number of specific 
disease processes from direct obstruction of cerebral arterial flow (e.g. embolic 
infarction) or from reduced perfusion (e.g. from raised intracranial pressure).  
 
Failure to adapt to hypoxia therefore has a high price. The mechanisms of such 
cellular adaption (for example, the sequelae resulting from the non-degradation 
of factors such as hypoxia-inducible factor 1α [HIF 1α], and its potential roles in 
cancer, cardiac and neuronal pathologies) have been extensively studied 
(Ogunshola and Al-Ahmad 2012; Ong and Hausenloy 2012; Rohwer, Zasada et 
al. 2012; Hu, Liu et al. 2013). This can be achieved in standard laboratory 
conditions. The study of macrocellular changes is more difficult. Rodent brains 
are very different to those of humans. Size and adaptation to upright posture 
mean that physiological changes in one may not necessarily translate to the 
other.  Studying patients is difficult because of the heterogeneity of disease 
(injury type), location (within the brain) and constitutional factors of patients.  
However, exploration of the mechanisms underlying differences in susceptibility 
to hypoxia-induced injury (be they physiological pathways such as those 
regulating compensatory oxygen delivery, pathophysiological pathways 
influencing oedema formation, or anatomical factors affecting cerebral or cranial 
compliance) may suggest novel prophylactic or therapeutic targets of broad 
clinical relevance.  A means by which to study the cerebral response to 
sustained hypoxia is required in order to achieve this. 
 
 
1.2.2 Changes in Atmosphere with Increasing Altitude 
 
Whilst barometric pressure decreases exponentially as altitude is gained, the 
percentage of each gas component of air remains the same up to 12,000m. 
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Hence, although the percentage of oxygen remains constant at 20.93%, 
increasing altitude results in a lower inspired partial pressure of oxygen (figure 
1-1). This reduction in driving gradient on the oxygen cascade may compromise 
the supply of adequate oxygen to the tissues (figure 1-2). 
 
Figure 1-1 The relationship between altitude (classified as high (1500-3500m), very high 
(3500-5500m) and extreme (>5500m)) (Dietz 2008), the partial pressure of inspired oxygen 
(PiO2), and some of the neurological consequences of acute and gradual exposure to 
these pressure changes. Note – the neurological consequences vary greatly from person 
to person and with rate of ascent. HACE is far more common at higher altitudes although 
there are case reports at 2,500m. Data are derived as follows: Hallucinations (Garrido, 
Javierre et al. 2000), MRI changes (Garrido, Castello et al. 1993) , Memory Retrieval 
(Kramer, Coyne et al. 1993), Learning (Kramer, Coyne et al. 1993) Spatial (Nelson 1982) , 
Psychomotor (Berry, McConnell et al. 1989) , CRT(Fowler, Elcombe et al. 1987), West and 
Milledge (West, Schoene et al. 2007)) 
 
 
Figure 1-2 The oxygen transport cascade at sea 
level (red line) and 4540m (blue line) illustrating 
oxygen partial pressure at the major stages of 
oxygen delivery, suggesting potential points of 
functional adaptation. Adapted from Beall, 2007 
(Beall 2007).  
 
Whilst compensatory hyperventilation, 
tachycardia, erythropoietin-induced 
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polycythaemia and increased cerebral blood flow partially maintain cerebral 
oxygen delivery at altitude (West, Schoene et al. 2007), the brain remains 
exquisitely sensitive to hypoxia and consequently is the first organ to be 
compromised when these mechanisms are inadequate. 
 
1.2.3 The History of the Effects of Acute Hypobaric Hypoxia 
 
The neurological effects of altitude exposure have long been recognised. 
Plutarch (326 BC) described several features of mountain sickness during 
Alexander’s march over India (Plutarch 1912) and Rustinian (1298 AD) 
recorded similar symptoms suffered by Marco Polo during his exploration of 
Tibet (Castelló-Roca 1993). Jose de Acosta, a Spanish Jesuit of the sixteenth 
century described headaches sickness and vomiting while crossing the Andes. 
 
On 5th September 1862 two British balloonists, Glaisher and Coxwell, ascended 
to over 8800m (Glaisher 1862; West 2004; Rodway 2007). Glaisher reported 
paralysis of his arms and legs and sudden loss of vision before losing 
consciousness (figure 1-3). Coxwell lost the use of 
his hands and could only open the valve to initiate 
balloon descent by pulling the cord with his teeth. 
After landing, they walked seven miles to the nearest 
village with no residual neurological deficits. Thirteen 
years later, the first deaths attributable to acute high 
altitude hypoxia exposure were reported when three 
Frenchmen lost consciousness ascending through 
7000m and two died (Bert 1943).  
 
Figure 1-3 James Glaisher (unconscious) and Henry Coxwell (pulling the valve chord 
with his teeth having lost use of his hands) above 8,800m (1862) (West 2004). 
 
These early accounts relate to the acute neurological effects of hypobaric 
hypoxia. The first detailed clinical descriptions of the consequences of slower 
ascent were given by Thomas Ravenhill in 1913 whilst a medical officer at the 
Collahuasi and Poderosa mines in northern Chile at altitudes between 4690m 
and 4940m (Ravenhill 1913; West 1996). He provided a classification of high 
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altitude illness and described the features of both high altitude cerebral and 
pulmonary oedema.  
 
1.3 Clinical Syndromes at Altitude 
 
1.3.1 Classification of Neurological Effects of Hypobaric Hypoxia in Adults 
 
 
Hypobaric hypoxia has a spectrum of 
pathophysiological effects on the 
brain (Box 1-1). Slowing the ascent 
rate can reduce the occurrence of 
most altitude specific syndromes. 
Too rapid ascent is thought to cause 
(in increasing severity) High Altitude 
Headache, Acute Mountain Sickness 
and then potentially life threatening, 
High Altitude Cerebral Oedema. 
Current recommendations are to 
sleep no higher than 300m above 
the previous night with a rest day for 
every 1000m climbed. “Climb high, 
sleep low” is a common adage.  
 
Box 1-1 Neurological effects of ascent to 
high altitude  
 
1.3.2 High Altitude Headache (HAH) 
 
The International Headache Society (2004) define the diagnostic criteria for 
HAH as A) headache exhibiting at least two of the following characteristics: 
frontal or fronto-temporal, dull or pressing, mild or moderate and aggravated by 
exertion, movement, straining, coughing or bending, and associated with; B) 
ascent to altitude over 2,500m, and which; C) has developed in the last 24 
hours and; D) resolves within 8 hours of descent.  
HAH occurs in up to 80% of visitors to altitude and can be difficult to distinguish 
from headache secondary to dehydration. HAH should resolve with use of 
Neurological Effects of Hypobaric Hypoxia 
High Altitude Headache 
Acute Mountain Sickness 
High Altitude Cerebral Edema  
 
Other neurological “events” reported at 
altitude 
Transient ischaemic attacks 
Cerebral infarction and haemorrhage 
Migraine 
Cerebral venous thrombosis 
Seizures 
High altitude syncope 
Cranial nerve palsies 
Ophthalmological disturbances: retinal 
haemorrhages; amaurosis fujax; cortical 
blindness 
Acute cerebral dysfunction of extreme 
altitude (related to additional acute 
cerebral hypoxia e.g. from HAPE – rapidly 
reverses with oxygen) 
 
Neuropsychological effects: 
Déjà vu 
Emotional lability  
Cognitive slowing/inaccuracies 
Hallucinations/third man  
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simple analgesics (paracetamol / ibuprofen) but further management consists of 
rehydration, stopping ascent, and descending if there is no improvement.  
 
1.3.3 Acute Mountain Sickness (AMS) 
 
AMS is commonly considered to represent progression of HAH. The Lake 
Louise Consensus Group defined AMS as the presence of headache in an 
unacclimatised person who has recently arrived at an altitude above 2500m, 
plus the presence of one or more of the following: gastrointestinal symptoms; 
anorexia, nausea or vomiting; insomnia; dizziness; and lassitude or fatigue 
(Roach, Bartsch et al. 1993). The group also established a scoring system to 
provide a quantitative element to AMS severity. A less commonly used (though 
more detailed) severity scoring system is the Environmental Symptom 
Questionnaire (Sampson, Cymerman et al. 1983). Box 1-2 lists possible risk 
factors for AMS. 
 
 
Box 1-2 Possible risk factors for AMS. Despite 
these being known, it is not currently possible to 
predict who, in a group of similar aged people 
travelling together to altitude for the first time, will 
develop AMS. 
 
 
Management of AMS consists of simple analgesia and descent to a lower 
altitude. For more severe cases acetazolamide, dexamethasone (see drugs at 
altitude Box 1-3), supplemental oxygen or use of a portable hyperbaric chamber 
may be required. 
  
Risk Factors for AMS:  
Rapid ascent 
Exertion 
Past history of altitude illness 
Young adults 
Genetic predisposition 
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The two main aims of pharmacological treatment for high altitude illness are to increase 
ventilation (e.g. with carbonic anhydrase (CA) inhibition) and to reduce inflammatory and 
cytokine responses (e.g. by steroids/antioxidants). In addition, descent and supplementary 
oxygen must be considered for increasingly severe symptoms. Medications that improve High 
Altitude Pulmonary Edema (HAPE) can also improve concurrent AMS and HACE by improving 
oxygenation. 
 
Acetazolomide (125-250mg bd): Is used in AMS prophylaxis and therapy (Bradwell, Wright et 
al. 1992; Grissom, Roach et al. 1992). It blocks CA in red blood cells, renal tubules, 
chemoreceptors, the brain and pulmonary/systemic blood vessels. Its mechanism of action is 
thought to principally be through renal CA inhibition causing a bicarbonate diuresis and 
metabolic acidosis that increases minute ventilation. CSF production is also reduced. The 
numbers needed to treat to prevent one case of AMS are between 8 (Basnyat, Gertsch et al. 
2003) and 4.5 (Bartsch and Schneider 2001). No benefit of 375mg bd over 125mg bd was 
demonstrated in a randomised trial (Basnyat, Gertsch et al. 2006). 250mg tds has been shown 
to improve cerebral oxygenation during exercise at 5700m but this effect is nullified with 
acclimatisation (Vuyk, Van Den Bos et al. 2006). Serious side effects are rare but an unpleasant 
taste to carbonated drinks, an initial diuresis and peripheral and perioral tingling that increases 
with dosage are commonly reported (Basnyat, Gertsch et al. 2006). 
 
Dexamethasone (For prophylaxis: up to 8mg/day; for acute treatment of HACE: 8mg by 
any route stat and 4mg 6 hourly (orally if tolerated) subsequently): Is thought to act by 
reducing cytokine release and capillary permeability. Dexamethasone 8mg/day in divided doses 
can prevent AMS (Johnson, Rock et al. 1984; Fowler, Elcombe et al. 1987; Hackett, Roach et 
al. 1988; West, Schoene et al. 2007) but potential side effects have limited its use to those in 
whom acetazolamide is contraindicated, and to rescue workers in whom rapid ascent is 
mandated and unavoidable. The benefits of steroid prophylaxis occur without altering 
physiological variables such as peripheral arterial oxygen saturation (Basu, Sawhney et al. 
2002). It is normally used to treat rather than prevent AMS/HACE. 
 
Ginko Biloba and anti-oxidants: Ginko biloba is a Chinese medicine that scavenges free 
radicals. Its benefits are unclear. Early studies suggested benefit (Roncin, Schwartz et al. 1996) 
however a recent (though poorly designed) large trial, failed to show evidence of AMS 
prevention (Gertsch, Basnyat et al. 2004). Antioxidant supplementation with ascorbic acid, 
tocopherol acetate and α-lipoic acid reduced AMS score and improved arterial oxygen 
saturations in a 10 day ascent to 5180m (Bailey and Davies 2001), however antioxidants may 
interfere with acetazolamide’s action. 
 
Pharmacotherapy for HAPE: 
By improving arterial oxygen saturation, these measures may aid concurrent HACE, but alone 
do not prevent AMS. 
 
Calcium Channel Blockers – e.g. Nifedipine (20mg slow release tds) Inhibit hypoxia induced 
pulmonary artery vasoconstriction. Slow release Nifedipine 20mg tds reduces HAPE in 
susceptible individuals (Bartsch, Maggiorini et al. 1991) and given orally every 6 hours can be 
used (with oxygen and rapid descent) to treat HAPE (Oelz, Maggiorini et al. 1989). Caution 
must be used as significant hypotension can result  
 
Phosphodiesterase Inhibitors – e.g. Sildenafil (50mg) increase cerebral and peripheral 
oxygenation by reducing pulmonary hypertension through inactivation of secondary messengers 
(Chan, Hoar et al. 2005). Tadalafil (10mg) has been shown to reduce HAPE in HAPE-prone 
subjects (Maggiorini, Brunner-La Rocca et al. 2006) but does not prevent AMS.  
Box 1-3 Pharmacotherapy to prevent and treat High Altitude Illness 
 
1.3.4  High Altitude Cerebral (O)edema (HACE) 
 
If the cerebral effects of altitude are considered to occur as a spectrum of 
disease, HACE is the final life-threatening stage. It is diagnosed clinically in 
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persons who have recently arrived at high altitude, most of whom will have 
features of AMS or HAPE. It is characterised by psychiatric changes of varying 
degree, confusion, ataxia of gait, and disturbances of consciousness that may 
progress to deep coma (Hackett and Roach 2004). The prevalence in trekkers 
at around 4500m is thought to be 0.5 - 1% (Hackett, Rennie et al. 1976). 
Management consists of urgent descent, and administration of oxygen and 
dexamethasone (8-10mg iv, im or PO then 4mg 6 hourly). If descent is not 
possible, and the airway can be protected, a portable hyperbaric chamber can 
be used. 
 
As I shall discuss later in this chapter, this clinical syndrome has the 
pathological descriptor of “oedema” in its title. Whilst limited data suggest that 
oedema has occurred in some (Hackett, Yarnell et al. 1998), this has not been 
shown to be universal. It may well be that there is another cause of the above 
symptoms and oedema is the final, pre-terminal result.  
 
1.3.5 High Altitude Illness in Children 
 
Many thousands of children are exposed to high altitude when travelling with 
their parents but the paediatric population has not been studied extensively 
(Pollard, Niermeyer et al. 2001). The incidence of AMS seems to be similar in 
children and young adults (Yaron, Waldman et al. 1998); however, diagnosis 
and distinguishing it from other pathologies may be more difficult in this group 
(Theis, Honigman et al. 1993). As in adults, no clear correlation between 
physiological changes and AMS symptoms has been demonstrated (Yaron, 
Niermeyer et al. 2003). The Lake Louise Scoring System can underestimate 
AMS prevalence in children because of difficulties in articulating symptoms 
(Southard, Niermeyer et al. 2007). A Children’s Lake Louise Score assessing 
parameters of unexplained fussiness, feeding, playfulness and sleeping may be 
of use in pre-verbal children (Pollard, Niermeyer et al. 2001). A slow ascent to 
prevent, and an early descent to treat AMS in children are imperative. 
 
1.3.6 Sleep at High Altitude 
 
Sixty percent of individuals ascending rapidly to 3500m describe sleep 
disturbance, of which recurrent awaking is the most common complaint 
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(Jafarian, Gorouhi et al. 2008). Periodic breathing (reflecting alternating 
respiratory stimulation by hypoxia and subsequent inhibition by 
hyperventilation-induced hypocapnia) is frequently observed and the resulting 
cyclical fall in arterial oxygen saturation is thought to significantly contribute to 
the pathogenesis of AMS (Burgess, Johnson et al. 2004).  In addition, periodic 
breathing disrupts sleep in fellow tent sharers and has significant 
neuropsychological effects (Virues-Ortega, Buela-Casal et al. 2004). 
Temazepam, Zopiclone and Acetazolamide are all considered safe at altitude, 
maintain oxygen saturations and reduce sleep disturbance, although it is not yet 
clear if combination therapy is advantageous (Luks 2008). 
 
1.3.7 Other High Altitude Related Neurological Conditions 
 
A number of usually focal “events” that also occur at sea-level (and fall outside 
the usual definition of altitude sickness) appear to have an increased incidence 
at altitude (Basnyat, Wu et al. 2004).  
 
Transient Ischaemic Attacks (TIAs) tend to occur in a younger population at 
altitude implying that aetiology does not reflect atherosclerosis and may be 
related to vasospasm, hypocapneic vasoconstriction or putative prothrombotic 
effects of hypoxia. Right to left shunts increase with both exercise and altitude, 
meaning that embolisation via a patent foramen ovale (PFO) may account for 
some focal neurological events, or episodes of migraine (Imray, Pattinson et al. 
2008). Such effects may also contribute to rare cases of cerebral infarction, to 
which dehydration and hypoxia-induced polycythaemia may also contribute 
(Clarke 2006). Transient global amnesia is reported and may occur through 
similar mechanisms in the limbic cortex.  
Migraine can be difficult to distinguish from AMS, but suspicion should be 
raised if it is associated with focal neurology.  
Cerebral venous thrombosis has been a common finding at autopsy of 
patients who die at altitude (Dickinson, Heath et al. 1983; Song, Asaji et al. 
1986) and may be related to volume depletion and polycythaemia (Zhou 1984). 
Altitude may also be a trigger in those genetically predisposed through familial 
thrombophilia (Boulos, Kouroukis et al. 1999; Baumgartner, Siegel et al. 2007; 
Nair, Mohapatro et al. 2008).  
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Seizures are relatively common even at sea level. It is not known if seizure 
frequency increases at altitude, although hypoxia and hyperventilatory 
hypocapnia are thought to be triggers (Hackett 2001).  
High altitude syncope is thought to be a vasovagal phenomenon related to 
hypoxaemia although increased frequency of arrhythmias may be contributory 
(Woods, Allen et al. 2008). It usually occurs at moderate altitude and rapidly 
resolves (Nicholas, O'Meara et al. 1992). 
Cranial nerve palsies are well recognised both in the presence and absence of 
AMS/HACE. Most commonly, the 6th cranial nerve is affected, perhaps due to 
trunk compression from adjacent brain swelling. Facial and Hypoglossal cranial 
nerve palsies have also been described (Basnyat, Wu et al. 2004).  
Ophthalmological disturbances: Retinal haemorrhages are a common 
occurrence with or without AMS symptoms. Unless the macula is involved, they 
are relatively benign and resolve spontaneously. Their pathogenesis is 
unknown, but may relate to increased blood flow, or breakdown in the blood-
retina barrier (Mader and Tabin 2003). The monocular blindness of amaurosis 
fujax may result from compromised blood supply to the retina and hence the 
aetiology may be similar to the TIAs described above. Similarly, cortical 
blindness may represent vascular compromise to the visual cortex.  
 
Obviously, many other neurological conditions that occur at sea level still occur 
at altitude (e.g. subarachnoid haemorrhage), and mild hypoxia can unmask 
more indolent conditions (e.g. cerebral tumours) (Zrinzo, Crocker et al. 2006). 
 
1.3.8 Chronic Mountain Sickness (CMS) 
 
CMS (also known as Monge’s disease after Carlos Monge who described it in 
1925) can develop after living at altitude for an extended time. Its central feature 
is an excessive erythrocytosis that drives polycythaemia, to which (through 
associated hyperviscocity) many of its associated symptoms can be related 
(headache, dizziness, tinnitus, sleep disturbance, fatigue and mental confusion). 
Pulmonary hypertension and cor pulmonale are common.   
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1.4 Current Pathophysiological theories 
 
Other than the occurrence of past altitude illness, there are no obvious 
predisposing factors that identify one individual as being at higher risk of 
developing AMS than another when ascending to the same altitude at the same 
rate. The indiscriminate nature of AMS led Ross in 1985 to write of “the random 
nature of cerebral mountain sickness” (Ross 1985). This is based on the Monro-
Kellie doctrine(Monro 1823; Kellie 1824) of the skull being a “closed box” and 
hence if a mass (tumour/blood/oedema) increases in volume within the skull, 
something else has to be displaced or pressure will rise. Ross’s “Tight Fit” 
hypothesis proposed that inter-individual variation in neuroaxis compliance (i.e. 
the inability of some to be able to accept brain swelling compared to others) 
accounted for similar variability in AMS susceptibility (figure 1-4). A number of 
factors influence such compliance: brain volume compared to skull volume (the 
atrophy of aging causes an increase in ventricular and sulcal size); and the 
volume of the spinal canal when compared to that of the spinal cord. A 
Pressure-Volume Index (PVI) can be calculated (the volume of fluid that needs 
to be added to CSF to raise the CSF pressure by a factor of 10) and this varies 
widely between individuals. For some 20 years the “tight fit” hypothesis (in 
which, because the skull is a closed box, oedematous brain increases 
intracranial pressure once compliance is reached) has been considered key to 
explaining differences in susceptibility to AMS, despite paucity of supporting 
data. If it is a key factor, then increases in cerebral volume (and thus pressure) 
need also to be explained. Whilst these may occur due to the occurrence of 
oedema (see above), an increase in cerebral blood flow, or obstruction to 
venous outflow, might also be postulated to play a role and this forms the basis 
of a core hypothesis studied in this thesis (see end of this chapter). 
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Figure 1-4 Schematic graph of the “Tight-Fit” hypothesis demonstrating that lack of CSF 
buffer results in a predisposition to a rise in ICP with oedema formation or increased 
blood volume.  
 
In addition to this anatomical predisposition, it has been suggested that there is 
a physiological predisposition to the formation of cerebral oedema itself. This 
may relate in part to an individual’s ability to maintain arterial oxygen saturation 
at altitude, especially during exercise (Roach and Hackett 2001). The classic 
adaptations to hypoxia (tachypnoea, tachycardia, and erythropoeisis to aid 
tissue oxygen delivery) are well known.  Variations in acute hypoxic ventilatory 
response may well be associated with differences in cerebral blood flow and 
hence oedema formation. Recently, an individual’s ability to alter oxygen 
utilisation efficiency at the mitochondrial level has also been suggested to 
account for some of the variations seen (Gore, Clark et al. 2007).  
 
1.4.1 Investigating the Tight Fit Hypothesis 
 
Assuming the “Tight Fit” hypothesis to be true, an elevated ICP should underpin 
the development of AMS. Evaluation of this hypothesis therefore requires 
measurement of ICP or its surrogates. 
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Indirect Measures of ICP 
• Lumbar CSF Pressures: There is little evidence that CSF pressures as 
measured by lumbar puncture are increased in AMS. Singh et al. (Singh, 
Khanna et al. 1969) demonstrated elevated lumbar spinal fluid pressures 
in 34 Indian soldiers who were rapidly transported from sea level to 
5867m. Lumbar CSF pressures were 6-21cm H2O higher than pressures 
after recovery. This may however reflect acute decompression effects. It 
is unclear whether these soldiers had AMS or HACE. While Hartig and 
Hackett demonstrated, in three subjects, that acute hypoxic gas 
inhalation resulted in a rise in lumbar CSF pressure, more gradual 
decompression to a simulated ascent of 5000m was not associate with 
any change, even in those in whom AMS developed (Hartig and Hackett 
1992). Similarly, Bailey et al found lumbar CSF pressures to be normal 
after exposure to 16 hours of 12% O2 and identified no difference in 
pressures between AMS and non AMS groups (Bartsch, Bailey et al. 
2004).  
• Tympanic Membrane Displacement (TMD): Wright et al. used a TMD 
technique to study 24 subjects before and during ascent to 5200m 
(Wright, Imray et al. 1995). Changes suggesting a rise in ICP were found 
with acute hypoxic exposure (ascending rapidly to 3400m), but there was 
no additional rise in ICP in those who developed mild to moderate AMS. 
They thus concluded that a rise in ICP, if it occurs, is a late phenomenon 
in AMS/HACE.  
• Optic Nerve Sheath Diameter (ONSD): Recently, ONSD has been used 
as a surrogate for the measurement of ICP at altitude and in those with 
AMS (Fagenholz, Gutman et al. 2007; Sutherland, Morris et al. 2008). In 
a study of 13 mountaineers, ONSD was measured ultrasonically with 
regression analysis used to explore correlation with a number of 
variables. ONSD was positively associated with increasing altitude 
(0.1mm increase per 1000m 95% CI 0.05-0.14) and AMS score (0.12mm 
per Lake Louise Score (CI 0.06 to 0.18). Associations were also found 
with resting heart rate and arterial oxygen saturation (0.2mm increase 
per 10% Sa02 decrease) (Sutherland, Morris et al. 2008).  A study of 287 
subjects similarly demonstrated a larger mean optic nerve sheath 
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diameter (ONSD: 5.34mm, 95%CI 5.18-5.51mm) in AMS sufferers 
compared to non-sufferers (4.46mm, 95%CI 4.39-4.54mm) (Fagenholz, 
Gutman et al. 2009). However a more recent study of 23 subjects has 
failed to show any difference in ONSD between AMS sufferers and non-
sufferers (Lawley, Oliver et al. 2012), once again providing conflicting 
data regarding the association of rising  ICP with AMS.  
• Pulistility Index (PI): As explained below, PI (measured using transcranial 
Doppler of ratios of flow velocities) may give an indication of ICP, but its 
reliability remains uncertain. 
 
Direct ICP Measurements 
Brian Cummins, a neurosurgeon from Bristol, is the only investigator to have 
directly monitored ICP in humans at altitude (Wilson and Milledge 2008)†. He 
first investigated intracranial pressure in three climbers using a telemetric ICP 
monitoring device inserted prior to departure. Only the youngest subject 
developed AMS. All of them had normal ICPs at rest at all altitudes. However 
the youngest subject suffered a dramatic rise in ICP at 4725m during any form 
of mild exertion. Mild exertion and neck turning can be simple manoeuvres that 
reduce venous outflow and hence tip an individual from the “compensating” part 
of the cerebral compliance curve into the decompensated part which results in a 
steep rise in ICP (figure 1-4). Such non-invasive manoeuvres in future may be 
used as tests of compliance.  
 
Field conditions limit the application of many technologies (such as magnetic 
resonance imaging) to the study of the brain at altitude. Two tools however, are 
portable and particularly useful at investigating brain oxygenation and brain 
blood flow: Cerebral Near Infrared Spectroscopy (NIRS) and Transcranial 
Doppler (TCD) respectively. Since they are used extensively during the studies 
described in this thesis, a background to them is given here although further 
technical details are provided in the methodology chapter (chapter 2) and the 
chapters concentrating on TCD (chapter 3) and NIRS (chapter 4). 
 
                                            
† His	  data	  from	  his	  expedition	  to	  Hagshu	  in	  Pakistan	  was	  thought	  to	  have	  been	  lost	  in	  a	  
car	  fire.	  However,	  I	  asked	  his	  wife	  Anne	  if	  I	  could	  write	  a	  historical	  piece	  and	  she	  found	  
the	  data	  in	  a	  box	  in	  the	  loft.	  Sadly	  Brian	  died	  in	  2004	  and	  hence	  I	  wrote	  it	  up	  for	  him. 
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1.4.2 Cerebral Oxygenation at Altitude 
 
Cerebral NIRS is a non-invasive technique utilising the differential absorptive 
properties of oxy- and de-oxyhaemoglobin for near infrared light (700-1100nm). 
The technique provides continuous monitoring of regional cerebral oxygenation 
(rSO2 – a mixed arterial, venous, capillary and tissue oxygenation measure of 
the area interrogated by the near infrared light, approximately 4cm deep to the 
light source/detector). NIRS has been used extensively for research purposes, 
but its clinical use is still in its infancy. Its use to optimise cerebral oxygenation 
during coronary artery bypass surgery results in a significantly lower prevalence 
of major organ dysfunction and shorter length of stay (Murkin, Adams et al. 
2007). Cerebral NIRS measurements have been shown to correlate with jugular 
venous bulb saturations in healthy volunteers undergoing isocapnic hypoxia 
(Henson, Calalang et al. 1998). The technique has also been validated with 
PET scanning (Rostrup, Law et al. 2002) and  133Xe washout methods (Boushel, 
Langberg et al. 2000). Most studies using NIRS have investigated frontal cortex 
rSO2.  
 
There is a progressive fall in resting rSO2 with ascent to altitude (Imray, Barnett 
et al. 1998),(Hadolt and Litscher 2003) but the fall does not correlate with AMS 
severity (Imray, Barnett et al. 1998). Supplemental CO2 increases rSO2 
(presumably by reducing hypocapnia-induced vasoconstriction) (Imray, Walsh 
et al. 2003) and acetazolomide helps to maintain cerebral oxygenation up to 
5700m (Vuyk, Van Den Bos et al. 2006). 
 
During exercise on a recumbent bicycle at sea level, rSO2 increases (from 
68.4% to 70.9% at submaximal exercise and to 69.8% at VO2Max, n=9) (Imray, 
Myers et al. 2005). However, at altitude (studied up to 5,260m), rSO2 decreases 
with increasing exercise. Similarly, Subudi et al. studied 13 cyclists exercising to 
VO2Max under normoxic and acute hypoxic (12% FiO2) conditions (Subudhi, 
Dimmen et al. 2007). In normoxia, frontal cortex rSO2 increased as workload 
increased from 25 to 75% of VO2 max then fell as workload increased further to 
100% of VO2 max. During hypoxia, however, cerebral rSO2 dropped across all 
work levels. It has therefore been suggested that cerebral oxygen delivery may 
contribute to the limit of exercise at altitude.  
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Brain Oxygen Consumption 
There are few published data relating to brain oxygen consumption or extraction 
at altitude as such field studies require both arterial and (jugular) venous 
measurements. Moller et al. studied cerebral metabolic rates of oxygen and 
glucose, and cerebral blood flow using the Kety-Schmidt technique in 9 
acclimatised subjects at rest and during exercise at sea level and 5,260m. 
Despite marked changes in breathing, no changes in cerebral blood flow or 
oxidative metabolism were demonstrated (Moller, Paulson et al. 2002).  
 
Positron Emission Tomography has demonstrated that Quechuas (high altitude 
natives of the Andes) have lower glucose metabolic rates in brain regions 
classically associated with higher cortical function (e.g. the frontal cortex) 
compared to low-landers. This could provide a defence mechanism to protect 
the brain from chronic hypoxia (Hochachka, Clark et al. 1994; Hochachka and 
Monge 2000).  
 
There is also evidence to suggest that animals that adapt well to hypoxia can 
reduce their brain oxygen consumption at high altitude (Curran-Everett, 
Iwamoto et al. 1991). Curran-Everett demonstrated that 7 out of 9 sheep 
exposed to 72 hours of hypoxia were able to reduce their cerebral oxygen 
extraction (Curran-Everett, Iwamoto et al. 1991). The “sick” sheep (defined as 
those that ate less and lay down more) all had the lowest oxygen extraction 
fractions during normoxia. Subsequently they also had a greater cerebral blood 
flow per unit of cerebral O2 consumption both during normoxia and hypoxia. 
These different cerebral responses to hypoxia may be related to individual 
variations to AMS susceptibility. 
 
1.4.3 Changes in Cerebral Blood Flow at Altitude 
 
One of the proposed mechanisms for the development of HACE is vasogenic 
oedema initiated by an increase in cerebral blood flow (CBF). The major 
determinants of CBF in normoxia are blood pressure, and the partial pressures 
of arterial oxygen and carbon dioxide. On ascent to altitude, hypoxia tends to 
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increase CBF, while hypocapnia decreases CBF, and the balance of these two 
effects is crucial in determining the overall CBF.    
 
Severinghaus et al. (Severinghaus, Chiodi et al. 1966) used the Kety-Schmidt 
nitrous oxide washout method (Wolff 2000) to describe the CBF response to 
ascent to 3810m. CBF had increased by 24% within 6- 12 hours, and was still 
13% higher at 3-5 days. Jensen et al. used radiolabelled Xenon to measure 
CBF in 12 subjects ascending from 150 to 3475m, and found that it increased 
by 24% (Jensen, Wright et al. 1990). Ascending from 3200m to 4785-5430m 
was associated with a further rise in CBF, to 53% above sea level values. 
However, no difference was seen between subjects with and without AMS.  
 
Transcranial Doppler (TCD) has been used extensively to assess relative 
changes in cerebral blood flow velocity at altitude. It requires an experienced 
sonographer using a consistent insonation window, angle and depth and a 
suitable temporal bone window. TCD measures flow velocity which has been 
assumed to represent overall flow volume. It has been hypothesised that the 
headache of AMS could be secondary to an increase in blood flow (Jensen, 
Wright et al. 1990; Jansen, Krins et al. 1999). Baumgartner et al. studied 10 
subjects immediately, 3 and 6 hours after decompression to 4,559m and found 
no significant changes in middle cerebral artery flow velocity (MCAv) and no 
correlation with the development of AMS (Baumgartner, Spyridopoulos et al. 
1999). The lack of very early change in MCAv was corroborated by carotid and 
vertebral artery flow studies (Reeves, Moore et al. 1985; Huang, Moore et al. 
1987) but there were substantial inter-individual differences in these studies. In 
contrast, 12-24 hours after arrival at altitudes ranging between 3475 and 4559m, 
several Doppler studies reported MCAv increases of 20% to 27% (Huang, 
Moore et al. 1987; Otis, Rossman et al. 1989; Baumgartner, Bartsch et al. 
1994). These ultrasound findings are in accordance with the results of 
Severinghaus (Severinghaus, Chiodi et al. 1966) and Jensen (Jensen, Wright et 
al. 1990). The delayed increase in MCAv could explain the delay in the 
development of AMS/HACE. 
 
Others have suggested that it is not the change in CBF, but the loss of 
autoregulation that is important in the development of AMS. Van Osta et al. 
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studied MCAv in 35 volunteers ascending to 4559m.  MCAv did not change, 
although a rise in the dynamic cerebral autoregulation index (ARI – calculated 
from recordings of MCAv and blood pressure during transient induced 
hypotension) correlated with the headache component of the AMS score (Van 
Osta, Moraine et al. 2005). 
 
It has been suggested that hypoxia may have a direct vasodilatatory effect on 
the large basal arteries of the Circle of Willis. This would lead to a 
underestimate of flow variation by MCAv and could explain the unchanging 
values of MCAv which Ter Minassian reported in the Operation Everest III study 
(Ter Minassian, Beydon et al. 2001). These authors ruled this out, quoting a 
paper written in 1930 to state that the vasodilatory effects of hypoxia act mainly 
on small pial and cortical arteries downstream of the Circle of Willis (Wolff and 
Lennox 1930). They further discount the possibility of hypoxia-induced MCA 
dilatation by stating that the increase in MCAv is of the same order of 
magnitude as the increase in CBF shown by nitrous oxide inhalation 
(Severinghaus, Chiodi et al. 1966) and the 133Xenon technique.  Giller has 
suggested that the lack of knowledge of changes in vessel diameter is a major 
handicap to the interpretation of TCD data (Giller 2003), and hypoxic-induced 
hyperventilation and subsequent reduction in PaCO2 may result in 
vasoconstriction. In the context of subarachnoid haemorrhage, neurosurgeons / 
neurointensivists interpret an increase in MCAv to mean vasoconstriction or 
vasospasm.  Another core aim of this thesis is to investigate cerebral artery 
vasodilatation in response to hypoxia. 
 
Pulsitility Index: Gosling’s Pulsatility Index (PI), is calculated from Transcranial 
Doppler measurements of the middle cerebral artery (MCA): PI = systolic 
velocity - diastolic velocity/mean velocity; a normal value being less than 1). In 
recent years, a good correlation between PI and ICP has been found in the 
context of non-specific intracranial pathologies (Bellner, Romner et al. 2004), 
trauma (Moreno, Mesalles et al. 2000; Tan, Feng et al. 2001; Voulgaris, 
Partheni et al. 2005; Bor-Seng-Shu, Hirsch et al. 2006), cerebral mass lesions 
(including haematomas)(Cardoso and Kupchak 1992; Harada, Hayashi et al. 
1993; Czosnyka, Richards et al. 1996), hydrocephalus (Norelle, Fischer et al. 
1989; Quinn and Pople 1992; Nadvi, Du Trevou et al. 1994; Goh and Minns 
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1995; Hanlo, Gooskens et al. 1995; Iacopino, Zaccone et al. 1995; Vajda, Buki 
et al. 1999; Rainov, Weise et al. 2000) and subarachnoid haemorrhage (Soehle, 
Chatfield et al. 2007). In general, correlation is strongest when ICP is over 20, 
meaning that PI may be a poor index of ICP in the normal or only slightly 
elevated range. The correlation between ICP and PI across such a range of 
pathologies implies that the technique may be of use in noninvasively assessing 
ICP at altitude.  
 
Ter Minassian measured PI during a simulated ascent of Mount Everest 
(Operation Everest III) in 2001 (Ter Minassian, Beydon et al. 2001). Eight 
subjects were studied in a hypobaric chamber decompressed to altitudes of 
5000, 6000, 7000 and 8000m. All measurements were done on day 3 after 
“arrival” at the altitude bar those of the 8000m altitude which were done after 4 
hours. They calculated both PI and Resistivity Index (RI): RI = (systolic velocity 
– diastolic velocity)/ systolic velocity). Their demonstration of a very clear 
reduction in PI at each altitude gain seems to conflict with the proposal that PI 
should rise with ICP (if one assumes that ICP is rising). Of note however, the 
PaCO2 values also fell dramatically and this hyperventilatory response to 
hypobaric hypoxia may alter the usefulness of PI since the fall in PaCO2 causes 
cerebral vasoconstriction. Variations in PaCO2 have previously been shown to 
alter PI independently (Homburg, Jakobsen et al. 1993; Czosnyka, Richards et 
al. 1996). 
 
Palma et al. (Palma, Macedonia et al. 2006) studied 9 individuals ascending to 
4300m. They assessed PI and Dynamic Flow Index (DFI, Mean Flow Velocity / 
PI). They found that DFI was increased in subjects with AMS at 4300m when 
compared to asymptomatic subjects. Whether this relates to changes in 
cerebral haemodynamics or intracranial pressure cannot be evaluated. 
 
There is a widespread view that exercise at altitude increases the likelihood of 
an individual developing AMS and HACE. Imray et al. assessed cerebral 
perfusion during exercise in 9 individuals ascending to 5,260m (Imray, Myers et 
al. 2005). They demonstrated an increase in resting MCAv with increasing 
altitude and a further increase during exercise up to 50% of VO2Max, beyond 
which MCAv declined. Marked rises in blood pressure and an elevated MCAv 
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could stress the blood brain barrier, possibly initiating vasogenic oedema. 
Subudi et al. have similar results and both groups suggest that cerebral blood 
flow and hypoxia may limit exercise performance (Subudhi, Lorenz et al. 2008). 
 
1.4.4 Animal Studies of Relevance 
 
Krasney and co-workers designed the first conscious animal model of HACE in 
1990 (Krasney, Curran-Everett et al. 1990; Curran-Everett, Iwamoto et al. 1991). 
In addition to measuring ICP invasively in the lateral ventricle of sheep (n=20), 
they also calculated cerebral oxygen extraction and investigated changes in 
wet-to-dry brain weight (n=9) with 72 hours of normobaric hypoxia (arterial 
oxygen tension of 40mmHg giving an arterial oxygen saturation of 50%). Whilst 
ICP did not change with the 72 hours of hypoxia, wet-dry brain weight ratios 
increased in all regions, but especially in the white matter, caudate nuclei and 
thalamus. The authors hypothesised that the lack of a rise in ICP with the 
increase in brain volume was due to reciprocal loss of volume from the 
ventricles. They noted that, in normoxia, it is possible to withdraw 3-4 mls of 
CSF from the ventricular catheter with ease. However, after 7 hours of hypoxia, 
it was often impossible to withdraw more than 0.5-1.0mls. In addition, this study 
demonstrated that cerebral blood flow per unit cerebral O2 consumption 
doubled and the cerebral O2 extraction fraction decreased in seven of nine 
sheep. 
 
Yang et al. (Yang, Sun et al. 1993) studied ICP in goats exposed to a PaO2 of 
40Torr (=40mmHg, equivalent to an altitude of 4000m). Although there were 
methodological issues, ICP and cerebral blood flow increased, and intracranial 
compliance decreased with 2 hours of hypoxia. Exposed to the same PaO2, ICP 
rose (and cerebral oedema occurred) in sheep which exhibited AMS behaviour 
(off food/water), but not in those behaving normally (Yang, Bergo et al. 1994). In 
New Zealand white rabbits, ICP did not rise with exposure to simulated 
hypobaric hypoxia of 5000m for 6 hours, whether or not steroids were 
administered (Pendon and King 2003). Meanwhile, bar-headed geese (Anser 
indicus) make an annual migration across the Himalayas flying between 5000 
and 9000m. The partial pressure of oxygen at 9000m is 30% of that at sea level 
hence it is amazing they can undertake the energy expensive process of 
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flapping flight. They have a number of adaptations to achieve this (Butler 2010). 
Firstly their haemoglobin has a higher affinity for oxygen than lowland birds. 
They are also able to hyperventilate to a greater extent. Most importantly, they 
do not suffer a reduction in cerebral blood flow as a result of the low partial 
pressures of CO2 that accompany their hyperventilation (Casey, Imray et al. 
2011).  Thus, an ability to continue to deliver oxygen to the brain without 
hyperventilation-induced vasoconstriction may well be a very advantageous 
adaptation.  
 
It must be remembered that cerebral anatomy of other mammals and birds is 
very different to that of humans. The postural differences also dramatically 
influence cerebral fluid pressures, the above studies must all be interpreted  
with extreme caution.  
 
1.4.5 Brain Imaging Investigations 
1.4.5.1 Imaging Changes with AMS 
 
CT scans performed on climbers with HAPE and neurological dysfunction have 
demonstrated the presence of small ventricles and cisterns, and the 
disappearance of cerebral sulci (Koyama, Kobayashi et al. 1988). Magnetic 
Resonance Imaging (MRI) allows improved assessment of oedema and, while 
not measuring ICP, can infer changes in ICP from changes in brain volume (e.g. 
loss of ventricular space, sulci effacement). It has been used in a number of 
studies where subjects have developed AMS, and there are clinical reports of 
MRIs of patients who have suffered with HACE. Overall, the results raise the 
question as to whether oedema has a significant role in AMS. 
 
Cytotoxic (intracellular) (Houston and Dickinson 1975) and vasogenic 
(extracellular water accumulation due to increased blood brain barrier 
permeability) (Hackett, Yarnell et al. 1998) oedema have both been postulated 
to be core mechanisms in HACE pathogenesis. A particularly useful MRI 
technique, diffusion weighting, differentiates between these two forms of 
oedema.  
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Amongst 9 subjects exposed to a simulated sudden ascent to 4572m, a 2.77% 
(36.2ml) increase in brain matter volume was found at 32 hours (Morocz, 
Zientara et al. 2001). These volume changes only occurred in grey (not white) 
matter, regardless of whether AMS symptoms were present or not. Meanwhile, 
in 10 subjects who had MRIs after 10 hours of exposure to a simulated altitude 
of 4500m (eight of whom suffered AMS), none had cerebral oedema (Fischer, 
Vollmar et al. 2004). They demonstrated that ventricular CSF volume 
decreased in all subjects, more so in those with severe AMS. This again implies 
that that the brain parenchyma or other intracerebral components expand in 
hypoxia. Meanwhile, in 22 subjects (half of whom suffered AMS, of which seven 
received metoclopramide and paracetamol), cerebral swelling of the order of 7 
+/-4.8ml (approximately 0.5% of total brain volume) was observed after 16 
hours of exposure to 12% O2 (equivalent to 4500m) (Kallenberg, Bailey et al. 
2007). In addition they studied T2 Relaxation Time (T2rT – a technique that 
reflects changes in parenchymal water content) and the Apparent Diffusion 
Coefficient (ADC – which reflects changes in the diffusibility of water molecules). 
ADC helps differentiate vasogenic oedema (as water moves intracellularly its 
diffusibility, and hence ADC, falls) from cytotoxic oedema (as water moves 
extracellularly its diffusibility and ADC increases). Specific regions of interest 
within the brain (white matter, basal ganglia, genu and splenium of corpus 
callosum and cerebellar white matter) were studied. Hypoxia resulted in a 
general increase in T2rT representing an increase in parenchymal oedema. 
ADC values were consistently lower in those who developed AMS symptoms. 
This suggested that hypoxia causes a generalised vasogenic oedema, but that 
with AMS may be associated with an additional cytotoxic (intracellular) 
component. This may occur through a reduction in the Na+/K+ ATPase pump 
(see below). This study also demonstrated that those developing AMS had a 
greater brain:intracranial volume ratio, supporting the “tight fit” hypothesis. 
 
Schoonman et al. (Schoonman, Sandor et al. 2008) studied 9 students exposed 
to isobaric hypoxia (N2 enriched air) to obtain arterial oxygen saturations of 75-
80% for 6 hours. Seven of the 9 developed AMS. Visual inspection of the MRIs 
failed to show any oedema. However, there was a general increase in ADC with 
hypoxia while ADC values negatively correlated with severity of cerebral 
symptoms. Hence, similarly to Kallenberg, the authors concluded that 
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vasogenic oedema occurs in isobaric hypoxia irrespective of AMS, while severe 
AMS is associated with an additional mild cytotoxic component. Fischer et al. 
demonstrated that, whilst exposure to a simulated altitude of 4500m did not 
induce demonstrable oedema, a mean 10% reduction in intracranial CSF 
volume occurred at 10-12 hours of exposure. This may well reflect cerebral 
swelling caused by increased cerebral blood flow even if oedema does not form 
(Fischer, Vollmar et al. 2004). 
 
Although studies using ADC thus suggest the development of vasogenic 
oedema in response to hypoxia, and possibly of cytotoxic oedema in those 
developing severe AMS, a more recent hypoxic MRI study (Dubowitz, Dyer et al. 
2009) demonstrates that hypoxia causes brain swelling without oedema 
formation. This study of 12 subjects found cerebral swelling and compression of 
ventricular CSF spaces after only 40 minutes of hypoxia.  
 
Matsuzama et al. (Matsuzawa 1992) reported slightly increased T2 signal 
intensity in 4 of 7 subjects with AMS in a 24 hour simulated altitude experiment. 
 
In summary, MRI studies of simulated ascents to “very high altitude” in 
hypobaric chambers demonstrate that acute hypoxia causes brain parenchymal 
enlargement. This may be a combination of vasogenic oedema with hypoxia 
and cytotoxic oedema when in the context of AMS, but this is by no means 
conclusive and another “volume” could be contributing to this apparent 
parenchymal enlargement.  
1.4.5.2 Imaging and Autopsy Changes with HACE 
 
Autopsy evidence from climbers and soldiers dying of HACE has confirmed the 
presence of gross cerebral oedema (Singh, Khanna et al. 1969; Dickinson, 
Heath et al. 1983). Animal experiments of severe hypoxia show similar oedema 
(Krasney 1994) as do imaging studies of patients with hypoxic/anoxic injury 
secondary to cardiac arrest, cyanide or carbon monoxide poisoning (Varnell, 
Stimac et al. 1987; James 1988; Kasamo, Okuhata et al. 1993; Mills, 
Gunasekar et al. 1999).   
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Hackett et al. (Hackett, Yarnell et al. 1998) reported a series of 9 subjects who 
had brain MRIs  from 16 to 132 hours after the onset of HACE. Eight of these 
subjects had severe concomitant HAPE. Seven of the 9 had increased T2 
signal intensity especially in the corpus callosum and centrum semiovale with 
no grey matter abnormalities. White matter is thought to be more prone to 
vasogenic oedema because of its orderly structure. They concluded that HACE 
is characterised by reversible white matter oedema suggestive of a vasogenic 
mechanism. Interestingly, the images from this paper (see figure 1-5) 
demonstrate that these subjects had large sulci and hence would not be 
expected to suffer with AMS if a purely tight fit hypothesis was true.  Further, a 
number of studies have shown that the 
corpus callosum develops restricted 
diffusion on MRI following death in 
hypoxic neonates (Takenouchi, Heier 
et al. 2010) and following cardiac 
arrest in adults (Bianchi and Sims 
2008).  
 
Figure 1-5 MRI of HACE patient after 
descending showing oedema in the corpus 
callosum. The large sulci argue against the 
“tight fit” hypothesis being integral to 
HACE. (From Hackett et al. 1998 (Hackett, 
Yarnell et al. 1998)).  
 
If HACE was simply a continuation of AMS, then one might expect to find some 
mild white matter changes (increased T2 signal intensity in the corpus callosum) 
in subjects with AMS during chamber studies of hypobaric hypoxia. This has not 
been the case (Morocz, Zientara et al. 2001). Hence, these changes appear to 
be specific to HACE, not altitude exposure or AMS.  
 
In addition to white matter oedema, autopsies of victims of HACE have 
commonly demonstrated ring haemorrhages (figure 1-6).  
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Figure 1-6 Ring haemorrhages 
seen at autopsy in HACE 
sufferers (Clarke 2006) 
 
Using MRI, Kallenberg et al. 
have demonstrated that 
these ring 
microhaemorrhages (as 
evidenced by multiple 
haemosiderin deposits) 
occur in those with nonfatal HACE but not AMS (Kallenberg, Dehnert et al. 
2008). These are found predominantly in the corpus callosum and persist at 
least many months after the episode of HACE (figure 1-7). 
 
Figure 1-7 Microhaemorrhages on T2* 
weighted sequence MRI (Kallenberg, Dehnert 
et al. 2008).  
 
The reason for the predilection for the 
corpus callosum is unknown, although it is 
supplied by small, short perforating 
arteries lacking adrenergic tone, which 
might thus be more susceptible to hypoxic 
vasodilatation, autoregulatory failure and 
hence over perfusion (Hackett 1999).  
 
Microhaemorrhages are, however, a 
hallmark of venous outflow obstruction (Tsai, Wang et al. 1995; Kim 2004) 
which is thus implicated in HACE pathogenesis on this basis.  Of note, the 
superficial veins lie in the (pain sensitive) subarachnoid space (Kilic and Akakin 
2008) and hence distension due to distal obstruction could prove to be a 
mechanism for headache even in AMS. Exploring this hypothesis is a main 
focus  of this thesis. 
 
Retinal venous dilatation is almost universal on rapid ascent to altitude and 
retinal haemorrhages are common even in those without AMS (figure 1-8). 
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Approximately 59% of those with HACE and a third of AMS sufferers develop 
them (Hackett and Roach 2004). This adds further weight to a venous 
hypertensive mechanism. Interestingly, the haemorrhages occur in the 
superficial and occasionally deep intraretinal layers of the retina in the same 
manner as haemorrhages from central retinal vein occlusion (a more complete 
and acute venous obstruction). 
Figure 1-8 Retinal 
haemorrhages resulting 
from a) ascent to altitude 
and b) central retinal vein 
occlusion 
 
 
 
 
 
 
 
1.4.6 AMS and HACE at a Vessel Level 
 
The ICP, cerebrovascular and MRI studies described above have given us a 
greater understanding of gross changes resulting from exposure to hypobaric 
hypoxia, but there are still many questions as to the mechanisms of these 
changes on a vascular and cellular level. 
 
1.4.7 Factors Affecting Vessel Tone 
 
Oxygen and Carbon Dioxide 
The relative importance of oxygen and carbon dioxide in regulating cerebral 
blood flow with exposure to altitude has been debated since the time of Bert 
(Bert 1878) and Mosso (Mosso 1898) over 100 years ago. Hypoxia is thought to 
cause vasodilatation and an increase in CBF (Jensen, Sperling et al. 1996). 
However, this is countered by a falling PaCO2 (due to the hypoxic ventilatory 
response) causing vasoconstriction (Brugniaux, Hodges et al. 2007). The CBF 
response to isocapnic hypoxia is therefore greater than the response to 
poikilocapnic hypoxia (Ainslie and Poulin 2004). If an individual can accept 
hypoxaemia without mounting a significant hypoxic ventilatory response, they 
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will remain hypoxaemic and normocapnic. If, however, an individual develops a 
significant hypoxic ventilatory response they will maintain (or even increase) 
oxygenation, but also develop hypocarbia (although paradoxical behaviour is 
occasionally seen (Zubieta-Calleja, Zubieta-Castillo et al. 1994)). Supporting 
oxygenation may well confer advantage at altitude. Whilst the acute addition of 
3-5% CO2 to inspired air induces a feeling of wellbeing during high altitude 
exposure (Harvey, Raichle et al. 1988) and improves brain oxygenation (Imray, 
Clarke et al. 2001; Imray, Walsh et al. 2003), possibly through a hypercarbic 
ventilatory drive mechanism, chronic exposure to raised CO2 may worsen 
symptoms (Maher, Cymerman et al. 1975). The exact mechanism by which CO2 
causes vasodilatation is not known. However, it may be that the altered pH 
activates potassium channels in the vascular smooth muscle wall (Nelson and 
Quayle 1995). Whatever the mechanism, it is faster than previously thought, 
with vessel diameter changes occurring within 6 seconds of altered pH / pCO2 
(Poulin, Liang et al. 1998). 
 
The hyperventilatory-induced hypocapnia of acute hypoxia results in respiratory 
alkalosis. Over a few days of acclimatisation the pH and PaCO2 relationship in 
central brainstem chemoreceptors is reset through an exchange of extracellular 
and cerebrospinal fluid bicarbonate.  
 
Autoregulation and Sympathetic Nervous System: 
Cerebral autoregulation refers to the changing of vessel calibre to ensure that 
CBF is matched to metabolic needs. Cerebral autoregulation can be divided 
into static (keeping CBF constant over gradual, progressive changes in cerebral 
perfusion) and dynamic (the rapid regulation in response to changes in arterial 
blood pressures that occur over seconds) (Zhang, Zuckerman et al. 2002). The 
sympathetic nervous system, which densely innervates the cerebral circulation, 
also appears to influence CBF though both systemic (e.g. cardiac output) and 
local actions.  
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Adenosine 
Brain adenosine levels increase rapidly within 30 seconds to 5 minutes of 
exposure to exposure, and mirror the increase in CBF (Winn, Rubio et al. 1981). 
This mechanism is thought to be involved in the very fast arteriole distension of 
hypoxic vasodilatation and it is thought that the adenosine expression must be 
close to arteriolar smooth muscle, e.g. from glial end feet. 
 
Potassium (K+) 
The hypoxia-induced local rise in K+ is also thought to be involved in 
vasodilatation. Endothelial K+ channel activation results in increased 
concentration of intracellular calcium which in turn results in release of Nitric 
Oxide (Faraci and Heistad 1998). 
 
Nitric Oxide (NO) 
Nitric Oxide Synthase III (endothelial Nitric Oxide Synthase – eNOS) produces 
NO or Endothelial Derived Relaxing Factor (Sanders, Kelley et al. 2000). NO 
has a short half-life and rapidly diffuses to vascular smooth muscle where it 
interacts with Ca2+ modulation mediated by cGMP. This results in vasodilatation. 
Inappropriate NO release with hypoxia has been implicated in altitude 
maladaptation syndromes. Appenzeller et al. (Appenzeller, Claydon et al. 2006) 
used TCD changes in response to an exogenous NO donor in 9 altitude–native 
Ethiopians and 9 altitude-native Peruvians (who as a race suffer considerably 
more with the maladaptation syndrome, chronic mountain sickness) to assess 
how adapted to altitude each race is. The circulatory response to NO was 
minimal in Ethiopians at low altitude, while Peruvians had a large response. In 
contrast, at high altitude, Ethiopians had a large response, whilst that in 
Peruvians was minimal. They concluded that Peruvians were well-adapted 
lowlanders while Ethiopians were highlanders adapted to that life.  
 
1.4.8 Underlying Mechanisms of Brain Oedema 
 
The use of steroids in the prevention and treatment of AMS and HACE perhaps 
offers indirect evidence that oedema is a component of their pathogenesis 
(Klatzo 1967; Fishman 1975). Multiple factors influence cerebrovascular tone, 
flow and permeability. Figure 1-9 provides an overview. 
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Figure 1-9 Mechanisms thought to underlie AMS and HACE demonstrated through a 
schematic vessel progressing from artery to vein form left to right. Mechanical factors 
(blue) increase intravascular pressure and hence can cause vasogenic oedema and 
vessel wall damage. These pressures can be arterial (increased hydrostatic pressure - 
associated with increased flow) or venous (if there is an element of venous outflow 
obstruction). The partial pressures of oxygen and carbon dioxide (orange) are thought to 
have direct vasoactive properties with hypoxaemia causing vasodilatation and 
hypocarbia causing vasoconstriction. A balance between these is found by the hypoxic 
ventilator response. Cytotoxic oedema may result from direct hypoxia induced Na+/K+ 
ATPase failure. Many chemical mediators have been implicated. Free radical formation 
could directly damage vessel basement membranes causing vasogenic oedema. Hypoxia 
Inducible Factor 1α accumulation and subsequent Vascular Endothelial Growth Factor 
upregulation could contribute to further basement membrane damage and oedema 
formation. Local hyperkalaemia could trigger calcium mediated nitric oxide release that 
in turn can act on vessel smooth muscle to cause vasodilatation. Neuronally mediated 
adenosine release could also cause vasodilatation. Vessel dilatation has been implicated 
in mediating pain via the trigeminovascular system and hence headache. The key 
element of HACE is microhaemorrhage formation that may relate to vessel damage from 
chemical mediators/cytokines or damage through increased hydrostatic pressure. 
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1.4.9 Factors Affecting Vessel Permeability 
 
Hydrostatic Pressure 
 A number of studies have demonstrated increased CBF at altitude 
(Severinghaus, Chiodi et al. 1966; Jensen, Wright et al. 1990; Jansen, Krins et 
al. 1999). This is thought to result in an increase in hydrostatic pressure. Such 
increases occur in other clinical conditions such as hypertensive 
encephalopathy and toxaemia of pregnancy. These conditions also cause a 
reversible increase in white matter T2 signal (Na, Hong et al. 2004). Impaired 
autoregulation may also result in greater hydrostatic pressure.  
 
Venous Hypertension  
Idiopathic (or Benign) Intracranial Hypertension (also known as pseudotumor 
cerebri) has recently been demonstrated to be closely related to sinovenous 
outflow obstruction (Farb, Vanek et al. 2003; Owler, Parker et al. 2005). This 
obstruction would directly increase hydrostatic pressures. Such anatomical 
variations that cause this clinically may only become apparent under the 
stressor of hypoxia and hence account in part for the predisposition some have 
for AMS/HACE. HAPE itself may increase central venous and hence jugular 
venous pressures which in turn could contribute to HACE if an underlying 
venous hydrostatic mechanism is true. The presence of retinal and cerebral 
haemorrhages also suggests this as a mechanism. 
 
Direct Effects of Hypoxia: 
Hypoxia itself can damage basal membrane structures (Miserocchi, Passi et al. 
2001). Houston proposed that hypoxia suppresses the sodium-potassium pump 
in cell membranes leading to cell swelling (Houston 1989). This was felt to be of 
relevance to acute but not gradual hypoxia. However, this theory has been 
rekindled by Kallenberg’s finding of cytotoxic oedema. A reduction in cellular 
PO2 decreases the expression and activity of the Na+/K+ ATPase in various cell 
types such as alveolar epithelial cells, endothelial cells and neuronal cells. This 
may represent a mechanism that cells (including possibly neurons) use to 
reduce energy expenditure in hypoxia. 
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Chemical Mediators of Permeability  
Hypoxia Inducible Factor (HIF) 
HIF-1 is a heterodimeric factor composed of HIF-1α and HIF-1β protein 
subunits. HIF-1α is constantly being made in large quantities in most cell types 
and, in normoxia, it is just as rapidly destroyed by HIF prolyl-hydroxylase. In 
hypoxia, HIF prolyl-hydroxylase is inhibited and HIF-1α therefore accumulates, 
is transported into the nucleus, binds to HIF1beta, and (as a heterodeimer) 
binds to promoter/enhancer elements causing increased transcription of classic 
hypoxia-inducible target genes. Such genes are involved in mediating a wide 
variety of responses, amongst them angiogenesis (Vascular Endothelial Growth 
Factor, VEGF (Yamakawa, Liu et al. 2003)) and erythropoesis (erythropoietin 
(Sanchez-Elsner, Ramirez et al. 2004)). Atrial naturetic peptide and nitric oxide 
synthase are also induced (Brzecka 2005).  
 
Vascular Endothelial Growth Factor (VEGF): 
Severinghaus first proposed an increase in VEGF expression as an explanation 
for increased vascular permeability in hypoxia (Severinghaus 1995). Hypoxia 
induces VEGF expression, whilst VEGF-specific antibodies prevent cerebral 
vascular leakage. Dexamethasone appears to block VEGF expression and 
hence reverse hypoxia-induced brain oedema (Schoch, Fischer et al. 2002). 
Early studies had shown no correlation between VEGF levels and AMS 
(Dorward, Thompson et al. 2007). Recently, however, the soluble VEGF 
receptor (sFlt-1) which can bind VEGF in the circulation and was not accounted 
for in earlier work, has been studied (Tissot van Patot, Leadbetter et al. 2005). 
In this study of 20 subjects who were driven to 4,300m to have blood samples 
taken, subjects who developed AMS had lower sFlt-1 and hence significantly 
higher levels of free plasma VEGF on ascent than well subjects.  
  
Free Radicals 
The study of free radicals is difficult due to their very short half-life. A number of 
studies however imply that neuroxidation and the subsequent inflammatory 
response may damage cerebrovascular endothelium (Bailey and Davies 2001; 
Bailey 2003; Bailey 2004; Bailey, Kleger et al. 2004; Bailey, Roukens et al. 
2006) (Chan, Schmidley et al. 1984).  In a recent study, Bailey et al. found that 
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there was a progressive increase in blood and CSF concentrations of free 
radicals (lipid derived alkoxyl and alkyl species) and IL-6 during a 16 to 18 hour 
simulated exposure to 4600m (12% O2) (Bailey, Roukens et al. 2006). Although 
this induced a mild (0.6% or 7ml) increase in brain volume, no underlying 
morphological changes (e.g. oedema) were seen on MRI. No correlation 
between free radical formation and AMS was observed. 
 
1.5 Genetic Predisposition to AMS  
 
The study of genetophysiology, in particular the genetics behind hypoxic 
adaptation, is one of the most rapidly developing areas in high altitude research 
(Grocott and Montgomery 2008). Because of the polygenic nature of the human 
response to hypobaric hypoxia, it is likely that several genetic loci, each with a 
small but significant contribution, determine phenotypic outcome (Stobdan, 
Karar et al. 2008). Studies can be divided into those that investigate a 
population’s adaptation to high altitude and those that correlate performance at 
altitude with polymorphic variations. 
 
Erythropoietin (EPO): The rise in serum EPO concentrations with hypoxia was 
the first example of hypoxia induced increase in gene expression to be 
identified. A dinucleotide marker DS7S477 is associated with variation in this 
response (Stobdan, Karar et al. 2008). EPO and the subsequent rise in 
haemoglobin are fundamental to acclimatisation and maintaining brain 
oxygenation. 
 
Hypoxia-inducible Factor 1 (HIF1): Polymorphic differences in HIF1α have been 
found between Sherpas and Japanese subjects (Suzuki, Kizaki et al. 2003). 
Variations have also been associated with differences in maximal exertional 
oxygen consumption (VO2max)(Prior, Hagberg et al. 2003). 
 
Angiotensin-1 converting enzyme (ACE): ACE is a key enzymatic regulator of 
circulatory homeostasis, being responsible for the synthesis of angiotensin II, a 
vasoconstrictor that also provokes aldosterone release and thus sodium and 
water retention. It also degrades vasodilator kinins. The absence (deletion, D 
allele) of a 287 base pair fragment is associated with higher ACE tissue activity 
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than its presence (Insertion, I allele) and hence may enhance vasoconstriction 
and fluid retention through increased levels of angiotensin II and aldosterone. 
An excess in prevalence of the I allele has been identified amongst elite 
mountaineers and Sherpas (Woods and Montgomery 2001; Woods, Pollard et 
al. 2002; Droma, Hanaoka et al. 2008). Such associations do not seem 
mediated through differences in AMS susceptibility: Koehle et al. found no 
association between ACE and Angiotensin II Receptor 1 gene polymorphisms 
and AMS in Nepalese Pilgrims ascending to 4380m (Koehle, Wang et al. 2006; 
Rupert and Koehle 2006). Similarly, in mountaineers ascending to 4559m, 
those of DD genotype did not appear to suffer more AMS (Dehnert, Weymann 
et al. 2002). Instead, such associations may be driven by differences in tissue 
ACE expression, regulating hypoxic ventilatory drive (Patel, Woods et al. 2003) 
and metabolic efficiency (Williams, Rayson et al. 2000).  
 
Aldosterone synthase: Elevated aldosterone levels have been associated with 
AMS (617±116 with vs 233±42 pmol/l without AMS) (Bartsch, Maggiorini et al. 
1991) and wild type polymorphisms of CYP11B2 which confer lower 
aldosterone levels are considerably more common in Himalayan highlanders 
compared to lowlanders (Rajput, Arif et al. 2006).  
 
Nitric Oxide Synthase 3 (NOS3): Higher levels of exhaled NO in Tibetans and 
Bolivian Aymara (Beall, Laskowski et al. 2001; Erzurum, Ghosh et al. 2007), 
and the success of inhaled NO in treating HAPE suggested NOS3 as a 
candidate gene. Polymorphic variations can render NOS3 more susceptible to 
intracellular proteases, reducing NO production and thereby impairing 
vasodilatation. An overrepresentation of Glu and 4b alleles in intron 4 of NOS3 
(G894T) in Sherpas and Ladakhi suggest it may have a role in evolutionary 
adaptation to high altitude (Stobdan, Karar et al. 2008).  
 
Polymorphisms of endothelin 1 (involved in pulmonary hypertension in hypoxia), 
β2-adrenergic receptor (which activates the Na+/K+ ATPase pump), fibrinogen 
(altering pro-coagulable properties), phosphodiesterase type 5A (involved in 
cGMP breakdown which in turn effects vascular smooth muscle tone) and of  
genes that may increase susceptibility to AMS/HACE are also being 
investigated (Stobdan, Karar et al. 2008). The results of these studies may 
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enable us to better understand the genetics of brain injury (Wilson and 
Montgomery 2007). 
 
Zhou et al investigated alterations in gene expression in rat brain with chronic 
constant and chronic intermittent hypoxia (Zhou, Saidel et al. 2008). They found 
that in rat cortex, the expression of 80 genes was altered by chronic intermittent 
hypoxia (16 up- and 64 down-regulated) and constant hypoxia increased this to 
137 genes (34 up- and 103 down-regulated). Expression of a similar number of 
genes was altered in the hippocampal region, although these were mostly 
upregulated. There are clearly many more genes to investigate. 
 
1.6 Neuropsychological Effects of Hypobaric Hypoxia 
 
A number of studies have shown impairment of arithmetic ability (Wu, Li et al. 
1998), memory and metamemory (Du, Li et al. 1999; Pelamatti, Pascotto et al. 
2003), language, perception, learning, cognitive flexibility and psychomotor 
skills (Bouquet, Gardette et al. 1999; Virues-Ortega, Buela-Casal et al. 2004) 
with ascent to altitude. Increases in reaction time (Kramer, Coyne et al. 1993; 
Bolmont, Bouquet et al. 2001) and auditory evoked potential P300 latency 
(Wesensten, Crowley et al. 1993), and a slowing of pupil constriction (Wilson 
2008) have also been observed, and indicate a fundamental slowing of 
neuronal processing. As with other symptoms, the neuropsychological changes 
relate to the rate of ascent and the altitude (Virues-Ortega, Buela-Casal et al. 
2004). As a result there are large differences between studies where different 
ascent protocols have been applied. In addition neuropsychological 
performance is susceptible to the influence of fatigue and also anxiety (Bolmont, 
Thullier et al. 2000). Sleep disturbance, either through periodic breathing and 
waking between periods of apnoea (Reite, Jackson et al. 1975) or secondary to 
disturbance by tent companions, is common and may contribute to daytime 
neuropsychological impairment.  
 
It is also important to distinguish between neuropsychological changes due to 
hypobaric hypoxia and changes due to AMS. The literature suggests that AMS 
has little effect on short-term memory, but is associated with significant 
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impairment in performance of conceptual tasks. Without AMS, conceptual tasks 
are scarcely effected (Forster 1985; Kramer, Coyne et al. 1993). 
 
Perception: Whilst no threshold change has been found for auditory stimuli, 
there is a rise in threshold for detecting visual stimuli when dark adapted 
(Kobrick and Appleton 1971). There are mixed results regarding changes in 
colour perception, but any change, if present, is of minimal significance (Virues-
Ortega, Buela-Casal et al. 2004).  
 
Memory: Short-term memory has been shown to decline at 4500m, an effect 
especially noticeable above 6000m, while long-term memory appears to be 
preserved (Berry, McConnell et al. 1989; Virues-Ortega, Buela-Casal et al. 
2004). Both animal (Nelson, Dunlosky et al. 1990) and human (Kramer, Coyne 
et al. 1993) studies have compared controlled and automatic processing tasks 
and the results imply that moderately rapid exposure to hypobaric hypoxia 
causes a reduced capacity to learn rather than to retrieve. Spatial memory has 
been found to become impaired between 3800 and 5000m (Nelson 1982).  
 
Cognitive flexibility has been assessed using Stroop Color and Word test or 
Wisconsin Card Sorting Test™. It has been shown to be significantly impaired 
in world class mountain climbers even months after their last ascent (Regard, 
Oelz et al. 1989).  
 
Motor Skills: Motor speed and precision are reduced compared to sea level 
(Berry, McConnell et al. 1989; Hornbein, Townes et al. 1989). The finger taping 
test (FTT) and Purdue pegboard tests have been used to assess psychomotor 
changes but confounding variables in the field include fatigue and the cold. This 
may explain the wide variation in altitudes between different studies where 
dysfunction is detected (Berry et al. at 3500m (Berry, McConnell et al. 1989), 
Bolmont et al. at 8000m (Bolmont, Thullier et al. 2000)). The American Medical 
Research Everest Expedition (AMREE-1981) demonstrated that 15 of the 16 
climbers had impaired FTT immediately after the expedition and 13 still had 
impairment a year on (West 1984) implying that some damage may be long 
term. 
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Alterations in balance have been quantitatively examined using a wobble board 
(Johnson, Simmons et al. 2005). A positive test (done on arrival at altitude) 
gave a predictive value for AMS of 66.7% at 4650m and 100% at 5005m. Brain 
oxygenation was also found to correlate with stability on the wobble board 
(while peripheral saturations did not).  
 
Psychological changes: New onset anxiety disorders are relatively common in 
trekkers to altitude (Fagenholz, Murray et al. 2007). These are often focused on 
health concerns. A heightened state of anxiety has been shown to offset some 
of the reduction in reaction time and psychomotor ability (Bolmont, Thullier et al. 
2000). 
 
Auditory and visual hallucinations (e.g. a “third man”) are common in climbers at 
very high altitude (Garrido, Javierre et al. 2000). It has been suggested that 
altitude-related hypoxia may account for the fundamental revelations 
contributing to the three monotheistic religions (Arzy, Idel et al. 2005) although 
Mount Hermon (2,814m) and Mount Sinai (2,285m) are not  high and a better 
argument could probably be made for Buddhism or Hinduism. 
 
Evidence of long-term brain injury: Anooshiravani et al. did not detect any 
functional or structural alterations (using MRI) in a group of 8 climbers who had 
climbed a 6000m peak (Anooshiravani, Dumont et al. 1999). However, Paola et 
al. have demonstrated that ascents to extreme altitude are associated with 
reduced white matter density and volume in areas related to the left motor 
cortex (Paola, Bozzali et al. 2008). Garrido et al. have performed studies 
demonstrating increased signal intensity in periventricular, posterior parietal, 
and occipital cortex in five of nine climbers who had ascended over 7000m 
(Garrido, Segura et al. 1995). Vichow-Robin spaces (CSF spaces around 
vessels) tend to be enlarged in regular climbers suggesting that chronic hypoxia 
induced brain atrophy (Garrido, Castello et al. 1993).  
 
1.7 Conclusions 
 
The brain is the most oxygen dependent organ in the body and many 
pathophysiological processes either cause and result from an interruption to its 
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oxygen supply. Insights into the causes and consequences of cerebral cellular 
hypoxia will help with the management of many acute neurological conditions. 
The last 25 years has seen a number of advances of our understanding of the 
neuropathophysiology induced by hypobaric hypoxia. It is also evident that the 
original “Tight Fit” hypothesis is oversimplified. Evidence is accumulating that 
while HACE may represent a continuation of AMS, there are key pathological 
differences (such as the formation of microhaemorrhages).  It may well be that 
the “oedema” component of its name is distracting from the underlying 
pathological mechanism.  
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1.8 Core Hypotheses Investigated in This Thesis 
 
This thesis sets out to investigate in greater depth some core cerebral 
physiological changes that occur in response to hypoxia. Specifically, these 
relate to cerebral blood flow into and out from the cranium, and to associated 
differences in brain oxygenation. The null hypotheses are: 
 
1) Cerebral arteries do not vasodilate or constrict with hypobaric 
hypoxia 
TCD has been used in many high altitude studies. The velocity of blood 
is invariably interpreted as “flow” and, as explained in the introduction, all 
previous high altitude TCD studies have assumed that vessel calibre 
remains constant. On the other hand, the common teaching is that 
hypoxia causes vasodilatation and hypocarbia vasoconstriction at a 
microcirculatory level. I aimed to explore whether Middle Cerebral Artery 
calibre changes with hypoxia.  
2) Brain oxygenation changes reflect peripheral oxygenation 
saturation changes 
High Altitude Headache does not appear to simply reflect a fall in brain 
oxygenation, given that no correlation between brain oxygenation and 
headache has previously been reported. By assessing brain oxygenation 
in a large cohort of subjects, a correlation between rSO2 changes (both 
at rest and during exercise) and headache score was sought.  
3) The venous system adequately drains the increased cerebral blood 
flow of hypoxia 
As explained above, the venous system appears to be involved in the 
formation of microhaemorrhages both in the retina and brain in hypoxia. 
A core hypothesis is that venous distension secondary to an inability to 
adequately drain the increased cerebral blood flow with hypoxia causes 
high altitude headache. Figure 1-10 demonstrates this “modified tight-fit” 
hypothesis in graphical format. 
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Figure 1-10 Schematic diagram of the modified “Tight Fit” hypothesis with venous 
hypertension/outflow obstruction. ICP will rise if contents increase with a concurrent 
failure to buffer. Factors that could therefore alter ICP and hence predispose to AMS 
include: 
An increase in volume of: 
Blood (arterial and capillary) from increased flow 
Oedema – both vasogenic and cytotoxic from hypoxia 
A failure in the buffer systems of: 
CSF – less CSF buffer resulting in earlier ICP rise (“Tight Fit”) 
Venous outflow – for example with a predisposition to obstruction (as in Benign 
Intracranial Hypertension or Sagittal/Transverse Sinus Thrombosis) 
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2 Chapter 2:  METHODOLOGY 
 
See “Design and conduct of Caudwell Xtreme Everest: an observational cohort 
study of variation in human adaptation to progressive environmental hypoxia” 
BMC Medical Research Methodology 2010, 10:98(Levett, Martin et al. 2010) 
and 
“Caudwell Xtreme Everest Expedition” High Altitude Medicine and Biology 2010, 
11, 2(Grocott, Martin et al. 2010) in the Appendix for Papers relating to the field 
study of this work. 
 
2.1 Introduction 
 
This thesis studies the effects of hypoxia on the brain using many different 
modalities. Broadly, the research can be divided into: 
 
a) HIGH ALTIUDE HYPOBARIC HYPOXIA STUDIES – These were 
performed during an expedition to Cho Oyu (8201m), mounted to test 
equipment durability and research methodologies to be deployed on a 
subsequent high altitude observational cohort study (the “Caudwell 
Xtreme Everest Expedition”). Only data from the later expedition is 
presented in this thesis. 
b) SEA LEVEL NORMOBARIC HYPOXIA STUDIES – These comprised 
sea level Magnetic Resonance Imaging Studies prior to and following the 
field studies. 
By far the largest component of this thesis relates to data from high altitude field 
studies, and comprises a number of anatomical, physiological and functional 
studies within it. These areas will be explained individually below. Firstly, 
however, an overview of the subjects, ascent profile and general aspects of the 
main field study (the Caudwell Xtreme Everest Expedition) will be provided.  
The nature of the neuroscience studies can be grouped as demonstrated in 
table 2-1. 
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Anatomical Physiological Functional 
High Altitude Studies 
Anthropomorphic 
Ultrasound Vessel 
Analysis 
Retinal Vessel 
Analysis 
Cerebral Blood Flow 
(Transcranial 
Doppler) 
Cerebral 
Oxygenation (Near 
Infrared 
Spectroscopy) 
Pupillometry 
Neuropsychology 
Headache 
Monitoring 
Sea Level Studies 
MRI Vessels and 
Compartment 
Volumes 
Morphology Studies 
MCA flow analysis 
Venous flow 
analysis 
Headache 
Monitoring 
 
Table 2-1 The main focus of each study can be classified as anatomical, physiological or 
functional. By collecting these data on all subjects, it is possible to cross-reference and 
correlate changes, although this was not the aim of this thesis. 
 
The specific methodology of each study is outlined in the chapter relevant to it. 
Following the generic description of the high altitude and sea level studies 
below, specific information regarding the equipment and considerations to each 
sub-study is given.  
 
2.1.1 Background 
 
This work is a continuation of earlier work investigating intracranial pressure 
(ICP) in astronauts (Torikoshi, Wilson et al. 1995) and attempts, amongst other 
things, to establish whether ICP increases at high attitude in mountaineers 
(Wilson 2008; Wilson and Milledge 2008).  
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In 2003 the Centre for Aviation (now Altitude), Space and Extreme Environment 
Medicine at UCL planned an Expedition to Everest in 2007. The purpose of this 
expedition was to investigate human physiology in hypoxia (Grocott, 
Richardson et al. 2007) with the more specific aim of improving our 
understanding of human adaptation to cellular hypoxia, a fundamental 
mechanism of injury in critical illness.  
 
Prior to this expedition, I joined the Birmingham Medical Research 
Expeditionary Society (BMRES) on an expedition to Ladakh. In addition to the 
cardiovascular work this group undertook, I carried out a simple experiment 
investigating the effects of hypoxia on pupil size and reaction speed (Wilson 
2008).  
 
In the two years prior to the Everest expedition, a great deal of planning was 
carried out. This included designing the experiments, resourcing equipment, 
obtaining ethical permission and then testing the equipment and protocols. An 
expedition to Cho Oyu in 2006 did this successfully (although personally, a 
rapid ascent following caring for another climber who had suffered a stroke, 
meant that I suffered from severe mountain sickness and retinal haemorrhages 
and hence did not summit).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1 Measuring brain oxygenation (left) during recumbent exercise in Ladakh 
(BMRES 2005) and (right) on an upright bike on Cho Oyu (CASE 2006). 
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2.1.2 Clinical Link 
 
Studying brain injury in patients is difficult. Brain injury is not a single disease 
entity, but multiple (extradural, subdural, contusion, haematoma, diffuse axonal 
injury etc.) that can affect different parts of the brain (frontal cortex, motor strip, 
brain stem) in different people (young, old), hence establishing physiological 
changes with these confounding variables is extremely difficult. Cellular hypoxia 
is a common final pathway for a number of these types of injuries. Mild hypoxia 
is also a reversible and ethical brain insult, hence our use of it to greater 
understand basic human physiology. 
By studying a large group of people, and because of recent developments in 
molecular genetics, a better understanding of individual variability and the 
effects of hypoxaemia/cellular hypoxia should be achieved. These translational 
findings are now evident.  
 
2.1.3 Ethics and Consent 
 
The trekker and investigator studies were all approved through the UCL Ethics 
committee (Codes 0292/005, 0292/007, 0292/008, 0292/009, 0292/010, 
0292/011, 0292/015 0292/016, 0292/017, 0292/018, 0292/022). The later sea 
level hypoxic MRI studies were also approved by UCL (2901/001). All subjects 
received documentation and verbal explanations of the studies and were free to 
withdraw at any time. Informed consent was obtained from all subjects. 
Following each study a report has been submitted back to the UCL ethics 
committee. 
 
2.2 High Altitude Hypobaric Hypoxia Studies: 
 
 
The Caudwell Xtreme Everest (CXE) Study: 
 
This observational cohort study of progressive incremental exposure to 
hypobaric hypoxia was designed to describe the spectrum of adaptive 
responses in humans exposed to graded environmental hypobaric hypoxia and 
identify factors (physiological and genetic) associated with individual variation in 
these responses.  
Many other body systems were investigated (e.g. gastrointestinal, 
musculoskeletal, cardiovascular, respiratory), however, the methodology of this 
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thesis will describe generic methods and then only those specific to the 
neuroscience work. 
The overall study design, risk management plan and each individual protocol 
were approved by the University College London Research Ethics Committee. 
The studies were conducted between January and June 2007. Verbal and 
written informed consent was obtained from all subjects. All funding was 
unrestricted. 
 
2.2.1  Subjects, Settings and Ascent Profile 
 
Subject Selection, Health Assessment and Exclusion 
All subjects were adults (over 18 years, no upper age limit) and underwent 
health screening at two stages prior to the study. Pregnant females, subjects 
with diabetes mellitus, significant cardiac or respiratory disease, and subjects 
who would normally be excluded from cardiopulmonary exercise testing (as 
based on the American Thoracic Society and American College of Chest 
Physicians guidelines(2003)) were excluded. Mountain medicine qualified 
doctors employed by the company arranging the logistics of the trek itself 
performed the initial screening. The second stage of the screening was 
performed within CXE to confirm fitness to travel and, in addition, fitness to 
undertake the research.  
 
Two groups of healthy volunteers were studied (figure 2-2): 
1) Group 1 (trekkers) – members of the public recruited by word of mouth 
and publicity. 
2) Group 2 (investigators) – selected individuals from the investigating team 
(a group of 60 doctors, scientists, health professionals and students). 
This group was further subdivided into base-camp laboratory staff and a 
climbing team. Requirements for group 2 included previous event free 
ascent above 4000m. Requirements for the climbing team included 
previous event free ascents over 6500m, and for those summiting, an 
event free ascent over 8000m. 
A breakdown of subject variables and the numbers of subjects completing the 
trek / climb in each group is given later in this chapter. 
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Figure 2-2 Diagram demonstrating the division of the 222 subjects of the Caudwell 
Xtreme Everest (CXE) Expedition. 
 
Setting: 
2.2.2 Baseline Study 
 
Baseline measurements for all studies were performed at UCL (75m) between 
January 4th and February 26th 2007. As part of the baseline study, 
anthropomorphic measurements were made to assess all subjects’ head 
volumes.  This was not subsequently repeated during the field study. 
 
2.2.3 Field Study 
 
Field studies were completed between 31st March and 6th June 2007. All studies 
were carried out in specially built laboratories manned by the trained 
investigator teams. The laboratories were at: Kathmandu (1300m), Namche 
Bazaar (3500m), Pheriche (4250m), Everest Base Camp (5300m), Western 
Cwm (6400m), South Col (7950m) and the Balcony (8400m). Laboratory 
altitudes, barometric pressures and inspired partial pressures of oxygen are 
summarised in table 2-2. 
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LONDON 75 24.1 
(1) 
1005 754 
(10) 
100.5 
(1.3) 
148.0 19.7 
KATHMANDU 1300 26.1 
(1.5) 
867 650 (3) 86.7 
(0.4) 
126.2 16.8 
NAMCHE 3500 19.6 
(2.6) 
670 505(3) 67.3 
(0.4) 
95.4 12.7 
PHERICHE 4250 13.1 
(1.7) 
615 461 (2) 61.5 
(0.3) 
86.7 11.6 
EBC 5300 21.5 
(5.6) 
538 404 (3) 53.8 
(0.3) 
74.7 9.9 
WCWM 6400 12.7 
(3.9) 
467 350 
(0.9) 
46.7 
(0.1) 
63.4 8.5 
SOUTH COL 7950 15 
(8.9) 
389 292 
(2.3) 
38.9 
(0.3) 
51.3 6.8 
BALCONY 8400 Not 
recorded 363 272 36.3 47.1 6.3 
Table 2-2 Laboratory altitude, mean barometric pressure, mean laboratory temperature 
and inspired partial pressure of oxygen. Data are presented as mean (standard deviation).  
 
 
Ascent profile: All subjects flew from London to Kathmandu (overnight).  They 
then flew to Lukla (2800m) in the Khumbu region and trekked to Everest Base 
Camp (EBC, 5300m) (see figure 2-3).  All subjects were sequentially tested at 
laboratories in Kathmandu, Namche Bazaar, Pheriche and Everest Base Camp.  
The time course and altitude ascent profiles for Group 1 and 2 are summarised 
in figure 2-3 and 2-4. Expedition day 1 was defined as the day of departure from 
Kathmandu. The ascent rate was chosen to minimise the incidence of high 
altitude illness and hence maximise the number of subjects able to contribute 
data at the highest laboratory. As such, this is a study of hypoxia, NOT altitude 
illness specifically. 
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Figure 2-3 Ascent profile, mean barometric pressure and mean PiO2 for group 1 
(Trekkers) and group 2 (Investigators: Climbers and Base Camp team). 
 
 
Figure 2-4 Schedule of testing for group 1 (Trekkers) and group 2 (Investigators). 
Expedition day 1 was defined as the day of departure from Kathmandu. UK: United 
Kingdom; K: Kathmandu 1300 m; N: Namche 3500 m; P: Pheriche 4250 m; E: Everest 
Base Camp 5300 m. Shaded boxes: Testing days Unshaded boxes Group 1: arrival day at 
laboratory Unshaded boxes Group 2: arrival day at laboratory and/or laboratory set up 
day. 
 
Group 1 (trekkers) was divided into 13 smaller groups of a maximum of 16 
subjects.  Two groups left the UK each week for the duration of the expedition.  
All Group 1 subjects followed an identical ascent profile arriving at EBC on day 
11. All Group 2 (Investigator) subjects followed an identical ascent profile to 
EBC on day 13 which was a modified version of group 1’s ascent necessary for 
the logistical demands during the set-up phase of the laboratories (additional 
time was spent in Kathmandu and two additional days were spent at Namche 
Bazaar, 3450m).  On rest days during the ascent to EBC, excursions were 
strictly limited such that all subjects remained within 300 vertical metres of the 
laboratory altitude at all times in order to guarantee an identical pattern of 
hypoxic exposure. 
 
The laboratory staff, (n = 10), subsequently remained
at EBC for the duration of the expedition (68 days). For
these investigators, excursions were limited to within
500 vertical metres of the EBC altitude for the duration
of the expedition. The climbing team (n = 14) followed
an identical ascent profile until the completion of all
testing at Camp 2 (Western Cwm), including identical
acclimatisation outings (figure 2). The labora ory st ff
were not exposed to supplemental oxygen for the dura-
tion of the expedition. Climbers were not expo ed to
any supplemental oxygen until the completion of testing
at Camp 2. All climbers used supplemental oxygen at
flow rates of 2-4l/min for the summit climb above
Camp 3 (7100 m) and at 0.5 l/min whilst sleeping at
and above Camp 3. Testing was repeated at the end of
the expedition (immediately prior to departure) for all
group 2 subjects at EBC (days 66 to 71).
Group 1 subjects were consistently tested either on
the day after arrival at any given altitude, or on the fol-
lowing day (Day 1 subjects, or Day 2 subjects: figu e 3).
For ach s bj ct the day of testing was kept constant to
control for the effects of continued adaptation at the
laboratory ltitu e. Furthermore, subjects were tested at
the same time of day at all laboratories to control for
diurnal variations in physiological responses. At Kath-
mandu, Namche and Everest Base Camp, group 2
Figure 2 Ascent profile, mean barometric pressure and mean PiO2 for Group 1 (Trekkers), Group 2: (Investigators: Climbers and Base
Camp Team). Legend: Laboratories where testing was performed are labeled, intermediate altitudes indicate overnight stops without testing.
Figure 3 Schedule of testing for Group 1 (Trekkers) and Group 2 (Investigators). Legend: Expedition day 1 was defined as the day of
departure from Kathmandu. UK: United Kingdom; K: Kathmandu 1300 m; N: Namche 3500 m; P: Pheriche 4250 m; E: Everest Base Camp 5300 m.
Shaded boxes: Testing days Unshaded boxes Group 1: arrival day at laboratory Unshaded boxes Group 2: arrival day at laboratory and/or
laboratory set up day.
Levett et al. BMC Medical Research Methodology 2010, 10:98
http://www.biomedcentral.com/1471-2288/10/98
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500 vertical metres of the EBC altitude for the duration
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an identical ascent profile until the completion of all
testing at Camp 2 (Western Cwm), including identical
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group 2 subjects at EBC (days 66 to 71).
Group 1 subjects were consistently tested either on
the day after arrival at any given altitude, or on the fol-
lowing day (Day 1 subjects, or Day 2 subjects: figure 3).
For each subject the day of testing was kept constant to
control for the effects of continued adaptation at the
laboratory altitude. Furthermore, subjects were tested at
the same time of day at all laboratories to control for
diurnal variations in physiological responses. At Kath-
mandu, Namche and Everest Base Camp, group 2
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The ten laboratory staff subsequently remained at EBC for the duration of the 
expedition (68 days).  For these investigators, excursions were limited to within 
500 vertical metres of EBC altitude for the duration of the expedition. The 
climbing team (n=14) followed an identical ascent profile until the completion of 
all testing at Camp 2 (Western Cwm), including identical acclimatisation outings 
(figure 2-3). Subjects were not exposed to any supplemental oxygen until the 
completion of core testing at Camp 2.   
 
All summit team climbers used supplemental oxygen at flow rates of 2-4l/min for 
the summit climb and 0.5l/min while asleep above Camp 3.  Testing was 
repeated at the end of the expedition (immediately prior to departure) for all 
group 2 subjects at EBC (days 66 to 71).  
 
Subjects in group 1 (trekker) were tested on either the day after arrival at any 
given altitude, or on the following day (Day 1 subjects, or Day 2 subjects).  
Group 2 (investigator) subjects were tested on Day 1, 2 or 3 after arrival at a 
given altitude. For each subject, the timing of such studies was kept constant to 
control for the effects of continued adaptation at the laboratory altitude.  
Furthermore, subjects were tested at the same time of day at all laboratories to 
control for diurnal variations in physiological responses. 
 
To minimise the confounding effects of hypoxic adaptation prior to the study 
period, all subjects refrained from any form of hypoxic training (hypoxic tents 
etc.) and did not travel above 3000 metres for 3 months prior to departure.  
Subjects did not take prophylactic medication (e.g. acetazolamide) to prevent 
acute mountain sickness.  Any individuals diagnosed with mountain sickness 
were treated appropriately using specific guidelines and a record of all 
medication taken during the expedition was kept. 
 
Cardiopulmonary Exercise Testing (CPET): CPET was an integral part of the 
study used to investigate oxygen consumption and efficiency during aerobic, 
anaerobic and maximal exercising. As part of the CPET test, I also monitored 
brain oxygenation (see chapter 4). Any subject diagnosed by the expedition 
medical team with altitude illness was excluded from CPET. Prior to CPET, 
each subject was monitored. Specific altitude dependent symptom and 
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physiological criteria were used to trigger referral to the expedition medical 
officer for consideration of exclusion from CPET testing at that laboratory (table 
2-3). 
 
Exclusion criteria for testing at field laboratories 
• Resting blood pressure >200 mmHg Systolic, and or >110 mmHg Diastolic  
• Acute systemic infection (discuss with medical officer)  
• AMS requiring treatment with acetazolamide, dexamethasone or nifedipine  
• Acute chest pain 
• New arrhythmias or ECG changes  
• Resting arterial Oxygen saturations <90% at sea level; <85% Kathmandu, 
<80% Namche <75% Pheriche, <70% at Everest Base Camp 
Criteria for stopping test 
• Excessive rise in blood pressure:  
○ >250 mmHg Systolic; >115 mmHg Diastolic 
• Drop in systolic blood pressure of >10 mmHg from baseline, with other 
indications of ischaemia (see below)  
• >2 mm ST depression or >1 mm ST elevation  
• Onset of angina or angina-like symptoms • Onset of new arrhythmia other than 
ventricular ectopics 
• Nervous system symptoms - ataxia, dizziness or near syncope  
• Subject requests termination of test 
Table 2-3 Criteria for exclusion from exercise testing at field laboratories and for 
stopping CPET 
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2.2.4 Specific Neurosciences Studies 
 
A number of neuroscience studies were completed. All are explained here in 
the methods, but not all the results are presented in this thesis. Their inclusion 
here is because some are mentioned later in the thesis, but also to demonstrate 
that beyond this thesis, combining studies may draw further conclusions. 
 
Core Studies: 
All subjects from group 1 and 2 underwent all of the following neuroscience 
studies: 1) Diary Monitoring: - A daily diary of physiological measurements and 
headache assessment 2) Resting and exercise assessment of brain oxygenation 3) Retinal Imaging  4) Anthropomorphic skull assessment (baseline study only) 5) Neurocognitive assessment (not reported in this thesis) 6) Pupillometry (not reported in this thesis) 
In addition, group 2 underwent additional studies investigating: 
1) Cerebral blood flow and resting supine brain oxygenation 
2) Intraocular pressure 
Twelve subjects pooled from both groups 1 and 2 also underwent a volumetric 
MRI scan (see below). 
 
2.2.4.1  Daily Diary - Physiological and Headache Assessments 
 
All subjects completed a physiological and symptoms scoring diary on each day 
of the expedition. The Lake Louise Score (Roach, Bartsch et al. 1993), 
Environmental Symptoms Questionnaire (Sampson, Cymerman et al. 1983) 
and a “Headache Severity Index” were recorded each morning. The headache 
severity index was calculated by grading the headache of the previous 24 hours 
(0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = excruciating) and multiplying 
it by the number of hours the headache persisted. In addition, location of 
headache was recorded using a skull diagram and the time of day the 
headache occurred (00:00 to 06:00; 06:00 to 12:00; 12:00 to 18:00; 18:00 to 
24:00 could be circled). Resting heart rate, blood pressure, respiratory rate and 
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peripheral saturations were also recorded after 10 minutes rest prior to 
breakfast each morning. 
2.2.4.2 Brain Oxygenation / Near Infrared Spectroscopy (NIRS) 
 
All subjects (Group 1 [n=198] and 2 [n=24]) had assessment of regional brain 
oxygenation (rSO2) at rest and during exercise using a Cerebral Near Infrared 
Oximeter (NIRS - Invos Model B or C, Somanetics, Pennsylvania, figure 2-5).  
 
Background to NIRS: Jobsis (Jobsis 1977) reported that transillumination of 
brain and myocardium with near infra-red light could be used to evaluate tissue 
oxygen saturation. NIRS is a technique that uses the differential absorption of 
near infrared light by oxy and deoxyhaemoglobin (Owen-Reece, Smith et al. 
1999). This was first used to study human brain in 1985, and by 1993 the first 
commercial monitor was available. By comparing the ratio of oxy to total 
haemoglobin, a regional saturation (rSO2) value is generated. The INVOS 
system (Model B or C, Somanetics, Pennsylvania) utilises a single emitting 
diode and two detecting diodes, one 3cm and one 4cm from the emitter. The 
closer detects blood that has been through scalp and skull, the more distant 
one through scalp, skull and brain (figure 2-6). By subtracting the differences in 
absorption between these two readings, a more “pure” brain rSO2 is generated. 
A brief description of principals of NIRS is given below. Greater detail with 
regards to the physics underlying the principals can be found in a number of 
reviews (Owen-Reece, Smith et al. 1999; Murkin and Arango 2009). 
 
Normal resting cerebral oxygen consumption is 3.5ml/100g brain/min (Rowell 
1993) and therefore the rate of oxygen consumption of the entire (on average 
1,400g) brain is 50ml O2/min. Hence, although the brain only weighs 2% of the 
total body weight of a 70Kg male, its oxygen consumption represents ~20% of 
the 250ml O2/min average metabolic rate for the entire body.  
 
The measurement of tissue oxygenation and haemoglobin content is 
determined by the difference in intensity between a transmitted and received 
light delivered at specific wavelengths as described by the Beer-Lambert law. 
Above a wavelength of 1300nm, water absorbs most light, below 700nm, light is 
scattered too much. Between this is the near infrared range and between 700 
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and 850nm the absorption spectra of Haemoglobin (Hb) and Oxyhaemoglobin 
(HbO2) are maximally separated. The isobestic point (wavelength at which oxy 
and deoxyHb species have the same molar absorptivity) is 810nm. 
 
The Beer Lambert law states that: 
∆A = L x µ 
where ∆A is the amount of light attenuation, L the differential photon path length 
through tissue and µ the absorption coefficient of chromophore X (which can be 
expressed as the tissue concentration of X multiplied by the extinction 
coefficient of chromophore X) hence the light attenuation is directly proportional 
to the concentration of X. If path length is known (estimated by computer 
modelling), absolute changes in chromophore concentration can be calculated. 
 
There are two computer interpretation systems from this stage. The first is a 
non-quantitative cerebral oximetry technique such as the INVOS system. This 
measures the ratio of light absorption by oxygenated 
and total haemoglobin, hence does not need to 
quantify haemoglobin concentration. The second 
system provides quantitative concentration 
measurements (such as the Hamamatsu 
(Hamamatsu City, Japan) and Critikon (Ascot, 
Berkshire, UK) systems). 
 
Figure 2-5 A subject demonstrating two NIRS forehead 
pads connected to a NIIS (Invos Model C) Niroscope.  
 
The INVOS system used in this study emits light at 730nm and 805nm from a 
single LED and this light is detected by optodes at 3 and 4 centimetres distal. 
Only rSO2 is calculated and recorded. They do not publish their algorithm for 
the calculation of rSO2 hence it is not possible to work back and calculate ratios 
of oxygenated to deoxygenated haemoglobin. The advantage of the INVOS 
system (and reason for its use in this study) was that the machines are rugged, 
relatively compact and can run on batteries. This makes them more suitable to 
the expedition environment. We also required two machines to run concurrently 
in Namche, Everest Base Camp and one on Everest itself. The free loan of the 
total 5 INVOS machines made this possible. However, in retrospect, the greater 
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analysis that would be possible with other machines would have yielded much 
more interesting and interpretable results. 
 
Note, our group has also studied skeletal muscle oxygenation during exercise 
at altitude which has been reported separately (Martin, Levett et al. 2009).  
 
Figure 2-6 Schematic 
demonstrating the 
patented Invos system of 
utilising the differential 
pathways of near infrared 
light through scalp, skull 
and brain to generate a 
more reliable brain rSO2. 
 
 
 
 
 
The NIRS readings were obtained while sitting upright on the cycle ergometer 
before and during CPET testing.  An Infrared emitter/receiver pad was placed 
on each side of the subject’s forehead and secured with a headband. The 
subject rested for 5 minutes prior to CPET testing, after which 3 bilateral NIRS 
measurements were taken. Brain oxygenation data were collected continuously 
at four-second intervals from rest throughout the CPET. Three simultaneous 
data values were averaged for both left and right rSO2 values at rest, after 3 
minutes of unloaded cycling, at anaerobic threshold and at VO2Max. This 
enabled a graphical demonstration of each subjects change in rSO2 during the 
exercise test.  (See the specific study regarding analysis of this data). 
Group 2 underwent an additional NIRS study as part of the Cerebral Blood Flow 
protocol (see below). As part of this study, resting rSO2 was recorded as above 
but while recumbent having rested for 5 minutes. 
All of these studies were performed at: baseline, 1300m, 3500m, 4250m, 
5300m and in the climbing group at 6400m and 7950m. 
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2.2.4.3 Retinal Imaging 
 
All subjects underwent retinal imaging (8TRC NW200 Non-Mydriatic Digital 
Ophthalmoscope; TopCon, Tokyo, Japan) in London and again on arrival at 
Everest Base Camp. Group 2 also underwent reimaging prior to descent from 
Base Camp. Prior to imaging, all subjects were asked to stare at an Amsler 
chart with the right, then left eye, to assess for any schotoma (see Appendix 
figure 2-A). If found, they were asked to draw the “blind spot” onto the Amsler 
chart. 
The TopCon 8MegaPixel Digital retinal camera (8TRC NW200 Non-Mydriatic 
Digital Ophthalmoscope; TopCon, Tokyo, Japan figure 2-7) enabled high quality 
retinal imaging (figure 2-8) without the need for pupil dilatation. Subsequent 
analysis included assessment of: retinal artery calibre (superior retinal artery), 
retinal vein calibre (superior and inferior retinal vein), optic disc margins, optic 
disc diameter and the presence of retinal haemorrhages. 
 
Figure 2-7 The TopCon 8MegaPixel Non-Dilating retinal camera in use in the research 
tent at Everest Base Camp (5300m). 
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Figure 2-8 Right and left retinal images demonstrating typical retinal haemorrhages. 
 
2.2.4.4 Neurocognitive Assessment 
 
All subjects underwent neurocognitive assessment. This comprised a series of 
studies that in total took 40 minutes to perform. These included: trail making, 
letter cancellation, word finding, Symbol Digit, Rey, Stroop, Grooved Pegboard 
and block design tests (see chapter 9 and appendix B). In addition State Trait 
Anxiety Inventory (STAI) and Center for Epidemiologic Studies – Depression 
Score (CED–D) were assessed. Investigators performing these tests were 
trained to ask the questions in the same manner to attempt to standardise 
measurements. Subsequent sea level control studies were also performed. 
The neurocognitive studies were performed at: baseline, 1300m, 3500m, 
4250m, 5300m and in the climbing group at 6400m and 7950m. Only a brief 
outline of results is reported in chapter 9. 
 
2.2.4.5  Anthropomorphic Study 
 
The “Tight Fit” Hypothesis implies that subjects with more compliant CSF 
systems will be less prone to a rise in ICP and hence high altitude headache, if 
that is the cause. It could therefore be hypothesised that subjects with relatively 
larger skull volumes would be protected from high altitude headache.  Using 
specially designed callipers (figure 2-9), all subjects underwent the following 
skull measurements (figure 2-10): 
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• Maximum head length (glabela to inion: L) 
• Maximum head breadth (between the two parietal eminences: W) 
• Auricular height (external acoustic meatus to bregma: H) 
• Head Circumference (from glabela to ionion) 
 
Figure 2-9 Callipers specifically designed for obtaining measurements described in 
Figure 2-10. a) measured length and width. b) with the base plate removed, height was 
measured. 
 
The first three measurements were then used in the Lee-Pearson Formula to 
calculate intracranial volume (Sahin, Acer et al. 2007).  
 
Male ICV: 0.000337 (L–11) × (B–11) x (H–11) + 406.01 
Female ICV: 0.0004 (L–11) × (B–11) × (H–11) + 206.60 
 
These calculations were subsequently compared with summations of daily Lake 
Louise scores. 
Figure 2-10 Illustrations showing the measurement of cranial height, length and width. 
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2.2.4.6 Pupillometry 
 
All subjects underwent pupillometry studies using a ForSite Digital Pupilometer 
(Neuroptics Inc, Irvine CA – figure 2-11). This is a battery operated, hand-held, 
portable device that incorporates a white light flash emitter and an infrared 
digital video camera to record the responding pupil changes. The device emits 
a constant infrared light, the wavelength of which (850 nm) is beyond the 
normal response of the human eye. To stimulate the pupil, it then emits a flash 
of white light of fixed intensity for a duration of 0.8 seconds. Simultaneously, an 
integrated video camera records the changes in pupil size at 40 frames per 
second. From this, the following dynamic pupillary variables are calculated: 
maximum and minimum pupillary diameters (Max A and Min A, respectively, 
measured to 0.1 mm), the percentage change in diameter before and after 
constriction (Max A - MinA/MaxA] / 100), constriction latency as well as the 
velocities of constriction (CV), and dilation (DV). Results are displayed on an 
LCD screen with a graphical representation and numerical values (figure 12). 
 
Prior to performing pupillometry, all subjects remained in darkness for 2 minutes 
under a black veil. The right eye was then assessed. In the case of failure to 
obtain data, the pupillometry was repeated after a further minute. The study 
was then repeated in the opposite eye. 
 
This study was performed on all subjects at baseline, 1300m, 3500m, 4250m, 
5300m and as many as possible at 6400m and 7950m. 
 
Figure 2-11 ForSite 
Digital Pupilometer 
(Neuroptics Inc, Irvine 
CA) being used without 
light excluding black 
cover. 
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Figure 2-12 Pupil images at maximum and minimum dilatation. Below is the digital 
readout.  
 
2.2.4.7 Additional Group 2 (Investigator Group) Studies 
 
In addition to the above, group 2 also underwent the following assessments: 
 
Resting Cerebrovascular Studies 
2.2.4.8 Transcranial Doppler (TCD) 
 
The aim of this TCD study was to assess the velocity of blood in, and the calibre 
of, the right Middle Cerebral Artery (MCA). This assessment was performed in 
all subjects in group 2. The subject rested supine for 5 minutes prior to the start. 
The right MCA was insonated via the temporal bone window (figure 2-13), by 
one of two skilled observers (MW/CI), using a 5-1 MHz Transducer 
MicroMaxxTM, (Sonosite, Bothell, WA, USA).  
 
ments were taken in the subsequent days of descent. While
at 3450 m, measurements were made in the same shaded
room. While trekking, a darkened tent provided consistent
lighting. The ambient light, as recorded by the pupillome-
ter, was equivalent in both settings and throughout the
day. All experiments were performed by a single operator
with the subject acclimatized to the ambient light, sitting
facing away from the ambient light source. Morning mea-
surements were made prior to ingestion of caffeine and be-
fore any exercise. The caffeine and exercise restrictions
were not applied to afternoon investigations. The results
were confirmed and recorded by a second observer. The
studies were performed on both eyes starting with the right
each time. Due to battery limitations while trekking, mea-
surements were restricted to once daily in the morning.
Subjects completed a self-assessment diary twice daily
to elucidate AMS symptomatology using the standardized
Lake Louise scoring system (LLSS) (Imray et al., 2004). This
comprises 4 graded responses (0 ! none, 3 ! severe) to 5
symptoms: headache, gastrointestinal symptoms, fatigue,
dizziness, and difficult sleeping. A common definition of
AMS is the presence of headache and one other symptom
after recent ascent to altitude with a total score of "3. For
this study, participants were divided into two groups,
those with AMS scores #1 and $5 and their pupil dy-
namics compared.
Statistical methods
Statistical analysis was performed using Excel (Mi-
crosoft™) and StatView™ software. Comparison of paired
mean data was performed by use of Student’s t-tests and, for
AMS data between groups, two-sample assuming unequal
variance t-tests were performed. Repeated data were tested
by analysis of variance (ANOVA) . Because of diurnal vari-
ation, statistical analysis was performed separately on morn-
ing and evening results.
Results
The pupillometer was robust and easy to operate and pro-
vided reproducible results in the field at altitude. Paired re-
sults of right and left eyes performed twice in Delhi dem-
onstrated no significant differences between eyes (p values !
Max A ! 0.25, Min A ! 0.77, pe ce tage change ! 0.33, la-
tency! 1, CV ! 0.61, DV !0.77) and a high level or repro-
ducibility within the same subject. Only the right eye data
are presented for the rest of the analysis.
Diurnal variation
At 3450 m, 50 morning and evening studies showed sig-
nificant (p % 0.05) diurnal variations in Max A, Min A, per-
centage change and latency (Table 2) but no differences in
constriction and dilation velocities.
CHANGES IN PUPIL DYNAMICS AT HIGH ALTITUDE 321
FIG. 1. Images from display screen video demonstrating automated measurements of pupil and iris during Max A and
Min A and the resulting computed output. Note that ICP is a variable that can be entered directly for documentation. It is
not calculated by the device.
Chapter 2 - METHODOLOGY 81 
	  
 
Figure 2-13 MW insonating right temporal window of 
an investigator. 
 
The clinoid process of the sphenoid bone, the 
Circle of Willis and the distal internal carotid 
artery were initially identified, and then the M1 
segment of the MCA was identified 
(characterised by flow towards the transducer). 
The Doppler gain was set in a standard fashion 
(Martinoli and Derchi 1997). An optimal portion 
of the MCA without branches and with laminar 
flow was then selected and the depth recorded. Once identified, the centre of 
the artery was insonated and MCA blood velocity (MCAVel), Peak Systolic 
Velocity (PSV), End Diastolic Velocity (EDV), Pulsatility Index (PI) and 
Resistively Index (RI) calculated by the inbuilt software (figure 2-14). 
 
Figure 2-14 Display of Sonosite Micromax demonstrating graph and calculations. 
 
On subsequent studies (at other altitudes), every effort was made to insonate 
the same depth (to within 1 mm). After 3-5 minutes of insonation, the 2D image 
movie sequence was saved, and the frame with the maximum vessel diameter 
(systole) studied. Using the on screen calliper tool, the width of the vessel at the 
point of insonation was measured and recorded. The angle of insonation was 
constant for each individual, since the position of the probe on the temporal 
Chapter 2 - METHODOLOGY 82 
	  
bone window and the position on the interrogated section of the MCA, were 
fixed. 
All measurements were performed without supplemental oxygen up to 6400m. 
At 7950m, subjects were off supplementary oxygen (2lmin-1) for at least 30 
minutes prior to the NIRS and TCD measurements being made. The NIRS and 
TCD studies were then repeated with the subjects receiving 2lmin-1 
supplemental oxygen via a TopOut re-breath regulator system (Topout Mask 
Mk 2, Topout Oxygeneering Ltd, Cotgrave, UK) to assess reversibility of the 
initial measurements. At 7950m, the investigating clinician used supplementary 
oxygen (2lmin-1). 
 
Flow and Oxygen Delivery Calculations: 
Blood Oxygen content was calculated using the formula: 
Blood Oxygen content = 1.39  x Hb x SaO2/100 
The small quantity of dissolved Oxygen (decreasing further at altitude) was not 
included in the estimation. 
 
Middle Cerebral Artery Blood Flow was calculated using the formula: 
Flow = π(MCAdiam/2)2 x MCAvel 
 
This estimation does not take account of vessel wall resistance or changes due 
to any turbulent flow. Oxygen delivery was calculated by multiplying blood 
oxygen content with flow. 
All variables were analysed and statistical significance sought using single 
factor ANOVAs within the groups n=24 to 5300m, n = 14 to 6400m and n=5 to 
7950m. Microsoft Excel™ and SPSS™ version 14 (Michigan, USA) statistical 
packages were used. 
 
2.2.4.9 Resting Near Infrared Spectroscopy (NIRS) 
 
Regional Brain Oxygen Saturation (rSO2) measurements were made 
immediately prior to TCD insonation (Invos Cerebral Oximeter 5100C, 
Somanetics, MI, USA – see above). After the skin was cleaned, probes were 
placed over the right and left frontal lobes avoiding both the sagittal and frontal 
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sinuses and left in situ during the TCD analysis. After this, three consecutive 
readings were taken from each side, from which means were calculated.  
 
2.2.4.10 Intraocular Pressure (IOP) 
 
Group 2 subjects who did not wear contact lenses had intraocular pressure 
measurements made in both eyes using a hand held Icare™ tonometer (TA01i, 
Espoo, Finland). This direct contact technique is different to air puff techniques 
previously used at altitude as it negates confounding problems with changes in 
air pressure. The device uses the average of 7 measurements to calculate IOP. 
This was performed with the subject resting (sitting) looking directly ahead in 
each eye at baseline, 1300m, 3500m, 4250m, 5300m and in some of the 
climbing group at 6400m and 7950m. 
 
Figure 2-15 An ICare tonometer measuring intraocular pressure. 
 
2.2.5 Non-Neuroscience Studies 
 
A number of non-neuroscience studies were performed and are not reported 
within this thesis. These include Maximum Exercise Capacity and Metabolic 
Efficiency (although NIRS was used to assess brain oxygenation during these 
studies), Spirometry, Systemic Oxygen Content, Plasma Biomarkers and Genes 
Associated with Hypoxia. Details of these studies can be found in the group 
methodology paper (Levett, Martin et al. 2010). 
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2.3 Numbers of Subjects Completing Neurosciences Studies 
 
Two hundred and eight volunteers applied to join the expedition as trekkers, 
and four withdrew prior to baseline sea level testing for personal reasons. One 
volunteer was advised not to trek as a result of medical screening.  Two 
hundred and three volunteers were tested at sea level and five of these 
withdrew prior to departure (one because of a back injury and four for personal 
reasons).  In the light of findings at baseline exercise testing, six subjects were 
withdrawn from subsequent maximum CPET testing, and three of these were 
also withdrawn from the steady state CPET testing.  Sixty-two applicants 
applied to join the investigator group of whom 60 were selected and able to 
participate.  Twenty-four were selected to be investigator subjects (investigators, 
group 2) at EBC of whom 14 met criteria to become part of the climbing team, 
10 of whom became the summit team.  One hundred and ninety eight trekkers 
(Group 1) and 24 investigators (Group 2) who had been tested in the UK 
commenced the trek.  The baseline characteristics of the study groups are 
summarized in Table 2-4. 
 
 Group 1 
(Trekkers) 
number (%) 
Group 2 
(Investigators) 
number (%) 
Total 198 (100) 24 (100) 
Male 125 (63) 18 (75) 
Previous Altitude Exposure (>3500m) 85 (43) 23 (96) 
Previous Extreme Altitude Exposure 
(>5000m) 
37 (19) 21 (88) 
Smoker 13 (7) 0 (0) 
Race - white 191 (97) 22 (92) 
Mean Age (SD) 44.7 (13.7) 
(range: 18-73) 
35.2 (9.3)  
(range: 19-59) 
Table 2-4 Baseline characteristics of the CXE study population. 
 
Of 198 trekkers who left the UK, 190 (96%) reached Everest Base Camp. Of the 
eight subjects who did not arrive at EBC, the reason for this was acute 
mountain sickness in three subjects (1.5% of total), and non-altitude specific 
medical conditions in five (2.5% of total) (table 2-5).  In the investigators group 
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(group 2), all 24 subjects reached Everest Base Camp.  Of the climbing team, 
all 14 subjects reached camp 2. Eight of ten summit climbers successfully 
reached the summit of Mount Everest.  One member of the climbing team 
descended because of altitude illness at camp 3.  One member of the climbing 
team turned back during a summit attempt with no altitude illness.  One member 
of the laboratory staff was evacuated prior to the completion of the expedition 
with non-altitude related illness (table 2-6). 
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Table 2- 5 GROUP 1 (Trekkers) - Number of subjects arriving at each laboratory and 
reasons for absence from laboratory. AMS = Acute Mountain Sickness. 
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absence 
n/a n/a n/a n/a n/a • HACE 
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• Septic 
Shock 
Table 2-6 Group 2 (Investigators) – Number of subjects arriving at each laboratory and 
reasons for absence from the laboratory. 
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The numbers of subjects tested in each neuroscience protocol at each 
laboratory for group 1 and group 2 are summarized in tables 2-5 and 2-6 
respectively.  Mean laboratory pressures and laboratory temperatures are 
recorded in table 2-1. 
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Subjects at 
laboratory 
198 198 197 195 190 
CORE STUDIES 
Daily diary 198 195 196 194 190 
CPX Ramp 
(+NIRS) 
190* 189 184 183 153 
CPX ME 195** n/a 191 n/a 164 
Neurocognitive 198 160 (on 
return) 
195 n/a 185 
Pupillometry 198 n/a 191 n/a 186 
Cranial 
measurements 
198 n/a n/a n/a n/a 
Retinal 
photography 
183 n/a n/a n/a 183 
ADDITIONAL STUDIES 
Structural and 
volumetric MRI 
study 
7 n/a n/a n/a n/a 
Table 2-5 Group1 (trekkers n=198) – Testing performed at each laboratory. *6 subjects 
withdrawn from incremental CPET prior to departure and 2 because of poor baseline data 
quality. ** 3 subjects withdrawn from efficiency CPET prior to departure. 
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Subjects at 
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CORE STUDIES 
Daily diary 24 24 24 24 24 23 14 5 
CPX Ramp 
(+muscle and 
brain NIRS) 
24 24 22 24 23 22 14 5 
Neurocognitive 21 21* 21 21 21 n/a 13 6 
Pupillometry 24 24 24 20 24 23 14 0 
Cranial 
measurement 
24 n/a n/a n/a n/a n/a n/a n/a 
Retinal 
photography  
24 n/a n/a n/a 24 23 n/a n/a 
ADDITIONAL STUDIES 
Cerebral 
Doppler 
24 24 24 24 24 24 13 5 
MR brain 
volumetric 
studies 
15 n/a n/a n/a n/a n/a n/a n/a 
Table 2-6 Group 2 (Investigators) (n=24) – Testing performed at Each Laboratory, * = on 
return. 
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2.4 Sea Level MRI Studies 
 
A total of three MRI studies are described in this thesis. While each investigated 
a specific question, they also contained elements that acted as pilot studies for 
the subsequent study.  Full details of each MRI study and technique is provided 
within the respective chapter. 
 
2.4.1 Anthropomorphic (Normoxic Study) 
 
The purpose of this study was to assess cerebral compartment volumes and 
attempt to correlate these volumes (brain parenchyma, CSF and venous 
volumes) with headache scores from the Everest expedition. 
Subjects: Twelve subjects (all male) recruited from Xtreme Everest volunteers 
and investigators underwent cranial MRI scans prior to and following the 
Everest expedition. These studies were performed in Oxford, UK using a 1.5 
Tesla MRI and included standard T1 and T2 volumetric protocols.  
Analysis: Only the T1, post-Everest images were used for this anthropomorphic 
component of the study. Each subject’s study was imported into a volumetric 
analysis software package (Analyze 9.0, Analyzedirect, KS, USA). A semi-
automated technique was used to demarcate and calculate the surface area of 
each structure in each slice. These were coded and the automated software 
then used the Calvari technique to sum the surface areas from each slice to 
calculate a volume. The following volumes were rendered and calculated by a 
single, blinded observer: total intracranial volume, supratentorial volume, 
infratentorial volume, total brain parenchyma volume, supratentorial CSF 
volume (excluding ventricles), infratentorial CSF volume (excluding ventricles), 
total non-ventricular CSF volume, lateral and 3rd ventricular volumes, aqueduct 
and 4th ventricular volumes, total ventricular volume (lateral + 3rd + aqueduct + 
4th ventricle), total supratentoiral CSF volume, total infratentorial CSF volume, 
total CSF volume. In addition the following were also calculated: the tentorial 
angle, the petrous angle, the tentorial-clival angle, the sagital and occipital sinus 
venous volumes, the left transverse sinus and jugular bulb volume, the right 
transverse sinus and jugular bulb and total venous volumes. Figure 2-16 
demonstrates examples of the volumetric images generated. 
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Figure 2-16: Exemplar images of a) total intracranial volume, b)brain and venous volume, 
2) lateral and third ventricular volumes and d) venous volumes, generated during the 
volumetric analysis study. 
 
2.4.2 Arterial (Hypoxic Study) 
 
The high altitude cerebral Doppler study demonstrated that the extreme 
hypobaric hypoxia experienced in the climbers higher on the mountain in the 
Western Cwm and on the South Col, resulted in significant increases in the 
diameter of the right Middle Cerebral Artery (see chapter 3). This result has 
implications not just for high altitude medicine but for the clinical use of 
transcranial Doppler. We therefore undertook a hypoxic MRI study to attempt to 
confirm our findings with another modality. 
Subjects: Seven subjects (5 male, 2 female) took part in this study. Subjects 
underwent resting NIRS, TCD and basic physiology (heart rate, blood pressure, 
end-tidal CO2) studies as outlined above. They had a normoxic MRI study (as 
outlined below). Following this, they were then connected to a hypoxicator 
(Everest Summit Hypoxic Generator, Hypoxic Systems, New York, NY, USA) 
exposing them to an FiO2 of 12% for three hours. Following this, further NIRS, 
TCD and basic physiological parameters were recorded at 90 minute and 3 
hours. Then, whilst still connected to the hypoxicator, the subjects underwent 
the MRI protocol again. 
MRI Protocol: A 3 Tesla MRI scanner (TIM Trio, Siemens AG, Eriangen, 
Germany) was used to obtain Magnetic Resonance Angiography (MRA) images 
at baseline and again after 3 hours exposure to hypoxia. A consistent section of 
the right proximal MCA (approximately 1 cm from the bifurcation to correspond 
to the TCD area of investigation) was studied to provide estimates of vessel 
diameter and blood flow velocity. Subsequent analysis measuring the diameter 
of both MCAs at three points along their lengths was also performed. Full 
methodological details are provided in chapter 3. 
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As part of this study, a pilot MRI sequence was performed to investigate venous 
changes. These susceptibility-weighted images were analysed qualitatively and 
are described within chapter 6. 
 
2.4.3 Venous (Hypoxic Study) 
 
The retinal imagining study, the anthropomorphic work and the venous pilot 
study component of the arterial MRI added strength to my belief that venous 
system was important in the pathogenesis of high altitude headache. A final 
hypoxic MRI study specifically designed to investigate the venous system was 
therefore undertaken. 
Subjects: Fourteen subjects (12 male, 2 female) were enrolled. All had full blood 
count and urea and electrolyte blood tests prior to their study to record 
haemoglobin and to ensure a normal estimated glomerular filtration rate prior to 
the administration of contrast. All completed the study. In a random order, the 
subjects had a normoxic MRI and a hypoxic MRI study separated by a minimum 
of 24 hours (to ensure no effect of hypoxia and no residual contrast). Subjects 
also underwent both normoxic and hypoxic retinal imaging. The hypoxic study 
comprised baseline physiological measurements followed by 1 hour of hypoxia 
delivered through a hypoxicator (Everest Summit Hypoxic Generator, Hypoxic 
Systems, New York, NY, USA). The subjects had continuous peripheral arterial 
oxygen saturation and end-tidal carbon dioxide measurements, while heart rate 
and 5 minute blood pressure recordings were also made. Symptoms of 
headache were enquired about at 30 minutes and 1 hour.  
MRI Protocol: A 3 Tesla MRI (TIM Trio, Siemens AG, Eriangen, Germany) was 
used. Standard T1 and T2 volumetric studies were performed followed by 
phase contrast and SWI sequences. To eliminate the effects that may be 
caused by the altered susceptibility of blood in hypoxia, gadolinium contrast as 
part of a timed venous phase MRI scan was administered to clearly delineate 
the venous structures. Velocities of blood flow in the sagittal and transverse 
sinuses were recorded. 
 
2.5 Statistical Analysis of Field and MRI Studies 
 
Statistical tools appropriate to each data set were applied using a combination 
of SPSS (version 17) and Excel. The statistical analysis for each experiment is 
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described in the corresponding chapter. Statistical support was provided by 
Shashi Hirani (UCL/City University) and by Professor Stanton Newman 
(UCL/City University). The power for individual studies is discussed in each 
chapter, however, many of the studies used the numbers of subjects they did 
for logistical reasons rather than specific power calculations.  
 
Overall Statistical Analysis 
Completeness of data, reasons for data loss (including subject drop out) are 
explained in each chapter.  Only within the brain oxygenation chapter was a 
small volume of data imputed. Statistical supervision was provided by an 
independent statistician Shashi Hirani. Frequency plots were performed to 
confirm that data had a normal distribution prior to statistical analysis.  
Relationships between variables were examined using Pearson’s r correlation 
when data were interval and parametric. Spearman’s Rho was used when data 
were non-parametric. When single correlations were sort, significance was set 
at p<0.05. To reduce the risk of falsely identifying significance, when multiple 
correlations were investigated from a single data source, correlations were only 
considered significant when p<0.01. The coefficient of determination (r2) is also 
reported as an indicator of the correlation effect size (this is especially so in the 
correlation of headache and physiological variables). 
 
2.6 Special Note on Headache Assessment 
 
The assessment of headache is a subjective and difficult measurement to make 
in comparison with most of the other physiological measurements within this 
thesis. The summation of “grades” of headache may not be a valid tool for 
comparing “headache burden” between subjects. This section explains the 
background to and the different headache assessment mechanisms used. 
 
Headache analysis and the use of Headache Severity Index for the 
temporal quantification of headache at altitude: 
 
2.6.1 Abstract 
 
The ability to assess the subjective symptom of headache in a quantifiable way 
is key to the subsequent interpretation of physiological and anatomical 
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differences that may contribute to high altitude headache. This short report 
discusses the use of the headache component of the Lake Louise Score and 
the calculation of a headache severity index in 24 subjects ascending to 5300m. 
 
2.6.2 Introduction 
 
Headache is a discomfort within the cranium, the subjective nature of which 
makes quantifying and comparing headaches across a group of people or 
across a time period difficult. It is, however, necessary to attempt to do this, to 
see how a patients headache varies over time, to assess if a treatment modality 
is effective and for high altitude research, to compare individuals who suffer 
with headaches to those that do not. More importantly, a good assessment tool 
should be able to discriminate the different severities of headache experienced. 
First, clear definitions of high altitude headache and acute mountain sickness 
are required. 
 
High Altitude Headache (HAH): The International Headache Society (2004) 
define the diagnostic criteria for HAH as A) exhibiting at least two of the 
following characteristics: frontal or fronto-temporal, dull or pressing, mild or 
moderate and aggravated by exertion, movement, straining, coughing or 
bending, and associated with; B) ascent to altitude over 2,500m, and which; C) 
have developed in the last 24 hours and; D) resolve within 8 hours of descent.  
 
Acute Mountain Sickness (AMS): AMS is commonly considered to represent 
progression of HAH. The Lake Louise Consensus Group defined AMS as the 
presence of headache in an unacclimatised person who has recently arrived at 
an altitude above 2500m plus the presence of one or more of the following: 
gastrointestinal symptoms: anorexia, nausea or vomiting; insomnia; dizziness; 
and lassitude or fatigue (Roach, Bartsch et al. 1993). The group also 
established a scoring system to provide a quantitative element to AMS severity. 
A less commonly used, though more detailed severity scoring system is the 
Environmental Symptom Questionnaire (Sampson, Cymerman et al. 1983). 
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The Lake Louise Assessment for headache comprises the following subjective 
scoring system (table 2-7). 
Headache 
severity 
Score 
None 0 
Mild  1 
Moderate 2 
Severe 3 
Table 2-7 The grades of headache used with the Lake Louise Scoring system. 
 
This is a good tool for an immediate assessment of a patient’s headache. Visual 
analogue scales can also be used (Lundqvist, Benth et al. 2009). 
 
The Environmental Symptom Questionnaire (ESQ-III) comprises 67 questions. 
A weighted factor score (AMS-C) is calculated for answers to 11 of the 67 items. 
If the AMS-C score is >0.7, the individual is classified as having AMS. There are 
a number of problems with the administration of the ESQ-III: 1) the length of 
time to complete; 2) inaccurate answers due to boredom; 3) intentional or 
unintentional skipping of questions and 4) multiple answers to the same 
question due to stray pencil marks (Beidleman, Muza et al. 2007). The Lake 
Louise Scoring system tends to overestimate AMS when compared to the ESQ-
III. 
 
Unfortunately, for the purposes of our studies, none of these systems 
accurately allow the cumulative assessment of headache over time (Beidleman, 
Muza et al. 2007).  
 
Compare the following examples using the Lake Louise score as a component 
within a diary.  A subject records that yesterday he had a headache of severity 
3 out of 3. Another had a headache of 1 out of 3. Just analysing this suggests 
the first subject had the worst headache. However, subject 1’s headache only 
lasted half an hour on waking while the second subjects lasted all day. Now 
who has the worst headache? 
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The Headache Severity Index is a tool used by the pharmaceutical industry to 
compare effectiveness of medications (Schrader, Stovner et al. 2001). It not 
only ascribes a momentary severity of headache score, but also a duration to 
each episode measured in hours. The scoring system is as follows: 
Each day a subject records the headache severity the previous day (0-4, table 
2-8) and the number of hours that headache was present. 
 
Headache severity Score 
None 0 
Mild  1 
Moderate 2 
Severe 3 
Excruciating 4 
Table 2-8 Grading system (0-4) for the Headache Severity Index 
 
Using such a method, a headache of grade 3 out of 4 for an hour has the same 
value as a headache of grade 1 out of 4 for three hours. 
For this study, we compared Lake Louise and Headache Severity Scores for 24 
subjects ascending to 5300m. 
 
2.6.3 Methods 
 
Twenty-four subjects (18 male) recruited from the investigators within the 
Caudwell Xtreme Everest Investigators team, ascended to 5300m (Everest 
Base Camp). The baseline studies, ascent profile and general methodology 
have been described above. 
Each subject had a diary to be completed each morning. This comprised a 
series of didactic questions relating to many aspects of their wellbeing. They 
recorded their Lake Louise score (and the individual components and grade of 
headache) daily. One section specifically asked questions regarding headache. 
Within this section the questions in table 2-8 were asked. 
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Grade of headache 
experienced in 
previous 24 hours 
(1-4)  
 Duration of 
headache (/hrs) 
 
Time of day of 
headache (please 
circle) 
00:00 – 06:00 
06:00 – 12:00 
12:00 – 18:00 
18:00 – 24:00 
Locations of 
headache 
(please mark on 
skull) 
 
Exacerbating factors  
Table 2-8 Table with the Ascent Headache Score (sum of each headache score for 
previous 24 hours after arrival at a new altitude), the Total headache Score (the sum of all 
daily headache scores irrespective of ascent) and the Headache Severity Index (the sum 
of headache score x duration/hours for each day). 
 
Using these latter data, a Daily Headache Score (grade x number of hours) was 
calculated for each subject and this value was summed for the period of arrival 
at altitude (3,300m) to three days after arrival at the destination (5,300m). 
Three scores will be compared. Firstly the sum of Lake Louise Scores only 
recorded on the morning after arrival at a new altitude (Ascent Headache 
Score). Since AMS tends to be worst at such time (and since few people drank 
alcohol while ascending in the previous 24 hours) this technique should remove 
most other causes of headache (e.g. alcohol that might contribute on day 2 or 3 
at a specific altitude). Secondly, the sum of Lake Louise scores for each 
individual on every day for the period of study (whether ascent had occurred or 
not) was calculated (the Total Headache Score). Finally, the Headache Severity 
Index was calculated for each subject daily and summed for the entire duration 
of study. 
If data points were missing from the diary, an attempt was made to establish a 
reason (e.g. illness). The following days’ figures were imputed.  
Chapter 2 - METHODOLOGY 96 
	  
Subject No 
Ascent 
Headache 
Score 
Total 
Headache 
Score 
Headache 
Severity 
Index 
X01 1 2 39 
X02 4 5 41 
X03 0 2 1.5 
X04 0 1 2 
X05 1 3 6 
X06 0 1 1 
X07 2 3 27.5 
X08 0 0 0 
X09 0 0 0 
X10 2 4 4 
X11 0 0 0 
X12 2 8 153 
X13 8 12 90 
X14 4 5 152.5 
X15 3 2 24 
X16 8 15 141.5 
X17 1 2 9 
X18 0 1 1 
X19 0 1 4 
X20 1 1 4 
X21 0 0 2 
X22 1 4 25 
X23 1 4 64 
X24 2 5 68 
 
Table 2-9 demonstrates these results for the entire investigator group.  
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2.6.4 Results 
 
Diary records were well maintained. The total (daily) headache score generates 
312 data points (24 subjects x 13 days of trekking). Of these, only 4 data points 
were missing. The Headache Severity Index generates twice the number of 
data points (as daily score and duration need to be recorded). Of these, 9 data 
points were missing. For these points, imputation using the mean duration of 
other headaches the individual had suffered was used. 
 
For the Investigators, it became clear from studying the diaries that duration of 
headache was very poorly documented. This may have been because of lack of 
understanding or because the diary is quite extensive with other data (such as 
heart rate, peripheral saturations, blood pressure) and this field was not 
considered important. Because of this, although we have good data for the 
investigator group, the trekker group rely on total and ascent headache score 
only. 
 
2.6.5 Conclusions 
 
By incorporating a duration component into the scoring system, a broader range 
of headache scores is produced. On broad inspection, this also appears to 
correlate well with the headaches reported to me as the Expedition Doctor at 
Base Camp. In future studies the importance of the duration field must be 
emphasised by trek leaders to their groups. 
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3 Chapter 3: ARTERIAL EFFECTS OF HYPOXAEMIA 
 
Please see (Wilson, Edsell et al. 2011) Cerebral artery dilatation maintains 
cerebral oxygenation at extreme altitude and in acute hypoxia – an ultrasound 
and MRI study. Journal of Cerebral Blood Flow and Metabolism June 2011, 31, 
2019-2029 in Appendix 
 
3.1 Abstract 
 
To understand cerebrovascular physiology in hypoxia, both arterial inflow and 
venous outflow must be studied. Transcranial Doppler is a widely used non-
invasive technique for assessing cerebral artery blood flow. All previous high 
altitude studies assessing cerebral blood flow in the field have used Doppler to 
measure arterial blood velocity and have assumed vessel diameter to not alter. 
Methods: This chapter reports two studies that demonstrate that this is not the 
case. Firstly, I report the highest recorded study of cerebral blood flow (7950m 
on Everest) and demonstrate that above 5300m, middle cerebral artery (MCA) 
diameter increases (n=24 at 5300m, 14 at 6400m and 5 at 7950m). Secondly I 
performed normobaric hypoxic (FiO2 = 12%) Magnetic resonance angiography 
(MRA) studies using a 3 Tesla MRI scanner to accurately measure MCA 
diameter (n=7).  
Results: Mean MCA diameter at sea level was 5.30mm, at 5300m 5.23 mm, at 
6400m 6.66mm and at 7950m 9.34mm (p<0.001 for change between 5300 and 
7950m). The dilatation that occurred at 7950m reversed with oxygen. The 
normobaric MRA also demonstrated significant dilatation of the MCA diameter 
and this correlated with MCA changes as measured by ultrasound.  
Conclusion: I thus conclude that that cerebral artery diameter is not constant, 
but can respond to alterations in inspired oxygen partial pressure. It also 
appears that transcranial 2D ultrasound can be used at the bedside or in the 
remote setting to assess middle cerebral artery calibre. 
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3.2 Introduction 
 
Normal cerebral function is dependent on an adequate and continuous supply 
of oxygen. With increasing altitude, barometric pressure falls, and with it the 
partial pressure of atmospheric and inspired oxygen. Acclimatisation to such an 
environmental hypobaric hypoxic stress involves a number of adaptive 
processes (including hyperventilation and a rise in haematocrit (Ward, Milledge 
et al. 2000)) which serve to restore arterial oxygen content towards sea level 
values. In addition, increased cerebral blood flow is believed to be one 
compensatory mechanism serving to maintain normal oxygen flux to the brain in 
the face of arterial hypoxaemia. Such hypoxaemia is common in critically ill 
patients and is thought to occur locally in ischaemic stroke, the third commonest 
cause of death in the UK (1995). A greater understanding of the 
cerebrovascular response to hypoxia is thus of broad interest, as would be the 
validation of clinically relevant techniques used in the assessment of flow in 
intracranial vessels. 
 
Transcranial Doppler (TCD) measurement of flow velocity in the Middle 
Cerebral Artery (MCA) has been used to assess cerebral blood flow (CBF) 
dynamics both at rest and during exercise at altitude (Otis, Rossman et al. 
1989; Baumgartner, Bartsch et al. 1994; Baumgartner, Spyridopoulos et al. 
1999; Jansen, Krins et al. 2000; Ter Minassian, Beydon et al. 2001; Jansen, 
Kagenaar et al. 2002; Appenzeller, Passino et al. 2004; Lysakowski, Von Elm et 
al. 2004; Imray, Myers et al. 2005; Norcliffe, Rivera-Ch et al. 2005; Van Osta, 
Moraine et al. 2005; Palma, Macedonia et al. 2006; Ainslie, Burgess et al. 2007; 
Feddersen, Ausserer et al. 2007; Subudhi, Dimmen et al. 2007). Assuming that 
cerebral arterial diameter remains constant in the face of sustained hypoxia, 
investigators have inferred changes in cerebral blood flow from changes in the 
velocity of blood in the MCA. This assumption is, however, disputed (Giller 
2003). Further, the opposite assumption is made in many clinical situations: in 
the management of subarachnoid haemorrhage, for example, changes in TCD-
derived blood velocity are assumed to represent changes in vessel diameter 
(vasospasm).  
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The profound hypoxaemia experienced by climbers at extreme altitude 
(>5500m) (Grocott, Martin et al. 2009) is known to be associated with cerebral 
dysfunction (Ward, Milledge et al. 2000; Virues-Ortega, Buela-Casal et al. 2004), 
which is thought to account for approximately 70% of deaths over 8000m on 
Everest (Firth, Zheng et al. 2008). Such data suggest that cerebral oxygenation 
may not be fully maintained through adaptive responses, which may include 
changes in cerebral blood flow. However, these blood flow responses remain 
poorly documented. Indeed, the only studies of CBF using TCD velocity under 
conditions of comparable hypoxaemia (performed in a hypobaric chamber) did 
not record vessel diameter (Ter Minassian, Beydon et al. 2001). 
 
In the past, the measurement of MCA diameter (MCADiam) has only been 
possible by direct vision at surgery (Giller, Bowman et al. 1993), by use of 
contrast angiography (Du Boulay and Symon 1971) or magnetic resonance 
angiography – techniques inappropriate for remote extreme altitude field studies. 
Transcranial Colour Doppler Power signal has previously been used to 
indirectly infer MCA cross-sectional area (MCAcsa) in a laboratory setting (Poulin 
and Robbins 1996; Poulin et al 2002). Under conditions of mild hypobaric 
hypoxia, no significant change in MCAcsa  was noted. The recent development of 
portable ultrasound devices that incorporate both 2D colour flow mapping and 
concurrent pulse wave Doppler ultrasonography permits measurement of both 
vessel diameter and the velocity of the blood within it. The 2D ultrasound 
ensures that the same segment of the artery can be reliably visualised and 
assessed.   
 
I thus aimed to use such ultrasound imaging and Doppler measurements to 
characterise the contribution of altered vessel diameter to changes in MCA flow 
(MCAFlow) and calculated oxygen delivery (MCAOD) seen in response to 
hypobaric hypoxia. In addition, a sea level MRA study was performed in 
normoxia and 12% hypoxia to determine whether acute hypoxia caused MCA 
vessel dilatation and to assess the level of correlation between TCD and MRA 
methodologies. 
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3.3 Methods 
 
Ethical approval for this study was provided by University College London 
(UCL) (Code 0292/015). Written informed consent was obtained from all 
participants. Please see chapter 2 for generic details of the CXE expedition.  
 
3.3.1 High Altitude TCD Study 
 
Twenty-four subjects, the investigators of the Caudwell Xtreme Everest 
Research Expedition (18 male, mean age 35.2, range 19-59, (Grocott, Martin et 
al. 2010)), were studied over 71 days.  In brief, and as described in chapter 2, 
all subjects trekked to 5300m (group 1, n = 24), of whom 14 subsequently 
continued to 6400m (group 2) and 5 to 7950m (group 3). Each subject was 
studied between 1 and 3 days after arrival at each new altitude. The study day 
was constant for each subject, the sole exception being at 7950m, where all 
subjects (n=5) were investigated on the second day after arrival. No caffeine or 
alcohol, or medications that could affect cerebral blood flow were consumed 
prior to the measurement on the study day. Immediately before each study, 
subjects rested in a horizontal position for 15 minutes. Climbers were not 
exposed to any supplemental oxygen until 7100m. At 7950m, subjects were off 
supplementary oxygen (2 lmin-1) for at least 30 minutes prior to the Near 
Infrared Spectroscopy (NIRS) and TCD measurements being made. The NIRS 
and TCD studies were then repeated with the subjects receiving 2lmin-1 
supplemental oxygen via a TopOut re-breath regulator system (Topout Mask 
Mk 2, Topout Oxygeneering Ltd, Cotgrave, UK) to assess reversibility of the 
initial measurements. At 7950m, the investigating clinician (CHEI) used 
supplementary oxygen (2 lmin-1). 
 
Measurements: 
 
Blood pressure was recorded (mean of three non-invasive recordings) using an 
automated cuff (Omron M7, IL, USA); arterial oxygen saturation (SaO2) by near 
infrared finger pulse oximetry probe (Nonin, Onyx Model 9500, Plymouth, MN 
USA); haemoglobin concentration of whole venous blood by photometry 
(Hemocue Whole Blood haemoglobin System, Hemocue AB, Angelhoim, 
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Sweden); and resting end-tidal  CO2 (ETCO2) by infrared capnometer (Cortex 
Metamax 3b, Leipzig, Germany).  
 
Near Infrared Spectroscopy (NIRS): Regional Brain Oxygen Saturation (rSO2) 
measurements were made immediately prior to TCD insonation (Invos Cerebral 
Oximeter 5100C, Somanetics, MI, USA). The skin was cleaned and probes 
were placed over the right and left frontal lobes avoiding both the sagittal and 
frontal sinuses, and left in situ during the TCD analysis. Three consecutive 
readings were taken from each side, from which means were calculated. NOTE: 
although resting brain oxygen was monitored during this study, the main study 
of brain oxygenation at rest and during exercise whilst hypoxic is described in 
chapter 4. 
 
Transcranial Doppler: In a supine subject (figure 3-1), the right MCA was 
insonated via the temporal bone window, by one of two skilled observers, using 
a 5-1 MHz Transducer MicroMaxxTM (Sonosite, Bothell, WA, USA). The clinoid 
process of the sphenoid bone, the Circle of Willis and the distal internal carotid 
artery were initially found, and then the M1 segment of the MCA identified 
(characterised by flow towards the transducer). Doppler gain was set in a 
standard fashion (Martinoli and Derchi 1997). An optimal portion of the MCA 
without branches and with near laminar flow was then selected and the depth 
recorded. Once identified, the centre of the artery was insonated and MCA 
blood velocity (MCAVel), Peak Systolic Velocity (PSV), End Diastolic Velocity 
(EDV), Pulsatility Index (PI) and Resistivity Index (RI) calculated by the inbuilt 
software (Figure 3-2a). In subsequent studies, every effort was made to 
insonate the same depth (to within 1 mm). After 3-5 minutes of insonation, the 
2D image movie sequence was saved, and the frame with the maximum vessel 
diameter (systole) studied. Using the on screen calliper tool, the width of the 
vessel at the point of insonation was measured and recorded (Figure 3-2b). The 
angle of insonation was constant for each individual, since the position of the 
probe on the temporal bone window and the position on the interrogated section 
of the MCA were fixed. 
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Figure 3-1 In a supine subject, the right MCA was insonated as described in the methods. 
 
3.3.2 Sea Level Hypoxic MRI Study 
 
Seven subjects (5 male; mean age: 34.4 range 22-48) were recruited from the 
Caudwell Xtreme Everest investigators. None had ascended above 1000m in 
the preceding 6 months.  Physiological, TCD and NIRS measurement 
techniques were identical to the field study and performed in normoxia, and with 
90 minutes and 180 minutes of hypoxic exposure. All TCD measurements were 
performed three times by both investigators. 
 
Hypoxia:  After baseline measurements, subjects were subjected to 3 hours of 
normobaric hypoxia (FiO2 = 12%; approximately equivalent to an altitude of 
4,400m) using a tight fitting mask and hypoxicator (Everest Summit Hypoxic 
Generator, Hypoxic Systems, New York, NY). Inspired oxygen concentration 
was regularly checked (Class R-17D Oxygen Sensor, Oxycheq, Florida, USA). 
Extended MRI-compatible tubing enabled the subjects to remain hypoxic during 
the MRI and TCD studies at 3 hours.  
 
MRI: A 3 Tesla MRI (TIM Trio, Siemens AG, Eriangen, Germany) was 
performed at baseline and at 3 hours of hypoxia. At both time points, 3-
dimensional time of flight (TOF) Magnetic Resonance Angiography (MRA) was 
performed (TR=8.6ms; TE 4ms; FA 20o; 3 acquisition slabs; matrix 256 x256 x 
15; voxel dimensions 1.2 x 1.0 x 7.0mm), principally to permit estimation of 
MCA diameter. To measure MCA blood flow velocity, a single-slice 2-
dimensional ECG-triggered segmented phase-contrast acquisition (TR 30.3ms; 
TE 5.5ms; FA 30o; matrix 384x384; voxel dimensions 0.5 x 0.5 x 6.0mm) was 
performed with through-plane flow-sensitization with velocity-encoding factor of 
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150 cm/s. An 800ms ECG-synchronized acquisition window was sampled with 
25 phases proving velocity sensitive images with an effective temporal 
resolution of 32ms. A consistent section of the right proximal MCA 
(approximately 1 cm from the bifurcation to correspond to the TCD area of 
investigation) was studied to provide estimates of blood velocity, the imaging 
plane being prescribed orthogonally to the main axis of the MCA.  
 
In order to estimate MCA diameter, TOF MRA data were post-processed using 
the maximum intensity projection (MIP) function on a calibrated Siemens 
Leonardo workstation (Siemens AG, Erlangen, Germany). An independent 
consultant neuroradiologist, blinded to the pre- or post- hypoxia induced status 
of the subjects, assessed the maximum and minimum diameters, the 
circumference and cross sectional area of both MCAs on 2data sets in all 
subjects. A semi-automated vessel tracing technique utilising the In-Space 
vessel analysis program (Syngo MMWP Software, version VE36A with service 
pack SP03) was performed to analyse the length of MCA on the post-processed 
3-dimensional rendered MIP images. This was done by manually entering 2 
data points; proximally at the A1/M1 bifurcation of the terminal internal carotid 
artery and distally at the distal M1 segment of the MCA at the bi/tri-furcation. 
Multiplanar views of the segmented length for analysis of the M1 segment were 
then automatically generated by the program, which included a true cross-
sectional view (Figure 2c). This automatically generated length of the M1 
segment of the MCA was then divided equally into 5 data points, which were 
replicated and were therefore consistent in both pre- and post- hypoxia studies 
for the respective lateralised M1 segment. The window width and level were 
standardised on the true cross sectional display panel at 200:100. A semi-
automated calculation of the cross-sectional area and circumference was 
performed by the program using a 'best-fit' algorithm with minimal refinement of 
the threshold levels and individual plotted data points. The maximum and 
minimum diameters were also determined at the same data point. This process 
was repeated at all 5 data points for each side (left and right M1 segments) in 
pre- and post- hypoxia studies in all patients. Similar vessel analysis techniques 
have been previously utilised by other researchers to interrogate TOF MRA 
acquisitions (Reese, Bochelen et al. 1999; Beckmann 2000; Besselmann, Liu et 
al. 2001; Choy, Ganesan et al. 2006).   
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MCA flow velocities were obtained from the phase-contrast imaging data also 
using software provided by Siemens (Argus Flow tool). The extent of the MCA 
margins was determined by manually defining an enclosing region of interest 
(ROI), which was adjusted for each phase to account for changes through the 
cardiac cycle. The software then automatically determined the average flow 
velocity for each subject. 
 
Figure 3-3 demonstrates the experimental protocol within the National Hospital 
for Neurology and Neurosurgery’s MRI facilities. 
 
Figure 3-2 Ultrasound images demonstrating a) MCA velocity and b) vessel diameter 
measurement;  c) composite of 4 MRI Images demonstrating MCA multiplanar 
reconstruction and analysis 
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Figure 3-3 Images of hypoxic subjects and undergoing MRI imaging while still hypoxic 
 
Flow and Oxygen delivery calculations: Blood Oxygen content was calculated 
using the formula: Blood Oxygen content = 1.36 x Hb x SaO2/100. The small 
quantity of dissolved oxygen (decreasing further at altitude) was not included in 
the estimation. 
 
Middle Cerebral Artery Blood Flow was calculated using the formula: Flow = 
π(MCAdiam/2)2 x MCAvel. This estimation does not take account of vessel wall 
resistance or changes due to any turbulent flow. Oxygen delivery was 
calculated as the product of blood flow and oxygen content. 
 
3.3.3 Statistics 
 
High Altitude Study: For each measure, differences in scores between altitudes 
were examined using the linear mixed models procedure in SPSS™ version 18 
(IBM, Michigan, USA) in order to maximize the utilisation of the data collected. 
The method of restricted maximum likelihood was used to estimate model 
parameters, and variance / covariance structures were modelled as 
heterogeneous Toeplitz. Pairwise comparisons within each analysis were 
conducted using estimated marginal means using Sidak's adjustment to 
compensate for multiple comparisons. For all tests, significance was set to 
<0.05. 
Sea Level Hypoxic MRI Study: Differences were again examined using the 
linear mixed models procedure in SPSS™ for consistency. The same means 
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and the same variables were found to reach significance when checked with 
general linear models. Relationships between variables were examined using 
Pearson's correlation. Correlations were considered significant when p<0.05. 
The coefficient of determination (r2) is also reported as an indicator of the 
correlation effect size. 
 
Inter-rater reproducibility for the MRI/TCD ratings was examined using intra-
class correlations (averaged measures) to examine the agreement between 
raters over the range of measures taken at different time points. 
 
3.4 Results 
 
3.4.1 High Altitude TCD Study: 
 
There were no technical problems encountered with the TCD and NIRS devices. 
Data were not available on one subject at 3500m (non-altitude related 
gastrointestinal disturbance) and one subject at 5300m (severe Acute Mountain 
Sickness). These missing data were accounted for as part of the multi-level 
modelling technique. Subject characteristics and basic physiological variables 
for the different groups at each altitude are presented in table 3-1. 
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Table 3-1 Subject characteristics and basic physiological variables with estimated 
marginal means, significance of change and confidence intervals (CI) using multilevel 
modelling. Note: altitudes with the same superscript letter do not differ significantly (i.e. 
they belong to a homogenous subset). 
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Table 3-2 summarises the means of measured variables, the confidence 
intervals and the significance of changes with increasing altitude.  
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Table 3-2 Estimated Marginal Means, significance of change and confidence intervals (CI) 
for each variable using multilevel modelling. Note: altitudes with the same superscript 
letter do not differ significantly (i.e. they belong to a homogenous subset).  
 
Regional cerebral oxygenation (rSO2) values (derived from NIRS), peripheral 
saturations (SaO2) and end-tidal CO2 (EtCO2) decreased with each increase in 
altitude (P<0.05). MCAvel did not change at any altitude. MCADiam remained 
constant until extreme altitude (6400 and 7950m) where a marked increase was 
observed (5.3mm at sea level, 6.66mm at 6400, 9.34mm at 7950m, p<0.002). 
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Figure 3-4 Composite of 7 graphs demonstrating changes in blood pressure, SaO2, rSO2, 
end-tidal CO2, peak systolic, end diastolic and mean velocities, MCADiam, calculated 
MCAFlow and Oxygen delivery (note, blood pressure and EtCO2 were not reassessed after 
oxygen administration at 7950m).  
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Sea Similarly, calculated MCA flow and MCA oxygen delivery markedly 
increased at 6400m and above (MCA flow from 13.3ml/sec at sea level to 
23.7ml/sec and 6400 and 41.2ml/sec at 7950; Oxygen delivery from 2.5ml/sec 
at sea level to 4.7ml/sec at 6400 and 7.0 ml/sec at 7950m; p<0.01 for all). 
Figure 3-4 demonstrates these changes in graphical format. 
 
3.4.2 Level Hypoxic MRI Study 
 
All 7 subjects completed 3 hours of hypoxia and underwent the complete study. 
Because of technical difficulties, one observer was unable to adequately 
measure the MCA values utilising TCD in one subject in normoxia. This data set 
was otherwise complete. Tables 3 displays the changes in mean blood 
pressure, pulse, SO2, rSO2, end-tidal CO2, Oxygen content, ultrasound and 
MRA-measured vessel diameters, and blood velocity and calculated blood flow 
and oxygen delivery. 
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Pulse (beats/min) 58.00 62.71 64.14 2 6.39 1.62 0.27 
CI (46.99–69.01) (53.39–72.035) (55.03–73.26)     
Systolic BP 
(mmHg) 
115.90 113.86 114.71 2 6.04 0.42 0.67 
CI 
(109.32–
122.40) 
(105.36–
122.36) 
(97.13–132.30)     
Diastolic BP 
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68.00 62.86 66.57 2 6.00 2.44 0.167 
CI (58.95-77.05) (59.30-66.42) (55.54-77.61)     
SaO2 (%) 98.29 
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CI (96.06-100.51) (67.66-84.34) (67.55-82.16)     
rSO2 (mean R&L) 
(%) 
71.10 a 50.47 b 50.33 b 2 5.70 65.71 <0.001 
CI (63.58-78.61) (45.92-55.03) (44.62-56.04)     
ETCO2 (kPa) 5.23
 a 2.64 b 2.63 b 2 6.20 44.08 <0.001 
CI (4.43-6.03) (1.95-3.33) (1.97-3.30)     
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Oxygen Content 
(ml per 100mls) 
18.78 a 14.57 b 14.34 b 2 6.37 29.20 0.001 
CI (17.84-19.71) (12.51-16.63) (12.53-16.15)     
TCD measured 
MCAv (cm/sec) 
65.23 a 74.29 b 71.60 a,b 2 6.15 15.08 0.004 
CI (48.36-82.10) (55.60-92.98) (51.51-91.68)     
MRA measured 
MCAv (cm/sec) § 
32.80 - 38.75 1 6.00 17.56 0.006 
CI (21.61-43.99) - (27.25-50.35)     
TCD measured 
Diameter (mm) 
5.44 a 6.23 b 6.28 a,b 2 4.16 11.28 0.021 
CI (5.17-5.70) (5.67-6.78) (5.61-6.95)     
MRA measured 
Diameter(mean 
R&L) (mm) § 
3.04 a - 3.27 b 1 6.00 17.56 0.006 
CI (2.79-3.29)  (3.01-3.53)     
TCD Calculated 
Flow (ml/sec) 
14.83 a 22.07 b 21.87 b 2 6.54 19.45 0.002 
CI (12.34-17.31) (18.31-25.84) (15.90-27.84)     
MRA Calculated 
Flow (ml/sec) § 
2.33 a - 3.23 b 1 6 12.40 0.013 
CI (1.65-2.99)  (2.28-4.18)     
TCD Calculated O2 
delivery 
(mlsO2/sec) 
2.77 3.18 3.15 2 6.35 2.14 0.184 
CI (2.38-3.15) (2.63-3.74) (2.15-4.14)     
MRA Calculated 
O2 delivery 
(mlsO2/sec)§ 
0.44 - 0.45 1 6.00 0.33 0.586 
CI (0.32-0.55)  (0.32-0.59)     
Table 3-3 Estimated Marginal Means, F values and Confidence Intervals (CI) of heart rate, 
blood pressure, periphral and regional brain saturations, End Tidal CO2, calculated 
oxygen content, transcranial Doppler, MRA measured velocities and Ultrasound and MRI 
measured diameters, calculated flows and calculated oxygen delivery (note, there was no 
MRI study at 90 minutes of hypoxia). 
 
Middle Cerebral Artery diameter increased after three hours exposure to 12% 
hypoxia, when measured using ultrasound or MRI (TCD: 5.44mm to 6.28mm; 
MRI: 3.04mm to 3.27mm P=<0.05 for both). Cerebral blood velocity did not 
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significantly increase when assessed with either method (TCD: 65.2cm/sec to 
71.6cm/sec; MRI: 32.8cm/sec to 38.8cm/sec (p=0.13)). 
 
Cerebral blood flow, calculated with either methodology, increased (TCD: 
14.8ml/sec to 21.9ml/sec; MRI: 2.3ml/sec to 3.2ml/sec p<0.01). Calculated 
Oxygen delivery was maintained whether measured using ultrasound or MRI. 
 
3.4.3 Correlation of TCD and MRI 
 
TCD and MRI measured vessel diameters correlate (r = 0.82 (Pearson’s). r2 
=0.67 (figure 3-4)). However, although there was a strong correlation, a 
sizeable, though constant, difference between TCD and MRI values was 
identified: for example, normoxia TCD measured MCADiam =5.44mm; normoxia 
MRA measured MCADiam = 3.04mm. This results in marked differences in 
calculated flow and oxygen delivery since the square of the radius has a large 
contribution to these calculations - see discussion).  
The interclass correlation between the two TCD observers was 0.76. 
 
Figure 3-4 Correlation between TCD and MRI measurements of MCA diameter 
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3.5 Discussion 
 
This is the first field study to assess cerebral perfusion over 5500m. The 
technical advance demonstrated in this study is that transcranial ultrasound can 
be used to measure changes in cerebral vessel diameters and the changes 
detected using such a technique correlate with MRI measurements. I have 
shown, for the first time, that exposure to hypoxia is associated with an increase 
in middle cerebral artery diameter and that this is a consistent finding in both 
normobaric and hypobaric hypoxia. Thus, the measurement of velocity alone is 
likely to be unreliable in evaluating middle cerebral artery blood flow. In 
acclimatised subjects ascending to extreme altitude, the vessel calibre change 
appears to be of greater importance to increasing flow than changes in the 
velocity of the blood within it. Oxygen supplementation at 7950m rapidly 
reversed the observed MCA dilatation. Such dilatation and its rapid reversal 
through administration of supplemental oxygen have not previously been 
described, and challenge currently accepted concepts relating to adaptive 
mechanisms. 
 
The main strength of this study is that two differing techniques (MRA and 
ultrasound) have demonstrated that MCA diameter increases with hypoxia and 
that these techniques are well correlated. I have demonstrated the same 
phenomenon in normobaric and hypobaric hypoxia and that vasodilatation is 
reversed by the administration of supplemental oxygen at 7950m. However, my 
studies do have inherent weaknesses which relate to subject selection, 
technical and logistical limitations. Firstly, subjects were all experienced high 
altitude climbers, whose physiological responses may, in some way, have been 
‘selected for’. Many were young (which may account for some of the differences 
in MCA diameter compared to angiographic/cadaver studies – see below). Thus, 
these findings require confirmation in those of different ages, sex and ethnic 
group as well as in non-mountaineers.  
 
Secondly, combining assessments of vessel anatomy (from colour mapping) 
and flow velocity (from pulse-wave Doppler) allows vessel flow to be estimated. 
Such calculations do, however, assume frictionless laminar flow. Further, only 
maximal MCADiam is used. True measures of flow would thus have to integrate 
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flow velocity with changes in vessel diameter across the cardiac cycle.  Caution 
should thus be applied when interpreting absolute values. However, I am 
confident about the observed trends and relative changes. In support, the 
marked increases in vessel diameter observed at extreme altitude (6400m and 
7950m) were rapidly reversed with supplemental oxygen. Further, in the high 
altitude study, the ascent profile of 17 days to 5300m was relatively gentle and 
all subjects were partly acclimatized when studied, having been at the study 
altitude for 1 to 3 days. The lack of increase in MCAVel which I observed is thus 
consistent with other studies of MCA velocity measured 24-72 hours after arrival 
at altitude(Chan, Hoar et al. 2005; Van Osta, Moraine et al. 2005; Brugniaux, 
Hodges et al. 2007; Ainslie, Ogoh et al. 2008). There was no change in 
MCADiam up to 5300m, suggesting repeated measurements of MCADiam using 
this technique are reliable and repeatable.  
 
Thirdly, the measurements at 7950m demonstrating the largest increase in 
MCADiam were performed within 36-48 hours of arrival, and all subjects had 
used supplementary oxygen to climb from 7100m to that altitude. It may be that 
these larger observed changes were a more acute effect. Further studies during 
exercise and with acute exposure, both of which may accentuate the changes, 
are advocated.  
 
Although changes in relative measurements of ultrasound and MRA-measured 
middle cerebral artery diameters correlated well, actual values were significantly 
different (for example, TCD diameter measurements in normoxia and hypoxia 
were 5.44mm and 6.28mm while corresponding MRA diameter measurements 
were 3.04mm and 3.27mm). Such disparity has been previously reported, 
ultrasound (both Colour Doppler as we used and Power Doppler) yielding larger 
diameter measurements than MRI (Table 3-4). Since my ultrasound and MRA 
measurements correlate well, this implies that although the ultrasound 
measured diameter may not be a true diameter, it reliably reflects changes in 
diameter. It may be that the plane of the ultrasound, although consistent, is not 
truly tangential to the vessel and hence the cross-sectional area may be more 
eliptiform. Alternatively, the increase in velocity of blood at the vessel wall 
edges may make it appear more visible on Doppler ultrasound and give the 
impression of a widened vessel. I note Poulin and Robbins previous work 
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(Poulin and Robbins 1996; Poulin et al 2002) that did not demonstrate a change 
in the Power signal (implying no change in vessel cross-sectional area). It may 
be that the actual cross-sectional diameter change is closer in value to that 
detected by MRI, in which case, Power signal may not change significantly.  
 
Measurement 
Modality 
Mean MCA diameter (mm) Number 
of 
subjects 
*Notes 
Cadaver 2.5-4mm  
(mean =3.35mm) (Pai, Varma et al. 
2005)  
5  
MRA  
(all 1.5Tesla) 
2.9mm (Serrador, Picot et al. 2000)  
2.73mm (Schreiber, Gottschalk et al. 
2000)  
2.23mm (Tarasow, Abdulwahed Saleh 
Ali et al. 2007)  
2.95mm (Hansen, Pedersen et al. 
2007)  
3.4mm (Valdueza, Balzer et al. 1997) 
12 
8 
36 
 
12 
6 
 
Angiography 2.38mm (Tarasow, Abdulwahed Saleh 
Ali et al. 2007) 
36  
Power Doppler 
Proximal MCA:  
Distal MCA: 
 
5.2mm 
4.3mm(Muller, Schwerdtfeger et al. 
2000) 
 
17 
Subjects 
suspected of 
having 
vasospasm 
TCCS 
Proximal MCA: 
Distal MCA: 
 
5.9mm  
4.9mm(Muller, Schwerdtfeger et al. 
2000) 
 
17 
Subjects 
suspected of 
having 
vasospasm 
Table 3-4 Results of various studies measuring mean MCA diameters using direct vision 
(in cadaver studies), MRA, angiography and Doppler. The differences between MRA- and 
Doppler-measured diameters are similar to my data. TCCS = Transcranial Colour-Coded 
Sonography 
 
My data imply that rSO2 decreases in the face of increased cerebral oxygen 
delivery at 7950m. An increased delivery of de-oxygenated blood would 
however not be expected to result in an increase in regional oxygen saturation. 
rSO2 measures the ratio of oxygenated to deoxygenated blood in the 
interrogated region and does not reflect the flux of blood (or flux of oxygen) 
passing through. In addition, many other factors (such as alterations in the 
contribution of arterial and venous compartments due to changes in intra-vessel 
volume) will affect rSO2 (Wolff, Richardson et al. 2007).  
 
There have not been many studies validating TCD- estimated changes in 
cerebral blood flow against other measures of cerebral perfusion. It is 
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interesting to note that some of the few studies that have attempted to correlate 
cerebral perfusion as measured using the Kety-Schmidt technique have found 
very poor correlations with TCD velocity measurements (Weyland, Stephan et 
al. 1994; Nuttall, Cook et al. 1996). Giller’s group investigated further the use of 
TCD during exercise and concluded that, because of probable vessel diameter 
change, the use of TCD velocities to interpret cerebral blood flow during 
exercise might be invalid (Giller, Giller et al. 2000). Our data supports the view 
that caution must be used when using TCD velocity data to imply changes in 
cerebral perfusion. 
 
3.5.1 Possible Mechanisms of Vasodilatation: 
 
In order to maintain cerebral oxygen delivery (COD) in an increasingly hypoxic 
environment, one would expect to see an increase in cerebral blood flow (CBF). 
This can be influenced by alterations in vessel diameter and the velocity of 
blood within it (which in turn is determined by blood pressure and blood 
viscosity - Poiseuille’s law). In this study, the first to measure both diameter and 
velocity with two techniques, vasodilatation appears to be the principal factor 
affecting flow.  It may be that with increasing viscosity of blood, vasodilatation 
becomes the most important mechanism. 
 
A number of mechanisms could be proposed to underlie vasodilatation: 
 
Hypoxia: Hypoxia-induced increases in adenosine and nitric oxide, previously 
thought to mediate vasodilatation at an arteriolar level, might cause arterial 
vasodilatation. Other factors (such as those mediated by Hypoxia Inducible 
Factor and the cascade it induces) are thought to occur over a longer time 
period (Wilson, Newman et al. 2009). The rapid reversal of arterial dilatation 
with oxygen suggests a direct hypoxic effect.  
 
Hypocarbia: A paradoxical phenomenon of hypocarbic vasodilatation has 
previously been observed in forced hyperventilation (Wollman, Smith et al. 
1968; Du Boulay and Symon 1971). Du Boulay and Symon noted vasodilatation 
angiographically with PaCO2 values of 20-25mmHg (2.6-3.33kPa). Whilst such 
a mechanism was not thought physiologically relevant, the extreme 
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hyperventilation and consequent hypocapnea that occurred at 7950m (mean 
ETCO2 = 12.8mmHg = 1.7KPa) might be inducing this paradoxical effect.  
 
3.5.2 Implications in High Altitude Illness 
 
The arterial oxygen content (CaO2) at rest in a sub-group of my subjects has 
previously been reported and is maintained at sea-level values up to and above 
7100m(Grocott, Martin et al. 2009). The reduction in CaO2 above that altitude 
coincides with the marked MCA arterial dilatation observed. Exercise at altitude 
is known to decrease CaO2 and increase blood pressure (Imray, Myers et al. 
2005). Similarly, Moller reported that CaO2 was not only maintained, but 
increased at rest at high altitude. Opposite to sea level observation, CaO2 
decreased slightly at the altitude of 5260m (Moller, Paulson et al. 2002). 
Although the increase in MCADiam only occurred above 5300m, a similar change 
may also occur at lower altitudes as a response to acute hypoxia, or during 
exercise at altitude (both of which are known to be potential triggers for AMS 
and HACE). According to LaPlace’s Law (vessel wall tension= blood pressure x 
radius), the observed increase in MCADiam will result in an increase in vessel 
wall tension.  
 
The trigeminovascular system has been implicated in the genesis of both high 
altitude headache and Acute Mountain Sickness (AMS) (Jansen, Krins et al. 
2000; Van Osta, Moraine et al. 2005). The observed cerebral vessel dilatation 
may act as a direct mechanical trigger for this system. Alternatively, failure to 
dilate might result in increased MCA velocities and raised arterial pressures in 
an attempt to maintain an adequate cerebral oxygen delivery, which could also 
have implications in the development of high altitude illness. 
 
Deaths above 8000m on Everest have been associated with cognitive 
impairment, ataxia, profound fatigue, late summit times and a tendency to fall 
behind (Firth, Zheng et al. 2008). Our group’s recent study with blood gas 
analysis at 8400m (n=4) demonstrated that mean PaO2 was 3.28kPa and 
PaCO2 was 1.77kPa (Grocott, Martin et al. 2009). It is therefore suggested that 
some climbers suffer an acute hypoxic cerebral dysfunction and it may be that 
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they are reaching the limits of the adaptive mechanisms for maintaining CaO2 
and Cerebral Oxygen Delivery.  
 
3.5.3 Clinical Implications 
 
Giller, in his editorial “The Emperor has no clothes”, challenged the long held 
assumption that any changes in cerebral artery diameter that might occur are of 
no significance (Giller 2003). Other studies have highlighted the need to obtain 
quantitative measures of cerebral blood flow if there is reason to suspect that 
the diameter of the MCA might not remain constant, for example, when drugs 
such as nitroglycerin are used (Zuj, Greaves et al. 2007). 
The two studies reported here confirm that marked cerebral hypoxia is 
associated with significant increases in cerebral artery diameter. The wider 
implication from this study is that any future investigations measuring cerebral 
vessel blood velocity must also consider potential changes in vessel diameter. 
Vasospasm is known to occur following subarachnoid haemorrhage (Gonzalez, 
Boscardin et al. 2007). This study demonstrates that hypoxia also affects vessel 
calibre. Other conditions and factors such as sepsis, inflammatory mediators, 
drugs and alterations in blood pH may have similar effects.  
These findings offer new insights into the possible underlying pathophysiology 
of AMS and HACE, and highlight the importance of concurrent measurement of 
vessel calibre when using Doppler velocities to infer flow. The correlation of 
ultrasound measurements with MRA measurements implies that ultrasound 
may enable repeated assessments of cerebral artery size and flow at the 
bedside, during hospital transfer or in the field (Wilson, Levett et al. 2011).   
 
3.6 Conclusions: 
 
This is the first field study of cerebral perfusion above 5500m, and the first to 
show that exposure to extreme hypobaric hypoxia is associated with an 
increase in MCA diameter that is rapidly reversed by inhaled supplemental 
oxygen. These field TCD findings have been replicated and confirmed using 
MRA in acute hypoxia at sea level. This has uniquely demonstrated that 
ultrasound and MRA MCA measurements correlate. The increased diameter, as 
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opposed to increased blood velocity, is the major factor increasing cerebral 
blood flow and maintaining oxygen delivery. This may have implications for the 
pathogenesis of cerebral high altitude illness and the acclimatization process. 
Future studies inferring cerebral blood flow from transcranial Doppler velocity 
measurements at altitude and clinical studies where oxygenation may change, 
must take vessel calibre into account. 
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4 Chapter 4: BRAIN OXYGENATION AT REST AND DURING 
EXERCISE TO VO2MAX AT ALTITUDE  
 
4.1 Abstract 
 
The cerebral hypoxia occurring on ascent to high altitude is thought to be 
central to a number of physiological processes and clinical conditions (such as 
Acute Mountain Sickness and High Altitude Cerebral Oedema). Cerebral 
hypoxia is exacerbated by exercise during exposure to systemic hypoxia. I 
sought to (i) better define this relationship (ii) characterise its inter-individual 
variation, and (iii) explore the extent to which sea-level variables might predict 
this response.  
Methods: Subjects were drawn from the Caudwell Xtreme Everest Expedition, 
as described in past chapters. Changes in regional cerebral oxygenation (rSO2) 
at rest and with exercise to VO2Max were sought amongst 171 individuals of the 
‘trekker’ cohort, ascending to 5300m. A smaller group (“investigators” n=24) 
ascending to 5300m and the resting cerebral oxygenation of a subgroup (n=7) 
ascending to 7950m were also studied. 
Results: Trekkers: At sea level, mean absolute rSO2 rose with increasing work 
intensity from rest to anaerobic threshold ([mean + SEM] 68.9 + 0.54% vs 71.3 
+ 0.55%, p <0.001), but fell when VO2Max was reached (67.4 + 0.71%% ; p 
<0.001 from anaerobic peak). Values of rSO2 at rest and at VO2Max both fell 
with increasing altitude (resting values 59.3 + 0.53% vs 53.6 + 0.62%, and at 
VO2Max 50.3 + 0.68% vs 45.11 + 0.62% for 3500m and 5300m respectively). 
Proportionally the relative reduction in rSO2 was greater than the relative 
reduction in SaO2, both at rest with increasing altitude and with exercise at 
altitude. The relative percentage reduction in resting SaO2 from 75m to 5300m 
was -22.23 ± 0.56%. The relative percentage reduction in resting rSO2 from 
75m to 5300m was -30.61 ± 1.28% (paired t test p<0.001). During exercise at 
5300m, SaO2 fell 9.2 + 0.59% between rest and VO2Max while rSO2 fell 15.6 
+0.97% between rest and VO2Max (expressed as a percentage of the 
respective resting Sa02/rSO2 value at that altitude) (paired t-test p=0.002). 
Cluster analysis demonstrated that those who had a greater cerebral 
desaturation at 75m during exercise have a greater desaturation at 5300m 
(p<0.05). The desaturation both at rest and during exercise in relatively acute 
hypoxia (arrival at 3500m) appeared to be greater in the right than left cerebral 
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hemispheres (p=0.005). At increasing altitude, a positive correlation between 
resting rSO2 and height and male gender was demonstrated, as was a negative 
correlation between age and female gender.  No correlation was found between 
rSO2 and headache score. 
Conclusions: Subjects who cerebrally desaturate during exercise at sea level 
tend to desaturate more at altitude. Although subjects who cerebrally 
desaturate more (both resting measures and with exercise) recorded a higher 
headache severity index this difference is not statistically significant. Further 
analysis (e.g. of neurocognitive data) may demonstrate a correlation between 
desaturation and mental performance, but that is beyond the scope of this 
chapter. 
 
4.2 Introduction 
 
Exercise-induced hypoxaemia of high altitude contributes to the pathogenesis 
of AMS (Hackett and Roach 2001) and also to impaired mental performance 
which, in extreme, may be significant factor in high altitude deaths (Firth, Zheng 
et al. 2008).  
Past studies of cerebral oxygenation (rSO2) at altitude have involved small 
numbers of highly selected subjects. I sought to extend these observations to a 
much larger cohort, and also to explore the hypotheses that: 
1) Changes in cerebral oxygenation during exercise at sea level are 
indicative of changes during exercise at altitude. 
2) Changes in cerebral oxygenation correlate with headache at altitude. 
 
4.3 Methods 
 
General methodology and exercise protocols of the Caudwell Xtreme Everest 
expedition have been described elsewhere (Grocott, Martin et al. 2010; Levett, 
Martin et al. 2010), being summarised in chapter 2. Ethical approval was 
granted by University College London.  
 
Subjects: The study was divided into two groups.  
Trekker Group: A group of 198 trekkers (125 male, age range 18.3 to 70.3; 
mean = 44.7 years) who ascended to 5300m over 11 days. 
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Investigator Group: A group of Base Camp investigators and climbers (n=24, 18 
male, mean age 35.2 years [range 19-59]) who ascended to 5300m over 13 
days. Fourteen of these (“Climbers”) ascended higher on the mountain with 7 
being studied at 7950m (the South Col of Everest). 
Ascent: Baseline studies were performed in London. Further studies were 
performed at 3500 (Namche Bazaar) and 5300m (Everest Base Camp).  The 
ascent profile is demonstrated in figure 2-3. 
 
Subjects were either studied on day 1 or day 2 after arrival at the new altitude 
and this study day was constant for each subject. Subjects were required to sit 
on an upright cycle ergometer (figure 4-1) whilst being prepared for the study.  
Pulse and peripheral arterial oxygen saturations (SaO2) were monitored 
throughout the study. Regional brain oxygenation (rSO2) was monitored using a 
cerebral oximeter (INVOS C NIRS device, Invos, Somanetics, MI, USA) with 
measurements being taken from both left and right frontal regions at 7-second 
intervals (figure 4-2). The probes had self-adhesive properties to stick to the 
skin but were, in addition, held with a black sweatband to help prevent 
movement and the incursion of extraneous light. rSO2 data were recorded 
internally within the NIRS devices and subsequently converted to excel format 
for analysis. After 3 minutes of rest, and a further 3 minutes of unloaded 
exercise, subjects underwent a graded exercise, with maximal exercise capacity 
assessed using an incremental cardiopulmonary exercise testing (CPET) 
standardised ramp with breath-by-breath expired gas analysis (below). The time 
point of AT and VO2Max was retrospectively calculated from CPET data (below). 
VO2 was calculated as the average oxygen consumption for the individual 
breaths taken during 20 second increments of the exercise test. The time for 
VO2Max was reported as the middle time point of the 20-second time interval 
with maximal VO2. Data were plotted on 
graphs of SaO2 versus time and were 
visually assessed for quality and 
completeness. 
Figure 4-2 is the display of the cerebral 
oximeter at the end of a study at 5300m. 
It has been annotated to demonstrate 
the time points subsequently studied. 
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Figure 4-1 Exercise testing on two upright cycle ergometers at Everest Base Camp. The 
NIRS forehead probes are secured under a sweatband. 
 
Exercise Protocol: The subjects performed an incremental ramp test to the limit 
of tolerance using an electromagnetically braked cycle ergometer (Lode Corival; 
Lode, Groningen, the Netherlands) and a breath-by-breath cardiopulmonary 
exercise testing system (Metamax 3b; Cortex, Leipzig, Germany). A full 
calibration of the breath-by-breath system was performed before each test. 
Prior to the incremental exercise test, subjects warmed up with a low- intensity 
30-minute constant work rate protocol. A ramp slope of 20 to 35 W/minute was 
chosen depending on the sex, age and physical fitness of the subjects in order 
to obtain a predicted test duration of approximately 10 to 15 minutes. The ramp 
slope was kept constant throughout each study. Readings were taken during 3 
minutes of complete rest, 3 minutes of unloaded cycling then during exercise to 
Anaerobic Threshold (AT - time variable per individual) and to maximal oxygen 
consumption (VO2Max – time variable per individual). NIRS readings continued 
into the recovery phase for a further 2 minutes. 
 
 
Figure 4-2 Labelled raw output of time vs rSO2 (regional brain oxygen saturation) 
displayed on the INVOS C. This demonstrates the left (white) and right (blue) values and 
the typical changes that occur at each stage of the cycle ergometer exercise to VO2Max 
at Everest Base Camp (5300m). 
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Variables: Basic physiological variables were recorded in addition to rSO2 at 
key time points. These included: peripheral arterial oxygen saturation (SaO2) 
measured on the subjects’ right index finger, blood pressure (only the mean 
arterial pressure MAP is reported here) and end-tidal CO2 (EtCO2). Details on 
the equipment used for these and the cycle ergometer is available separately 
(Levett, Martin et al. 2010), and summarised in chapter 2. 
 
Additional variables were calculated from those recorded: 
Percentage Changes: Because SaO2 and rSO2 are not directly comparable 
(virtually all subjects will have a normoxic resting peripheral saturation of 95 to 
99%, while the resting rSO2 values have greater variability and start lower).  
Hence two terms are used for clarity in reporting – Absolute percentage 
changes (of raw SaO2 and rSO2 values) and relative percentage changes 
(relative to baseline values). The relative baseline for resting values at each 
altitude uses the value at rest at sea level. For the exercise experiments, the 
relative changes are expressed as a percentage of the resting value at the 
corresponding altitude.  
 
Arterial Oxygen Extraction: Arterial Oxygen Extraction (AOE) is calculated as:  
 
AOE = (p+1)(1-rSO2/SaO2)  ≈ 1.39 x (1-rSO2/SaO2) 
 
This assumes the ratio (p) of arterial blood (Va) to venous blood (Vv) within the 
area of investigation is constant (the ratio being Va/Vv = 0.39) (Wolff, 
Richardson et al. 2007). As explained in the introduction, I believe that the 
venous component of intracranial blood volume increases. AOE is however 
commonly calculated hence I have included it in the analysis but will interpret it 
cautiously.   
 
4.3.1 Study Power: 
 
The number of subjects in the CXE groups overall were largely determined by 
logistic constraints.  However, with α=p=0.05 and power (ß) = 0.8, detecting an 
effect size of 0.5 between two populations who respond differently would need 
N=64 in the two populations. Assuming the populations are of equal size this 
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would require N = 128 (Cohen 1992). Allowing for attrition of subjects, the 
expedition aimed to study 200 subjects. In reality, this specific study analyses 
171data sets. 
 
Cluster and Statistical Analysis:  
The technique of cluster analysis is explained within the section on cluster 
analysis below. For comparative analyses, SaO2 or rSO2 values were 
expressed as a percentage either of the resting value at 75m (when studying 
changes with altitude) or as a percentage of the resting value at the start of an 
exercise protocol (when studying changes with exercise). 
No basic data from the trekking group were imputed (subjects with such missing 
data were excluded). For the core group (n=24), two subjects missed exercising 
testing at 3500m (Namche) and their NIRS data was imputed using linear 
modelling. 
Multilevel modelling was used to maximise the use of all available data. Hence, 
the number of subjects at each altitude varies (see results). Estimated marginal 
means were calculated for each variable. Post-hoc tests within multi-level 
modelling were used to compare means. Additional comparisons were 
performed with either independent or paired T-tests. For correlations between 
demographic features (e.g. age, smoking, height, sex) Pearson’s 2 tailed 
correlations were used, correlations between dichotomas and serial variables 
were point biserial. Statistical significance was set at 0.05, but when large 
numbers of correlations were analysed, was set at 0.01 to avoid capitalising on 
chance.  
 
4.4 Results 
 
Note – because of the large amount of data collected, a brief summary and 
explanation of some results is given within the results section. A more detailed 
discussion of relevant results is given within the Discussion. 
 
4.4.1 Trekker Group:  
 
Of 198 starting, 190 subjects reached Everest Base Camp (5300m) and had 
data recorded (6 subjects withdrew from incremental CPET prior to departure 
and 2 were removed because of poor baseline data quality). Missing data 
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principally resulted from: 1) subjects being unwell and unable to ascend/ 
complete exercise or 2) technical error during the study.  
 
Of the 190 data sets, 16 had studies done on incorrect days, hence they were 
excluded (leaving 174 studies). Three studies were missing more than one 
altitudes data set and were also removed. Of the remaining 171 subjects, 6 
were missing London (75m) data, 3 were missing Namche (3500m) data and 27 
were missing data from Everest Base Camp (3500m); hence the number of 
data sets at each altitude was 165, 168 and 144 respectively. Note, of the 27 
missing data at Everest Base Camp, 14 had acute mountain sickness, 6 
diarrhoea and vomiting, 4 respiratory tract infections, 1 hypertension and 2 
arrhythmias.  
 
 
Figure 4.3: Explanation of subject and data attrition.  
 
Descriptive Results 
4.4.1.1 General Results 
 
Regional Cerebral Oxygenation (rSO2): 
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Table 1 shows the estimated marginal mean rSO2 using a mixed model analysis 
for left, right and mean rSO2 during rest, unloaded cycling, at anaerobic 
threshold (AT) and maximal oxygen consumption (VO2Max) at each of the 
altitudes studied (75m, 3500m and 5300m). In addition it displays the estimated 
marginal mean of the lowest rSO2 values recorded in each rSO2 variable (i.e. 
the point of maximal brain desaturation which was usually in the order of 18-24 
seconds after VO2Max (see below)). Finally, the estimated marginal mean 
arterial oxygen extraction during rest, unloaded cycling, at AT, at VO2Max and 
at the point of maximum desaturation is displayed. Superscript letters 
demonstrate significant differences between groups i.e. a is significantly 
different to b, which is significantly different to c. n=171, except for AOE at AT, 
VO2Max and Lowest where some SaO2 data was missing – for these data 
resting AOE n = 171, unloaded AOE n= 171, AT AOE n = 167, VO2Max AOE n= 
165, the lowest AOE n = 164.  
 
Table 4-1 Table of rSO2, AOE and percentage change values at each altitude during each 
stage of exercise. *See text for further details. Groups with different superscript letters 
are significantly different from each other.  
  
Chapter 4 – BRAIN OXYGENATION 130	  
	  
 Mean 75m 3500m 5300m dF F Sig 
R
es
tin
g 
Mean Left 
rSO2 
69.03a 59.69b 53.55c 184.53 391.38 <0.005 
99% CI 67.59–70.47 58.37-61.01 51.91-55.18    
Mean Right 
rSO2 
68.89a 58.57b 53.40c 180.67 371.67 <0.005 
99% CI 67.43-70.35 57.17-59.97 51.70-55.09    
Mean rSO2 68.96a 59.13b 53.45c 178.54 506.62 <0.005 
99% CI 67.60-70.32 57.88-60.38 51.90-55.01    
Mean AOE 0.401a 0.459b 0.452b 169.63 44.16 <0.005 
99% CI 0.38-0.42 0.44-0.48 0.43-0.48   n=171 
U
nl
oa
de
d 
Mean Left 
rSO2 
69.17a 59.10b 52.10c 179.97 425.28 <0.005 
99% CI 67.74-70.61 57.73-60.47 50.41-53.79    
Mean Right 
rSO2 
69.26a 58.07b 52.00c 182.70 419.86 <0.005 
99% CI 67.81-70.72 56.63-59.52 50.30-53.71    
Mean rSO2 69.21a 58.59b 52.02c 175.77 552.67 <0.005 
99% CI 67.85-70.57 57.29-59.88 50.43-53.62    
Mean AOE 0.397a 0.467b 0.478b 170.65 68.88 <0.005 
99% CI 0.38-0.42 0.45-0.49 0.45-0.51   n=171 
rSO2 %age  +0.43a -0.94b -2.81c 177.83 41.04 <0.005 
99% CI -0.53to+0.91 -1.52 to-0.35 -3.62to-2.08    
A
T 
A
T 
Mean Left 
rSO2 
71.29a 55.52b 48.86c 174.26 758.82 <0.005 
99% CI 69.78-72.80 54.15-56.89 47.16-50.55    
Mean Right 
rSO2 
71.38a 54.74b 48.44c 179.99 808.83 <0.005 
99% CI 69.86-72.90 53.30-56.18 46.84-50.05    
Mean rSO2 71.33a 55.14b 48.63c 174.12 1029.6
1 
<0.005 
99% CI 69.91-72.75 53.82-56.45 47.08-50.17    
rSO2 %age  +3.55a -6.79b -9.04c 181.70 429.19 <0.005 
99% CI +2.73to+4.37 -7.82to-5.76 -10.12to-7.95   * 
Mean AOE 0.38a 0.45b 0.42b 138.58 20.41 <0.005 
99% CI 0.34-0.41 0.43-0.47 0.39-0.45    
VO
2 M
ax
 
Mean Left 
rSO2 
67.64a 50.66b 45.28c 184.59 545.12 <0.005 
99% CI 65.64-69.63 48.95-52.37 43.48-47.09    
Mean Right 
rSO2 
67.13a 49.81b 45.10c 198.72 495.32 <0.005 
99% CI 65.17-69.09 47.98-51.64 43.48-46.71    
Mean rSO2 67.38a 50.24b 45.17c 192.79 681.61 <0.005 
99% CI 65.53-69.23 48.57-51.91 43.59-46.76    
Mean AOE 0.41 a 0.52 b 0.49 b 149.98 54.63 <0.005 
99% CI 0.38-0.44 0.49-0.55 0.46-0.53   * 
rSO2 %age  -2.29a -15.12b -15.67b 217.34 200.66 <0.005 
99% CI -4.06to-0.54 -17.25to-12.98 -17.66to-13.68    
Lo
w
es
t 
 
Mean Left 
rSO2 
64.89a 48.53b 43.32c 181.78 445.81 <0.005 
99% CI 62.86-66.92 46.80-50.26 41.52-45.12    
Mean Right 
rSO2 
64.87a 48.02b 43.97c 205.17 450.63 <0.005 
99% CI 62.91-66.83 46.18-49.85 42.31-4562    
Mean rSO2 64.87a 48.28b 43.64c 193.97
6 
584.39 <0.005 
99% CI 63.01-66.74 46.59-49.96 42.05-45.23    
Mean AOE 0.45a 0.55b 0.52b 147.10 44.45 <0.005 
99% CI 0.42-0.48 0.52-0.58 0.49-0.55   * 
rSO2 %age  -5.96a -18.41b -18.54b 222.30 171.51 <0.005 
99% CI -7.74to-4.17 -20.61to-16.22 -20.51to-16.58    
R
ec
ov
er
y 
Mean Left 70.93 a 60.54 b 52.41 c 192.58 403.82 <0.005 
99% CI 69.26 – 72.59 59.07 – 62.01 50.73 – 54.09    
Mean Right 70.04 a 59.28 b 51.94 c 196.48 321.18 <0.005 
99% CI 68.38 – 71.71 57.66 – 60.91 50.23 – 53.65    
Mean rSO2 70.49 a 59.92 b 52.16 c 193.44 491.60 <0.005 
99% CI 68.97 -72.01 58.48 – 61.36 50.58 – 53.74    
rSO2 %age  2.33 a 1.58 b -2.37 c 254.51 28.61 <0.005 
99%CI 1.03 to 3.64 -0.16 to 3.32 -3.87 to -0.86    
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4.4.1.2 Summary of Basic Data and Spilt by Day of Study 
 
Table 4-2 reports the changes of basic variables that are important in 
interpreting brain oxygenation changes at each altitude during the exercise 
protocol (HR, SaO2, Hb, MAP, EtCO2, average Headache Score (HA) and total 
Headache Score (Tot HA). The mean rSO2s and arterial oxygen extractions are 
also shown:  
 
N Males / Females Mean Age Weight (75m) Weight (5300m) 
171 106/65 44.57 (SE 1.03) 74.34 (SE = 0.98) 72.25 (SE = 1.02) 
No of Smokers = 12
 
Table 4-2 Mean (+/-SEM) figures for the group as a whole (combining both day 1 and day 
2 subjects).  HR = Heart Rate (/beats per minute), SaO2 = Peripheral oxygen saturation 
(/%), Hb = Haemoglobin concentration (/mg/dl), MAP = Mean Arterial Pressure (/mmHg), 
PEtCO2 = end tidal CO2 partial pressure (/mmHg). HA = Headache Score, rSO2 = brain 
oxygenation (/%), AOE = Arterial Oxygen Extraction (/%). 
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Comparison of subjects studied on Day 1 and Day 2: 
Table 3 demonstrates the same data, divided by day of exercise testing: on the 
day after arrival at the altitude (Day 1 – table 4-3a) or on the second day after 
arrival (Day 2- table 4-3b).  
 
Day N Males/Females Mean Age Weight (75m) Weight (5300m) 
1 87 56/31 45.98 (SE 1.40) 76.45 (SE 1.52) 73.55 (SE1.57) 
 
 
Table 3a 
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Day N Males / Females Mean Age Weight (75m) Weight (5300m) 
2 84 50/34 43.1 (1.51) 72.17 (SE 1.2) 70.74 (SE 1.25) 
 
 
Table 3b 
Table 4-3 a and b respectively display results for basic variables and for brain 
oxygenation on subjects studied on day 1 and day 2. HR = heart rate, SaO2 = peripheral 
oxygen saturation, Hb = haemoglobin, MAP = mean arterial pressure, HA = Headache 
square, PetCO2 = end tidal CO2, rSO2 = regional brain oxygenation, AOE = arterial oxygen 
extraction. 
  
Chapter 4 – BRAIN OXYGENATION 134	  
	  
4.4.1.3 Other variables – a summary of these results 
 
Note – graphs for some of the following variables appear in chapter 5. 
 
Heart Rate: Resting heart rate (HR) increases with altitude (mean resting HR at 
75m (Mean ± SEM) = 78.1 ±0.92 bpm. Mean resting HR at 5300m = 90.9 
±1.1bpm; p = <0.001). Heart rate clearly increases with exercise (from resting 
78.1 ±0.92 bpm to VO2Max 170.4 ± 1.0bpm) at sea level, but this increase is 
reduced at 5300m (from resting 91.1 ±1.1 to VO2Max 138.4 ±1.5; p<0.001). 
 
SaO2: Although significant, the decrease in peripheral saturation (SaO2) during 
exercise at sea level is considerably less than during exercise at altitude (at 
75m resting SaO2  = 96.9 ±0.09%, VO2Max SaO2 = 96.3 ±0.096 p = 0.001; at 
5300m resting SaO2 = 80.0 ±0.40%, VO2Max SaO2 = 72.1 ±0.49% p <0.001). 
 
Haemoglobin: The mean haemoglobin increased from 14.5 ±0.98g/dl to 15.8 
±1.1g/dl over the 11 days of ascent (p<0.001). 
 
Mean Arterial Pressure: Resting mean arterial blood pressure (MAP) increased 
from 96.9±1.1mmHg at 75m to 98.9±0.9mmHg at 5300m (p<0.001). MAP 
increased to a greater extent with exercise (from rest at 75m 96.9±1.1mmHg to 
VO2Max at 75m 131.2±1.9mmHg; p<0.001) however at altitude, this increase is 
less (from rest at 5300m 98.9±0.9mmHg to 121.6±1.5mmHg at VO2Max; p 
<0.001) Note - no blood pressure was recorded at Anaerobic Threshold as the 
time of this was calculated retrospectively. 
 
Headaches: The Average Headache Score (HA) on the day of study (out of a 
total of 4) was consistently low, being 0.06 ±0.02 at 75m, 0.17 ±0.3 at 3500m 
and 0.38 ±0.05 at 5300m. Although the differences are statistically significant 
(p<0.001), the low values probably reflect the slow ascent profile. 
 
Mean rSO2: The mean rSO2 increases at AT when not hypoxic (75m), and 
returns to a normal or slightly sub-normal at VO2Max (Mean rSO2 at 75m at rest 
68.9 ±0.5%, at AT 71.3±0.6, at VO2 Max = 67.4±0.7; all values are significantly 
different from their previous value p<0.001). At altitude, there is a consistent 
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decrease in mean rSO2 with exercise. (Mean rSO2 at 5300m at rest = 53.7 
±0.6% at AT = 48.84±0.6% and at VO2Max = 45.3 ±0.6% (p=<0.001 between 
these). The mean rSO2 (at rest and during exercise) is consistently higher on 
the second day after ascent than on the first day (e.g. at rest on Day 1 mean 
rSO2 at 5300m = 53.36±0.74%, on day 2 = 54.04±1; at VO2Max day 1 = 
44.8±0.9%, day 2 = 45.9±0.9% (p<0.001). This implies that an element of 
acclimatisation has occurred.   
 
Arterial Oxygen Extraction:  As can be seen from table 4-1, AOE does not 
significantly change during exercise when normoxic (75m) (AOE at 75m at rest 
= 0.41±0.01%, at VO2 Max = 0.41±0.01% (p=0.44). However, on ascent to 
altitude, the AOE significantly increases both at rest (AOE at 75m at rest 
=0.40±0.01%, at 5300m at rest = 0.45±0.1%, p <0.001) and during exercise 
(AOE at 5300m at rest = 0.43 ±0.01%, at VO2Max = 0.49±0.01%, p<0.001). It 
should also be noted that these results must be interpreted with extreme 
caution as they may actually represent a change in arterial:venous 
compartment ratio rather than a genuine increase in arterial oxygen extraction. 
 
4.4.1.4 rSO2 at VO2Max and Lowest rSO2 
 
At altitude, many subjects exhibited a further drop in rSO2 after they had 
reached VO2Max. Hence, rSO2 was recorded at the time of VO2Max, but the 
lowest three values following this were also recorded. At 75m, the value of rSO2 
at VO2Max usually did not have any areas with a significantly different rSO2 
value around it (before or after), however an attempt was made to find a lower 
value to be consistent. The values of lowest rSO2 and the time to the lowest 
rSO2 at sea level are probably meaningless. The values at 3500m and 5300m 
are real. 
 
The mean (and SEM) rSO2 values at VO2Max, the lowest values and the mean 
time between them at each altitude are displayed in table 4-4. 
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rSO2 68.94 68.31 64.89 29.2 59.11 50.11 48.17 18.4 53.68 45.33 43.54 24.2 
SE 0.54 1.02 0.71 3.75 0.48 0.64 0.65 4.6 0.61 0.63 0.64 3.4 
Table 4-4 The differences between rSO2 at VO2Max and the lowest rSO2 reading at each 
altitude with the mean time difference (time diff) between the readings. 
 
The further reduction of rSO2 after VO2Max could be technical (e.g. a delay in 
the cerebral oximeter analysing and displaying the result) or biological (e.g. 
there is a period of further cerebral desaturation before restoration of normal 
cerebral oxygenation occurs). This study is not designed to investigate this 
although it is discussed in greater depth in the discussion. 
 
There is close correlation (figure 4-4) between VO2Max and the lowest rSO2 (at 
both 3500m and 5300m, the correlation is 0.97 (p<0.005)). Hence, since it is not 
clear what the lowest rSO2 values mean, only rSO2 at VO2Max is reported 
beyond this point. 
 
 
Figure 4-4: The 
correlation between 
rSO2 (/%) at VO2max 
and the lowest recorded 
rSO2 at 5300m. 
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CORRELATIONS: 
4.415 – Correlation Within rSO2 Readings 
Correlation between Left and Right rSO2 Values: 
Paired sample correlations and t-tests were used to compare mean left and 
right rSO2 values at each altitude and at rest, unloaded cycling, AT and VO2Max. 
Table 4-5 reports the mean values for left and right rSO2, the number of 
subjects, standard deviation and standard error of the mean, at each altitude at 
rest, unloaded, AT and VO2Max. 
 
Table 4-5 Comparison of left and right rSO2 values at each altitude and at each stage of 
the exercise protocol (Key: L/R = Left/Right; rSO2 = regional saturation; L = London 150m, 
N = Namche 3500m, BC = Everest Base Camp 5300m; Rest = Resting, Unload = Unloaded 
cycling, AT = Anaerobic Threshold, VO2Max = VO2Max). A significant difference was 
found between right and left rSO2 values throughout the exercise protocol at 3500m 
(Namche, underlined). 
 
The left and right rSO2 values were consistently and highly correlated (>0.7, 
and p < 0.001). There was only one location where there was a significant 
difference (p<0.01) between left and right rSO2 values: at Namche (3500m), 
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where the mean resting left rSO2 exceeded that on the right at rest (by 1.15%, 
p=0.005) and throughout the exercise protocol (underlined in Table 4-5). 
4.4.1.5 Correlation between rSO2 and SaO2 
 
Figure 4.5 demonstrate a graph of resting peripheral saturations and mean 
rSO2 in London (75m), Namche (3500m) and Everest base Camp (5300m). 
 
 
Figure 4-5 A plot of all resting SaO2 values against corresponding rSO2 values. The 
different symbols specify location. 
 
Using a Pearson 2 tailed correlation (Table 4-A in Appendix), there is only a 
correlation between resting SaO2 and rSO2 at Everest Base Camp. The 
correlation at Namche does not achieve significance. 
 
Relative Percentage changes in SaO2 and rSO2 at rest compared to 75m 
Expressing the resting SaO2 and rSO2 values at 3500m and 5300m as a 
percentage of their values at 75m (baseline) demonstrates how these variables 
alter in relation to one another.  
Table 4-6 demonstrates absolute resting SaO2 and rSO2 values and their 
relative percentage of baseline values. 
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 Absolute 
value at 75m 
Absolute 
value at 
3500m 
3500m value 
expressed as 
a percentage 
of 75m value  
Absolute 
value at 
5300m 
5300m value 
expressed as 
a percentage 
of 75m value 
SaO2 96.9 88.4 91.2 79.4 81.9 
SEM 0.1 0.2 0.26 0.3 0.36 
rSO2 68.9 59.1 86.0 53.7 77.5 
SEM 0.5 0.5 0.5 0.6 0.7 
Table 4-6 The fall in resting SaO2 and resting rSO2 at altitude expressed as a percentage 
of their original value. 
 
When expressed as a percentage of the original value, rSO2 decreased by 
4.4%% more than SaO2 (paired t-test p<0.001). 
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Percentage changes in SaO2 and rSO2 during exercise at each altitude 
 
Table 4-7 Changes in SaO2 and rSO2 with exercise at each altitude expressed as a 
percentage of their value when at rest at that altitude 
 
From this it can be seen that at altitude (both 3500m and 5300m), exercise to 
AT and VO2Max is associated with a fall in SaO2 to approximately 90% of their 
starting values. Cerebral oxygenation (expressed as a percentage of the rSO2 
at rest at the corresponding altitude) falls to 93.2 ±0.4% and 91.0 ±0.4% of its 
starting values at AT (at 3500m and 5300m respectively p<0.001), but falls 
considerably further (to 84.8 ±0.8% and 84.2 ±0.8% at 3500m and 5300m 
respectively p<0.001) when exercising harder to VO2Max. This continuous 
desaturation to VO2Max does not occur in the peripheral circulation (expressed 
as a percentage of the resting SaO2 value at that altitude) at 3500m at AT = 
92.6 ±0.3 and at VO2Max = 90.6 ±0.3% (p = 0.06) and at 5300m is AT = 90.9 
±0.6% and at VO2Max = 90.2 ±0.6% (p = 0.2). 
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4.4.1.6 Correlations between rSO2 and Demographics and time to VO2Max 
 
Age 
There is a significant negative correlation between subject age and rSO2 at AT 
(Pearson correlation = -0.19 p=<0.05) and VO2Max (Pearson correlation -0.26 
p=<0.05) when normoxic (75m) (table 4.8). Similarly, at 3500m, this negative 
correlation between subject age and rSO2 continues (figure 4.6). Only at 
VO2Max at 5300m did this not quite achieve significance (see table 4.8). 
Although age seems associated with rSO2, the spread of data is large. 
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Pearson Corr -0.13 -0.19* -0.26* -1.5* -0.21* -0.16* -0.19* -0.22* -1.6 
Sig (2-tailed) 0.10 0.02 0.01 0.04 0.01 0.04 0.02 0.01 0.05 
Table 4-8 Pearson’s correlation results and their significance for correlations between 
rSO2 and age during exercise. * = Significant (p<0.05) 
 
Figure 4-6 demonstrates graphically the correlation between age and rSO2 
during exercise where this correlation is strongest, at 3500m (Namche). 
 
Figure 4-6 Relationship between rSO2 and age at VO2Max at 3500m. (p=0.04) 
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Smoking 
No correlation was found at any altitude or at any stage of the exercise protocol 
between smoking and rSO2. This may reflect the small numbers; only 12 people 
were recorded as regular smokers. 
 
Height 
There was a consistent significant positive correlation between height and rSO2.  
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Pearson Corr 0.23* 0.32* 0.37* 0.36* 0.38* 0.28* 0.33* 0.34* 0.25* 
Sig (2-tailed) 0.002 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.002 
Table 4-9 Pearson’s correlation between exertional rSO2 and subject height. 
 
 
 
Figure 4-7 Correlation between subject height and rSO2 at VO2Max at 3500m (p<0.001). 
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Gender 
Figures 4-8 and 4-9 demonstrate the rSO2 values and changes in rSO2 by 
gender. Actual rSO2 values were consistently lower in females than in males 
(ANOVA p=0.000 at all points in Figure 4-8).  
 
Figure 4-8 Gender differences in rSO2 values at each altitude (London 75m, Namche 
150m, EBC 5300m) at each level of exercise (rest, 6 minutes unloaded cycling, AT = 
Anaerobic Threshold, VO2Max and the Lowest rSO2 reading post-VO2Max) with 95%CT 
and p values demonstrated. 
 
 
Figure 4-9 Gender differences in rSO2 percentage change values (with the values 
expressed as a percentage of the resting rSO2 value at that altitude). (London 75m, 
Namche 150m, EBC 5300m) at each level of exercise (6 minutes unloaded cycling, AT = 
Anaerobic Threshold, VO2Max and the Lowest rSO2 reading post-VO2Max) with 95%CT 
and p values demonstrated. 
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Other Physiological variables: 
 
EtCO2 
See chapter 5 for correlations between rSO2 and ETCO2.  
 
Time to VO2Max 
It could be hypothesised that a correlation would exist between the time to 
reach VO2Max and the percentage fall in rSO2 at VO2Max. Table 4-B in the 
appendix demonstrates that such a correlation does not exist.  
 
4.4.1.7  Correlation between rSO2 and Basic Headache Data 
 
Table 4-C in the appendix uses a 2-tailed Pearson correlation of all rSO2 
variables (including absolute figures and percentage change) to explore their 
relationship with headache presence and headache score (as recorded at the 
time of exercise). Correlation reached significance between rSO2 values at 
3500m and headache at Everest Base Camp. This may be because the ascent 
to 3500m was actually the greatest relative increase in altitude and hence the 
greatest reduction in inspired oxygen partial pressure. However, the lack of 
correlation with other variables does not provide good evidence for rSO2 
changes being responsible for headache. Correlations analysis was also 
performed using rSO2 absolute and percentage values with arterial oxygen 
extraction and headache scores (recorded from diary data). No significant 
correlation was demonstrated. In chapter 5, I analyse headaches in greater 
detail using additional scoring systems that demonstrate minor correlations. 
 
4.4.1.8 Cluster Analysis 
 
One aim of the brain oxygenation study was to attempt to demonstrate if 
changes in brain oxygenation at sea level during exercise could predict brain 
oxygen desaturation at altitude. The process of cluster analysis is a tool to 
group people into similar clusters (in terms of cerebral desaturation at sea level) 
and differences in how these clusters perform at altitude can then be studied. 
Four methods of hierarchical cluster analysis (Between Groups, Furthest 
Neighbour, Within Groups, and Ward’s methods) were employed to ascertain 
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the optimal number of clusters in each analysis. The number of clusters to seek 
was indicated on the plot of the agglomeration coefficients against the number 
of clusters formed, where there was a sharp jump in the size of adjacent 
coefficients (i.e. the measure of similarity or dissimilarity). For the cluster 
procedure, squared Euclidean distance was employed and item scores were 
standardised. The FocalPoint function within the ClustanGraphics8 programme 
was utilised to ascertain that the cluster solution was not destabilised by case-
order. The ‘top solution’ of the FocalPoint analysis (based on a k-means 
iterative analysis) was employed to allocate subjects to the clusters. The ‘top 
solution’ is defined as unique classifications corresponding to the lowest 
Euclidian sum of squares (ESS) criterion value for a given number of clusters). 
Stability of the solution is indicated by its reproducibility, calculated as the 
percentage of 1000 randomly ordered samples producing the same solution 
and the percentage of overlapping cases with alternative cluster membership 
classifications.  
 
The initial attempt to group subjects at sea level was based on raw resting rSO2 
values. This resulted in 3 clusters, broadly described as those with high rSO2 
values, those with medium and those with low rSO2 values. This however is not 
a useful clustering as Near Infrared Spectroscopy is designed to be a trend 
monitor and absolute rSO2 values have many confounding variables when 
trying to compare individuals. For example, differences in skin and skull 
thickness and blood supply will cause different results between people. Table 4-
D in the appendix demonstrates this. 
 
It is therefore more useful to cluster according to the pattern of rSO2 changes. 
For example, at sea level, some people appear to increase the rSO2 value as 
they exercise while others lower their rSO2 value. This was therefore used to 
cluster subjects. 
 
A cluster analysis was performed on the entire trekker data set (unlike the 
earlier NIRS work, not excluding those who did not complete at Base Camp).  
This was done by running the London (75m) percentage desaturations through 
Clustan software (Clustan Graphics 8, Edinburgh, Scotland). Plots of the 
agglomeration coefficients from the four methods of clustering (Between 
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Groups, Furthest Neighbour, Within Groups, Ward’s) suggested that the best 
solution was reflected in a two-cluster solution. The dendogram in figure 4-10 
demonstrates the spilt between clusters 1 and 2.  
 
Figure 4-10 Dendogram 
demonstrating 2 cluster 
solution which was the 
most stable solution 
found.   
 
 
 
 
The Agglomeration Schedule for this cluster analysis is in Appendix Figure 4A 
Table 4-E in the Appendix lists of subjects in each cluster at each altitude.  
Cluster 1 comprised 78 people cluster 2 had 87 (6 were not assigned). 
 
Figure 4-11 demonstrates the percentage change in rSO2 values during the 
exercise protocol for both clusters.  The original cluster designation was based 
entirely on London data. In the London data it can be clearly seen that cluster 1 
desaturate at VO2Max while cluster 2 either maintain or increase their rSO2. 
 
At Namche and Everest Base Camp, both clusters desaturate with exercise, but 
cluster 1 desaturates further. Hence, desaturating at sea level tends to predict 
greater desaturation at altitude.   
 
Figure 4-11 The mean percentage desaturation in rSO2 for Clusters 1 and 2. 
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Figure 4-12 Graphs of changes in SaO2 and rSO2 at different exercise intensities at 3 
different altitudes ( London = 150m, ?Namche = 3500m and ▲Everest Base Camp (EBC) 
= 5300m) for each cluster. a) Actual changes in SaO2 , b) actual changes in rSO2, c) 
percentage changes in SaO2 from rest (with rest being 100%), d) percentage changes in 
rSO2 from rest (with rest being 100%). All graphs have 95%CI bars. 
 
Figure 4-12 demonstrates the actual and percentage changes in SaO2 and 
rSO2 with exercise at each altitude for each cluster. The mean SaO2 value 
decreased at rest with gain in altitude. This decrease is virtually identical for 
Cluster 1 and Cluster 2 (hence peripheral arterial oxygen saturation at rest 
would not discriminate the clusters). With exercise at each altitude, the 
peripheral saturations are not significantly different between the two clusters. 
The rSO2 values provide greater discrimination. Figure 4-11b shows that cluster 
1 had cerebral desaturation at VO2Max at sea level while cluster 2 increased 
their cerebral oxygenation slightly. This was probably the basis of the 
automated clustering. At 3,500m and 5,300m, both cluster 1 and 2 have very 
similar resting rSO2 values, implying that at rest, the two clusters cannot be 
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discriminated. With exercise, cluster 1 appears to consistently desaturate more 
than cluster 2 at both 3500m and 5300m. Figures 4-11c and 4-11d demonstrate 
the same data but as a percentage change from the resting values. Again, there 
is no difference of SaO2 between the clusters. There are two things to note from 
Figure 4-11c and d. Firstly, the percentage desaturation is considerably greater 
for rSO2 than it is for SaO2 (figure 4-11c). This suggests either greater oxygen 
extraction or an increased cerebral venous volume. Secondly, this phenomenon 
is consistently greater for Cluster 1 implying that Cluster 1 either have a higher 
arterial oxygen extraction, or they develop a greater venous compartment than 
cluster 2 (see discussion). 
 
The implication of this cluster analysis is that there is something anatomically or 
physiologically different between the two groups that, with the same peripheral 
saturations, cause one group to have a greater fall in cerebral oxygenation. It is 
unlikely that one group has a greater cerebral metabolic use of oxygen and 
hence an increase in venous volume in one cluster relative to the other (causing 
a cerebral desaturation) should be considered.  
 
Headache Correlation for the Clusters: 
 
I hypothesised that the cluster with the greatest desaturation would have the 
greatest headache score.  
Figure 4-13 demonstrates the mean Headache Severity Index (HSI) (a) and the 
components that make up the HSI (Headache score (b) and headache duration 
(c)). 
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Figure 4-13 The mean Headache Severity Index (a) and the components that make up HIS 
(Headache score (b) and headache duration (c)) for each cluster. 
 
 
On average, cluster 1 subjects had a greater headache severity index (M=47.5, 
SE = 5.3) than cluster 2 (M=41.1, SE = 3.77). This difference was not however 
significant t(131) = 0.94, p>0.05. Note, there were significant differences in 
variance between the two groups (Levene’s test for Equality of Variances p= 
0.02). The failure to achieve significance may relate to the large spread of 
headache scores between the two groups. Although not significant, it is noted 
that it is headache duration that is greater (and has wider error bars) in cluster 
1. This cluster analysis had 165 subjects. A post hoc power calculation 
confirmed that this was more than the 134 subjects required to detect a medium 
effect size (0.3) with α=0.05 and power (1-β) = 0.95. However, if the effect size 
is small (0.1) this would need to be 1289 subjects.  
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Headaches when grouping Trekkers into those who have greater and less 
than average peripheral and cerebral desaturations at rest and during 
exercise 
 
Using independent t-tests and grouping the trekker groups into those who have 
above and below mean saturation changes may demonstrate a difference in 
headache severity between the two groups: 
 
Changes in mean rSO2 at rest between 75m and 5300m:  
Mean percentage change in rSO2 (at rest) between 75 and 5300m = -22.50%. 
The mean headache severity index of those with >-22.50% change = 47.25 (SD 
= 46.9 SEM =5.6). The mean headache severity index of those with <-22.50% 
change = 41.22 (SD = 36.6 SEM = 4.4). t (-.85 df 137) p=0.4. 
 
Changes in mean rSO2 at rest to VO2max at 5300m: 
Mean percentage change in rSO2 from rest to VO2Max at 5300m was -15.9%. 
The mean headache severity index of those that had a >-15.9% change was 
47.84 (SD = 47.8 SEM=5.5). The mean headache severity index of those with 
<-15.9% change = 33.2 (SD = 33.2 SEM = 4.2) p = 0.16. 
 
Hence, in summary, both the cluster analysis and techniques to split the trekker 
group into those that desaturate with altitude and with exercise at altitude 
reveals that there is not a significant difference between any of the groups. In all 
cases the groups with greater desaturation had more headaches but this never 
achieved significance. The large spread of headache data (see large standard 
deviations) may be a factor in this. 
 
Note: In the following chapter, as part of the multiple variables at each altitude 
studied in relation to headache burden, one rSO2 value group consistently 
correlated significantly. This was right-sided rSO2 values (at rest and during 
exercise) at Namche (3500m) with total headache score. This may be because 
in our study this was the most acute hypoxic “jump” subjects were exposed to. 
See next chapter for more details. 
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CORE GROUP: 
4.4.2 Core Group Ascent to Base Camp 
 
All 24 Subjects ascended to 5300m. Two subjects did not undergo exercise 
testing at 3500m. Because rS02 was not recordable on one subject at any 
altitude, this study reports n=23 with the two missingdata sets at 3450m being 
imputed. 
Figure 4-13 demonstrates the mean changes in rSO2 at rest, after 3 minutes of 
unloaded cycling, at AT and at VO2Max. 
 
Figure 13-a Mean peripheral arterial oxygen saturation (SaO2) at rest, AT and VO2Max at 
each altitude (75, 3500 and 5300m). Figure 13-b demonstrates the mean rSO2 values 
during rest, unloaded cycling, at AT and VO2Max at the same three altitudes. Note: 
Although monitored throughout, SaO2 was not specifically recorded during unloaded 
cycling.  
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Individual Core Member Changes: 
In the appendix, Figures 4-B (i, ii and iii) demonstrate rSO2 for each of the 23 
subjects at 75m, 3500m and 5300m respectively. From this it can be seen that 
individuals tend to retain their ranking.  
 
No correlation could be demonstrated for resting rSO2 at 5300m, rSO2 at 
VO2Max or percentage change in rSO2 at VO2Max and headache score. 
The number of subjects in the core group was too small for cluster analysis. 
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Resting rSO2 in Climbing Group to 7950m (n=7) 
Table 11 demonstrates changes in SaO2, ETCO2 and left and right rSO2 for a 
subgroup of 7 subjects studied up to 7950m (the South Col).  
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97.63 a 95.67 b 89.75 c 85.88 d 79.63 e 75.13 e 65.90 f 95.03 a,b 7 13.91 215.18 <0.001 
CI (97.24-
98.02) 
(95.01-
96.32) 
(88.39-
91.11) 
(84.01-
87.74) 
(77.68-
81.60) 
(72.35-
77.91) 
(63.74-
68.07) 
(92.78-
97.27)     
End 
Tidal 
CO2 
(mmHg
) 
35.53 a 32.27 b 27.36 c 25.65 d 20.62 e 16.75 f 13.00 g - 6 37.89 205.64 <0.001 
CI (34.23-
36.82) 
(30.97-
33.57) 
(26.12-
28.60) 
(24.42-
26.88) 
(19.54-
21.70) 
(15.72-
17.78) 
(11.99-
14.01)      
Left 
rSO2 
(%) 
68.77 a 66.00 a 62.62 b 58.94 c 54.16 c,d 49.27 d 41.95 e 62.57 a,b,c,e 7 10.01 80.27 <0.001 
CI (65.91-71.63) 
(64.30-
69.70) 
(59.87-
65.37) 
(55.89-
61.99) 
(51.07-
57.25) 
(44.84-
53.70 
(39.76-
44.15) 
(57.02-
68.12)     
Right 
rSO2 
(%) 
69.47 a 67.75 a 61.36 b 58.57 b,c 
53.98 
c,d 50.95 
d 39.55 e 61.75 
b 7 12.43 82.87 <0.001 
CI (66.74-72.20) 
(64.57-
70.93) 
(58.88-
63.84) 
(55.90-
61.24) 
(51.11-
56.85) 
(47.23-
54.67) 
(36.14-
42.96) 
(61.42-
62.08)     
Table 4-11 Peripheral arterial oxygen saturations, end-tidal CO2 and left and right rSO2 for 
a subgroup of 7 subjects studied up to 7950m (the South Col). 
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4.5 Discussion 
 
This study has demonstrated in a large number of people who ascended to 
5300m, that there is a fall in brain oxygenation and this is exacerbated during 
exercise. This cerebral desaturation is greater than peripheral desaturation and 
varies for individuals. Those who desaturate more at sea level, also desaturate 
more at altitude.  
 
One principal hypothesis studied was 
that those with greater cerebral 
desaturation would have a greater 
headache burden. Although in each 
group (when clustered based on 
desaturation during exercise at sea-
level, and when subdivided based on 
desaturation at rest and during 
exercise at altitude) those who 
desaturated had a greater mean 
headache severity index, at no point 
did this achieve significance. 
 
Box 1: lists the key findings of this 
research. 
 
 
 
4.5.1 Explanation of Brain Oxygenation Results 
 
Please see the methods chapter for a general background of NIRS. Note, since 
rSO2 starts as a smaller percentage compared to SaO2, if could be argued that 
the relative percentage fall in rSO2 will be greater simply because I am 
comparing relatives values. However, this would not explain the significantly 
greater relative fall with exercise between 3500m and 5300m.  
 
Inter-individual differences: 
Unlike peripheral saturation (which at sea level are similar in most people), 
cerebral oxygenation (as measured using NIRS) appears to have a much wider 
Key Findings from this study: 
1) At rest rSO2 falls to a greater 
extent (of its percentage 
baseline) than SaO2. 
2) During exercise rSO2 again 
decreases to a greater extent 
than SaO2. 
3) Those who desaturate during 
exercise at sea level appear to 
desaturate more at altitude. 
4) The left hemisphere 
desaturates less in acute 
hypoxia. 
5) On average males, those who 
are younger and taller people 
have higher rSO2 values. 
6) Although there is a trend for 
those with greater cerebral 
desaturation to have more 
headaches, this does not 
achieve significance.  
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range of values (London resting rSO2 ranged from 37.6 to 86.6%). Because of 
this, NIRS (especially the INVOS system) is generally considered a trend 
monitor. I used it as a trend monitor within individuals at different altitudes and 
during exercise. I also studied the changes in these trends between individuals. 
Many factors contribute to the rSO2 value which could account for the variation. 
In anatomical and physiological terms, these differences can be extracerebral 
(skin/scalp/skull) and arterio-venous partitioning. I shall explain these prior to 
further analysis of the study findings. 
 
Extracerebral Tissue / Spatial resolution: The mean depth of photon penetration 
is approximately 1/3rd of the transmitter/receiver separation (hence a 5cm 
separation gives a 1.7cm depth penetration). The INVOS system uses one near 
infra-red source and two optodes 3 and 4 cm from the source hence the closer 
detects superficial tissues while the 4cm separated optode monitors superficial 
and deeper tissues. A subtraction algorithm gives a measure of deeper “cortical” 
saturation. It has been estimated, using computer modelling, that a typical 
volume interrogated by NIRS is approximately 30% brain and 70% non-cerebral 
(skin and scalp) (Hiraoka, Firbank et al. 1993). With the INVOS system it has 
been estimated that 85% of cerebral rSO2 is derived from cortical tissue with the 
remaining 15% derived from overlying extracerebral tissue (Murkin and Arango 
2009). A study using a pneumatic tourniquet to produce scalp ischaemia 
resulted in a reduction in rSO2. This demonstrates that the INVOS system does 
not eliminate the contribution of skin and scalp completely (Germon, Kane et al. 
1994). This may be one reason for inter-individual differences and may also 
account for the gender differences noted. 
 
Cerebral arterial / venous (A/V) blood partitioning: Cerebral NIRS measures 
mean tissue oxygenation and hence incorporates arterial venous and capillary 
blood. The cerebral cortex average tissue haemoglobin is classically thought to 
be distributed approximately 30% arterial, 70% venous (some authors use 25% 
arterial: 75% venous) (Watzman, Kurth et al. 2000; Ohmae, Ouchi et al. 2006). 
There appears to be however, a considerable biological variation in A/V rations 
between individuals (Watzman, Kurth et al. 2000). Watzman et al demonstrated 
(using NIRS and jugular bulb saturation monitoring) that, in 20 children, the 
mean A/V ratio was 16:84, but this varied from 40:60 to 0:100.  
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The INVOS system does not allow access to their algorithms or other recorded 
values other than rSO2. It is therefore not possible to get any other ratios (e.g. 
of oxygenated haemoglobin and total haemoglobin) hence calculation of 
arterial: venous ratios are not possible. Wolff et al have previously published 
demonstrating that arterial oxygen extraction (E calculated as 1.39 (1 – 
rSO2/SaO2)) remains constant for brain at a low altitude but decreases at 
altitudes of around 5000m (Wolff, Richardson et al. 2007).  They also stated 
that the ratio (p) of arterial to venous blood in the area of investigation can be 
calculated from rSO2 = (SaO2.p+SaO2(1-E)/p+1)). However, we cannot assume 
that oxygen extraction is constant and without knowing the jugular venous 
saturation or the ratios as outlined above, it is not possible to calculate A:V 
ratios. We note in our study that rSO2 values fall to a much greater extent than 
SaO2 values at altitude. This either reflects a greater oxygen extraction, or more 
likely, an increase in the venous component of cerebral blood volume. 
 
In our study there was little change in SaO2 during exercise at sea level. This is 
in contrast to the initial rise then fall of rSO2. This is demonstrated especially 
well in the Cluster analysis (figure 4.12). In this, it can be seen that Cluster 1 
has a considerably more precipitous fall in rSO2, even though SaO2 is the same 
as cluster 2. Either the first cluster has a higher oxygen extraction or this group 
develops venous engorgement during the exercise. 
 
Actual meaning of rSO2: The demonstration that rSO2 is a trend monitor was 
made very eloquently by Schwartz et al (Schwarz, Litscher et al. 1996). They 
found that the mean value of rSO2 in 18 dead subjects was 51+/- 27% 
compared with 68+-/5% in healthy adults. Six of the 18 dead subjects had a 
value greater than the lowest values of the healthy adults. In our study, some 
subjects (one from the core group and one from the trekker group) had 
consistently low rSO2 values that did not alter with hypoxia or exercise (e.g. 
15%). These subjects were excluded. This may represent a very large frontal 
sinus or persistent obstruction to the infra-red light. Such interpretation of NIRS 
studies probably reflects the limited data that can be gained from machines that 
just give a single rSO2 value without any explanation of how it was derived. 
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More detailed oxygenation ratios would almost certainly enable more robust 
conclusions.  
 
4.5.2 Gender 
 
No study has previously been large enough to clearly demonstrate a significant 
difference in brain oxygenation between the sexes at altitude. Jausovec has 
reported a significantly higher oxygenated haemoglobin level in males 
compared to females (n=155) (Jausovec and Jausovec 2010) at baseline. 
Others have noted a generally higher brain oxygenation in males than females 
during verbal fluency tasks (Kameyama, Fukuda et al. 2004). Very large 
numbers of subjects are required to show these differences. This may be a 
genuine physiological difference (for example, females are far more at risk of 
idiopathic intracranial hypertension, and hence there may be an element of 
predisposition to venous insufficiency and hence venous congestion), or they 
may simply be artefact e.g. related to an extracranial / skin / scalp/frontal sinus 
phenomenon.  
 
4.5.3 Age 
 
During hypoxic exercise, greater cerebral desaturation appears to occur with 
advancing age. This has not been demonstrated before.  It may be the 
underlying factor as to why the two clusters separated out since there was a 
significant difference of mean age between the two. 
 
4.5.4 Comparisons with previous studies using NIRS at altitude  
 
To place my results in context, I shall outline a number of studies that have 
used NIRS at altitude, both to investigate cerebral oxygenation at rest and 
during exercise. 
 
4.5.4.1 Experiments investigating rSO2 changes with altitude 
 
Hadolt and Litscher (using an INVOS 3100 machine) gave an account in 2003 
of the use of NIRS on 17 volunteers at altitude. 2 had AMS and they thought 
that this might correlate to an acute drop in rSO2 (Hadolt and Litscher 2003). 
However, they had a faster ascent rate and studied people within 6 hours of 
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arrival at altitude (not at 2-3 days as in the current study). In a similar manner to 
our results, they also found that cerebral saturations decreased to a greater 
extent than peripheral.   
 
In contrast, Imray et al (with a Critikon 2020 system) demonstrated that cerebral 
oxygenation fell less than peripheral saturations up to 4680m and that 
medroxyprogesterone resulted in higher peripheral and cerebral saturations 
(Imray, Barnett et al. 1998). This may reflect the more acute ascent of this 
group, or it may represent a difference in cerebral oximetry technique. Imray et 
al have also demonstrated that increasing inhaled CO2 at altitude increases 
cerebral oxygenation (Imray, Brearey et al. 2000; Imray, Clarke et al. 2001; 
Imray, Walsh et al. 2003).  
 
4.5.4.2 Experiments investigating the temporal change in rSO2 during 
exercise 
 
Saito et al were the first to report on the effects of exercise at altitude on 
cerebral oximetry in 1999. Using an INVOS 3100 system, they found that rSO2 
fell during exercise at altitude while it was maintained at sea level (Saito, 
Nishihara et al. 1999). Again, the reduction of rSO2 was greater than SpO2. 
 
Our group has also studied exercising skeletal muscle at altitude and found that 
the pattern of absolute oxygenation remains the same at altitude and at sea 
level (Martin, Levett et al. 2009). This is different to our findings that at sea level, 
rSO2 tends to increase at AT and approach baseline again at VO2Max, while at 
altitude there is a progressive desaturation to VO2Max. 
 
In a small study (n=6) Shibuya and colleagues investigated brain oxygenation at 
sea level at supramaximal intensities (150% of VO2Max). This (like our study) 
demonstrated an increase in cerebral oxygenation initially but at maximal and 
supramaximal exercise, then cerebral oxygenation fell (Shibuya, Tanaka et al. 
2004). This is the earliest recording of a rise in rSO2 with exercise at sea-level. 
Other studies have also demonstrated that cerebral rSO2 can increase 
especially during lower work rates in normoxia (Hiura, Mizuno et al. ; Ekkekakis 
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2009) and that changes in rSO2 in hypoxia are larger than in normoxia(Subudhi, 
Dimmen et al. 2007).  
 
Imray et al studied brain oxygenation during supine exercise up to 5,260m (n=9) 
(Imray, Myers et al. 2005). They also demonstrated that at sea level, brain 
oxygenation was maintained during exercise, but at altitude, above 30% of 
VO2Max, rSO2 fell. 
 
Rooks et al have compiled a meta-analysis of NIRS studies during exercise at 
sea level (Rooks, Thom et al. 2010). Their meta-analysis is difficult to interpret 
as they included different NIRS techniques, however, with “hard” and “very hard” 
(= VO2Max and above) exercise, they demonstrated an increase in total 
haemoglobin concurrent with a fall in brain oxygenation. This implicates an 
increase in the venous component of the intracerebral mixture. 
 
There are a number of neuropsychological studies correlating brain oxygenation 
with function. For example, Ando et al demonstrated that cerebral oxygenation 
decreases with exercise in hypoxia and this correlates with an increased 
reaction time to peripheral visual stimuli (Ando, Yamada et al. 2010). At the time 
of writing, the neuropsychology data from our study has not been completely 
analysed, hence we cannot comment on this. 
 
Some studies have suggested that the fall in rSO2 is due to a fall in cerebral 
blood flow secondary to hypocapnia induced vasoconstriction (Bhambhani, 
Malik et al. 2007). Others have implied it may well be that an increase in the 
venous component of NIRS may contribute (Heine, Subudhi et al. 2009). 
4.5.4.3 Experiments investigating rSO2 changes both with exercise and 
altitude 
 
With acute isocapnic hypoxia, the desaturation of brain oxygenation is greater 
than that of muscle NIRS (Peltonen, Kowalchuk et al. 2007). Subudhi and 
colleagues (Subudhi, Dimmen et al. 2007) studied 13 male cyclists in normoxia 
and hypoxia (FiO2 = 12%) during incremental exercise up to a maximum of 25 
Watts/min using an Oxymom (Artinis, The Netherlands) oximiter. As reported 
above, in normoxia there was an initial rise in brain oxygenation up to 75% 
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maximum, then a fall. In hypoxia, brain oxygenation fell progressively with 
exercise. They also studied muscle oxygenation and demonstrated that in both 
normoxia and hypoxia, there was a progressive desaturation with exercise. 
Rupp and Perrey demonstrated very similar results with sustained contraction 
exercise (Rupp and Perrey 2009). Perry has also written a comprehensive 
review of NIRS in exercise (Perrey 2008). 
 
Subudhi has shown that during exercise, prefrontal areas desaturate more than 
premotor and motor regions, suggesting that this cortical desaturation may 
contribute to an integrative decision to stop exercising (Subudhi, Miramon et al. 
2009). A number of other authors have suggested that it is cerebral 
desaturation rather than skeletal muscle impairment that limits exercise capacity 
in hypoxia (Smith and Billaut 2010). More recently, we have performed “Rush 
and Rest” studies at altitude and although not published yet, the results imply 
that the limits of exercise capacity in hypoxia (be that cerebral or skeletal 
muscle) vary between individuals.  
 
4.5.5 Brain Oxygenation and Headache 
 
I had believed that with the large numbers of subjects in this study, we would be 
able to demonstrate a difference in cerebral oxygenation between those who 
suffered headaches and those who did not. Although an independent t-test of 
headache severity between clusters and the group split into those above and 
below average desaturation at rest while ascending and desaturation with 
exercise at altitude demonstrated that those who desaturated more had a 
greater headache burden, this was not statistically significant with the number 
of subjects in this study. Other studies of headache and NIRS are rare. 
Previously Vuyk et al investigated the response of  rSO2 to acetazolamide 
treatment (Vuyk, Van Den Bos et al. 2006) in 16 subjects ascending Cho Oyu. 
At 3700m, the 8 taking acetazolomide had a significantly lower Lake Louise 
Score (LLS – 0.75+/-1) compared to those that were not (2.9+/-2 p<0.05). High 
LLS were associated with low rSO2 both at rest and during exercise. 
 
No other studies have attempted to correlate headache with rSO2 at altitude. 
The study described above by Vuyk et al used the Lake Louise Score and 
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demonstrated a significantly higher score in those that desaturated more, 
however, the effect size is small and the other variables that comprise the LLS 
(e.g. difficulty sleeping, nausea) may be more relevant. The subjects (n=16) 
were also exposed to a much greater altitude (Cho Oyu summit 8201), hence 
the lower altitude and slower ascent profile of our study might account for some 
differences.  
 
4.5.6 What Causes the Reduction in rSO2 at Altitude and During Exercise? 
 
I have shown that, at sea level, one group of people at least (cluster 1) have a 
fall in rSO2 when exercising despite unchanged SaO2. This might be explained 
by hyperventilation-induced vasoconstriction, a substantial increase in brain 
oxygen extraction, or the presence of cerebral venous congestion. The latter 
might be postulated to occur with thoracic pressure increases (lip pursing) 
during exercise. At altitude, rSO2 decreases at a greater rate again than SaO2.  
Again, this implies either hyperventilation induced vasoconstriction, greater 
oxygen extraction or venous congestion. 
Heine et al used canonical correlation analysis (CCA) with an Oxymon MKIII 
(Artnis Medical Systems, The Netherlands) system to investigate this in 23 
subjects(Heine, Subudhi et al. 2009). They found that cerebral blood flow 
velocity shared the least amount of variance with NIRS measurements and the 
reduction in CBFv was not accompanied by a reduction in cerebral blood 
volume. The venous contribution to NIRS appeared to explain a larger amount 
of variation in cerebral oxygenation than hypocapnia-induced reduction in CBFv. 
 
A broader review providing evidence for venous congestion at altitude is 
provided in the appendix (Wilson, Imray et al. 2011). 
 
4.5.7 Future Study 
 
To demonstrate that a fall in rSO2 is associated with a higher headache score, a 
much harsher ascent profile is required.  
 
To conclusively demonstrate using NIRS that there is an increase in the venous 
component of cerebral blood volume, either a NIRS system that provides a ratio 
of oxygenated to total haemoglobin must be used, or concurrent jugular venous 
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bulb sampling is required. However, I have gone on to use magnetic resonance 
imaging and retinal analysis (chapters 5 and 6) to investigate the presence of 
venous engorgement at altitude.  
 
4.6 Conclusion 
 
Changes in cerebral oxygenation during exercise at sea level can give an 
indication of the changes that occur at altitude. Males, younger and taller 
subjects appear to preserve brain oxygenation and, in relatively acute exposure, 
the dominant left cerebral hemisphere maintains a very slightly (but 
significantly) higher rSO2. 
Regional brain oxygenation decreases at rest and during exercise at altitude at 
a faster rate than peripheral arterial oxygen saturation. This supports the 
contention that a component of the reduction in rSO2 might relate to changes in 
cerebral venous engorgement. This issue is dealt with in chapters 5 and 6. 
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5 Chapter 5: HIGH ALTITUDE HEADACHE ASSESSMENT AND 
CORRELATION WITH BASIC ANTHROPOMORPHIC AND 
PHYSIOLOGICAL DATA 
 
 
5.1 Abstract 
 
Aim: To document headache burden during ascent to 5300m and attempt to 
correlate headache with anatomical (anthropomorphic) and physiological 
variables. 
Methods: Twenty-four core team and 198 trekkers from the CXE expedition 
kept daily diaries of headache severity (providing 4 different scoring systems) 
and basic physiological measures. Prior to departure, skull measurements were 
performed to calculate intracranial volumes. In London (75m), Namche (3500m) 
and at Everest Base Camp (EBC, 5300m) additional physiological variables 
were recorded as part of an exercise to VO2Max test. Relationships between 
these demographic (age, sex, smoking), anatomical (intracranial volume) and 
physiological (heart rate, peripheral saturations, altitude specific rSO2, blood 
pressure, End Tidal O2 and End Tidal CO2, and haemoglobin concentration) 
variables and headache burden were sought. 
Results: There was no correlation between headache score derived from any 
methodology, and calculated intracranial volume or patient sex. Total headache 
score was greater in the young (Pearson’s = -2.47 (p=0.001 n=182)) and 
increased with lower resting peripheral arterial oxygen saturations at EBC 
(5300m) (Pearson’s = -2.11 (p=0.004, n=182)). At Namche, right sided rSO2 
values (at rest and during exercise) were consistently and significantly 
correlated with total headache score. EtO2 and EtCO2 values consistently 
correlated with total headache score, from rest through to maximal exercise at 
all altitudes, from sea-level to 5300m. There was no correlation between 
headache burden and haemoglobin concentration. 
Conclusion: There is no relationship between calculated intracranial volume and 
high altitude headache and no difference in headache burden between sexes. 
EtO2 and EtCO2 appear closely related to headache burden. With the greater 
hypoxic challenge of ascent to Namche (3500m) it appears that left sided 
cerebral oxygenation is protected and right-sided cerebral oxygenation values 
correlate with headache.  
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5.2 Introduction 
 
For the past 20 years the two main pillars that have been accepted as the 
cause of high altitude headache have been the anatomical “tight fit” hypothesis 
put forward by Ross (Ross 1985) and the physiological “hypoxaemia” 
hypothesis described by Hackett and Roach (Hackett and Roach 2001). 
 
The Caudwell Xtreme Everest Study (Grocott, Martin et al. 2010) was principally 
designed to investigate the effects of hypoxia. The slow ascent rate with 
multiple stops at the same altitude meant the study was not ideal for the 
analysis of high altitude illness or headache, which the ascent profile had been 
designed to avoid. However, with the large number of people ascending, it 
offered an opportunity to document the headaches that occurred and to attempt 
to correlate them with anatomical and physiological variables. 
 
Headache Burden: The quantitative assessment of the subjective symptom of 
headache burden has not been well validated. Ascribing a headache a score 
within a range or on a visual-analogue scale (Rupp, Jubeau et al. 2012) is 
straightforward, but the validity of calculating a “burden” over a period of time by 
summing these semi-categorical results has not been demonstrated. The Lake 
Louise Score classifies headache as: Not present (0), mild (1), moderate (2) or 
severe (3). The headache pharmaceutical industry uses a “Headache Severity 
Index” which comprises a headache score (none (0), mild (1), moderate (2), 
severe (3), excruciating (4)) multiplied by the number of hours that headache is 
experienced to give a more accurate idea of burden (Schrader, Stovner et al. 
2001). Within this study I used a number of these headache assessment 
systems.  
 
Anatomical Cranial Measurements: A study of 10 subjects in 1985 (Wilson and 
Milledge 2008) implied that subjects with greater ventricular volume and relative 
cerebral parenchymal atrophy suffered less with headaches. Whilst it would not 
have been possible to perform magnetic resonance imaging (MRI) on all of the 
subjects on the Caudwell Xtreme Everest project, it was possible to measure 
cranial dimensions and estimate intracranial volume. Whilst clearly this does not 
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reflect intracranial compliance, it provides a large number of subjects to 
investigate any protective effect a large cranium may have in headache 
susceptibility. 
 
Physiological Measurements: In addition to daily headache assessment, the 
large cohort of subjects recorded daily measurements of basic physiological 
variables (pulse, resting peripheral arterial oxygen saturation, blood pressure). 
Further measurements were made as part of the VO2Max test (see chapter 2 
and (Levett, Martin et al. 2010)). Brain oxygenation was also monitored at rest 
and during exercise, with data being previously reported in chapter 4. 
Correlations of these basic physiological variables and rSO2 values at specific 
altitudes with headache were sought.  
 
5.3 Methods 
 
One hundred and ninety-eight trekkers (see chapter 2) were studied during 
ascent to 5300m over 11 days. Twenty-four investigators were studied during 
ascent to 5300m over 13 days. Because of the larger cohort size and more 
acute ascent, these results focus on the 198 trekkers although the investigator 
group is discussed at the end of the chapter. 
 
5.3.1 Headache Assessment 
 
On waking and prior to breakfast, each subject completed a personal diary each 
morning. The classic high altitude assessment tools, the Environmental 
Symptoms Questionnaire and Lake Louise assessment which included a 
“headache” score, grades severity from 0-3 (none, mild, moderate and severe). 
In addition to this component of the diary, a table (figure 5-1) was provided for 
more detailed headache assessment. The Environmental Symptoms and Lake 
Louise assessments do not quantify duration of headache (which may be an 
important consideration in evaluating “headache burden”). In this table the 
grade of headache over the preceding 24 hours ranging from 0-4 (none, mild, 
moderate, severe, excruciating) and the duration of that headache (in hours) 
was reported. This meant that a headache severity index (HSI = grade x 
duration) could be calculated on a daily basis. By adding the daily HSI scores, a 
cumulative headache burden was calculated. Boxes were also available to 
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indicate the time of day at which the headache was most severe, the location of 
headache and exacerbating factors. Also within the diary were sections for 
medication taken and alcohol consumption. 
 
Grade of headache 
experienced in 
previous 24 hours 
(1-4)  
 Duration of 
headache (/hrs) 
 
Time of day of 
headache (please 
circle) 
00:00 – 06:00 
06:00 – 12:00 
12:00 – 18:00 
18:00 – 24:00 
Locations of 
headache 
(please mark on 
skull) 
 
Exacerbating factors  
Figure 5-1 The diary table in which headache symptoms and duration were reported by 
each subject on a daily basis.  
 
The main headache scores studied were: 
 
Lake Louise Headache Score (LL) – Headache Score (from 0-3 none, mild, 
moderate and severe). The Total LL = the cumulative (sum) of daily LL 
headache scores. 
Ascent Headache Score (AHS) – This was the sum of the LL scores upon 
days following ascent only (total = 7 days of ascent). This attempted to remove 
other causes of headache (especially exertion from exercise testing and 
alcohol). 
Headache Severity Score (HSS) – The headache score (from 0-4 none, mild, 
moderate, severe, excruciating). The Total HSS = the cumulative (sum) of daily 
HSS. 
Headache Duration (HD) – the duration of headache each day. Total 
Headache Duration = the sum of each headache duration a subject recorded 
irrespective of grade 
Headache Severity Index (HSI) – headache severity score (0-4) x duration 
each day. Total Headache Severity Index = the sum of the daily HSIs.  
 
5.3.2 Anthropomorphic Assessment 
 
One hundred and ninety-eight subjects (125 male, mean age 44.6 (range 18-
73) underwent cranial measurement using specially designed callipers (chapter 
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2). The following skull measurements were measured (see chapter 2 for 
images). 
 
The following were measured: 
• Maximum head length (glabella to inion: L) 
• Maximum head breadth (between the two parietal eminences: W) 
• Auricular height (external acoustic meatus to bregma: H) 
• Head circumference (from glabella to ionion) 
 
For height we measured the distance from the right external auditory meatus to 
the bregma, removing the calliper arm nearest the handle to allow close 
apposition to the skull, and keeping the distal calliper arm horizontal using the 
spirit level in the callipers arm. 
 
All measurements were calculated in millimetres, in the normal anatomical 
position. All measurements were repeated three times by the same investigator, 
the average of the three measurements was then used to calculate ICV. To 
reduce inter-observer bias, all measurements were performed by one of two 
investigators.  
 
Cranial volumes were calculated using the Lee-Pearson formula (Manjunath 
2002; Golalipour, Jahanshaei et al. 2005) .  
  
Male ICV: 0.000337 (L–11) × (B–11) x (H–11) + 406.01 
Female ICV: 0.0004 (L–11) × (B–11) × (H–11) + 206.60 
 
These formulae have a reported mean error of 3-4% (Haack and Meihoff 1971) 
and have been shown to be reliable for calculating intracranial volume (Sahin, 
Acer et al. 2007). In addition, a non-gender specific formula (the Dekaban 
formula) was also compared (Dekaban 1977). This is: 
 
0.523 x (L=2t) x B (Bx2t) x (Ht –t) 
 
where t is the thickness of the cranial vault and soft tissues (for simplicity 
considered to be 7.5mm for this study). 
Chapter 5 - HEADACHE AND BASIC ANTHROPOMORPHIC STUDIES 168	  
	  
5.3.3 Physiological Assessment 
 
Each subject recorded the following with their headache scores: resting heart 
rate, resting peripheral arterial oxygen saturations, and three resting blood 
pressure readings. Subjects also underwent an upright cycle ergometer test to 
VO2Max (full details chapter 4). Brain oxygenation was recorded during this in 
London (75m), Namche Bazaar (3450m) and Everest Base camp (5300m). The 
brain oxygenation components are reported in chapter 4. The following 
physiological parameters were also reported: pulse, blood pressure, peripheral 
saturations (SaO2), end tidal Oxygen (EtO2) and Carbon Dioxide (EtCO2); and 
oxygen consumption at rest, at anaerobic threshold (AT) and at maximal 
oxygen consumption (VO2Max). Haemoglobin concentration was also 
measured at each altitude. 
 
An association of headache scores with all of these anatomical and 
physiological measurements was sought.  
 
5.4 Results 
 
5.4.1 Trekker Results 
 
Of the 198 trekkers, 190 reached Everest Base Camp. Two suffered with acute 
mountain sickness, the other 6 with non-altitude related illness.  
 
Of the 190 subjects, 182 had full anthropomorphic and basic diary data.  None 
of the 8 subjects in whom data sets were incomplete were reported to be 
suffering from high altitude illness. One hundred and sixty-nine subjects had 
complete VO2Max data in London, 167 in Namche and 144 at Everest base 
camp.  
 
Descriptive Data: 
 
Table 5-1 provides means, standard deviations, maxima, minima, interquartile 
range values and histograms for the basic demographic and anthropomorphic 
data demonstrating that continuous data mostly had a normal distribution. 
Headache measures (the sum of ordinal measures) were not normally 
distributed as large numbers of subjects report no or minimal headache. 
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5.4.1.1 Demographic and Anthropomorphic Variables: 
 
Frequency for Parametric Data: 
 n Mean SD Min/Max IQR Histogram 
Age/years 182 43.91 13.46 18 
/ 
73 
32.00 
/ 
56.00 
 
Height/cm 182 172.68 9.18 150 
/ 
193 
165.75 
/ 
180.00 
 
Weight/Kg 182 74.99 13.52 49 
/ 
117 
64 
/ 
83.25 
 
Resting 
Sats EBC 
182 77.79 5.30 62 
/ 
91 
74.00 
/ 
81.00 
 
Male ICV 
/ mls 
112 1491.90 102.09 1235 
/ 
1751 
1429.25 
/ 
1569.75 
 
Female ICV 
/ mls 
70 1287.87 111.58 1235 
/ 
1751 
1212.25 
/ 
1373.25 
 
Dekaban 
Formula 
182 1520.92 196.83 1088 
/ 
2019 
1363.75 
/ 
1656.25 
 
Cranial AP 
Distance / 
cm 
182 19.35 0.84 17.23 
/ 
21.43 
18.70 
/ 
19.97 
 
BiparietalDi
stance / cm 
182 14.81 0.70 12.83 
/ 
16.77 
14.33 
/ 
15.27 
 
Cranial 
Height 
/ cm 
182 13.12 0.78 11.20 
/ 
15.13 
12.53 
/ 
13.63 
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Cranial 
Circumfere
nce 
/cm 
182 57.11 1.99 51.90 
/ 
61.27 
55.63 
/ 
58.45 
 
Post Fossa 
Length 
182 9.14 0.90 6.6 
/ 
12.1 
8.59 
/ 
9.65 
 
LL HS 182 5.57 4.35 0 
/ 
21 
2.00 
/ 
8.00 
 
Ascent HS 182 3.89 3.05 0 
/ 
13 
1.00 
/ 
6.00 
 
THS 182 10.82 6.41 0 
/ 
30 
6.00 
/ 
14.00 
 
THD 182 29.57 23.66 0.00 
/ 
139.00 
12.95 
/ 
39.50 
 
THSI 182 47.58 45.30 0.00 
/ 
230.0 
18.87 
/ 
60.63 
 
 
Table 5-1 Table of descriptive data for basic demographic / diary data, anthropomorphic 
measurements and headache scores. Resting Sats EBC = resting peripheral saturations 
(SaO2) at Everest Base Camp (5300m). Male ICV = male intracranial volume calculated 
using the Lee Paterson formula. Female ICV = female intracranial volume calculated 
using the Lee-Paterson formula. Dekaban Formula = intracranial volume (both sexes) 
calculated using the Dekaban formula. Cranial APD = cranial anterior-posterior distance, 
Biparietal Distance = cranial width, Cranial Height = height from external auditory meatus 
to vertex. Post fossa length = distance form external auditory meatus to occipital 
prominence. LLHS = the sum of each days headache component of the Lake Louise 
Score. Ascent headache Score  = the sum of the headache scores on days following an 
increase in altitude only.  THS = Total Headache Score (the sum of all of the headache 
scores that went up to make the headache severity index). THD = Total Headache 
Duration (the sum of all the hours of headache for each individual). THIS = Total 
Headache Severity Index = Sum of headache severity scores x duration for each day. 
 
 
5.4.1.2 Physiological Variables 
 
Multiple physiological variables were studied at each altitude, all of which follow 
a normal distribution. These have been included in Tables 5-A, B and C in the 
Appendix. Means of some of these variables are displayed in Table 5-2.  
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 London (75m) Namche (3450m) EBC (5300m) 
Hb/g/dl 14.48 14.72 15.77 
Resting Sys BP 125.2 125.93 124.86 
Resting Dia BP 81.9 83.61 85.82 
Resting SaO2 96.91 88.36 79.4 
Resting HR 78.12 84.12 90.91 
Resting EtO2 108.30 62.38 48.88 
Resting EtCO2 33.78 27.02 20.46 
Resting Mean 
rSO2 
68.94 59.11 53.68 
    
AT SaO2 96.49 81.73 72.6 
AT HR 129.25 127.21 118.68 
AT EtO2 101.15 62.46 50.08 
AT EtCO2 42.13 28.7 21.04 
AT Mean rSO2 71.34 55.07 48.85 
    
VO2Max SaO2 96.34 80.01 72.1 
VO2 Max HR 170.41 159.63 138.42 
VO2 Max EtO2 115.90 73.13 57.63 
VO2 Max EtCO2 36.06 24.13 17.67 
VO2 Max Mean 
rSO2 
67.40 50.11 45.33 
 
Table 5-2 Means of some physiological data at 75m, 3450m and 5300m. Further details 
with numbers of subjects, SD, interquartile ranges and frequency histograms are 
displayed in appendix tables A, B and C. 
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5.4.1.3 Assessment of Headache Scoring Systems 
 
The mean results for the different headache scoring systems are shown in table 
5-3 
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Mean 5.57 3.89 10.82 29.57 47.58 
SD 4.35 3.05 6.41 23.66 45.30 
SEM 0.32 0.23 0.48 1.75 3.36 
Max 21 13 30 139 230 
Min 0 0 0 0 0 
Quartile  2 1 6.25 13 19.25 
Quartile 
3 8 6 14 39.5 60 
IQR 6 5 7.75 26.5 40.75 
Numbers 181 181 182 182 182 
 
Table 5-3 The Headache Scores for 182 subjects who ascended to EBC (5300m) and had 
adequate diary records. Where LL Headache Score is the sum of the headaches recorded 
as part of the daily dairy Lake Louise survey. (Headaches scored 0 Nil, 1 Mild, 2 Moderate, 
3 Severe). Ascent Headache Score is the sum of the individual LL Headache Scores on 
days after an ascent. Total Headache Score is the sum of all headaches recorded each 
day within the Headache Severity Index part of the diary. (Headaches scored 0 Nil, 1 Mild, 
2 Moderate, 3 Severe, 4 Excruciating). Total Headache Duration is the sum of the number 
of hours each individual headache was endured (part of HSI calculation). Total Headache 
Severity Index (HSI) is the sum of all individual HSIs (Headache Score x Duration). 
 
 
The Lake Louise Headache Score (and its derivative Ascent Headache Score) 
were reported separately to the Headache Severity Index (with its components 
being the headache score and duration). One would expect all of these 
measures to correlate and table 5-4 confirms this.  
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LL headache Score 1 .938** .701** .594** .652** 
Sig (2 tailed)  0 0 0 0 
n 181 181 181 181 181 
Ascent Headache Score .938** 1 .653** .567** .616** 
Sig (2 tailed) 0  0 0 0 
n 181 181 181 181 181 
Total Headache Score .701** .653** 1 .651** .726** 
Sig (2 tailed) 0 0  0 0 
n 181 181 182 182 182 
Total Headache Duration .594** .567** .651** 1 .934** 
Sig (2 tailed) 0 0 0  0 
n 181 181 182 182 182 
Total HSI .652** .616** .726** .934** 1 
Sig (2 tailed) 0 0 0 0  
n 181 181 182 182 182 
a) Pearson’s Correlation** = Correlation is significant at the 0.01 level 
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LL headache Score 1 .931** .697** .612** .639** 
Sig (2 tailed) . 0 0 0 0 
n 181 181 181 181 181 
Ascent Headache Score .931** 1 .632** .553** .578** 
Sig (2 tailed) 0 . 0 0 0 
n 181 181 181 181 181 
Total Headache Score .697** .632** 1 .680** .760** 
Sig (2 tailed) 0 0 . 0 0 
n 181 181 182 182 182 
Total Headache Duration .612** .553** .680** 1 .953** 
Sig (2 tailed) 0 0 0 . 0 
n 181 181 182 182 182 
Total HSI .639** .578** .760** .953** 1 
Sig (2 tailed) 0 0 0 0 . 
n 181 181 182 182 182 
b) Spearman’s Correlation ** = Correlation is significant at the 0.01 level 
Table 5-4 Tables demonstrating good correlations between all headache scoring 
systems; a using Pearson’s Correlation and b using Spearman’s. Total HIS = Total 
headache Severity Index. 
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From the above it could be assumed that all headache-measuring systems are 
comparable. The graphs in figure 5-2 demonstrate “headache score” (mean = 
green line, total = red) with each ascent profile (blue line). There is a very large 
spread of data and hence the error bars have intentionally been left off of these 
graphs. 
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Figure 5-2 Graphs demonstrating mean (green) and total (red) Headache Scores (the sum 
of every subjects Lake Louise Score on each of the 13 days), the mean and total 
headache duration (the sum of each of the subjects headache duration on each of the 13 
days) and the mean and total headache severity Index (the sum of each subjects HIS on 
each of the 13 days) compared with altitude (blue). 
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Correlations:  
 
5.4.1.4 Correlations between Headache Score, basic demographics and 
gender 
 
Basic demographic data are demonstrated in Table 5-5. Mean headache data 
for males and females are demonstrated in Tables 5-6a and b respectively. 
There was no significant correlation for subject sex except when using a 
Spearman’s correlation (Table 5-7b) with Total Headache Score when a 
significant difference (p=0.049) of females having more headaches was just 
achieved. However, with multiple-analyses, a p value of 0.01 should probably 
be required. Independent t-tests demonstrated no significant differences 
between males and females for any headache scores.  
 
No significant correlations were demonstrable between any of the headache 
scoring systems and height, weight or smoking habits (Table 5-7 and b).  
Similarly, no significant differences (anatomical, or headache scoring) were 
demonstrated between smokers and non-smokers. 
 
 Male/Female Age 
Height Weight 
Resting 
Sats at 
EBC/ % 
(diary) 
Mean 112/70 43.87 172.67 74.99 77.79 
SD  13.44 9.17 13.51 5.29 
SEM  1.00 0.68 1.00 0.39 
Max  73.4 193 117 91 
Min  18.3 150 49 62 
Quartile 
1 
 
32.575 165.625 64.125 74 
Quartile 
3 
 
56.25 179.5 83 81 
IQR  23.675 13.875 18.875 7 
Numbers  182 182 182 182 
Table 5-5 Basic demographics for all those arriving at EBC (5300m) 
 
  
Chapter 5 - HEADACHE AND BASIC ANTHROPOMORPHIC STUDIES 176	  
	  
Mean Headaches for Males/Females: 
 
 LL AHS THS THD THIS 
Mean 5.42 3.90 10.72 28.89 44.70 
SD 4.08 2.98 6.51 22.69 38.70 
SEM 0.30 0.22 0.48 1.68 2.87 
Max 21 13 30 139 203 
Min 0 0 0 0 0 
Quartile 1 2 1 6.75 11.63 17.23 
Quartile 3 8 6 14 40.44 61 
IQR 6 5 7.25 28.81 43.78 
Numbers 111 111 112 112 112 
Table 6a Headache Data for Males  
 
 LL AHS THS THD THIS 
Mean 5.81 3.87 10.97 30.67 52.19 
SD 4.77 3.18 6.30 25.27 54.21 
SEM 0.35 0.24 0.47 1.87 4.02 
Max 19 12 26.5 113.5 230 
Min 0 0 0 0 0 
Quartile 1 2 2 6.25 13.6875 22.43525 
Quartile 3 8 5 14.75 38.375 53.77 
IQR 6 3 8.5 24.6875 31.33475 
Numbers 70 70 70 70 70 
Table 6b Headache Data for Females 
 
Table 5-6 Headache data for a) males and b) females 
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Smoking -0.057 -0.066 0.02 0.065 0.043 
Sig (2-tailed) 0.447 0.375 0.784 0.383 0.569 
n 181 181 182 182 182 
Height 0.04 0.064 0.12 0.054 0.022 
Sig (2-tailed) 0.594 0.394 0.107 0.473 0.77 
n 181 181 182 182 182 
Weight 0.044 -0.005 0.019 0.037 0.081 
Sig (2-tailed) 0.557 0.95 0.8 0.624 0.28 
n 181 181 182 182 182 
Sex 0.066 0.092 0.124 -0.024 -0.017 
Sig (2-tailed) 0.376 0.217 0.097 0.746 0.817 
n 181 181 182 182 182 
Table 7a Correlation between smoking, height, weight or sex and headache score using 
Pearson’s Correlation. None achieve significance. 
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Smoking -0.061 -0.074 0.034 0.112 0.106 
Sig (2-tailed) 0.418 0.321 0.645 0.132 0.153 
n 181 181 182 182 182 
Height 0.085 0.09 0.13 0.106 0.106 
Sig (2-tailed) 0.256 0.231 0.081 0.154 0.156 
n 181 181 182 182 182 
Weight 0.008 -0.028 0.009 0.01 0.023 
Sig (2-tailed) 0.92 0.711 0.904 0.897 0.754 
n 181 181 182 182 182 
Sex 0.116 0.138 .146* 0.021 0.031 
Sig (2-tailed) 0.119 0.064 0.049 0.774 0.673 
n 181 181 182 182 182 
Table 7b Correlations demonstrable between smoking, height, weight and headache 
score using Spearman’s correlation. None achieve significance at p <0.01. Females have 
significantly more headaches when p = 0.05. 
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5.4.1.5 Correlation With Age 
 
Only the Total Headache Score correlated with age (Pearson’s = -2.47 
(p=0.001, n=182); Spearman’s = -2.25 (p=0.002, n=182). LL, AHS, THD and 
HSI did not correlate. The effect size of this is however small (r = 0.24). 
 
 
 
Figure 5-3 Correlation of age and total headache score. (Pearson’s = -2.47 (p=0.001, 
n=182); Spearman’s = -2.25 (p=0.002, n=182). 
 
Correlations of Headache with Anatomy - Anthropomorphic Data: 
 
5.4.1.6 Calibration with MRI and Correlations between Intracranial Volume 
measurement techniques 
 
Chapter 6 explains the use of MRI to calculate multiple intracranial volumes. 
Since 11 of the subjects also had calliper measurements, I used this as a 
reference tool to check the validity of the calliper technique (figure 5-4).  
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Figure 5-4 Relationship between ICV calculations from calliper tools and MRI measured 
intracranial volume. A good correlation was demonstrated (r = 0.62). The mean calliper 
measured ICV was 1547.47mls (SD 85.39 using the Lee-Paterson formula)) while the 
mean MRI measured ICV was 1619.60mls  (SD 66.66) r = 0.62. 
 
The mean calliper measured ICV was 1547.47mls (SD 85.39) while the mean 
MRI measured ICV was 1619.60mls  (SD 66.66). 
 
As can be seen a good correlation between calliper and MRI measured 
intracranial capacity was found. 
 
Consistent differences were shown between intracranial volumes (for male and 
female versions of the Lee-Patterson formula and for the Dekaban formula as 
well as the individual measurements (AP, bipatertal diameter, head height and 
circumference) that make them (p<0.01 in all cases) (Table 5-8). It would be 
expected that males and females have different intracranial volumes and this 
was confirmed.  
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ICV 
Male 
Pear
sCor. 
1 .b 1.000
** 
.581*
* 
.662*
* 
.775*
* 
.710** 0.05
8 
 Sig.  . 0 0 0 0 0 0.54
4 
 N 113 0 113 113 113 113 113 113 
ICV 
Female 
Pear
sCor. 
.b 1 1.000
** 
.737*
* 
.710*
* 
.834*
* 
.822** 0.21 
 Sig.  .  0 0 0 0 0 0.08
3 
 N 0 69 69 69 69 69 69 69 
Dekaba
n 
formula 
Pear
sCor. 
1.000** 1.000** 1 .763*
* 
.780*
* 
.843*
* 
.854** .156
* 
 Sig.  0 0  0 0 0 0 0.03
5 
 N 113 69 182 182 182 182 182 182 
Mean 
Cranial 
AP 
Pear
sCor. 
.581** .737** .763** 1 .421*
* 
.487*
* 
.866** .344
** 
 Sig.  0 0 0  0 0 0 0 
 N 113 69 182 182 182 182 182 182 
Mean 
Bipariet
al 
Pear
sCor. 
.662** .710** .780** .421*
* 
1 .459*
* 
.667** 0.01
7 
 Sig.  0 0 0 0  0 0 0.82
1 
 N 113 69 182 182 182 182 182 182 
Mean 
Height 
Pear
sCor. 
.775** .834** .843** .487*
* 
.459*
* 
1 .568** 0.05 
 Sig.  0 0 0 0 0  0 0.50
3 
 N 113 69 182 182 182 182 182 182 
Mean 
Circumf
erence 
Pear
sCor. 
.710** .822** .854** .866*
* 
.667*
* 
.568*
* 
1 .197
** 
 Sig.  0 0 0 0 0 0  0.00
8 
 N 113 69 182 182 182 182 182 182 
Mean 
Post 
Fossa 
Pear
sCor. 
0.058 0.21 .156* .344*
* 
0.017 0.05 .197** 1 
 Sig.  0.544 0.083 0.035 0 0.821 0.50
3 
0.008  
 N 113 69 182 182 182 182 182 182 
Table 5-8 Correlation (Pearson’s 2 tailed) between the different calculations of 
Intracranial Volume (ICV) and the measurements that contribute to those calculations. 
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5.4.1.7  Correlation between ICV and Headache Score 
 
However, no correlation was demonstrated between any of the headache 
scoring systems and any of the intracranial volume measuring systems (Table 
5-9). 
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Intracranial Volume Male -0.014 0.039 -0.027 -0.097 -0.072 
Sig (2-tailed) 0.888 0.685 0.773 0.305 0.447 
N 112 112 113 113 113 
Intracranial Volume Female 0.051 0.103 0.053 0.144 0.061 
Sig (2 tailed) 0.68 0.398 0.666 0.237 0.621 
N 69 69 69 69 69 
Dekaban Formula -0.002 0.064 0.001 -0.01 -0.04 
Sig (2 tailed) 0.981 0.391 0.99 0.895 0.592 
N 181 181 182 182 182 
Table 5-9a Pearson’s correlations between intracranial volume measurements and 
headache scoring systems. No correlations reach significance.  
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Intracranial Volume Male -0.023 0.033 -0.044 -0.081 -0.061 
Sig (2-tailed) 0.813 0.731 0.643 0.396 0.519 
N 112 112 113 113 113 
Intracranial Volume Female 0.053 0.111 0.04 0.127 0.089 
Sig (2 tailed) 0.666 0.366 0.746 0.297 0.467 
N 69 69 69 69 69 
Dekaban Formula 0.008 0.069 -0.016 -0.005 -0.028 
Sig (2 tailed) 0.917 0.354 0.827 0.942 0.712 
N 181 181 182 182 182 
Table 5-9b Spearman’s correlation between intracranial volume measurements and 
headache scoring systems. No correlations reach significance.  
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5.4.1.8 Correlation between Headache Score and Basic Physiology 
 
Resting Saturations at EBC (as measured by subjects in diary): 
Total headache Score correlated with Resting peripheral oxygen saturations 
(SaO2) at EBC (Pearson’s = -2.11 (p=0.004, n=182). It also achieved 
significance with ascent headache score (-0.195, p=0.008, n=181). The effect 
size is small (r= 0.21). 
 
A correlation between resting peripheral arterial oxygen saturation at 5300m 
and headache was found with all headache measurement systems: 
(Spearman’s correlation: with THS = -2.30 (p=0.02, n=182); LL score = -1.74 
(p=0.019, n=181);  AHS = -2.16 (p=0.04, n=181); THD = -0.157 (p=0.0034, 
n=182); THIS =-1.87 (p=0.012, n=182). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-5 Correlation between resting SaO2 and headache score. Although this achieves 
significance, the effect size is small (r = 0.21) 
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Correlations with other physiological variables:  
 
5.4.1.9 Correlations in London (75m) 
 
No significant correlation was demonstrated between any of the headache 
measuring systems and: 
 
SaO2 - Resting, AT or VO2Max 
Heart Rate - Resting, AT or VO2Max 
Systolic, Diastolic or Mean Blood Pressure at rest or VO2Max 
Time to AT, VO2Max or recovery time 
Arterial Oxygen Extraction 
Haemoglobin concentration 
 
Although resting EtO2 ad EtCO2 did not correlate with headache, they did at AT 
(with THS) and at VO2Max (with THD and THIS) as demonstrated in table 5-10.  
 
There was similarly a significant correlation between right (and hence mean) 
rSO2 values and THD and THIS at AT and VO2Max, though not THS.  
 
Table 5.10 is a table of significant correlations between Headache Scores and 
Physiological Variables in London (Spearman’s Rho). The reason for including 
the rSO2 values is to demonstrate the persistent small correlation with right 
rSO2 values.  
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EtO2 at AT Correlation coefficient -.176* -0.127 -0.94 
Sig (2 –tailed) 0.022 0.101 0.22 
n 169 169 169 
EtCO2 at AT Correlation coefficient 0.203** 0.182* 0.151 
Sig (2 –tailed) 0.008 0.018 0.050 
n 169 169 169 
EtO2 at VO2Max Correlation coefficient -0.135 -0.211** -0.176* 
Sig (2 –tailed) 0.79 0.006 0.022 
n 169 169 169 
EtCO2 at VO2Max Correlation coefficient 0.128 0.210** 0.171** 
Sig (2 –tailed) 0.098 0.006 0.387 
n 169 169 127 
Left rSO2 at AT 0.062 0.147 0.125 
Sig (2 –tailed) 0.433 0.061 0.113 
n 163 163 163 
Right rSO2 at AT 0.062 0.159* 0.141 
Sig (2 –tailed) 0.429 0.042 0.073 
n 163 163 163 
Mean rSO2 at AT 0.077 0.17* 0.152 
Sig (2 –tailed) 0.33 0.03 0.053 
n 163 163 163 
Left rSO2 at VO2Max 0.129 0.159 0.136 
Sig (2 –tailed) 0.101 0.043 0.083 
n 163 163 163 
Right rSO2 at VO2Max 0.093 0.187* 0.169* 
Sig (2 –tailed) 0.239 0.017 0.031 
n 163 163 163 
Mean rSO2 at VO2Max 0.115 0.178* 0.156* 
Sig (2 –tailed) 0.144 0.023 0.046 
n 163 163 163 
• = significant at the 0.05 level, ** = significant at the 0.01 level 
Table 5-10 Significant correlations between headache scores and physiological variables 
measured during VO2max testing in London (75m). 
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5.4.1.10 Correlations at Namche (3450m) 
 
No significant correlation was demonstrated between any of the headache 
measuring systems and: 
Heart Rate - Resting, or at AT or VO2Max 
Systolic, Diastolic or Mean Blood Pressure at rest or VO2Max 
Time to AT, VO2Max or recovery time 
AT or VO2max/litres or Kg 
Haemoglobin concentration 
 
Again, significant correlations were shown between EtO2 and EtCO2 at rest, AT 
and VO2Max, as were correlations with right rSO2 (table 5-11). 
 
Total Headache Score (though not THD or THIS) correlated with SaO2 at rest 
(Spearman’s =-0.173, p =0.026, n=166), AT (Spearman’s = -0.27, p = 0.001 
n=151) though not at VO2Max. 
 
Again, right rSO2 values appear to correlate with headache considerably more 
often than left. Arterial Oxygen Extraction correlated at rest (Spearman’s = -
0.194, p = 0.012, n=165) and VO2Max (Spearman’s = -0.194, p=0.017, n=150) 
with Total Headache Scores.  
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EtO2 at Rest Correlation coefficient -0.222** -0.167* -0.176* 
Sig (2 –tailed) 0.004 0.031 0.023 
n 167 167 167 
EtCO2 at Rest Correlation coefficient 0.259** 0.204** 0.189* 
Sig (2 –tailed) 0.001 0.008 0.015 
n 167 167 167 
EtO2 at AT Correlation coefficient -0.25** -0.254** -0.254** 
Sig (2 –tailed) 0.001 0.001 0.001 
n 167 167 167 
EtCO2 at AT Correlation coefficient 0.245** 0.236** 0.23** 
Sig (2 –tailed) 0.001 0.002 0.003 
n 167 167 167 
EtO2 at VO2Max Correlation coefficient -0.152 -0.223** -0.204** 
Sig (2 –tailed) 0.051 0.004 0.008 
n 166 166 166 
EtCO2 at VO2Max Correlation coefficient 0.183* 0.243** 0.211** 
Sig (2 –tailed) 0.018 0.002 0.006 
n 166 166 166 
Left rSO2 at Res 0.081 0.089 0.066 
Sig (2 –tailed) 0.298 0.254 0.396 
n 166 166 166 
Right rSO2 at Rest 0.192* 0.235** 0.239** 
Sig (2 –tailed) 0.013 0.002 0.002 
n 166 166 166 
Mean rSO2 at Rest 0.147 0.175* 0.166* 
Sig (2 –tailed) 0.058 0.024 0.033 
n 166 166 166 
Left rSO2 at AT  0.061 0.07 0.057 
Sig (2 –tailed) 0.435 0.371 0.462 
n 166 166 166 
Right rSO2 at AT 0.146 0.194* 0.199* 
Sig (2 –tailed) 0.061 0.012 0.01 
n 166 166 166 
Mean rSO2 at AT 0.115 0.14 0.138 
Sig (2 –tailed) 0.139 0.073 0.077 
n 166 166 166 
Left rSO2 at VO2Max 0.044 0.044 0.044 
Sig (2 –tailed) 0.575 0.574 0.573 
n 166 166 166 
Right rSO2 at VO2Max 0.128 0.182* 0.186* 
Sig (2 –tailed) 0.102 0.019 0.016 
n 166 166 166 
Mean rSO2 at VO2Max 0.092 0.126 0.13 
Sig (2 –tailed) 0.24 0.106 0.095 
n 166 166 166 
• = significant at the 0.05 level, ** = significant at the 0.01 level 
Table 5-11 Significant correlations between headache scores and physiological variables 
measured during VO2max testing at Namche (3450m). 
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5.4.1.11 Correlations at Everest Base Camp (5300m) 
 
Again, no significant correlation was demonstrated between any of the 
headache measuring systems and: 
 
Heart Rate - Resting, or at AT or VO2Max 
Systolic, Diastolic or Mean Blood Pressure at rest or VO2Max 
Time to AT, VO2Max or recovery time 
AT or VO2Max/litres or Kg 
Haemoglobin concentration 
 
Again, significant correlations were shown between EtO2 and EtCO2 at rest, AT 
and VO2Max (Table 5-12). However, the weak association with right rSO2 
values that occurred at Namche was no longer present. Similarly, any 
correlation with Arterial Oxygen Extraction was lost also.  
 
Total Headache Score (though not THD or THIS) correlated with SaO2 at rest 
(Spearman’s =-0.223, p =0.007, n=144), AT (Spearman’s = -0.313, p = 0.001 
n=143) and VO2Max (Spearman’s = -0.248, p = 0.012, n=101). 
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EtO2 at Rest Correlation coefficient -0.356** -0.268** -0.287** 
Sig (2 –tailed) 0 0.001 0 
n 145 145 145 
EtCO2 at Rest Correlation coefficient 0.327** 0.316** 0.332** 
Sig (2 –tailed) 0 0 0 
n 144 144 144 
EtO2 at AT Correlation coefficient -0.325** -0.283** -0.291** 
Sig (2 –tailed) 0 0.001 0 
n 143 143 143 
EtCO2 at AT Correlation coefficient 0.268** 0.285** 0.291** 
Sig (2 –tailed) 0.001 0.001 0 
n 143 143 143 
EtO2 at VO2Max Correlation coefficient -0.189* -0.231** -0.227** 
Sig (2 –tailed) 0.024 0.006 0.007 
n 142 142 142 
EtCO2 at VO2Max Correlation coefficient 0.225** 0.249** 0.255** 
Sig (2 –tailed) 0.007 0.003 0.002 
n 142 142 142 
Left rSO2 at Res -0.086 0.034 -0.024 
Sig (2 –tailed) 0.305 0.681 0.777 
n 144 144 144 
Right rSO2 at Rest 0.006 0.149 0.109 
Sig (2 –tailed) 0.947 0.074 0.195 
n 144 144 144 
Mean rSO2 at Rest -0.025 0.118 0.066 
Sig (2 –tailed) 0.767 0.159 0.432 
n 144 144 144 
Left rSO2 at AT -0.11 -0.018 -0.075 
Sig (2 –tailed) 0.192 0.836 0.373 
n 142 142 142 
Right rSO2 at AT -0.038 0.091 0.05 
Sig (2 –tailed) 0.652 0.282 0.551 
n 142 142 142 
Mean rSO2 at AT -0.061 0.058 0.007 
Sig (2 –tailed) 0.474 0.491 0.931 
n 142 142 142 
Left rSO2 at VO2Max -0.041 0.023 -0.011 
Sig (2 –tailed) 0.63 0.784 0.901 
n 141 141 141 
Right rSO2 at VO2Max 0.008 0.117 0.105 
Sig (2 –tailed) 0.927 0.168 0.217 
n 141 141 141 
Mean rSO2 at VO2Max -0.016 0.078 0.054 
Sig (2 –tailed) 0.854 0.356 0.522 
n 141 141 141 
• = significant at the 0.05 level, ** = significant at the 0.01 level 
Table 5-12: Significant correlations between headache scores and physiological 
variables measured during VO2Max testing at Everest Base Camp. 
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5.4.1.12 Correlations between Headache and End Tidal Gas Analyses 
 
EtO2 and Total Headache Score 
 
 Resting AT VO2 Max 
To
ta
l H
ea
da
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e 
S
co
re
 
   
 EtO2/mmHg 
 r in London = 0.036 r in London = 0.144 r in London = 0.198 
 r in Namche = 0.175 r in Namche = 0.266 r in Namche = 0.134 
 r in EBC =  0.294 r in EBC =  0.328 r in EBC =  0.186 
Table 5-13 Table of EtO2 readings with headache score at sea level (red), Namche bazaar 
(green) and at Everest Base camp (blue) 
 
EtCO2 and Total Headache Score 
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 EtCO2/mmHg 
 r in London = 0.114 r in London = 0.199 r in London = 0.175 
 r in Namche = 0.267 r in Namche = 0.28 r in Namche = 0.208 
 r in EBC =  0.295 r in EBC =  0.286 r in EBC =  0.262 
Table 5-14 Table of EtCO2 readings with headache score at sea level (red), Namche 
bazaar (green) and at Everest Base camp (blue) 
 
Although the r-values are not large, EtO2 and EtCO2 consistently correlate with 
headache, from rest through to maximal exercise at all altitudes, from sea-level 
to 5300m. 
 
5.4.1.13  Correlation of rSO2 and EtCO2 
 
Because EtCO2 correlated with headache, a correlation was sought between 
EtCO2 and rSO2. Although (like right rSO2 and Total Headache Score) a 
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significant correlation was demonstrable at rest, AT and VO2Max at sea level, 
this correlation (Table 5-15) was diminished by Namche and had disappeared 
at EBC (figure 5-16) 
 
 London Namche EBC 
 Rest AT VO2 
Max 
Rest AT VO2 
Max 
Rest AT VO2 
Max 
Cor 
Co 
0.35 
** 
0.47 
** 
0.34 
** 
0.18
* 
0.21 
** 
-0.025 -0.095 -0.015 -0.116 
Sig 0.00 0.00 0.00 0.20 0.005 0.752 0.258 0.856 0.172 
m 165 165 165 168 168 167 143 142 141 
Table 5-15: Correlation coefficients and Significance for respective EtCO2 and rSO2 at 
rest, AT and VO2Max and each altitude. ** = Significant at the 0.01 level. * = Significant at 
the 0.05 level. The correlation is lost with increasing altitude. 
 
 London Namche EBC 
rS
O
2 
/ %
 
   
 EtCO2 / mmHg 
Figure 5-16: Graphs demonstrating the differences in EtCO2 and the correlating rSO2 at 
the three work rates and the three altitudes. Red square = at rest, blue diamond = at AT, 
green triangle = at VO2Max. 
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5.4.2 Investigator results 
 
Headache Scores for Investigator group (n=24): 
 
Subject No 
Ascent 
Headache 
Score 
Total 
Headache 
Score 
Headache 
Severity 
Index 
X01 1 2 39 
X02 4 5 41 
X03 0 2 1.5 
X04 0 1 2 
X05 1 3 6 
X06 0 1 1 
X07 2 3 27.5 
X08 0 0 0 
X09 0 0 0 
X10 2 4 4 
X11 0 0 0 
X12 2 8 153 
X13 8 12 90 
X14 4 5 152.5 
X15 3 2 24 
X16 8 15 141.5 
X17 1 2 9 
X18 0 1 1 
X19 0 1 4 
X20 1 1 4 
X21 0 0 2 
X22 1 4 25 
X23 1 4 64 
X24 2 5 68 
 
Table 5-16 A table demonstrating the various headache scores for individual members of 
the core investigator team. This demonstrates that headache severity index spreads 
headache score, however, because of the small numbers further correlations are not 
studied in this text. 
 
Further analysis of the investigator headaches is not reported here as more 
inferences can be made from the larger trekker data set. 
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5.5 Discussion 
 
The main aim of this study was to look for an underlying correlation between 
basic anthropomorphic of physiological variables and the headache burden 
experienced by subjects ascending a relatively gentle ascent to 5300m.  In 
doing so it also assessed a number of techniques for quantifying headache 
burden and for measuring intracranial volume. 
 
5.5.1 Headache Assessment 
 
All the headache assessment techniques used in this study (summations of 
Lake Louise Headache Scores, summation of scores only days immediately 
after ascent, summation of headache scores multiplied by duration (headache 
severity index)) correlated. This is to be expected as some are derived from 
components of the others. However, it confirms that any of these headache 
assessment tools can be used for future study. The main problems I had were 
with data collection itself.  
 
Problems with headache data collection: 
1) It is a subjective measurement – the self-assessment of headache, an 
ordinal/categorical variable, suffers because some people report pain 
more easily than others, while others try to cover pain up, especially 
when in a group to ensure that they are not held back. Other than 
keeping reporting anonymous (which we did through personalised diaries 
rather than having to report headache to a third person), and having 
clear definitions of categories of headache, there is little that can be done 
to improve this.  
2) Recording of headache - In hindsight the headache self-assessment box 
(table 5.1) could have been better designed. I planned that subjects 
would circle the period that they had their headache (morning, afternoon, 
evening, night time) and then write in the duration of the headache (in 
hours). Unfortunately, many just circled the hours (e.g. 06:00 – 12:00). 
By recording headache severity more regularly (for example hourly 
through the use of a phone App), data collection could be much 
improved. 
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3) Influence of other variables – Exercise is thought to exacerbate high 
altitude headache. As a result, our subjects’ headache experiences could 
have been influenced by the exercise tests they also underwent. More 
importantly, the large quantity of alcohol consumed by some core staff 
and trekkers could also account for some headaches experienced. 
Interestingly, Group G consumed more alcohol than all other trek groups 
combined, but the headache burden in this group did not differ from that 
in other groups. By having a score that just assessed the day 
immediately after ascent (when few people had drunk the night before – 
ascent headache score), this gave us the opportunity to see how much 
this influenced the result. The total headache scores still correlated with 
the ascent headache score hence this method of headache assessment 
is probably not necessary. 
4) There are many causes of headache - Dehydration and fatigue are often 
quoted to be common causes of headaches and some of the headaches 
reported in this study will relate to this rather than altitude. A large 
number of subjects had a headache on arrival in Kathmandu. Clearly this 
is not altitude related but due to the stress of getting away / the flight.  
 
As a community, it would be worth developing a tool that included duration as 
well as severity of pain for high altitude headache assessment and monitoring. 
The Headache Severity Index introduced here helps spread the data although it 
has no clear advantage in this study. 
 
 
5.5.2 Anthropomorphic Assessment 
 
This study has demonstrated a good correlation between Lee-Pearson and 
Dekaban estimations of intracranial volume. Previous studies comparing 
anthropometry with water volume of cadaveric skulls have suggested that 
anthropometry overestimates actual skull volume (Sahin, Acer et al. 2007). In 
my study, it would appear that compared to MRI measurements, in most 
circumstances it slightly underestimates volumes. However, it does 
demonstrate that there is a correlation between calliper and MRI measurements 
and hence those with larger skull volumes should be distinguishable from those 
with smaller volumes. Not surprisingly, this “intracranial volume” does not 
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correlate with any of the measures of headache burden. Even if a “tight-fit” 
mechanism was the underlying mechanism of high altitude headache, 
intracranial volume bears little relationship to compliance (brain atrophy / 
ventricular size etc are very variable) and hence this study was perhaps unlikely 
to yield a positive finding. Such a negative result does not refute the tight fit 
hypothesis, or the possibility that those with less compliance are more 
susceptible to headaches. On searching the literature, there has previously 
been very little study into any correlation between cerebral anatomy and 
headache. Cumming’s work (Wilson and Milledge 2008)(which is discussed in 
chapter 6) used CT to assess compliance, but little else is published.  
 
5.5.3 Headache, End Tidal O2 and End Tidal CO2 
 
It is probably not surprising that subjects with lower end tidal partial pressure of 
oxygen and higher end tidal partial pressure of carbon dioxide experience 
greater headaches, although this does not appear to have been previously 
reported in the literature. The ability to tolerate hypoxaemia without its driving 
an increase in minute ventilation could theoretically result in higher partial 
pressures of CO2, vasodilatation, increased cerebral blood flow and hence 
increased cerebral volume.  
 
5.5.4 Headache and rSO2 
 
Whilst I had expected a strong correlation between rSO2 and headache score, I 
was unable to demonstrate this in my studies. However, the correlation 
between right-sided rSO2 at Namche (3,500m - the place of the most acute drop 
in FiO2) is noteworthy. This is also the altitude at which (as discussed in the 
previous chapter) I found the left cerebral hemisphere to be significantly 
protected from hypoxia compared to the right. Further acute studies (rather than 
on day 2 and 3 following arrival at altitude) with a faster ascent profile may 
demonstrate this relationship with more confidence. It is also interesting to note 
that (see chapter 7) this group also have greater retinal venous distension. 
 
5.6 Conclusion 
 
This study has demonstrated a number of techniques for assessing headache 
burden and shown strong correlation between them all. A number of algorithms 
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to estimate intracranial volumes have also been compared with each other and 
with MRI analysis. No correlation, however, has been shown between 
headache volume and intracranial volume. A negative correlation between age, 
peripheral saturations end tidal Oxygen and headache burden has been found, 
with a positive correlation between end tidal carbon dioxide and headache 
burden. The only measure of cerebral oxygenation that appeared to correlate 
with headache burden was right-sided NIRS measurements up to Namche 
Bazaar (3,500m). Further studies are needed if the pathogenesis of high 
altitude headache is to be better understood.  
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6 Chapter 6: ANTHROPOMORPHIC MRI INVESTIGATION INTO 
ANATOMICAL PREDISPOSITION TO HIGH ALTITUDE 
HEADACHE  
 
This study is published as: The Cerebral Venous System and Anatomical 
Predisposition to High Altitude Headache (Wilson, Davagnanam et al. 2013) 
(see appendix). 
 
Introduction and Background: 
It was apparent that basic anthropomorphic measurements did not demonstrate 
any correlation with high altitude headache. I therefore undertook a more 
detailed experiment on a small number of subjects to investigate possible 
associations of headache with intracranial compartment volumes and 
intracranial venous volumes. This study and the following chapter (chapter 7) 
on retinal analysis are grouped together because both focus on the cerebral 
venous system. Following the results of these studies, I then undertook studies 
of the venous vasculature under hypoxic conditions (chapter 8).  
 
6.1 Abstract 
 
Introduction: If the “tight-fit” hypothesis is correct, there should be a correlation 
between cranial volumes and headache. If venous system hypertension 
contributes to high altitude headache, any increase in outflow resistance could 
exacerbate such symptoms. This study therefore aimed to evaluate CSF, 
parenchymal and venous compartment volumes. 
Methods: Twelve subjects (all male) who ascended to 5300m underwent a T1 
cranial MRI study on return to the UK. From this, volumetric analyses of brain, 
CSF and vascular compartments within the skull were performed and correlated 
with headache burden (ascent headache score).  
Results: Ascent headache score was found to correlate with: lateral and 3rd 
ventricular volume (Spearman’s rho =-0.5 p = 0.05); infratentorial CSF volume 
excluding ventricles (the pericerebellar CSF volume) (Spearman’s rho = -0.56 p 
= 0.03), and; the volume of the smallest transverse sinus correlated with 
headache (Pearson’s = -0.7 p=0.006, Spearman’s = -0.557 p = 0.03).   
Conclusions: Anatomical differences between individuals may contribute 
towards susceptibility of high altitude headache. The ability to buffer 
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parenchymal or vascular changes (through CSF) may provide some protection 
from headache. Probably of greater importance, a more restricted venous 
drainage pattern correlates with greater headache burden.  
 
6.2 Introduction 
 
In 1985, Ross put forward the “tight fit” hypothesis to explain the random nature 
of high altitude sickness (Ross 1985). In simple terms, the hypothesis states 
that a subject with greater cranial and spinal compliance will be able to 
accommodate more brain swelling before a rise in intracranial pressure (ICP). 
Assuming that it is the rise in ICP that causes a headache, those with “tight” 
intracranial contents will be more susceptible to altitude as a causative trigger 
for headache. Although the backbone of our current understanding (Hackett 
1999), this has been modified to incorporate a physiological component. 
Exercising at altitude is thought to exacerbate cerebral hypoxemia, exacerbate 
cerebral oedema and make altitude illness worse (Roach and Hackett 2001). 
 
There is, however, minimal evidence supporting the “tight-fit” hypothesis as it 
stands (Wilson, Newman et al. 2009). Some studies have not found cerebral 
oedema even with severe acute mountain sickness (AMS) (Fischer, Vollmar et 
al. 2004). Others have found that vasogenic oedema occurs in most subjects, 
but those with AMS have more cytotoxic oedema (Kallenberg, Bailey et al. 
2007). 
 
There are some reports (and chapter 5 in the thesis) that support the widely 
held belief that younger (rather than older) adults are more susceptible to AMS 
(Serrano-Duenas 2000; Silber, Sonnenberg et al. 2003). It could be 
hypothesized that this is because the brain atrophies over time, allowing the 
skulls of older climbers to better accommodate brain swelling. It could also be 
argued that young climbers tend to ascend rapidly which may also 
independently make them more vulnerable. Of note, one recent study has 
shown no difference in AMS between adolescents and adults (Dallimore and 
Rowbotham 2009).  
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Brain Cummins investigated headaches in 10 subjects during an expedition in 
1985 (Wilson and Milledge 2008). Each had a CT scan prior to departure. An 
independent neurologist was asked to grade the ventricles as large, normal or 
small. There appeared to be a correlation with headache and AMS scores, the 
subjects with the smallest ventricles suffering the worst. Whilst this provides 
evidence for tight fit, it may also be a secondary correlation e.g. the younger 
subjects (who might be more prone to headaches at altitude for another reason) 
have the least atrophic brains. 
 
6.3 Methods 
 
6.3.1 MRI Study 
 
Twelve subjects (all male, mean age 35.78 years [range 24-48.2]) underwent a 
1.5T MRI study (T1/T2, 1.5mm interval) both prior to and on return (within 1 
month) from the CXE expedition (described in chapter 2). Only the post-climb 
images were analysed for this study. The T1 images were imported into 
Analyze 9.0 (AnalyzeDirect, KS, USA) and a single independent blinded 
observer segmented and calculated the following volumes for each subject: 
total intracranial volume, supratentorial volume, infratentorial volume, total brain 
volume, supratentorial CSF volume (=supratentorial volume minus 
supratentorial brain volume), infratentorial CSF volume (infratentorial volume 
minus infratentorial brain volume), both lateral ventricle and 3rd ventricle volume, 
aqueduct of Sylvius and 4th ventricular volume, total ventricular volume, total 
CSF volume, Sagittal and Occipital Sinus volume and total venous volume. In 
addition, the angle of the tentorium in relation to the base of skull and the angle 
between the two petrous bones were measured. Figures 6-1, 6-2 and 6-3 
demonstrate the calculation of some of these volumes and angles. 
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Figure 6-1 Analysis of MRI scans to enable volume calculations. a) the inner table of the 
skull is demarcated to measure total intracranial volume. b) the brain surface is 
demarcated using the inbuilt software. c) the ventricles are demarcated. d) where there 
are small pockets of CSF, for example, in deep sulci that are missed with the software, 
they are then added. e) other structures, such as venous sinuses are demarcated. Note: 
for this study, arterial volumes were not calculated. 
 
 
Figure 6-2 Once all structures have been rendered, each can be added and removed and 
its volume calculated. 
 
 
Figure 6-3 In addition to volumes, angles relating to the posterior fossa were also 
measured. These included: a) the tentorial angle (the angle between the tentorium and a 
line drawn from the hard palate on mid-sagittal MR); b) the petrous angle (the angle 
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between the lines drawn along the axis of the petrous bones ventral to the internal 
auditory canals on axial MR) and c) the tentorial-clival angle (the angle formed between 
the top of the tentorium and the top of the clivus). 
 
6.3.2 Calibration Study 
 
The intracranial volumes estimated using callipers were compared to the 
volumes calculated from the MRI studies (see chapter 5 for results). 
 
6.3.3 Headache 
 
Headache scores were calculated from daily diary monitoring in which, at the 
beginning of each day, each subject was asked to grade their headache (0-3) 
as part of the Lake Louise assessment. (Please see chapters 2 and 5 for more 
details.) In this study the Ascent Headache Score (the sum of the headache 
scores in the 24 hours after the seven ascents) was used. This was used to 
maximise headaches related to altitude and minimise any contribution from 
alcohol although I have previously shown (chapter 5) that all headache-scoring 
systems correlated.  
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6.4 Results 
 
6.4.1 Compartment Volumes Angles and Headache Correlation 
 
Table 6-1 reports the correlations (Spearman’s rho) with ascent headache score 
for the compartment volumes and angles described.  
Volume or angle measured Volume/mls 
(or angle/ 
degrees) 
Range / 
mls 
Stand 
Dev 
Spearman’s rho 
Correlation 
coefficient & ascent 
headache score 
n 
Intracranial volume 1619.60 1519.80- 
1735.69 
66.67 0.06 0.42 
Supratentorial 
volume 
958.41 897.91- 
1024.22 
57.72 0.15 0.32 
Infratentorial volume 327.05 279.34- 
365.81 
30.39 -0.36 0.13 
Brain parenchyma 
volume 
1285.49 1179.95- 
1385.51 
64.53 -0.06 0.43 
Supratentorial CSF 
volume (excl. ventricles) 
217.54 169.64- 
181.53 
36.45 0.01 0.48 
Infratentorial CSF volume 
(excluding ventricles) 
62.40 45.34- 
85.94 
13.09 -0.56* 0.03 
Total non ventricular 
CSF volume 
279.95 221.60- 
33-42 
45.82 -0.11 0.37 
Lateral and 3rd 
Ventricle 
24.01 13.14- 
32.95 
6.46 -0.5* 0.05 
Aqueduct and 4th 
ventricle 
2.20 1.61- 
3.14 
0.5 0.27 0.20 
Ventricular volume 
(= lateral +3rd 
+aqueduct +4th) 
26.29 15.21- 
35.83 
6.57 -0.47 0.06 
Total supratentorial 
CSF 
241.63 183.74- 
305.78 
41.36 -0.16 0.31 
Total infratentorial 
CSF 
64.60 47.70- 
88.83 
13.32 -0.49 0.05 
 
Total CSF 306.23 244.71- 
394.61 
51.18 -0.16 0.31 
Sagittal and occipital 
sinus venous volume 
15.98 12.45- 
21.44 
2.63 -0.15 0.32 
Left transverse sinus and 
jugular bulb 
6.14 2.72- 
10.08 
2.02 -0.05+ 0.44 
Right transverse sinus 
and jugular bulb 
5.80 1.98- 
8.51 
2.34 -0.39+ 0.11 
Total venous volume 27.91 20.72- 
35.77 
4.18 -0.39 0.10 
Tentorial angle 55.26 42.5-61.7 5.71 0.51* 0.05 
Petrous angle 101.76 84.3-132.2 14.05 -0.12 0.35 
Tentorial-clival angle 106.78 98.5-126.6 6.79 0.24 0.22 
 
Table 6-1: Cranial compartment volumes in 12 male subjects. Correlation coefficients 
(non-parametric single tailed) and p values demonstrating correlation with ascent 
headache scores are reported. *=p<0.05 using a single tailed Spearman’s Rho. + = not 
significant when analysed as a whole. However, when the smallest transverse sinus 
volume is compared to headache score, the result is significant (Pearson’s = -.07 p = 
0.006, Spearman’s = -.0557 p = 0.03).  
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6.4.2 Transverse Sinus Volumes and Headache 
 
There appeared to be a correlation between transverse sinus volume and 
headache. Studying this further reveals that those suffering more tend to have 
one narrow transverse sinus (<3mls) (figure 6-4). 
  
Figure 6-4 Left (LTS, mls) and right (RTS, mls) transverse sinus volume in a) the four 
subjects with the lowest ascent headache scores (HS) and b) the four subjects with the 
highest ascent headache scores. Three of four in group b (all bar the last subject) have 
marked LTS/RTS asymmetry with marked narrowing of the non-dominant sinus to <3 mls 
in volume. The last subject had bilateral narrowing. 
 
There is a good correlation (Pearson’s = -.07 p = 0.006, Spearman’s r=-0.56, p 
= 0.03) between the volume of the smallest transverse sinus and the ascent 
headache score as demonstrated in figure 6-5.  
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Figure 6-5 Relationship between the volume of the smallest transverse sinus and high-altitude 
headache score in 12 male subjects (Pearson’s = -0.7 p=0.006, Spearman’s = -0.557 p = 0.03). 
 
6.4.3 Calibration Study 
 
See Chapter 5 for the calibration of callipers with MRI measurements. 
 
6.5 Discussion 
 
This study has two principal anatomical findings. Firstly, having a small 
ventricular CSF volume or small pericerebellar CSF volume is associated with 
greater headache burden. Secondly having a relatively narrow transverse sinus 
is associated with more severe headaches.  
 
The first finding that those with smaller ventricular CSF volumes and less 
pericerebellar space have greater headaches is in keeping with Ross’s tight fit 
hypothesis (Ross 1985). It implies that the CSF may buffer cerebral 
engorgement. This is also in keeping with a study originally performed by Brian 
Cummings which after his death I subsequently analysed and published (Wilson 
and Milledge 2008). In this study, ventricular volume (independently graded as 
large, normal or small) correlated with headache in 10 subjects ascending to 
5030m. Other studies have demonstrated headache syndromes in those with a 
“crowded” posterior fossa (Chen, Lirng et al. 2004). Hence our findings also 
imply that in those with minimal posterior fossa compliance, hypoxia may 
induce headache. 
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My second principal finding, that transverse sinus narrowing was associated 
with greater high altitude headaches, is consistent with a venous pathogenesis 
of headache. Clinically, transverse sinus stenosis and venous insufficiency is 
associated with a syndrome called Idiopathic (or benign) Intracranial 
Hypertension (IIH) (Rohr, Bindeballe et al. 2012).  It has been claimed that all 
headaches are mediated by the trigeminocervical nucleus (Bogduk 1995). This 
receives innervations from the dura lining the brain and sinuses. Hence, 
increases in the cavernous and other sinuses because of relative venous 
insufficiency would be interpreted as headache. It may be that the increased 
cerebral blood flow with hypoxia tips people who normally drain their cerebral 
circulation adequately, over into this IIH like state. This is discussed in more 
detail in the thesis discussion and in “The Headache of High Altitude and 
Microgravity – Similarities with Clinical Syndromes of Cerebral Venous 
Hypertension” (Wilson, Imray et al. 2011). 
 
6.5.1 Headache Score 
 
Headache is a very subjective phenomenon: one individual reporting a “grade” 
of headache might be quite different to another. However, it is the best 
assessment we can make. There are also many causes of headache. By 
restricting headaches that count to the headache score the morning after an 
ascent, we aimed to maximise the recording of altitude specific related 
headaches. As explained in chapter 5, all techniques of headache scoring we 
used correlated.  
 
6.6 Conclusion 
 
This study has implicated both the cerebral compliance (volume of CSF) and 
the inability to drain venous blood adequately as being components of the 
pathogenesis of high altitude headache. This is consistent with my hypothesis 
that increased cerebral blood flow in hypoxia, in some, cannot be drained 
adequately and those who are unable to buffer this increased cerebral volume 
develop headaches. Further studies looking at the venous system dynamically 
were required and have been reported in chapter 8. 
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7 Chapter 7: HYPOXIA CAUSES RETINAL VENOUS 
DISTENSION WHICH CORRELATES WITH HEADACHE 
 
This study has been accepted for publication as: The Cerebral Venous System 
and Anatomical Predisposition to High Altitude Headache, Wilson et al Annals 
of Neurology (Wilson, Davagnanam et al. 2013). 
 
7.1 Abstract 
 
Background: High Altitude Retinopathy (HAR) is a well-recognised complication 
of ascent to high altitude. The mechanism of retinal haemorrhage formation with 
hypoxia is not well understood. With the retinal venous system draining directly 
intracranially, I hypothesised that retinal venous distension should occur if 
venous hypertension or outflow restriction contributes to high altitude headache. 
Aim: This study was designed to investigate retinal vessel changes during a 
gradual ascent to 5300m and to correlate such changes with headache 
symptoms. 
Methods: Twenty-four subjects ascended from 1100m (Kathmandu) to 5300m 
(Everest Base Camp) over 17 days. Digital retinal images were obtained at sea 
level and at 5300m within 3 days of arrival. During the ascent, a daily diary of 
headache severity was recorded by each subject. Subjects peripheral 
saturations and ETCO2 were also recorded as part of the exercise study (see 
chapter 4).  
Results: Twenty-three subjects exhibited retinal venous distension ranging from 
5 to 44%. The degree of this distension correlated with ascent headache score 
(Pearson’s = 0.496, p=0.014; Spearman’s rho = 0.553, p=0.005). A correlation 
was also demonstrated between peripheral saturation at 5300m and the change 
in venous retinal vessel diameter (r = -0.55, p = 0.005). Similarly, ETCO2 at 
5300m also correlated with retinal venous vessel diameter (r=-0.4, p = 0.05). 
Conclusions: The correlation of retinal venous distension with headache 
severity supports a venous component to the pathogenesis of high altitude 
headache. The correlations with peripheral saturations and ETCO2 imply that 
those with a greater hypoxic ventilatory response (maintaining peripheral 
saturations and lowering ETCO2) have less venous engorgement and less 
headache burden. 
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7.2 Introduction 
 
The current generally accepted theory of high altitude headache is that of 
cerebral oedema developing to a greater extent in individuals who are more 
hypoxic (a physiological component) while a relative lack of cranial compliance 
results in a rise in intracranial pressure in those susceptible to high altitude 
headache (an anatomical component) (Roach and Hackett 2001). I have 
already reported the dramatic changes in arterial cerebral blood flow with 
hypoxia (Wilson, Edsell et al. 2011). It is often forgotten however that the same 
amount of blood needs to leave the skull vault. 
The retina receives its blood supply intracranially via the ophthalmic artery and 
its venous drainage is via ophthalmic veins intracranially to the cavernous sinus, 
internal cerebral veins, vein of Galen, and Transverse and Sigmoid sinuses 
before finally entering the jugular system. Since both the retina’s blood supply 
and drainage originate largely intracranially, changes in these vessels probably 
reflect cerebral vascular changes. 
Singh et al were the first to describe retinal changes at altitude (Singh, Khanna 
et al. 1969). There have subsequently been many descriptions of retinal 
haemorrhage at altitude (Lang and Kuba 1997; Wiedman and Tabin 1999) 
(Mullner-Eidenbock, Rainer et al. 2000) and pathogenic mechanisms proposed 
including Hypoxia Inducible Factor 1α (HIF-1α) (Arjamaa and Nikinmaa 2006) 
and increased arterial flow mechanisms (Mullner-Eidenbock, Rainer et al. 2000). 
  
I have hypothesised that cerebral venous congestion plays a central role in high 
altitude headache (HAH). As such, it would be expected that retinal venous 
changes should reflect this. Hence, this study investigates retinal arterial and 
venous changes during a gradual ascent to 5300m and correlates vessel 
diameter changes with headache severity. 
 
 
7.3 Methods 
 
This prospective observational cohort study was a component of the Caudwell 
Xtreme Everest Study (chapter 2) and ethical approval was given by University 
College London.  
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Subjects: Twenty-four subjects (the Investigators, 18 male, mean age 35.2 
years (range 19-59)) were recruited. None had any known pre-existing ocular 
disease. 
Ascent profile: All 24 subjects ascended as a group to 5300m over 17 days as 
described in chapter 2.  
 
7.3.1 Retinal Imaging 
 
All subjects underwent bilateral retinal imaging (8TRC NW200 Non-Mydriatic 
Digital Opthalmoscope; TopCon, Tokyo, Japan) in London and again within 2 
days of arrival at Everest Base Camp. Prior to imaging, all subjects were asked 
to stare at an Amsler chart with the right, then left eye, to assess for any 
schotoma (see Appendix Fig 2-A). If found, they were asked to draw the “blind 
spot” onto the Amsler chart.  
 
7.3.2 Retinal Analysis 
 
Subsequent retinal image analysis was performed independently by two 
investigators. Direct exact measurements were not possible (since there is no 
reference or scale with retinal images) hence the pre- and post-climb images 
were matched in size and Arbitrary Units (AU) used to enable measurement 
and percentage change calculations. The diameter of the optic disc was 
measured and a standard distance (200 AU) between the centre of the optic 
disc and the relevant vessels was measured to locate the position on the vessel 
for calibre measurements. As part of multiple measurements, the diameter of 
the superior and inferior retinal veins and the diameter of the superior temporal 
retinal artery were measured using Topcon™ (Topcon, Japan) and Sante™ 
software (Santesoft Ltd, Greece; figure 7-1). This was measured in both eyes 
by two independent clinicians and mean percentage venous and arterial calibre, 
and optic disc diameter change was calculated for each subject.  The number of 
retinal haemorrhages and a grade of papilloedema (0-5, based on the optic disc 
margins using the Modified Frisén scale (Scott, Kardon et al. 2010) (Appendix 
Fig7-A)) were also recorded. 
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Figure 7-1 Image demonstrating measurement of the optic disc, superior and inferior 
retinal veins and superior temporal retinal artery (units do not correspond to millimetres). 
 
7.3.3 Headache Severity 
 
Each subject recorded his or her headache score (ranging from 0 (no 
headache) to 4 (severe)) for the preceding 24 hours each morning. In addition 
the duration of that headache (in hours) was reported (see chapter 2). The use 
of any medication was noted. Two headache scores were used for the retinal 
study. Firstly the Total Headache Severity Index (the sum of each daily 
headache score multiplied by its duration) was used to correlate retinal vascular 
changes with headache burden. Secondly, to reduce the contribution of non-
altitude related headaches, the ascent headache score (sum of the headache 
scores following 24 hours after an ascent – 7 ascents in total) were used to 
group the subjects into those who suffered headaches (score ≥1, n= 15) and 
those that did not (score = 0, n=9).  
 
7.3.4 Statistics 
 
The results were analysed using Spearman’s Rho and Wilcoxon Rank Sum 
Tests in SPSS 14.0™. 
 
Other Physiological Variables: Pulse, blood pressure and peripheral arterial 
oxygen saturations were recorded daily. At sea level and at 5300m subjects 
also had resting end tidal CO2 (ETCO2) measurements and brain oxygenation 
(rSO2) measurements performed as part of the exercise tests as explained in 
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chapter 5. This enabled correlation of retinal changes with these variables as 
well. 
 
7.4 Results 
 
All 24 subjects completed the ascent. Cumulative headache scores ranged from 
0 to 8 (median = 1). Both venous and arterial calibre increased significantly on 
ascent (p = <0.01). Figure 7-2 demonstrates the typical increase in vessel 
diameter. 
 
  
Figure 7-2 Retinal venous distension. Figure 4a – retinal image at sea level; 4b – retinal 
image at 5300m. 
 
Arterial Changes  
Mean arterial distension was 20.6% (SD 14.5%). There was no significant 
correlation with Headache Severity Index (Pearson’s Correlation = -0.11, 
p=0.61; Spearman’s = 0.19 p=-0.38) (Figure 7-3). 
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Figure 7.3 a) Arterial Distension (%) vs frequency demonstrating a normal distribution. b) 
graph of arterial distension (%) vs Headache severity index. There is no relationship. 
 
The mean (±SD) arterial distension in those that suffered headache was 22.8% 
(±14.8)(n=15) while in those with no headaches it was 17.0%(±13.9)(n=9). 
Using an independent t-test, there is no significant difference between these 
groups (t=0.95 p=0.35). 
 
Venous Changes 
Mean venous distension was 24.5% (SD 11.2%). There was a significant 
correlation with Headache Severity Index (Pearson’s Correlation = 0.54 p<0.01, 
Spearman’s = 0.67 p<0.001) (Figure 7.4). 
 
Figure 7.4 a) Venous Distension (%) vs frequency (number of subjects) demonstrating a 
normal distribution with slight kurtosis b) graph of venous distension (%) vs Headache 
Severity Index. The correlation between Headache Severity Index and venous distension 
is significant (p<0.01). 
 
The mean (±SD) venous distension in those that suffered headache was 29.3% 
(±7.9)(n=15) while in those with no headaches it was 16.4%(±11.7)(n=9). Using 
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an independent t-test, this difference in venous distension between the groups 
is significant (t=3.2 p=0.004). 
 
Optic Disc: There was no significant increase in mean disc size (+0.3% (SD 
2.3%)). As can be seen from Fig 7.5, the centre of the distribution of changes in 
disc diameter is 0.0, hence the variability around this point probably reflects 
variance caused by the measurement technique. There was no significant 
correlation between optic disc diameter and headache severity index 
(Pearson’s Correlation = 0.21 p = 0.34; Spearman’s = 0.38, p = 0.08). 
  
Figure 7.5 a) Optic Disc diameter change (%) vs frequency (number of subjects) 
demonstrating a normal distribution. b) graph of optic disc diameter change (%) vs 
Headache severity index. The correlation is not significant (p>0.05). 
 
The mean (±SD) optic disc diameter change in those that suffered headache 
was 0.8% (±2.4)(n=14) while in those with no headaches it was -
0.3%(±2.1)(n=9). Using an independent t-test, this difference in venous 
distension between the groups is not significant (t=1.2 p=0.25). 
 
Only one subject developed retinal haemorrhages (which were detectable on 
Amsler chart challenge). Four subjects had the lowest grade of papilloedema at 
5300m. 
 
The relationship between changes in arterial diameter and peripheral arterial 
oxygen saturation at 5300m (Figure 7-6) or ETCO2, (Figure7-7) are shown 
below. Similarly, the relationship between changes in venous diameter and 
peripheral arterial oxygen saturation at 5300m or ETCO2  are shown in Figures 
7-7 and 7-8 respectively.  
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Arterial changes with other physiological variables: 
 
 
Figure 7-6 Peripheral arterial oxygen saturation at 5300m vs percentage change in 
arterial diameter. r = -0.18, r2 = 0.035 (Pearson’s correlation = -0.18 p=0.38). 
 
 
Figure 7-7 Percentage fall in EtCO2 from baseline vs percentage change in arterial 
diameter.  r = 0.26, r2 = 0.066. (Pearson’s correlation = -0.26 p=0.23). 
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Venous Changes with other physiological variables: 
 
Figure 7-8 Peripheral saturation at 5300m vs percentage change in venous diameter. r = 
0.55 r2 =0.3 (Pearson’s correlation = -0.55 p = 0.005). 
 
Figure 7-9 Correlations between venous diameter and end tidal CO2. r = 0.4 r2 = 0.16 
(Pearson’s correlation = -0.4  p= 0.05). 
 
Both peripheral arterial oxygen saturation at 5300m and the fall in EtCO2 
correlated significantly with venous distension, but not with arterial changes. 
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7.5 Discussion 
 
The principal finding in this study is that hypobaric hypoxia induces retinal 
venous and arterial distension, but only venous distension correlates with 
headache severity. This finding gives considerable strength to the hypothesis 
that the venous system is implicated in the development of high altitude 
headache. The correlations with peripheral saturations and ETCO2 imply that 
those with a greater hypoxic ventilatory response have less venous 
engorgement and less headache burden. 
 
7.5.1 Strengths and Weakness 
 
As explained earlier in this thesis, headache is a subjective measure. As such, 
caution is required when treating it as a linear measure and comparing this to a 
physiological measure. In addition, this study used a gradual ascent and 
images were taken 24 hours after arrival at altitude by which time, some degree 
of acclimatisation may have occurred, hence the percentage changes may be 
smaller than that shown by others (Bosch, Merz et al. 2009).  
 
General Discussion 
Brinchmann-Hansen et al demonstrated in 1989 that both arteries and veins 
dilate on exposure to hypobaric hypoxia of altitude (Brinchmann-Hansen, Myhre 
et al. 1989) .  More recently, Bosch et al (Bosch, Merz et al. 2009) have 
demonstrated a correlation between both arterial and venous distension and 
headache severity.  In our study, these results are supported although venous 
distension appeared to be a greater and more significant component. This may 
be a reflection of the 24 hours between arrival and imaging. 
 
In a separate study Bosch et al (Bosch, Barthelmes et al. 2008) have also 
demonstrated that 59% of climbers to 6865m developed optic disc swelling and 
that this was more prevalent in those with higher AMS scores. More recently, 
work related to the Tuebingen High Altitude Ophthalmology (THAO) study 
(Willmann, Fischer et al. 2011) has demonstrated that Optic Nerve sheath 
oedema occurred in 79% of 18 volunteers who ascended to 4559m. The 
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incidence of AMS was 55% and there was no correlation between quantification 
of Optic Nerve sheath oedema and AMS or peripheral arterial oxygen saturation 
or heart rate. 
 
7.5.2 Possible Mechanism of Venous Distension: 
 
A number of theories as to the cause of retinal vascular changes at altitude 
have previously been suggested. Mechanical distension may occur through the 
increase in cerebral blood flow velocity that has been demonstrated by 
transcranial Doppler measurement (Imray, Myers et al. 2005).  
Chemical and molecular mediators such as HIF-1α (Arjamaa and Nikinmaa 
2006), nitric oxide and VEGF may also contribute. However, while it is clear that 
such mediators could cause arteriolar and capillary dilatation, they would 
probably not be the cause of the large venous distension seen. 
Significantly in this study, the venous changes also correlate with other 
physiological variables, namely peripheral arterial oxygen saturation at 5300m 
and the fall in EtCO2 between 75m and 5300m. Arterial changes do not. This 
finding might be explained by direct or indirect effects.  Venous distension was 
greater in subjects with lower SaO2 at 5300m and those who had less reduction 
in EtCO2. If those with lower hypoxic ventilatory drive (a smaller reduction in 
EtCO2) also had elevated venous pressures (perhaps due to higher 
intrathoracic pressures or restriction in downstream venous capacitance), this 
could explain their increased retinal venous distension. However, other causes 
are possible, and remain to be explored. 
 
Further analysis of Group 1 (trekker) data (in progress) will hopefully clarify 
these findings.  
 
7.6 Conclusions 
 
On exposure to hypobaric hypoxia, both retinal arteries and veins dilate. The 
venous distension correlates with headache but no such correlation exists for 
arterial changes. Venous distension is greater in those with lower peripheral 
saturations at 5300m and in those who have less of a fall in EtCO2 between 
75m and 5300m, i.e. those who have less hypoxic ventilatory drive. Hence this 
study supports the venous system being instrumental in the pathogenesis of 
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high altitude headache and suggests that this may relate to hypoxic ventilatory 
response. 
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8 Chapter 8: HYPOXIC VENOUS MRI STUDIES 
 
8.1 Hypoxia Causes Cerebral Venous Distension – a MRI Pilot Study 
 
This pilot study is reported in The Headache of High Altitude and Microgravity – 
Similarities with Clinical Syndromes of Cerebral venous hypertension (Wilson, 
Imray et al. 2011). 
 
8.1.1 Abstract 
 
Hypoxia causes retinal venous distension. Clinically, cerebral venous 
hypertension causes headache. This study aimed to explore whether hypoxia 
causes cerebral venous distension. 
Methods: Seven subjects had susceptibility weighted MRI scans prior to and 
upon completion of a 3-hour hypoxic (FiO2 = 12%) episode. This was done as 
part of a study principally looking at arterial inflow (chapter 3). 
Results: Five subjects reported headaches while 2 reported a feeling of 
“fullness”. MRI images appeared to demonstrate cerebral venous distension in 
all subjects. 
Conclusions: The hypothesis that hypoxia causes cerebral venous distension 
appears to be true. However, further study is required to confirm these findings.  
 
8.1.2 Introduction 
 
My retinal study, and other studies, have demonstrated that hypobaric hypoxia 
causes retinal venous distension and the severity of headache reflects the 
degree of distension (Bosch, Merz et al. 2009). Venous hypertension is known 
to cause headache in a number of different pathologies such as Idiopathic 
Intracranial Hypertension (IIH) (Sander, Poppert et al. 2011). I have already 
demonstrated that hypoxia causes a very significant rise in cerebral blood flow 
(Wilson, Edsell et al. 2011) and hence, I hypothesised that any degree of 
venous obstruction may cause cerebral venous distension to occur. With the 
dense innervation of areas such as the cavernous sinus with sympathetic and 
trigeminal fibres, this could result in the perception of pressure headache.  
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This study was principally a pilot test performed at the end of the hypoxic MRI 
study described in chapter 3 (hence subjects had been exposed to 3 hours of 
hypoxia). Following the arterial study sequences I performed a susceptibility-
weighted sequence. Such a sequence is particularly good at demonstrating 
blood and hence venous vessels can be clearly seen. 
 
8.1.3 Methods 
 
The study was approved by UCL Ethics committee. Volunteers were 7 subjects 
from the Xtreme Everest group (5 male; mean age 34.4years, range 22-48).  
Full details of the methods of the study and MRI sequences are explained in 
chapter 3.  Hypobaric hypoxia (FiO2 = 12%) was achieved using a hypoxicator 
(Everest Summit Hypoxic Generator, Hypoxic Systems, New York, NY, USA) 
with 4 metres of elephant tubing to enable maintenance of hypoxia during the 
MRI acquisition. At the end of the normoxic MRI sequence and again at the end 
of the hypoxic MRI sequence, a susceptibility-weighted sequence was acquired.  
Concurrent brain oxygenation (rSO2) was measured outside the MRI scanner 
as previously explained. Subjects were also asked if they had a headache or 
other symptoms to report. 
 
8.1.4 Results 
 
Five of the subjects reported having a headache at the end of the 3 hours of 
hypoxia. Two described a feeling of head “fullness”.  
Mean peripheral saturations fell from (mean (±SEM)) 98.3% (±1.13) in normoxia 
to 74.9% (±3.72) at 3 hours of hypoxia (p<0.001). Mean cerebral oxygenation 
fell from 71.1% (±3.83) to 50.3% (±2.91) (p<0.001). Whilst it was not possible to 
quantify changes in cerebral venous dimensions (see technical limitations in 
discussion), all subjects appeared to demonstrate cerebral venous distension 
(figure 8-1). Despite the small numbers, the two subjects known to suffer with 
the worst headaches at altitude appeared to have the greatest cerebral venous 
distension. 
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Figure 8-1 Corresponding susceptibility weighted images from the same subject in 
normoxia and hypoxia (Fi02 =12%). The cortical and thalamostriate veins appear more 
prominent and distended in the hypoxic sequence. 
 
8.1.5 Discussion 
 
This study appears to demonstrate that cerebral venous structures distend with 
hypoxia. However, the small numbers and technical limitations meant that a 
further definitive study is required.  
 
Technical Limitations 
In designing this study, I sought advice regarding the best MRI imaging 
technique to study venous anatomy. Susceptibility-weighted images 
demonstrate blood vessels well because of the paramagnetic properties of 
blood. Because of other sequences that were being aquired concurrently 
(arterial spin-labelling), our radiologist did not want to use contrast. However, it 
became apparent after the study that the paramagnetic properties of oxy and 
deoxygenated-blood are themselves different. Hence, some aspects of the 
changes visible in the normoxic and hypoxic scans may actually be due to the 
changes in the paramagnetic properties of the blood as it desaturated rather 
than actual change to vessel calibre. As such, this precluded further analysis or 
quantification other than the qualitative findings described. 
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It was apparent that a more detailed study using a technique to image vessels 
that does not alter with the oxygenation of blood, would be necessary. I 
therefore designed another study that would also investigate where venous 
obstruction might be occurring. 
 
8.1.6 Conclusion 
 
From this initial pilot study it would appear that in hypoxia there is distension of 
intracerebral veins. However, this study has small numbers and the altered 
susceptibility weighting of blood means it should be repeated with bigger 
numbers and gadolinium to confirm my findings. 
  
Chapter 8: HYPOXIC VENOUS MRI STUDIES 221	  
	  
8.2 Restricted venous drainage causes greater cerebral venous 
distension in hypoxia 
 
This study has been published as: The Cerebral Venous System and 
Anatomical Predisposition to High Altitude Headache, (Wilson, Davagnanam et 
al. 2013). 
 
8.2.1 Abstract 
 
I postulated that high altitude headache (HAH) results when hypoxia-associated 
increases in cerebral blood flow occur in the context of restricted venous 
drainage. This study investigated this hypothesis. 
Methods: Eleven subjects underwent Gadolinium-enhanced Magnetic 
Resonance Venography before and during a hypoxic challenge (FiO2= 0.11, 1 
hour).  Subsequent images were analysed for degree of cerebral venous 
engorgement and transverse sinus narrowing. 
Results: Cerebral and retinal vein engorgement correlated (Spearman Rho 
0.598, p=0.05), and rose as Combined (cerebral venous efferent) Conduit 
Score (CCS) fell (a measure of venous outflow restriction: r=-0.66, p<0.05 and 
r=-0.75, p<0.05 respectively). 
Conclusion: This study supports the hypothesis that a relative restriction in 
venous outflow results in venous distension when cerebral blood flow is 
increased in the context of hypoxia. 
 
8.2.2 Introduction 
 
I have previously shown that retinal venous distension occurs at altitude and 
this correlates to headache severity.  Similarly, a number of clinical headache 
syndromes relate to venous hypertension and have many characteristics similar 
to High Altitude Headache. I have reported a pilot Hypoxic MRI study which 
appeared to demonstrate cerebral venous distension with hypoxia, however, 
because of technical limitations it was not possible to report this confidently, nor 
was it possible to quantify this effect. I therefore sought to demonstrate cerebral 
venous engorgement (and to define the cerebral venous anatomy) using a more 
robust method. 
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8.2.3 Methods 
 
Subjects: Eleven subjects (2 women; mean age = 37.2, range 21-74 years) 
were recruited (experienced trekkers/mountaineers from the Centre for Altitude, 
Space and Environment and from the Birmingham Medical Research 
Expeditionary Society). Following retinal imaging in normoxia, an intravenous 
cannula was inserted. Subjects then lay supine for 10 minutes, before 
continuous monitoring of peripheral arterial oxygen saturations (Nonin, Onyx 
Model 9500, Plymouth, MN USA) and brain oxygenation (rSO2 using NIRS, as 
described in chapter 2) was commenced.  Subjects were then rendered hypoxic 
for 60 minutes (vide infra), at the end of which period (and whilst still hypoxic) 
cranial magnetic resonance imaging was performed. The mean of three 
consecutive rSO2 values was documented at each of three time points 
(normoxia, and after 30 and 60 minutes of hypoxia). Subjects were asked to 
describe and grade (0-4) any headache they had at the end of 1 hour of 
hypoxia. In the same manner, and after a minimum of 10 minutes recumbent 
rest, magnetic resonance imaging was performed under normoxic conditions at 
least 24 hours before or after hypoxic exposure.  
 
Retinal Imaging: Each subject underwent bilateral retinal imaging (8TRC 
NW200 Non-Mydriatic Digital Opthalmoscope ; TopCon, Tokyo, Japan).  This 
was done in normoxia prior to the study, and whilst still hypoxic at the end of the 
hypoxic MRI study. These images were subsequently analysed by a blinded 
observer with calibre measurements taken of retinal arteries and retinal veins.  
 
Hypoxia: After baseline measurements, subjects were exposed to 1 hour of 
normobaric hypoxia (FiO2 = 11%; approximately equivalent to an altitude of 
4,400 m), using a tight fitting mask  (Everest Summit Hypoxic Generator, 
Hypoxic Systems, New York, NY, USA) and extended MRI-compatible tubing. 
Inspired oxygen concentration was regularly monitored (Class R-17D Oxygen 
Sensor, Oxycheq, Marianna, FL, USA).  
 
Magnetic Resonance Venography: MR venography was performed (3 tesla TIM 
TRIO, Siemens, Erlangen, Germany) using a 3D bolus-tracked gadolinium-
enhanced MRV sequence. A 0.2ml/kg intravenous bolus of Dotarem (Guerbet, 
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Villepinte, France) was administered. Bolus tracking (Siemens CARE Bolus, 
Siemens, Erlangen, Germany) was performed at the posterior aspect of the 
superior sagittal sinus, with the MRV scan triggered at the first appearance of 
contrast. Parameters for the 3D MRV sequence were: TR 3.07ms, TE 1.11ms, 
FOV 300mm, flip angle 18°, 224 slices of 1mm thickness, voxel dimensions 1.0 
x 0.8 x 1.0mm, centric phase-encoding order, acquisition time 1.01min. To 
prevent any residual gadolinium affecting the later imaging, hypoxic and 
normoxic MRI scans were performed at least 24 hours apart.  
 
Image analysis: To equilibrate the windowing, the imaging window level and 
width were set respectively to a factor of half and double the value of contrast 
signal intensity within the sagittal sinus just proximal to the torcula. A single, 
blinded Consultant Neuroradiologist analysed the resultant images with axial, 
sagittal and coronal Subtracted Maximal Intensity Projection (MIP) 
reconstructions. Normoxic and hypoxic images were presented simultaneously, 
and images graded on a scale of being the same (0), having mild greater 
prominence of venous structures (1) or having considerably greater prominence 
of venous structures (2). Attempts to perform this analysis quantitatively (using 
digital subtraction, for example with FMRIB Software Library (FSL)) were not 
successful, largely because of small differences in extra-cranial contrast 
enhancement.  
 
Combined Conduit Score (CCS): As a result of the findings in the high altitude 
study, the appearances of the transverse and sigmoid sinus were graded using 
the Combined Conduit Score (CCS) (Farb, Vanek et al. 2003). This system 
grades left and right drainage systems (using the sagittal sinus as the 
reference) as follows: 0 (aplastic), 1 (hypoplastic / severe stenosis: <25% of the 
lumen of the distal superior sagittal sinus), 2 (moderate narrowing: 25-50%), 3 
(mild narrowing: 50-75%) and 4 (no significant narrowing: 75-100%). The two 
figures (out of 4) for each side are summed to give the combined conduit score, 
with 8 being the maximum signifying no narrowing. A diagram with the 
technique for calculating this score is in the Appendix (Figure 8-A). 
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8.2.3.1 Statistical Analysis  
 
The primary endpoints were (i) cerebral venous distension with hypoxia and (ii) 
its relationship with CCS.  SPSS (version 20, IBM, NY, USA) was used for 
analysis. Bivariate correlations were used (Pearson’s for continuous data, 
Spearman’s Rho for ordinal) as appropriate. Statistical significance was set at 
p≤0.05. 
 
8.2.4 Results 
 
8.2.4.1 General Result  
 
Cerebral venous engorgement occurred in all subjects in response to hypoxia 
(Table 8-1).  
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Mean 2.18 1.00 -27.15 -37.21 16.58 1.36 3.36 2.91 6.27 
SD 0.66 0.77 9.81 15.72 8.91 0.50 1.03 1.04 1.27 
Upper 
CI 1.74 0.48 -33.74 -48.45 10.59 1.02 2.67 2.21 5.42 
Lower 
CI 2.63 1.52 -20.57 -25.97 22.57 1.70 4.05 3.61 7.13 
Table 8-1 Subject data recorded at the end of 1 hour of exposure to hypoxia (FiO2 0.11). 
EtCO2 represents end tidal CO2. Venous prominence is scored as 0 (the same), 1 (mild) 
and 2 (considerable). Right and left Transverse Sinus (TS) scores and combined conduit 
scores (CCS) are described in the methods. 
 
Figure 8-1 illustrates the typical changes that occur in venous drainage with 
hypoxia. 
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Figure 
8-1 Exemplar of the increase in venous prominence noted in response to normobaric 
hypoxia (FiO2 =11%).  This subject has asymmetry in venous drainage, with relative 
narrowing of the left transverse sinus (CCS = Right 4; Left = 1. Total = 5). 
 
8.2.4.2 Venous Changes and CCS 
 
Reductions in venous CCS were associated with increasing distension of 
cerebral veins (Pearson’s = -0.637, p<0.05; Spearman’s Rho correlation = -
0.655, p <0.05) and retinal veins (mean increase in retinal venous diameter 
+16.6% (±8.9%);  Pearson Correlation = -0.775 p<0.005, Spearmen’s Rho 
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correlation =-0.745, p<0.05). Two of the subjects with the smallest CCS also 
had the worst headaches, however, with the small numbers of this study and 
the subjective nature of headache after only 1 hour of hypoxia, a correlation 
between CCS and headache score was not possible. 
8.2.4.3 Retinal Changes 
 
Mean retinal venous diameter rose by 16.6% (±8.9%), the magnitude of 
engorgement correlating with that of the cerebral veins (Spearman Rho 0.598, 
p=0.05). There was a strong correlation between retinal venous distension and 
CSS (Pearson Correlation = -0.775 p<0.005, Spearman’s Rho correlation =-
0.745, p<0.05).  
8.2.4.4 Brain Oxygenation 
 
Those with large transverse sinuses (higher CCS) tended to have a smaller 
reduction in rSO2 (Figure 8-2) although the correlation did not achieve 
significance (r = 0.61, p = 0.061). 
 
 
Figure 8-2: Change in rSO2 with CCS. Although there is a positive correlation (r=0.61) it 
does not achieve significance (p=0.06) 
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8.2.5 Discussion 
 
This study supports the hypothesis that venous engorgement (both retinal and 
cerebral) occurs with hypoxia.  It also supports the concept that subjects with a 
greater restriction in venous outflow (smaller CCS score) have greater 
distension of cerebral veins. 
 
I have been very cautious interpreting the headache scores in this small study. 
Headache data in this study were documented for reasons of safety. Only 8 of 
the 11 subjects actually reported headache, which was self-graded on our 
reported 1-4 scale (5 grade 1; 3 grade 2). Whilst two of the three subjects with 
the worst headache scores also had amongst the worst CCS scores (CSS = 5 
in both), such data should be considered with extreme caution. High altitude 
headache may take some time to both develop and become established and 
maximal after physiological changes (such as those in vascular response) have 
occurred. Thus, any symptoms recorded with exposure to a single isolated and 
unsustained degree of normobaric hypoxia may not be expected to mirror those 
observed upon sustained exposure to a range of altitudes. The generally mild 
nature of the headaches observed reinforces these issues. 
 
This study did not monitor EtCO2. In view of the correlation between retinal 
venous distension and EtCO2 we are currently undertaking another MRI study 
investigating arterial and venous changes concurrently (over 24hours of 
hypoxia) and EtCO2 is monitored as part of this.  
 
Overall however, this study appears to support my other work demonstrating 
greater headaches in those with narrower transverse sinuses (smaller CSS 
scores – chapter 6) and retinal venous distension with hypoxia (chapter 7). It 
also validated our pilot study. 
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8.2.6 Conclusion 
 
This small hypoxic MRI study demonstrated venous distension with hypoxia and 
that this correlates with the degree of transverse sinus narrowing (CCS score). 
This is the first published study demonstrating cerebral venous distension with 
hypoxia and supports this thesis’ hypothesis of venous system involvement in 
the development of high altitude headache.  
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9 Chapter 9: SUMMARY OF ADDITIONAL NEUROSCIENCE 
STUDIES NOT CORE TO THIS THESIS 
 
9.1 Pupillometry 
 
Pupillometry was performed on all 198 subjects during their ascent to Everest 
Base Camp. Unlike my previous study in Ladakh (Wilson 2008) where pupil 
dynamics were investigated within an hour of arrival and immediately the 
following morning, on the Everest expedition, pupil dynamics were studied 24 
hours or 48 hours after arrival. The changes therefore in this study were much 
smaller presumably because an element of acclimatisation had occurred. 
Figure 9.1 demonstrates pupil aperture change with peripheral saturations for 
all trekkers in London (75m), Namche (3500m) and at Everest Base Camp 
(5300m). There is slightly less percentage change in pupil size following 
exposure to light as SaO2 falls. The correlation is significant (Pearson’s 
correlation - r=0.1365, p=0.003) 
 
Figure 9.1 Graph of peripheral saturations (SaO2/%) vs pupil aperture change (/%) for all 
trekkers (n=198) in London (75m), Namche (3500m) and at Everest base camp (5300m) 
p=0.003. 
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9.2 Intraocular Pressure  
 
I measured intraocular pressure in the investigator team during the ascent to 
Everest Base Camp. No significant changes occurred during ascent and no 
correlation with headache reporting was noted. 
 
9.3 Neuropsychology 
 
Multiple neuropsychological studies were performed on all of the investigators 
and trekkers as detailed in chapter 2. Upon return a considerable amount of 
work was required to create a control group to study the learning effect that 
occurs with repeated neuropsychological tests. As such, we now have the 
largest controlled neuropsychological data set at altitude. Correlations of 
individual neuropsychological changes with physiological variables (e.g. SaO2, 
rSO2) still needs to be analysed, however group changes have been calculated. 
 
The following tests were undertaken: 
Trail Making (A and B) – Trail making A is simply a timed join the numbered 
circles exercise. Trail making B is join the circles 1, A, 2, B, 3, C etc (see 
appendix Figure 2Bi). 
Controlled Oral Word Association Test (COWA): This tests the timed oral 
production of spoken words beginning with a designated letter. It consists of 
three word-naming trials, each lasting 1 minute, and the score is the sum of 
acceptable words on all three trials.  
Stroop Color Word test (SCWT): This determines selective attention and 
executive functions (see Appendix figure 2-Bii). In part A, the time needed to 
complete reading 100 colour names is recorded. Part B is the time needed to 
say the 100 colours of words that are printed in different coloured ink to the 
colour they spell. The total number of correct/failures were registered.  
Letter Cancellation: This is a timed test in which the subject has to cross out all 
the instances of a designated letter from a printed sheet (see Appendix figure 2-
Biii). 
Digit Symbol Modalities Test: Subjects are presented with a key containing a list 
of individual digits and corresponding abstract symbols (Appendix figure 2-Biv). 
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The subject then has to rapidly translate a long string of symbols into their 
corresponding digits. Scores reflect the number correct within 90 seconds. 
Grooved Pegboard: This test of manual dexterity requires the subject to place 
25 pegs into holes on a board varying in orientations using one hand moving 
from left to right with the right hand and right to left with the left hand. Scores 
indicate time to completion. 
Block Design: This is designed to assess visuospatial reasoning (Appendix 
figure 2B-vi). The subject is presented with a set of red and white blocks along 
with a set of patterns presented one at a time. The blocks have to be 
assembled as rapidly as possible to match the pattern. Responses were scored 
for speed and accuracy. 
 
Data Analysis: In order to assess change at a group level, cognitive outcomes 
were compared between baseline and follow-up assessments for the trekker 
and control groups using a series of mixed factor analyses of variance 
(ANOVA). This design consists of a within subject variable (neuropsychological 
test), with two levels (Baseline and each of the follow up assessments across 
ascent), and one between-subjects variable (group). 
 
The reliable change index (RCI) method (Lewis, Maruff et al. 2007) was used to 
determine individual differences on test scores controlling for the effect of 
measurement error, and practice effects. RCIs were determined by subtracting 
the baseline score (X1) from the follow up scores (X2), giving [DELTA]X for each 
individual participant for a given task. The mean expected change for the 
controls, [DELTA]Xc, calculated in the same way, was then subtracted from this, 
removing any practice effect. This score was then divided by the within subject 
standard deviation for control group (WSD), controlling for the expected 
variability.  
 
These RCI scores were then used to create individual and combined test score 
(Zcombined) using the sum of z RCI scores for each test divided by the standard 
deviation of this summation in the control group. This technique identifies 
cognitive decline by comparing the changes in test scores of an individual 
trekker with changes in the test scores of the control group over the same 
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interval. The sign is adjusted so that negative z scores indicate deterioration 
from the baseline test. Confidence intervals were set at 95%. 
 
Results 
Complete cognitive data across all four assessments could be obtained in N = 
153 trekkers with missing data being N = 13 in Namche; N = 23 in Everest Base 
Camp and N = 48 in Kathmandu. 
 
Reasons for missing data include being unable to complete testing due to poor 
health/injury or tiredness (N=8 in Namche; N=12 in EBC; N=13 in Kathmandu); 
unable to complete due to other reasons (e.g. preoccupied with other concerns; 
no reading glasses) (N=6 in EBC; N=1 in Kathmandu), failure to 
administer/score part or whole assessment missing due to logistic difficulties 
(e.g. weather conditions; early flight departures; malfunction in testing 
apparatus/ timer) (N=4 in Namche; N = 5 in EBC; N=33 in Kathmandu), not 
motivated/withdrawal (N=1 in Kathmandu). 
 
Changes in Cognitive Functioning 
All participants scored within the reference range (within one standard deviation 
[SD] of general population test norms) in all neuropsychological testings. 
Trekkers and control had equivalent NP performance with the exception of REY 
Total where control outperformed trekkers on all assessments including 
baseline.  
Generally, mean cognitive performance across NP tests was significantly better 
from baseline to follow-up assessments (in both trekkers and controls 
participants), albeit not uniformly so for all tests (i.e. TMT-A and COWA in 
Namche; GPND and REYD in EBC), showing evidence of the expected practice 
effects with repeated NP administrations over short time intervals (ps <.05).  
Interaction effects were significant only for TMT-A (Namche p=.024); TMT-B 
(Namche p=.009); COWA (EBC p=.032; K p=.003); LCT (Namche p=.035; K 
p=.007); BD (Kathmandu p=.001; EBC p=.003; Kathmandu p=.001); SD 
(Namche TREND p=.056) and SPCWC (Kathmandu p=.034). Post-hoc tests 
showed that improvements over repeat assessments were greater in the control 
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group relative to trekkers where slopes were less steep but still significant.  
Evidence of a significant decline at the group level was not revealed on any 
neuropsychological measure for either group. 
 
Individual Differences:  
 
Controlling for practice effects using RCI methodology revealed decline in 
cognitive performance for the trekkers across ascent. As shown in Table 9-1, 
mean RCI scores were negative signifying cognitive decline across ascent for 
all tasks except for the GPD, GPND and AVLT-L, which only deteriorated at the 
highest point of ascent  (i.e. Everest Base Camp).  
Decline was more pronounced in tests of verbal ability (e.g. COWA; LCT) and 
executive function (e.g. Block Design; Trails B).  
Incidence Of Cognitive Decline: 
The numbers and percentages of declines, improvements, stability on NP tests 
across ascent as defined by RCI methodology are shown in Table 6-2. 90% 
RCI confidence intervals (not displayed) were used to classify individual 
performance – individuals whose RCI scores fell within the 90% CI were 
classified as cognitively stable on that test whereas scores outside were 
designated as significantly ‘improved’ or ‘deteriorated’. As can be seen there is 
considerable heterogeneity with changes in both directions. In comparing 
baseline performance to the subsequent testing points across ascent, 39.7% to 
51.3% displayed decline in Namche, 39.3% to 49.2% in Everest Base Camp 
and 37.3% to 49.1% in Kathmandu. Notably however an almost equal 
percentage of individuals performed over 90% CI indicating improved 
performance. 
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Namche 
 
EBC 
 
Kathamandu 
 
 
M (Sd) 95% CI M (Sd) 95% CI M (Sd) 95% CI 
Trails A*  -.69 (1.38) -.89, -.50 -.16 (1.30) -.35, .02 -.41 (.82) -.54, -.28 
Trails B*  -.80 (1.42) -1.01, -.060 -.63 (.155) -.86, -.41 -.05 (.79) -.18, .06 
COWA Total+  -.72 (1.76) -.98, -.47 -.72 (1.45) -.94, -.51 -.83 (1.17) -1.02, -.64 
LCT Time*  -.75 (1.66) -.98, -.51 -.54 (1.59) -.77, -.31 -.95 (1.48) -1.18, -.71 
Stroop Time*  -.17 (1.15) -.33, -.004 -.24 (.99) -.38, -.09 -.30 (.90) -.45, -.16 
GPD*  1.13 (2.61) .76, 1.50 -.15 (2.29) -.49, .17 .12 (1.74) -.14, .39 
GPND*  .56 (1.36) .37, .75 -.32 (2.44) -.68, .03 .24 (1.71) -.02, .50 
AVLT-L+  .06 (1.64) -.16, .29 -.08 (1.79) -.34, .17 .14 (1.46) -.08, .37 
AVLT-D+  -.48 (1.42) -.69, -.28 -.56 (2.39) -.91, -.21 -.47 (1.91) -.77, -.17 
Symbol Digit+  -.60 (1.32) -.79, -.42 -.14 (1.29) -.33, .04 -.43 (1.03) -.59, -.27 
Block 
Design+    
-.87 (1.06) -1.02, -.71 -.74 (.95) -.89, -.59 
Total RCI 
Score/no.tests  
-.25 (.62) -.34, -.16 -.36 (.71) -.47, -.25 -.27 (.49) -.35, -.18 
 
Table 6.1. Mean Reliable Change Index (RCI)(SD) score and upper and lower boundaries 
at 95% confidence interval. 
  
Chapter 9 – OTHER STUDIES 235	  
	  
 
NP  tests NAMCHE EVEREST BASE CAMP KATHAMANDU 
  
Worse Stable Better Worse Stable Better Worse Stable Better 
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
TMTA 
81 
(41.5) 
27 
(13.8) 
87 
(44.6) 
85 
(45.9) 
25 
(13.5) 
75 
(40.5) 
72 
(45) 
30 
(18.8) 
58 
(36.3) 
TMTB 
77 
(39.7) 
22 
(17) 
84 
(43.3) 
75 
(40.5) 
21 
(11.4) 
89 
(48.1) 
74 
(46.8) 
26 
(16.5) 
58 
(36.7) 
LCT 
78 
(40.2) 
21 
(10.8) 
95 
(49) 
76 
(41.3) 
18 
(9.8) 
90 
(48.9) 
57 
(35.8) 
30 
(18.9) 
72 
(45.3) 
STROOP 
76 
(40.9) 
30 
(16.1) 
80 
(43) 
78 
(43.8) 
16 (9) 
84 
(47.2) 
59 
(39.3) 
29 
(19.3) 
62 
(41.3) 
GPD 
89 
(45.6) 
21 
(10.8) 
85 
(43.6) 
77 
(41.6) 
23 
(12.4) 
85 
(45.9) 
78 
(49.1) 
13 
(8.2) 
68 
(42.8) 
GPND 
86 
(44.3) 
27 
(13.9) 
81 
(41.8) 
86 
(46.7) 
23 
(12.5) 
75 
(40.8) 
59 
(37.3) 
34 
(21.5) 
65 
(41.1) 
SD 
83 
(42.8) 
26 
(13.4) 
85 
(43.8) 
85 
(46.2) 
21 
(11.4) 
78 
(42.4) 
71 
(44.4) 
30 
(18.8) 
59 
(36.9) 
AVLT-L 
79 
(40.9) 
20 
(10.4) 
94 
(48.7) 
80 
(43.7) 
29 
(15.8) 
74 
(40.4) 
71 
(44.7) 
17 
(10.7) 
71 
(44.7) 
AVLT-D 
96 
(49.7)  
97 
(50.3) 
72 
(39.3) 
54 
(29.5) 
57 
(31.1) 
67 
(42.1) 
31 
(19.5) 
61 
(38.4) 
COWA 
97 
(51.3) 
15 
(7.9) 
77 
(40.7) 
77 
(42.8) 
29 
(16.1) 
74 
(41.1) 
62 
(39.7) 
25 
(16) 
69 
(44.2) 
BD 
   
91 
(49.2) 
19 
(10.3) 
75 
(40.5) 
69 
(45.1) 
15 
(9.8) 
69 
(45.1) 
Total NP 
75 
(42.6) 
25 
(14.2) 
76 
(43.2) 
72 
(42.4) 
20 
(11.8) 
78 
(45.9) 
63 
(45) 
19 
(13.6) 
58 
(41.4) 
TOTAL 
PLUS BD    
70 
(41.2) 
25 
(14.7) 
75 
(44.1) 
58 
(43.3) 
21 
(15.7) 
55 
(41) 
Table 6-2: Patterns of change (frequency and percentage change) across ascent points 
compared to baseline (95% CI). 
Note: The block design was not performed in Namche so total scores were calculated 
with and with block design in subsequent assessments. 
 
 
Discussion: 
 
This is the largest study to prospectively investigate the altitude-related 
changes in cognitive abilities across a trekking medical research expedition to 
Mount Everest. At the group level, cognitive performance improved in both 
trekkers and controls. While decline on individual tests was not evident at the 
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group level, this is almost certainly because repeat testing obscures 
deterioration of function because any “loss of ability” (i.e. worse NP 
performance) may be compensated by the gain made because of practice 
effect due to short time intervals between assessments. 
Adjusting for practice effects using RCI methodology, study results provided 
clear evidence of overall cognitive impairment related to conditions of hypoxia. 
Trekkers were found to experience neuropsychological decline (as indexed by 
negative mean RCI scores) across several domains during the trek to Everest 
from baseline at sea levels to testing points at high altitude. Cognitive domains 
with greatest reliable declines across the ascent included visuo-spatial 
processing, complex attention, and verbal skills. Cognitive performance 
worsened with higher altitude with declines being uniformly evident in all NP 
tasks at the highest point of ascent, i.e. Everest Base Camp (5,300 m). Notably, 
cognitive decline persisted when trekkers descended to lower altitude. Although 
mean RCI of cognitive performance improved from Everest Base Camp to 
return to Kathmandu (1,300m) it did not return to baseline levels and was still 
lower than Namche (3,500m) on ascent, indicating that return to lower attitude 
does not readily/immediately restore the cognitive effects of exposure to 
extreme hypoxia.  
 
Futher Analysis: 
Further analysis of this data set and correlation with physiological variables 
(such as peripheral and regional brain saturation) are on going and will be 
published in due course. 
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Conclusion: 
The initial analysis of the neuropsychological study data demonstrates that 
hypoxia is associated with a cognitive decline across a number of different 
modalities. Further analysis with physiological variables is required to study this 
in greater depth. 
 
Chapter 10 - DISCUSSION 238	  
	  
10 Chapter 10: DISCUSSION 
 
10.1 Summary of This Thesis 
 
This thesis set out to investigate in greater detail the cerebrovascular 
physiological changes that occur with hypoxia. The main findings that add to 
our knowledge are that: 
 
1) Large cerebral arteries (demonstrated with the middle cerebral artery) 
dilate in response to hypoxia and this is detectable using ultrasound and 
MRI (chapter 3).  
2) Subjects who experience cerebral oxygen desaturation with exercise at 
sea level tend to face greater desaturation during exercise at altitude. 
Such desaturation does not correlate with headache (chapter 4). 
3) Those with smaller ventricular volumes and less pericerebellar CSF have 
a greater headache burden on ascent to altitude (chapter 5). 
4) Both the retinal and cerebral venous systems distend in response to 
acute and sustained hypoxia (chapter 6) but only retinal venous 
distension correlates with headache burden. 
5) Retinal venous distension negatively correlates with peripheral saturation 
at 5300m and with fall in EtCO2 between 75m and 5300m. This implies 
that retinal venous distension is greater in those with a lower hypoxic 
ventilatory response.  
6) Both retinal and cerebral venous distension correlate with restriction in 
venous drainage (chapter 6) which in turn correlates with headache 
severity. 
 
The above findings fundamentally change the current understanding of high 
altitude headache from being a pure intracranial pressure, “tight-fit” problem to 
being a mismatch of arterial inflow and ability to drain venous blood. The “tight-
fit” element, from the studies reported here, relates to the compliance (in terms 
of CSF space) that can accommodate this arterial/venous imbalance. Of note, 
this insufficiency of venous drainage is now thought to be fundamental in the 
development of “Space Flight Induced Intracranial Hypertension and Vision 
Alterations” (Alexander, Gibson et al. 2012) (see below) (Wilson, Imray et al. 
2011). 
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Lack of Evidence for Raised ICP at Altitude 
In addition to my studies, a number of other studies have occurred concurrently 
which imply that it is not a rise in intracranial pressure specifically that causes 
headache. For example, optic disc oedema occurs in a large proportion of 
subjects but its quantification does not correlate with AMS (Willmann, Fischer et 
al. 2011). Similarly, optic nerve sheath diameter (possibly the best non-invasive 
ICP monitoring technique currently available) has also been shown not to relate 
to high altitude headache (Lawley, Oliver et al. 2012). Henry Querfurth has 
developed an opthalmodynamometry technique for non-invasively monitoring 
ICP. This technique uses the measure of retinal vein occlusion pressures to 
infer intracranial pressure and has been validated with concurrent invasive ICP 
monitoring on intensive care(Querfurth, Arms et al. 2004). Like Marchbank’s 
tympanic membrane displacement technique (Wright, Imray et al. 1995), 
opthalmodynamometry does not show any correlation between inferred ICP and 
AMS symptomatology (Querfurth, Lieberman et al. 2010).  
 
In my initial review (chapter 1), I stated that the evidence for oedema causing 
high altitude headache syndromes was weak (Kallenberg, Bailey et al. 2007). 
Since then, other studies have demonstrated that a small amount of cerebral 
swelling does occur with hypoxia but this does not appear to correlate with the 
occurrence of AMS (Dubowitz, Dyer et al. 2009). 
 
I shall now briefly review my main findings and the literature that has resulted 
from them. 
 
10.2 Arterial Inflow 
 
I have demonstrated that hypoxia causes a significant dilatation of the middle 
cerebral artery. The assumption that only pial vessels control CBF (as put 
forward by Fog in 1938 (Fog 1938)) no longer appears to be true in extreme 
hypoxia, and under such conditions, the increase in cerebral blood flow is 
probably greater than would be appreciated by any increase in velocity alone. 
This should be taken into account when reviewing early studies using 
transcranial Doppler during hypoxia. I assume that the changes I have 
observed in the middle cerebral artery occur across all intracranial vessels.  
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It can be noted from my study that although the correlation between MRA and 
ultrasound measurements of MCA diameter correlate well (r2=0.674), the 
absolute values were quite different (mean TCD diameter measurements in 
normoxia and hypoxia were 5.44 and 6.28 mm, while corresponding MRA 
diameter measurements were 3.04 and 3.27mm). Colino and Binsted (Colino 
and Binsted 2012) questioned my data and demonstrated that there was a 
proportional bias in the sample measured by the regression line (y=0.59x 
+0.01). They noted that a sizeable proportion of my data lay above the upper 
limit of agreement (which expresses the maximum deviation between any two 
repeated observations with 95% certainty), the upper limit being 3.23 and the 
lower being 2.04. To investigate this further they transformed this data, logging 
the differences in ultrasound and MRA measured diameters and plotting this 
against the mean log of the ultrasound and MRA measured diameter (figure 10-
1). From this they concluded that there was indeed good agreement between 
ultrasound and MRA measured MCA diameters, despite a systematic bias and 
therefore only a correction factor need be applied to the data to correct the bias. 
They also stated that the data points in figure 10-1 are homoscedastic (uniform 
over a measurement range, parametrically confirmable via Levene’s test), thus 
random error can be estimated using the standard error of the mean, coefficient 
of variation and standard deviation. The coefficient of variation from the log-
transformed data (figure 10-2) is uniform across the measurement range and 
maintains a value of ~4.1% from which they concluded that the measurement 
tools were well calibrated.  
While it is convenient that Colino and Binsted’s work demonstrates good 
calibration of my TCD and MRI measurements, it should be noted that graphing 
a difference (TCCD – MRA) of related variables that have previously been 
shown to have a linear relationship would result in a linear plot. Hence some of 
their conclusions may actually relate to the technique they have used to analyse 
the two variables. 
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Figure 10-1 MRA and ultrasound MCA vessel diameter comparison. The abscissa depicts 
the mean of ultrasound and MRA diameter measurement in a participant-wise manner. 
The ordinate depicts the difference of ultrasound and MRA within each subject. There is 
a proportional bias in the sample measured by the regression line (y= 0.59x +0.01). The 
limits of agreement (depicted by two dashed lines) cannot be used to measure 
agreement because it assumes there is no relationship between error and the magnitude 
of the measured value. Therefore the data needs to be transformed to eliminate 
proportional bias. This virtually eliminates the proportional bias in the sample.  From 
Colino and Binsted’s analysis of my data (Colino and Binsted 2012). 
 
 
Figure 10-2 MRA and ultrasound log MCA vessel diameter comparison. The abscissa 
depicts the mean log ultrasound and MRA diameter measurement in a participant-wise 
manner. The ordinate depicts the difference of the log ultrasound and log MRA within 
each subject. Logarithmic transformation of the data virtually eliminated the proportional 
bias in the sample (regression line: -0.08x +0.72). The limits of agreement (two dashed 
lines) is better suited to this transformed data. From a sample of 14 data points, Colino 
and Binsted conclude that there is good agreement between ultrasound and MRA vessel 
diameter measurements despite a systematic bias. Therefore a correction factor need 
only be applied to the data to correct this bias. From Colino and Binsted’s analysis of my 
data (Colino and Binsted 2012). 
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Following my study, Ogoh et al. used a similar technique to investigate velocity 
and calibre changes in the internal carotid and vertebral arteries during hypoxia 
and concluded that isocapnic hypoxia (FiO2 =12%) increased flow in both, while 
hypocapnic hypoxia only increased flow in the vertebral arteries (Ogoh, Sato et 
al. 2012). Similarly, Willie et al (Willie, Macleod et al. 2012) have studied intra 
and extra-cranial vessel changes both to hypoxia and hypo/hypercarbia. They 
demonstrated that PaCO2 has a marked effect on extracranial vessels, the 
internal carotid artery for example “dilating” from 47mm (when PaCO2 = 
15mmHg) to 59mm (when PaCO2 = 65mmHg) (n=12), and similarly an 
approximate ~25% increase in diameter in the vertebral as well.  Although 
velocities increased in extracranial vessels with hypoxia, there was no change 
in calibre of the internal carotid artery, although the vertebral artery did increase 
in size (by 9% with an SaO2 of 70%). They conclude that, as I have said in my 
publication, there is now ample support in the literature to preclude the 
assumption of constant cerebral vessel diameter at extremes of blood gases. 
 
In the year following our expedition to Everest, Dubowitz’s group reported that, 
using arterial spin labelling MRI, cerebral blood flow was found to increase in 12 
subjects rendered hypoxic for 30 minutes (FiO2 = 12.5%), but there was no 
difference between those who were AMS susceptible (n=6) and AMS resistant 
(n=6) nor was there any difference between grey and white matter blood flow 
(Dyer, Hopkins et al. 2008). These are small numbers, but again this study 
points away from arterial blood delivery being the primary cause of high altitude 
headache. 
 
10.2.1 Clinical Implications of Arterial Findings 
 
The finding that middle cerebral artery calibre is not constant has significant 
implications for the use of transcranial Doppler in the clinical setting when a 
patient’s oxygenation status may alter. It should therefore become routine that, 
while measuring velocity, a vessel calibre measurement should also be made, if 
nothing more than to confirm consistency in location of insonation and no gross 
changes in calibre. 
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10.3 Brain Oxygenation 
 
My studies demonstrated that: 
 
1) At sea level rSO2 rises with exercise to AT and in many (approximately 
half) is still increased at VO2Max compared to baseline. 
2) There was a degree of acclimatisation with improved rSO2 in the day 2 
group over day 1 group. 
3) Following VO2Max at altitude, there is commonly a further dip in rSO2 
(between 24 and 48 seconds later) where rSO2 is at its lowest – this 
could be biological or a technological phenomenon. 
4) Left and right NIRS readings correspond at all altitudes except on arrival 
at Namche (3500m) which is the location of the biggest fall in FiO2. 
Hence in acute hypoxia, there may be an element of protection given to 
the dominant (in most people left) cerebral hemisphere. 
5) At rest, rSO2 falls to a greater extent (of its percentage baseline) 
compared to SaO2. 
6) During exercise, especially when more hypoxic (at 5300m), rSO2 falls to 
a greater extent than SaO2. This and the previous point could imply a 
greater cerebral usage of oxygen than in the periphery or it could imply a 
shift in the arterial:venous compartment volumes. 
7) Mean rSO2 falls with increasing age and increases with increasing height. 
Although statistically significant both of these are probably clinically 
insignificant. 
8) The mean female rSO2 is consistently less than the mean male rSO2. 
9) In the cluster analysis there is no differences between Cluster 1 and 
Cluster 2’s peripheral saturations, at rest or during exercise at any 
altitude; however, cluster 1 consistently (at all altitudes and exercise 
levels) cerebrally desaturate more than cluster 2. This would imply that 
cluster 1 either extracts more oxygen or develops a greater venous 
compartment than cluster 2. 
10) Those who cerebrally desaturate more had greater headache scores 
however this did not achieve significance.  
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I had hoped to be able to analyse the components of NIRS data that contribute 
to the rSO2 algorithm in greater detail.  Prior to our trip to Everest, I used a 
Hamamatsu NIRS device (Hamamatsu Photonics, Tokyo, Japan) and I had 
wanted to use other systems that would enable greater interpretation of the 
near infra-red signal beyond just rSO2. However, I had to balance this with also 
taking a light-weight, robust, battery powered system that was affordable (we 
used 2 machines at each lab concurrently, i.e. a total of 8 niroscopes were 
required). Because of this, I used the Invos system.  
 
Subudhi et al have questioned whether cerebral oxygen delivery limits 
incremental exercise performance (Subudhi, Olin et al. 2011). They 
hypothesised that raising end tidal pCO2 during exercise would increase 
cerebral blood flow, oxygen delivery and hence peak power output on a cycle 
ergometer. However, manipulating EtCO2 like this was not found to increase 
power output.  
 
10.3.1 Clinical Implications of Brain Oxygenation Findings 
 
My study, the largest cohort of brain oxygenation monitoring during ascent to 
altitude, did not reveal any correlation between rSO2 and headache. Possibly 
the most useful lesson is that it is very difficult to interpret rSO2 in isolation. A 
greater understanding of what the value is derived from would enable greater 
interpretation. Despite this, it appears that some people are better at 
maintaining rSO2 (especially during exercise) in hypoxia than others.  
 
10.4 Venous Outflow 
 
One of the main findings in this thesis is that an imbalance between arterial 
inflow and venous outflow could be the underlying mechanism in the 
development of high altitude headache. This may be the initial step (rather than 
oedema formation) that subsequently leads to an ICP rise (if the later actually 
occurs).  
 
The venous system tends to be the forgotten component of cerebral circulation. 
There have been many high altitude studies investigating arterial inflow but 
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none (until ours) investigating venous outflow. As such, a brief reminder of 
venous anatomy and physiology is provided below. 
 
 
Figure 10-3 A Simplified diagram of basic intracranial venous structures (from an article I 
wrote for High Altitude Medicine and Biology) (Wilson, Imray et al. 2011). 
 
At rest, the brain receives approximately 14% of the cardiac output, around 
700ml per minute (McArdle, Katch et al. 2006).  This volume also needs to be 
drained per minute, a factor often overlooked. The average male intracranial 
volume is only twice this (1473ml) (Abbott, Netherway et al. 2000). The internal 
jugular veins are the main venous drainage in humans and hence any 
obstruction in this exit route will increase venous and subsequently intracranial 
pressures (as well known to any neurointensivist / neurosurgeon who regularly 
sees raised intracranial pressure secondary to tight cervical collars).  
 
As bipeds with large brains, humans have developed unique anatomical 
differences compared to other mammals. Neurosurgeons are distinctly aware 
that the sagittal sinus has a negative pressure when patients are in the sitting 
position as this can result in (potentially fatal) air embolism if opened. When 
supine, bleeding from the sinuses can be torrential. Most other mammals do not 
have such pressure changes with which to contend. 
 
Three main venous drainage systems converge into the internal jugular veins 
(figure 10-3): 
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a) Cortical venous drainage occurs via bridging veins that cover the brain 
surface. These veins drain into the superior sagittal sinus which flows 
posteriorly to the torculla (confluence of sinuses) and then to the 
transverse sinus (in most people, to the right transverse sinus). 
b) Deeper (anterior) venous drainage occurs into the cavernous sinuses 
anteriorly, which in turn drain via superior and inferior petrosal sinuses 
into the jugular bulbs.  
c) Central (thalamic) areas drain via a series of small veins into the internal 
cerebral veins superiorly and the basal veins of Rosenthal inferiorly. 
These unite (behind the splenium of the corpus callosum) to form the 
Great Vein of Galen which then drains via the straight sinus to join the 
torcula and then to the transverse sinus (in most people, to the left 
transverse sinus).  
 
The final common venous outlets for all the above tributaries are the two 
internal jugular veins. Very minor additional venous drainage is provided by 
orbital veins and vertebral venous plexi (the latter of which are far more 
important in supine mammals such as swine).  
The sinuses themselves comprise dura mater lined with endothelium hence are 
very susceptible to external compression and distension. The cavernous sinus 
has extensive sympathetic innervation and other sinuses have trigeminal 
innervation hence distension can be interpreted as pain / pressure before any 
rise in ICP.  
The work demonstrated in chapter 6 implies that both the retinal and cerebral 
venous systems distend with hypoxia. Our studies are the first to demonstrate: 
1) Cerebral venous distension with hypoxia. 
2) Greater headache burden in subjects with relative venous outflow 
insufficiency. 
3) and to correlate intracerebral venous distension with retinal venous 
distension. 
This represents a fundamental change in our understanding of the 
pathogenesis of high altitude headache. From a clinical perspective, it 
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demonstrates that the currently static Monro-Kellie doctrine needs to be revised 
to a dynamic model.  
Another study that was carried out as part of the Caudwell Xtreme Everest 
project was led by Dan Martin. This investigated sublingual microcirculatory 
changes using sidestream dark-field (SDF) imaging (figure 10-4). He 
demonstrated both on Cho Oyu (8201m) and on Everest  (8848m) (Martin, Ince 
et al. 2009; Martin, Goedhart et al. 2010) that the microcirculatory flow index 
reduced in small and medium sized blood vessels. Figures 10-5 and 10-6 show 
typical images at 75 and 4,900m respectively.  It is not yet clear why the 
microcirculation slows to such a great extent. It may be a rise in haematocrit 
increases blood viscosity. It has also been suggested that the appearances are 
very similar to those seen in heart failure resembling a venous stagnation. 
Although the circulation studied using SDF is extracerebral, it may be that a 
similar phenomenon is occurring intracerebrally.  
 
 
 
 
Fig 10-4 Dan Martin using the SDF camera to assess his sublingual microcirculation.  
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Figure 10-5a Typical still image captured from video footage of sublingual 
microcirculatory blood flow at sea level (75m). 
 
Figure 10-5b Typical still image captured from video footage of sublingual 
microcirculatory blood flow at altitude (4,900 m). 
 
Since starting my work, a number of other studies have failed to demonstrate 
any link between ICP / oedema formation and high altitude headache. 
 
Mairer et al have recently demonstrated (again) that simulated hypoxia  (FiO2 = 
11%) causes very mild oedema which is increased with hypoxic exercise. 
Despite this, oedema formation does not correlate with AMS scoring /headache 
(Mairer, Gobel et al. 2012). 
  
To date studies using different modalities to assess intracranial pressure are 
failing to show a correlation with headache. Most recently, optic nerve sheath 
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diameter, probably the best non-invasive ICP monitoring technique currently 
available, appears not to correlate with high altitude headache (Lawley, Oliver 
et al. 2012). 
 
10.4.1 Clinical Implications of Venous Findings 
 
10.4.1.1 Idiopathic Intracranial Hypertension (IIH) 
 
Idiopathic Intracranial Hypertension (IIH) is a condition characterised by 
headache, nausea and vomiting. Both IIH and high altitude headache are 
commonly and successfully treated with acetazolamide (Bono, Messina et al. 
2008). I have drawn extensive comparisons between IIH and high altitude 
headache and space adaptation syndrome in our hypothesis paper (Wilson, 
Imray et al. 2011).  Bilateral transverse sinus stenosis is found in 90% of IIH 
sufferers (Pickard, Czosnyka et al. 2008) and is successfully treated with 
endoluminal stenting (Higgins, Cousins et al. 2003). More recently, Sander 
(Sander, Poppert et al. 2011) has reported that using Duplex ultrasound with 
contrast, the “Time to peak” (the time for contrast to go from the antecubital 
fossa, through the common carotid then peak in the internal jugular) is 
prolonged in patients with IIH.  This itself implies venous congestion.  
 
It may well be that the venous system is involved in more “idiopathic headaches” 
and hence it should be considered when no other cause can be found. Hypoxia 
may be a tool to “induce” headaches for study in those susceptible. 
 
10.4.1.2 Trauma 
 
Hypoxia is a common sequelae of trauma. This can occur, for example, with the 
loss of airway following head injury. In addition to the obvious ischemic effect 
this has on neurons, Goodman et al have demonstrated that inflammatory 
cytokines (interleukin-6, keratinocyte-derived chemokine, macropharge 
inflammatory protein-1α and neuron specific enolase) all increased with hypoxic 
exposure to simulate a flight transfer after head injury in mice (Goodman, 
Makley et al. 2011). Hence hypoxia following brain injury could contribute to a 
further secondary injury.  
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Our study would also imply that hypoxia has a direct cerebrovascular effect 
resulting in venous hypertension. There is increasing evidence for this clinically 
as well. Swelling brain compresses venous sinuses which result in greater 
venous pressures and a cycle of worsening cerebral swelling. This Starling 
resistor effect may account more for the upstroke in pressure with increasing 
volume than the “tight fit” closed box model itself. Intervening early to reduce 
this pressure on the venous system may be more important than the 
intervention to improve cerebral perfusion pressure (Wilson, Wise et al. 2012). 
 
10.4.2 Microgravity 
 
My interest in this field started in 1994 trying to assess intracranial pressure 
non-invasively in astronauts.  At the time it was thought that the rise in 
intracranial pressure might account for the space adaptation syndrome or space 
motions sickness that was occurring in over 70% of astronauts in the first few 
hours of space flight (Torikoshi, Wilson et al. 1995). NASA have not yet flown 
any of the non-invasive ICP monitoring tools that have been developed, partly 
because of cuts in budget and partly because none of the techniques 
developed are yet truly reliable enough to be used for space deployment. 
 
Over the last 2 years however, there has been a dramatic increase in interest in 
intracranial pressure and the venous system in space.  Many astronauts have 
reported problems with reduced visual acuity, increasing with duration of space 
flight. This has obvious implications with any planned long duration mission to 
Mars (minimum duration 630 days).  
 
In post flight questioning of nearly 300 astronauts, 23% reported subjective 
visual deterioration following short-duration flight (< 2 weeks) while 47% 
reported deterioration with long-duration (~6 month) flights (Mader, Gibson et al. 
2011).  Specifically in the 37 crewmembers who have completed longer term 
International Space Station (ISS) missions, 21 have been evaluated for visual 
loss, of which 16 have signs and symptoms (of varying severity) (Personal 
Communication Yael, Barr, Visual Impairment / Intracranial Pressure Project 
Scientist). A recent evidence report from NASA 
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(http://humanresearchroadmap.nasa.gov/Evidence/reports/VIIP.pdf)(Alexa
nder, Gibson et al. 2012) goes through many of these cases in great detail and 
concludes, as I suggested in my hypothesis paper (Wilson, Imray et al. 2011), 
that the underlying pathology is likely to be venous hypertension.  
Jugular venous distension is a consistent and well-described finding upon 
arrival in microgravity (Herault, Fomina et al. 2000; Arbeille, Fomina et al. 2001). 
Tom Weiner has coined the term “Space Obstructive Syndrome” (Wiener 2012) 
and believes that the level of obstruction is the internal jugular vein, principally 
under the sternocleidomastoid muscle. 
 
10.4.3 Hypoxia in Critical Care 
 
One of the principal tenants of the Caudwell Xtreme Everest project was to 
learn more of the effects of hypoxia to translate this knowledge into the critical 
care environment (Grocott, Montgomery et al. 2007). There are many non-
neuroscience studies that have results directly relevant to critical care  (Grocott, 
Martin et al. 2009; Martin, Levett et al. 2009; Edwards, Murray et al. 2010; 
Holloway, Montgomery et al. 2011; Levett, Fernandez et al. 2011; Levett, 
Radford et al. 2012). My principal findings, relevant to critical care, are that 
arterial vessel diameter increases with hypoxia (hence TCD may be unreliable) 
and that the venous system can become engorged when hypoxic. The latter 
suggests that minimising venous engorgement by preventing hypoxia may be 
essential in treating venous hypertension and raised intracranial pressure.  
 
10.4.4 Psychological changes 
 
I performed extensive psychological testing as part of my studies with the aim of 
correlating this with other physiological variables. Bjursten et al compared 
neurocognitive function and S100B (a marker of brain injury) release (Bjursten, 
Ederoth et al. 2010).  They demonstrated a correlation between increased 
S100B and Lake Louise score and some neurocognitive tests. However, their 
study sample size was only 7 people, hence little can actually be concluded. 
Further analysis of our neuropsychological study may reveal correlations with 
physiology. 
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10.5 Study Limitations and Further Studies 
 
The studies described within this thesis have a number of limitations. The 
ascent rate was such that the principal aim was to study the effects of hypoxia 
and adaptation rather than acute hypoxia (and headache / resulting clinical 
problems). Also, by performing the investigations at 24 and 48 hours after 
arrival at each altitude, large acute changes (such as those expected with 
pupillometry) may have diminished with acclimatisation. Certain tools such as 
headache burden assessment would be simplified in a future study and raw 
measurements (e.g. that make up brain oxygenation calculation) would be 
recorded rather than just the resulting figure. 
 
I have looked at cerebral blood flow independently from cerebral venous 
drainage. A further study will be to demonstrate that subjects vary in the 
increase in cerebral blood flow that is required to maintain cerebral oxygenation 
for a given reduction in FiO2. Some subjects in my studies have been able to 
maintain peripheral saturations to a greater extent than others. They have a 
lower headache burden (chapter 4), presumably because even if they have 
slight restrictions in outflow, they do not mount such an increase in CBF. 
Conversely subjects who are unable to maintain SaO2 probably increase CBF 
to a greater degree, unmasking any outflow restriction. I am currently 
undertaking this study with Warwick University in Coventry.  
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10.6 Summary 
 
This PhD thesis has investigated arterial cerebral blood flow, brain oxygenation 
and venous outflow in hypoxia. It has used both high altitude (hypobaric) 
hypoxic and sea-level (normobaric) hypoxia to demonstrate the following: 
• Cerebral Arteries: 
o Distend / dilate in hypoxia (demonstrated both with ultrasound and 
MRI) – which results in a dramatic increase in cerebral blood flow. 
This has negated the long held assumption applied to the use of 
transcranial Doppler at altitude, that the vessel diameter remained 
constant. 
• Brain Oxygenation: 
o Brain oxygenation decreases at altitude, that in acute jumps, the 
left cerebral hemisphere appears to be relatively protected from 
hypoxia and, since brain oxygen falls to a greater extent than 
peripheral arterial, an element of cerebral venous engorgement 
occurs. 
• Venous System: 
o The retinal veins distend at altitude and this correlates to 
headache severity 
o Cerebral veins distend in hypoxia. 
o Transverse sinus anatomy correlates with headache at high 
altitude and with the degree of venous distension in normobaric 
hypoxia. 
 
Hence, this PhD has demonstrated that venous congestion may be the 
underlying mechanism of high altitude headache and subsequent 
oedema formation. 
 
10.7 Final Conclusion 
 
The Monro Kellie Doctorine is a simple static concept. However, with nearly a 
litre of blood entering and leaving an individual’s cranium each minute, the 
system is in fact very dynamic. Small changes in this very important dynamic 
component of intracranial physiology could account for the development of high 
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altitude headache in the same way that it does in idiopathic intracranial 
hypertension. A greater understanding of this concept is important in 
understanding intracranial pressure changes at altitude, in headache 
syndromes and trauma, and as is now being discovered, in microgravity. 
REFERENCES 255	  
	  
 
11 References 
 (1995).	   "Tissue	   plasminogen	   activator	   for	   acute	   ischemic	   stroke.	   The	   National	  Institute	  of	  Neurological	  Disorders	  and	  Stroke	  rt-­‐PA	  Stroke	  Study	  Group."	  N	  Engl	  J	  Med	  333(24):	  1581-­‐1587.	  (2003).	  "ATS/ACCP	  Statement	  on	  cardiopulmonary	  exercise	  testing."	  Am	  J	  Respir	  Crit	  Care	  Med	  167(2):	  211-­‐277.	  (2004).	   "The	   International	   Classification	   of	   Headache	   Disorders:	   2nd	   edition."	  Cephalalgia	  24	  Suppl	  1:	  9-­‐160.	  Abbott,	  A.	  H.,	  D.	  J.	  Netherway,	  et	  al.	  (2000).	  "CT-­‐determined	  intracranial	  volume	  for	  a	  normal	  population."	  The	  Journal	  of	  craniofacial	  surgery	  11(3):	  211-­‐223.	  Ainslie,	   P.	  N.,	   K.	   Burgess,	   et	   al.	   (2007).	   "Alterations	   in	   cerebral	   dynamics	   at	   high	  altitude	   following	   partial	   acclimatization	   in	   humans:	   wakefulness	   and	  sleep."	  J	  Appl	  Physiol	  102(2):	  658-­‐664.	  Ainslie,	  P.	  N.,	  S.	  Ogoh,	  et	  al.	  (2008).	  "Differential	  effects	  of	  acute	  hypoxia	  and	  high	  altitude	   on	   cerebral	   blood	   flow	   velocity	   and	   dynamic	   cerebral	  autoregulation:	  alterations	  with	  hyperoxia."	  J	  Appl	  Physiol	  104(2):	  490-­‐498.	  Ainslie,	   P.	   N.	   and	   M.	   J.	   Poulin	   (2004).	   "Ventilatory,	   cerebrovascular,	   and	  cardiovascular	  interactions	  in	  acute	  hypoxia:	  regulation	  by	  carbon	  dioxide."	  J	  Appl	  Physiol	  97(1):	  149-­‐159.	  Alexander,	  D.	  J.,	  O.	  D.	  Gibson,	  et	  al.	  (2012).	  Evidence	  report:	  Risk	  of	  Space-­‐Induced	  Intracranial	  Hypertension	  and	  Vision	  Alterations.	  Lyndon	  B	  Johnson	  Space	  Center,	  Houston,	  Texas,	  National	  Aeronautics	  and	  Space	  Administration.	  Ando,	   S.,	   Y.	   Yamada,	   et	   al.	   (2010).	   "Reaction	   time	   to	   peripheral	   visual	   stimuli	  during	  exercise	  under	  hypoxia."	  J	  Appl	  Physiol	  108(5):	  1210-­‐1216.	  Anooshiravani,	   M.,	   L.	   Dumont,	   et	   al.	   (1999).	   "Brain	  magnetic	   resonance	   imaging	  (MRI)	  and	  neurological	  changes	  after	  a	  single	  high	  altitude	  climb."	  Med	  Sci	  Sports	  Exerc	  31(7):	  969-­‐972.	  Appenzeller,	  O.,	  V.	  E.	  Claydon,	  et	  al.	  (2006).	  "Cerebral	  vasodilatation	  to	  exogenous	  NO	  is	  a	  measure	  of	  fitness	  for	  life	  at	  altitude."	  Stroke	  37(7):	  1754-­‐1758.	  Appenzeller,	  O.,	  C.	  Passino,	  et	  al.	   (2004).	  "Cerebral	  vasoreactivity	   in	  Andeans	  and	  headache	  at	  sea	  level."	  J	  Neurol	  Sci	  219(1-­‐2):	  101-­‐106.	  Arbeille,	   P.,	   G.	   Fomina,	   et	   al.	   (2001).	   "Adaptation	   of	   the	   left	   heart,	   cerebral	   and	  femoral	  arteries,	  and	  jugular	  and	  femoral	  veins	  during	  short-­‐	  and	  long-­‐term	  head-­‐down	   tilt	   and	   spaceflights."	   European	   journal	   of	   applied	   physiology	  
86(2):	  157-­‐168.	  Arjamaa,	   O.	   and	  M.	   Nikinmaa	   (2006).	   "Oxygen-­‐dependent	   diseases	   in	   the	   retina:	  role	  of	  hypoxia-­‐inducible	  factors."	  Exp	  Eye	  Res	  83(3):	  473-­‐483.	  Arzy,	   S.,	   M.	   Idel,	   et	   al.	   (2005).	   "Why	   revelations	   have	   occurred	   on	   mountains?	  Linking	  mystical	  experiences	  and	  cognitive	  neuroscience."	  Med	  Hypotheses	  
65(5):	  841-­‐845.	  Bailey,	  D.	  M.	  (2003).	  "Radical	  dioxygen:	  from	  gas	  to	  (unpaired!)	  electrons."	  Adv	  Exp	  Med	  Biol	  543:	  201-­‐221.	  Bailey,	  D.	  M.	  (2004).	  "Ascorbate,	  blood-­‐brain	  barrier	  function	  and	  acute	  mountain	  sickness:	  a	  radical	  hypothesis."	  Wilderness	  Environ	  Med	  15(3):	  231-­‐233.	  Bailey,	  D.	  M.	  and	  B.	  Davies	  (2001).	  "Acute	  mountain	  sickness;	  prophylactic	  benefits	  of	  antioxidant	  vitamin	  supplementation	  at	  high	  altitude."	  High	  Alt	  Med	  Biol	  
2(1):	  21-­‐29.	  
REFERENCES 256	  
	  Bailey,	   D.	   M.,	   G.	   R.	   Kleger,	   et	   al.	   (2004).	   "Pathophysiological	   significance	   of	  peroxidative	  stress,	  neuronal	  damage,	  and	  membrane	  permeability	  in	  acute	  mountain	  sickness."	  J	  Appl	  Physiol	  96(4):	  1459-­‐1463.	  Bailey,	  D.	  M.,	  R.	  Roukens,	  et	  al.	   (2006).	   "Free	  radical-­‐mediated	  damage	  to	  barrier	  function	   is	   not	   associated	  with	   altered	   brain	  morphology	   in	   high-­‐altitude	  headache."	  J	  Cereb	  Blood	  Flow	  Metab	  26(1):	  99-­‐111.	  Bartsch,	  P.,	  D.	  M.	  Bailey,	  et	  al.	  (2004).	  "Acute	  mountain	  sickness:	  controversies	  and	  advances."	  High	  Alt	  Med	  Biol	  5(2):	  110-­‐124.	  Bartsch,	   P.,	   M.	   Maggiorini,	   et	   al.	   (1991).	   "Prevention	   of	   high-­‐altitude	   pulmonary	  edema	  by	  nifedipine."	  N	  Engl	  J	  Med	  325(18):	  1284-­‐1289.	  Bartsch,	   P.,	   M.	   Maggiorini,	   et	   al.	   (1991).	   "Enhanced	   exercise-­‐induced	   rise	   of	  aldosterone	  and	  vasopressin	  preceding	  mountain	  sickness."	   J	  Appl	  Physiol	  
71(1):	  136-­‐143.	  Bartsch,	   P.	   and	   M.	   Schneider	   (2001).	   "Pharmacological	   prevention	   of	   acute	  mountain	  sickness.	  Same	  ascent	  rates	  must	  be	  used	  to	  assess	  effectiveness	  of	  different	  doses	  of	  acetazolamide."	  Bmj	  322(7277):	  48-­‐49.	  Basnyat,	   B.,	   J.	   H.	   Gertsch,	   et	   al.	   (2006).	   "Acetazolamide	   125	   mg	   BD	   is	   not	  significantly	  different	  from	  375	  mg	  BD	  in	  the	  prevention	  of	  acute	  mountain	  sickness:	   the	   prophylactic	   acetazolamide	   dosage	   comparison	   for	   efficacy	  (PACE)	  trial."	  High	  Alt	  Med	  Biol	  7(1):	  17-­‐27.	  Basnyat,	  B.,	  J.	  H.	  Gertsch,	  et	  al.	  (2003).	  "Efficacy	  of	  low-­‐dose	  acetazolamide	  (125	  mg	  BID)	  for	  the	  prophylaxis	  of	  acute	  mountain	  sickness:	  a	  prospective,	  double-­‐blind,	  randomized,	  placebo-­‐controlled	  trial."	  High	  Alt	  Med	  Biol	  4(1):	  45-­‐52.	  Basnyat,	  B.	   and	  D.	  R.	  Murdoch	   (2003).	   "High-­‐altitude	   illness."	  Lancet	  361(9373):	  1967-­‐1974.	  Basnyat,	   B.,	   T.	   Wu,	   et	   al.	   (2004).	   "Neurological	   conditions	   at	   altitude	   that	   fall	  outside	   the	   usual	   definition	   of	   altitude	   sickness."	   High	   Alt	  Med	   Biol	  5(2):	  171-­‐179.	  Basu,	  M.,	  R.	  C.	  Sawhney,	  et	  al.	  (2002).	  "Glucocorticoids	  as	  prophylaxis	  against	  acute	  mountain	  sickness."	  Clin	  Endocrinol	  (Oxf)	  57(6):	  761-­‐767.	  Baumgartner,	   R.	   W.,	   P.	   Bartsch,	   et	   al.	   (1994).	   "Enhanced	   cerebral	   blood	   flow	   in	  acute	  mountain	  sickness."	  Aviat	  Space	  Environ	  Med	  65(8):	  726-­‐729.	  Baumgartner,	   R.	   W.,	   A.	   M.	   Siegel,	   et	   al.	   (2007).	   "Going	   high	   with	   preexisting	  neurological	  conditions."	  High	  Alt	  Med	  Biol	  8(2):	  108-­‐116.	  Baumgartner,	  R.	  W.,	  I.	  Spyridopoulos,	  et	  al.	  (1999).	  "Acute	  mountain	  sickness	  is	  not	  related	   to	   cerebral	   blood	   flow:	   a	   decompression	   chamber	   study."	   J	   Appl	  Physiol	  86(5):	  1578-­‐1582.	  Beall,	   C.	   M.	   (2007).	   "Two	   routes	   to	   functional	   adaptation:	   Tibetan	   and	   Andean	  high-­‐altitude	  natives."	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  104	  Suppl	  1:	  8655-­‐8660.	  Beall,	   C.	   M.,	   D.	   Laskowski,	   et	   al.	   (2001).	   "Pulmonary	   nitric	   oxide	   in	   mountain	  dwellers."	  Nature	  414(6862):	  411-­‐412.	  Beckmann,	   N.	   (2000).	   "High	   resolution	   magnetic	   resonance	   angiography	   non-­‐invasively	  reveals	  mouse	  strain	  differences	  in	  the	  cerebrovascular	  anatomy	  in	  vivo."	  Magn	  Reson	  Med	  44(2):	  252-­‐258.	  Beidleman,	   B.	   A.,	   S.	   R.	   Muza,	   et	   al.	   (2007).	   "Validation	   of	   a	   shortened	   electronic	  version	  of	   the	  environmental	  symptoms	  questionnaire."	  High	  Alt	  Med	  Biol	  
8(3):	  192-­‐199.	  Bellner,	   J.,	  B.	  Romner,	  et	  al.	   (2004).	   "Transcranial	  Doppler	  sonography	  pulsatility	  index	   (PI)	   reflects	   intracranial	   pressure	   (ICP)."	   Surg	  Neurol	  62(1):	   45-­‐51;	  discussion	  51.	  
REFERENCES 257	  
	  Berry,	   D.	   T.,	   J.	   W.	   McConnell,	   et	   al.	   (1989).	   "Isocapnic	   hypoxemia	   and	  neuropsychological	  functioning."	  J	  Clin	  Exp	  Neuropsychol	  11(2):	  241-­‐251.	  Bert,	   P.	   (1878).	   La	   Pression	   Barometrique.	   Paris,	   Columbus	   Ohio	   College	   Book	  Company.	  Bert,	   P.	   (1943).	   Barometric	   Pressure;	   Researches	   in	   Experimental	   Physiology,	  (1878).	  Hitchcock	  MA	  and	  HitchcockFA,	  Columbus:	  College	  Book:	  171-­‐192,	  704-­‐707,	  963-­‐983.	  Besselmann,	  M.,	  M.	  Liu,	  et	  al.	   (2001).	   "MR	  angiographic	   investigation	  of	   transient	  focal	  cerebral	  ischemia	  in	  rat."	  NMR	  Biomed	  14(5):	  289-­‐296.	  Bhambhani,	  Y.,	  R.	  Malik,	   et	   al.	   (2007).	   "Cerebral	  oxygenation	  declines	  at	   exercise	  intensities	   above	   the	   respiratory	   compensation	   threshold."	  Respir	   Physiol	  Neurobiol	  156(2):	  196-­‐202.	  Bianchi,	  M.	   T.	   and	   J.	   R.	   Sims	   (2008).	   "Restricted	   diffusion	   in	   the	   splenium	  of	   the	  corpus	  callosum	  after	  cardiac	  arrest."	  Open	  Neuroimag	  J	  2:	  1-­‐4.	  Bjursten,	   H.,	   P.	   Ederoth,	   et	   al.	   (2010).	   "S100B	   profiles	   and	   cognitive	   function	   at	  high	  altitude."	  High	  Alt	  Med	  Biol	  11(1):	  31-­‐38.	  Bogduk,	  N.	  (1995).	  "Anatomy	  and	  physiology	  of	  headache."	  Biomed	  Pharmacother	  
49(10):	  435-­‐445.	  Bolmont,	   B.,	   C.	   Bouquet,	   et	   al.	   (2001).	   "Relationships	   of	   personality	   traits	   with	  performance	   in	   reaction	   time,	   psychomotor	   ability,	   and	  mental	   efficiency	  during	   a	   31-­‐day	   simulated	   climb	   of	   Mount	   Everest	   in	   a	   hypobaric	  chamber'."	  Percept	  Mot	  Skills	  92(3	  Pt	  2):	  1022-­‐1030.	  Bolmont,	   B.,	   F.	   Thullier,	   et	   al.	   (2000).	   "Relationships	   between	   mood	   states	   and	  performances	   in	   reaction	   time,	  psychomotor	  ability,	   and	  mental	   efficiency	  during	  a	  31-­‐day	  gradual	  decompression	   in	  a	  hypobaric	   chamber	   from	  sea	  level	  to	  8848	  m	  equivalent	  altitude."	  Physiol	  Behav	  71(5):	  469-­‐476.	  Bono,	   F.,	   D.	   Messina,	   et	   al.	   (2008).	   "Bilateral	   transverse	   sinus	   stenosis	   and	  idiopathic	   intracranial	   hypertension	   without	   papilledema	   in	   chronic	  tension-­‐type	  headache."	  Journal	  of	  neurology	  255(6):	  807-­‐812.	  Bor-­‐Seng-­‐Shu,	  E.,	  R.	  Hirsch,	  et	  al.	  (2006).	  "Cerebral	  hemodynamic	  changes	  gauged	  by	   transcranial	   Doppler	   ultrasonography	   in	   patients	   with	   posttraumatic	  brain	  swelling	  treated	  by	  surgical	  decompression."	  J	  Neurosurg	  104(1):	  93-­‐100.	  Bosch,	  M.	  M.,	  D.	  Barthelmes,	  et	  al.	  (2008).	  "High	  incidence	  of	  optic	  disc	  swelling	  at	  very	  high	  altitudes."	  Arch	  Ophthalmol	  126(5):	  644-­‐650.	  Bosch,	  M.	  M.,	  T.	  M.	  Merz,	  et	  al.	  (2009).	  "New	  insights	  into	  ocular	  blood	  flow	  at	  very	  high	  altitudes."	  J	  Appl	  Physiol	  106(2):	  454-­‐460.	  Boulos,	   P.,	   C.	   Kouroukis,	   et	   al.	   (1999).	   "Superior	   sagittal	   sinus	   thrombosis	  occurring	   at	   high	   altitude	   associated	   with	   protein	   C	   deficiency."	   Acta	  Haematol	  102(2):	  104-­‐106.	  Bouquet,	   C.	   A.,	   B.	   Gardette,	   et	   al.	   (1999).	   "Psychomotor	   skills	   learning	   under	  chronic	  hypoxia."	  Neuroreport	  10(14):	  3093-­‐3099.	  Boushel,	   R.,	   H.	   Langberg,	   et	   al.	   (2000).	   "Regional	   blood	   flow	   during	   exercise	   in	  humans	  measured	  by	  near-­‐infrared	  spectroscopy	  and	  indocyanine	  green."	  J	  Appl	  Physiol	  89(5):	  1868-­‐1878.	  Bradwell,	   A.	   R.,	   A.	   D.	   Wright,	   et	   al.	   (1992).	   "Acetazolamide	   and	   high	   altitude	  diseases."	  Int	  J	  Sports	  Med	  13	  Suppl	  1:	  S63-­‐64.	  Brealey,	   D.,	   M.	   Brand,	   et	   al.	   (2002).	   "Association	   between	   mitochondrial	  dysfunction	  and	  severity	  and	  outcome	  of	  septic	  shock."	  Lancet	  360(9328):	  219-­‐223.	  
REFERENCES 258	  
	  Brinchmann-­‐Hansen,	   O.,	   K.	   Myhre,	   et	   al.	   (1989).	   "Retinal	   vessel	   responses	   to	  exercise	   and	   hypoxia	   before	   and	   after	   high	   altitude	   acclimatisation."	   Eye	  (Lond)	  3	  (	  Pt	  6):	  768-­‐776.	  Brugniaux,	  J.	  V.,	  A.	  N.	  Hodges,	  et	  al.	  (2007).	  "Cerebrovascular	  responses	  to	  altitude."	  Respir	  Physiol	  Neurobiol	  158(2-­‐3):	  212-­‐223.	  Brzecka,	  A.	  (2005).	  "Brain	  preconditioning	  and	  obstructive	  sleep	  apnea	  syndrome."	  Acta	  Neurobiol	  Exp	  (Wars)	  65(2):	  213-­‐220.	  Burgess,	   K.	   R.,	   P.	   Johnson,	   et	   al.	   (2004).	   "Acute	   mountain	   sickness	   is	   associated	  with	  sleep	  desaturation	  at	  high	  altitude."	  Respirology	  9(4):	  485-­‐492.	  Butler,	   P.	   J.	   (2010).	   "High	   fliers:	   the	   physiology	   of	   bar-­‐headed	   geese."	   Comp	  Biochem	  Physiol	  A	  Mol	  Integr	  Physiol	  156(3):	  325-­‐329.	  Cardoso,	   E.	   R.	   and	   J.	   A.	   Kupchak	   (1992).	   "Evaluation	   of	   intracranial	   pressure	  gradients	   by	  means	   of	   transcranial	   Doppler	   sonography."	   Acta	   Neurochir	  Suppl	  (Wien)	  55:	  1-­‐5.	  Casey,	   D.	   P.,	   C.	   H.	   Imray,	   et	   al.	   (2011).	   "Comments	   on	   point:	   counterpoint:	   high	  altitude	  is/is	  not	  for	  the	  birds!"	  Journal	  of	  applied	  physiology	  111(5):	  1520-­‐1524.	  Castelló-­‐Roca,	  A.	  (1993).	  Hombre,	  Montaña	  y	  Medicina	  [Man,	  Mountains	  and	  Medicine].	  Barcelona,	  Editor	  Service.	  Chan,	   C.	   W.,	   H.	   Hoar,	   et	   al.	   (2005).	   "Effect	   of	   sildenafil	   and	   acclimatization	   on	  cerebral	  oxygenation	  at	  altitude."	  Clin	  Sci	  (Lond)	  109(3):	  319-­‐324.	  Chan,	   P.	   H.,	   J.	   W.	   Schmidley,	   et	   al.	   (1984).	   "Brain	   injury,	   edema,	   and	   vascular	  permeability	  changes	   induced	  by	  oxygen-­‐derived	  free	  radicals."	  Neurology	  
34(3):	  315-­‐320.	  Chen,	   Y.	   Y.,	   J.	   F.	   Lirng,	   et	   al.	   (2004).	   "Primary	   cough	  headache	   is	   associated	  with	  posterior	  fossa	  crowdedness:	  a	  morphometric	  MRI	  study."	  Cephalalgia	  :	  an	  international	  journal	  of	  headache	  24(9):	  694-­‐699.	  Choy,	   M.,	   V.	   Ganesan,	   et	   al.	   (2006).	   "The	   chronic	   vascular	   and	   haemodynamic	  response	  after	  permanent	  bilateral	   common	  carotid	  occlusion	   in	  newborn	  and	  adult	  rats."	  J	  Cereb	  Blood	  Flow	  Metab	  26(8):	  1066-­‐1075.	  Clarke,	   C.	   (2006).	   "Acute	   mountain	   sickness:	   medical	   problems	   associated	   with	  acute	   and	   subacute	   exposure	   to	   hypobaric	   hypoxia."	   Postgrad	   Med	   J	  
82(973):	  748-­‐753.	  Cohen,	  J.	  (1992).	  "A	  power	  primer."	  Psychol	  Bull	  112(1):	  155-­‐159.	  Colino,	   F.	   L.	   and	   G.	   Binsted	   (2012).	   Theory	   and	   Practice	   of	   MRA-­‐Guided	  Transcranial	   Doppler	   Sonography.	   Applied	   Aspects	   of	   Ultrasonography	   in	  Humans.	  P.	  N.	  Ainslie.	  Rijeka,	  Croatia,	  InTech:	  41-­‐55.	  Curran-­‐Everett,	   D.	   C.,	   J.	   Iwamoto,	   et	   al.	   (1991).	   "Intracranial	   pressures	   and	   O2	  extraction	  in	  conscious	  sheep	  during	  72	  h	  of	  hypoxia."	  Am	  J	  Physiol	  261(1	  Pt	  2):	  H103-­‐109.	  Czosnyka,	   M.,	   H.	   K.	   Richards,	   et	   al.	   (1996).	   "Relationship	   between	   transcranial	  Doppler-­‐determined	   pulsatility	   index	   and	   cerebrovascular	   resistance:	   an	  experimental	  study."	  J	  Neurosurg	  84(1):	  79-­‐84.	  Dallimore,	  J.	  and	  E.	  C.	  Rowbotham	  (2009).	  "Incidence	  of	  acute	  mountain	  sickness	  in	  adolescents."	  Wilderness	  Environ	  Med	  20(3):	  221-­‐224.	  Dehnert,	   C.,	   J.	   Weymann,	   et	   al.	   (2002).	   "No	   association	   between	   high-­‐altitude	  tolerance	   and	   the	   ACE	   I/D	   gene	   polymorphism."	   Med	   Sci	   Sports	   Exerc	  
34(12):	  1928-­‐1933.	  Dekaban,	  A.	  S.	  (1977).	  "Tables	  of	  cranial	  and	  orbital	  measurements,	  cranial	  volume,	  and	  derived	  indexes	  in	  males	  and	  females	  from	  7	  days	  to	  20	  years	  of	  age."	  Annals	  of	  neurology	  2(6):	  485-­‐491.	  
REFERENCES 259	  
	  Dickinson,	   J.,	  D.	  Heath,	  et	  al.	   (1983).	  "Altitude-­‐related	  deaths	   in	  seven	  trekkers	   in	  the	  Himalayas."	  Thorax	  38(9):	  646-­‐656.	  Dietz,	  T.	  E.	  (2008).	  "An	  Altitude	  Tutorial."	  from	  http://www.issmed.org.	  Dorward,	   D.	   A.,	   A.	   A.	   Thompson,	   et	   al.	   (2007).	   "Change	   in	   plasma	   vascular	  endothelial	  growth	  factor	  during	  onset	  and	  recovery	   from	  acute	  mountain	  sickness."	  Respir	  Med	  101(3):	  587-­‐594.	  Droma,	   Y.,	   M.	   Hanaoka,	   et	   al.	   (2008).	   "Adaptation	   to	   high	   altitude	   in	   Sherpas:	  association	  with	   the	   insertion/deletion	  polymorphism	   in	   the	  Angiotensin-­‐converting	  enzyme	  gene."	  Wilderness	  Environ	  Med	  19(1):	  22-­‐29.	  Du	  Boulay,	  G.	  H.	  and	  L.	  Symon	  (1971).	  "The	  anaesthetist's	  effect	  upon	  the	  cerebral	  arteries."	  Proc	  R	  Soc	  Med	  64(1):	  77-­‐80.	  Du,	   J.	   Y.,	   X.	   Y.	   Li,	   et	   al.	   (1999).	   "[Effects	   of	   acute	  mild	   and	  moderate	   hypoxia	   on	  human	  short	  memory]."	  Space	  Med	  Med	  Eng	  (Beijing)	  12(4):	  270-­‐273.	  Dubowitz,	  D.	   J.,	  E.	  A.	  Dyer,	  et	  al.	  (2009).	  "Early	  brain	  swelling	   in	  acute	  hypoxia."	   J	  Appl	  Physiol	  107(1):	  244-­‐252.	  Dyer,	  E.	  A.,	  S.	  R.	  Hopkins,	  et	  al.	  (2008).	  "Regional	  cerebral	  blood	  flow	  during	  acute	  hypoxia	   in	   individuals	   susceptible	   to	   acute	   mountain	   sickness."	   Respir	  Physiol	  Neurobiol	  160(3):	  267-­‐276.	  Edwards,	   L.	  M.,	   A.	   J.	  Murray,	   et	   al.	   (2010).	   "The	   effect	   of	   high-­‐altitude	  on	  human	  skeletal	   muscle	   energetics:	   P-­‐MRS	   results	   from	   the	   Caudwell	   Xtreme	  Everest	  expedition."	  PloS	  one	  5(5):	  e10681.	  Ekkekakis,	  P.	  (2009).	  "Illuminating	  the	  black	  box:	  investigating	  prefrontal	  cortical	  hemodynamics	   during	   exercise	   with	   near-­‐infrared	   spectroscopy."	   J	   Sport	  Exerc	  Psychol	  31(4):	  505-­‐553.	  Erzurum,	   S.	   C.,	   S.	   Ghosh,	   et	   al.	   (2007).	   "Higher	   blood	   flow	   and	   circulating	   NO	  products	  offset	  high-­‐altitude	  hypoxia	  among	  Tibetans."	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  104(45):	  17593-­‐17598.	  Fagenholz,	   P.	   J.,	   J.	   A.	   Gutman,	   et	   al.	   (2007).	   "Evidence	   for	   increased	   intracranial	  pressure	   in	  high	  altitude	  pulmonary	  edema."	  High	  Alt	  Med	  Biol	  8(4):	  331-­‐336.	  Fagenholz,	  P.	  J.,	  J.	  A.	  Gutman,	  et	  al.	  (2009).	  "Optic	  nerve	  sheath	  diameter	  correlates	  with	   the	   presence	   and	   severity	   of	   acute	   mountain	   sickness:	   evidence	   for	  increased	  intracranial	  pressure."	  J	  Appl	  Physiol	  106(4):	  1207-­‐1211.	  Fagenholz,	  P.	   J.,	  A.	   F.	  Murray,	   et	   al.	   (2007).	   "New-­‐onset	   anxiety	  disorders	  at	  high	  altitude."	  Wilderness	  Environ	  Med	  18(4):	  312-­‐316.	  Faraci,	  F.	  M.	  and	  D.	  D.	  Heistad	  (1998).	  "Regulation	  of	  the	  cerebral	  circulation:	  role	  of	  endothelium	  and	  potassium	  channels."	  Physiol	  Rev	  78(1):	  53-­‐97.	  Farb,	   R.	   I.,	   I.	   Vanek,	   et	   al.	   (2003).	   "Idiopathic	   intracranial	   hypertension:	   the	  prevalence	   and	   morphology	   of	   sinovenous	   stenosis."	   Neurology	   60(9):	  1418-­‐1424.	  Feddersen,	   B.,	   H.	   Ausserer,	   et	   al.	   (2007).	   "Right	   temporal	   cerebral	   dysfunction	  heralds	  symptoms	  of	  acute	  mountain	  sickness."	  J	  Neurol	  254(3):	  359-­‐363.	  Firth,	   P.	   G.,	   H.	   Zheng,	   et	   al.	   (2008).	   "Mortality	   on	   Mount	   Everest,	   1921-­‐2006:	  descriptive	  study."	  Bmj	  337:	  a2654.	  Fischer,	   R.,	   C.	   Vollmar,	   et	   al.	   (2004).	   "No	   evidence	   of	   cerebral	   oedema	   in	   severe	  acute	  mountain	  sickness."	  Cephalalgia	  24(1):	  66-­‐71.	  Fishman,	  R.	  A.	  (1975).	  "Brain	  edema."	  N	  Engl	  J	  Med	  293(14):	  706-­‐711.	  Fog,	   M.	   (1938).	   "The	   Relationship	   between	   the	   Blood	   Pressure	   and	   the	   Tonic	  Regulation	  of	   the	  Pial	  Arteries."	   Journal	  of	  neurology	  and	  psychiatry	  1(3):	  187-­‐197.	  
REFERENCES 260	  
	  Forster,	  P.	  J.	  (1985).	  "Effect	  of	  different	  ascent	  profiles	  on	  performance	  at	  4,200	  m	  elevation."	  Aviat	  Space	  Environ	  Med	  56(8):	  758-­‐764.	  Fowler,	   B.,	   D.	   D.	   Elcombe,	   et	   al.	   (1987).	   "The	   threshold	   for	   hypoxia	   effects	   on	  perceptual-­‐motor	  performance."	  Hum	  Factors	  29(1):	  61-­‐66.	  Garrido,	   E.,	   A.	   Castello,	   et	   al.	   (1993).	   "Cortical	   atrophy	   and	   other	   brain	  magnetic	  resonance	   imaging	   (MRI)	   changes	   after	   extremely	   high-­‐altitude	   climbs	  without	  oxygen."	  Int	  J	  Sports	  Med	  14(4):	  232-­‐234.	  Garrido,	  E.,	  C.	   Javierre,	  et	  al.	   (2000).	   "Hallucinatory	  experiences	  at	  high	  altitude."	  Neuropsychiatry	  Neuropsychol	  Behav	  Neurol	  13(2):	  148.	  Garrido,	   E.,	   R.	   Segura,	   et	   al.	   (1995).	   "New	   evidence	   from	   magnetic	   resonance	  imaging	   of	   brain	   changes	   after	   climbs	   at	   extreme	   altitude."	   Eur	   J	   Appl	  Physiol	  Occup	  Physiol	  70(6):	  477-­‐481.	  Germon,	   T.	   J.,	   N.	   M.	   Kane,	   et	   al.	   (1994).	   "Near-­‐infrared	   spectroscopy	   in	   adults:	  effects	  of	  extracranial	   ischaemia	  and	   intracranial	  hypoxia	  on	  estimation	  of	  cerebral	  oxygenation."	  Br	  J	  Anaesth	  73(4):	  503-­‐506.	  Gertsch,	   J.	   H.,	   B.	   Basnyat,	   et	   al.	   (2004).	   "Randomised,	   double	   blind,	   placebo	  controlled	  comparison	  of	  ginkgo	  biloba	  and	  acetazolamide	  for	  prevention	  of	  acute	  mountain	  sickness	  among	  Himalayan	  trekkers:	  the	  prevention	  of	  high	  altitude	  illness	  trial	  (PHAIT)."	  Bmj	  328(7443):	  797.	  Giller,	   C.	   A.	   (2003).	   "The	   Emperor	   has	   no	   clothes:	   velocity,	   flow,	   and	   the	   use	   of	  TCD."	  J	  Neuroimaging	  13(2):	  97-­‐98.	  Giller,	  C.	  A.,	  G.	  Bowman,	  et	  al.	  (1993).	  "Cerebral	  arterial	  diameters	  during	  changes	  in	   blood	   pressure	   and	   carbon	   dioxide	   during	   craniotomy."	   Neurosurgery	  
32(5):	  737-­‐741;	  discussion	  741-­‐732.	  Giller,	   C.	   A.,	   A.	  M.	   Giller,	   et	   al.	   (2000).	   "Evaluation	   of	   the	   cerebral	   hemodynamic	  response	  to	  rhythmic	  handgrip."	  J	  Appl	  Physiol	  88(6):	  2205-­‐2213.	  Glaisher,	   J.	   (1862).	   "Notes	   of	   effects	   experienced	   during	   recent	   balloon	   ascents."	  Lancet	  2:	  559-­‐560.	  Goh,	  D.	   and	  R.	  A.	  Minns	   (1995).	   "Intracranial	  pressure	  and	   cerebral	   arterial	   flow	  velocity	   indices	   in	   childhood	  hydrocephalus:	   current	   review."	   Childs	  Nerv	  Syst	  11(7):	  392-­‐396.	  Golalipour,	  M.	  J.,	  M.	  Jahanshaei,	  et	  al.	  (2005).	  "Estimation	  of	  Cranial	  Capacity	  in	  17-­‐20	   year	   olds	   in	   South	   East	   Caspian	   Sea	   Border	   (North	   of	   Iran)."	   Int	   J	  Morphol	  23(4):	  301-­‐304.	  Gonzalez,	   N.	   R.,	   W.	   J.	   Boscardin,	   et	   al.	   (2007).	   "Vasospasm	   probability	   index:	   a	  combination	   of	   transcranial	   doppler	   velocities,	   cerebral	   blood	   flow,	   and	  clinical	   risk	   factors	   to	   predict	   cerebral	   vasospasm	   after	   aneurysmal	  subarachnoid	  hemorrhage."	  J	  Neurosurg	  107(6):	  1101-­‐1112.	  Goodman,	  M.	   D.,	   A.	   T.	  Makley,	   et	   al.	   (2011).	   "Hypobaric	   hypoxia	   exacerbates	   the	  neuroinflammatory	  response	  to	  traumatic	  brain	  injury."	  J	  Surg	  Res	  165(1):	  30-­‐37.	  Gore,	   C.	   J.,	   S.	   A.	   Clark,	   et	   al.	   (2007).	   "Nonhematological	  mechanisms	  of	   improved	  sea-­‐level	  performance	  after	  hypoxic	  exposure."	  Med	  Sci	  Sports	  Exerc	  39(9):	  1600-­‐1609.	  Grissom,	  C.	  K.,	  R.	  C.	  Roach,	  et	  al.	  (1992).	  "Acetazolamide	  in	  the	  treatment	  of	  acute	  mountain	  sickness:	  clinical	  efficacy	  and	  effect	  on	  gas	  exchange."	  Ann	  Intern	  Med	  116(6):	  461-­‐465.	  Grocott,	   M.	   and	   H.	   Montgomery	   (2008).	   "Genetophysiology:	   using	   genetic	  strategies	  to	  explore	  hypoxic	  adaptation."	  High	  Alt	  Med	  Biol	  9(2):	  123-­‐129.	  
REFERENCES 261	  
	  Grocott,	   M.,	   H.	   Montgomery,	   et	   al.	   (2007).	   "High-­‐altitude	   physiology	   and	  pathophysiology:	   implications	   and	   relevance	   for	   intensive	   care	  medicine."	  Crit	  Care	  11(1):	  203.	  Grocott,	  M.,	  A.	  Richardson,	  et	  al.	  (2007).	  "Caudwell	  Xtreme	  Everest:	  a	  field	  study	  of	  human	  adaptation	  to	  hypoxia."	  Crit	  Care	  11(4):	  151.	  Grocott,	  M.	  P.,	  D.	  S.	  Martin,	  et	  al.	  (2009).	  "Arterial	  blood	  gases	  and	  oxygen	  content	  in	  climbers	  on	  Mount	  Everest."	  N	  Engl	  J	  Med	  360(2):	  140-­‐149.	  Grocott,	   M.	   P.,	   D.	   S.	   Martin,	   et	   al.	   (2010).	   "Caudwell	   xtreme	   Everest	   expedition."	  High	  Alt	  Med	  Biol	  11(2):	  133-­‐137.	  Haack,	  D.	  C.	  and	  E.	  C.	  Meihoff	  (1971).	  "A	  method	  for	  estimation	  of	  cranial	  capacity	  from	  cephalometric	  roentgenograms."	  Am	  J	  Phys	  Anthropol	  34(3):	  447-­‐452.	  Hackett,	  P.	  (2001).	  High	  altitude	  and	  common	  medical	  conditions.	  An	  Exploration	  of	  Human	  Adaptation.	  H.	  T.F.	  and	  S.	  R.B.	  New	  York,	  Marcel	  Dekker:	  839-­‐885.	  Hackett,	  P.	  H.	   (1999).	   "The	  cerebral	  etiology	  of	  high-­‐altitude	  cerebral	  edema	  and	  acute	  mountain	  sickness."	  Wilderness	  Environ	  Med	  10(2):	  97-­‐109.	  Hackett,	  P.	  H.,	  D.	  Rennie,	  et	  al.	  (1976).	  "The	  incidence,	  importance,	  and	  prophylaxis	  of	  acute	  mountain	  sickness."	  Lancet	  2(7996):	  1149-­‐1155.	  Hackett,	  P.	  H.	  and	  R.	  C.	  Roach	  (2001).	  "High-­‐altitude	  illness."	  N	  Engl	  J	  Med	  345(2):	  107-­‐114.	  Hackett,	  P.	  H.	  and	  R.	  C.	  Roach	  (2004).	  "High	  altitude	  cerebral	  edema."	  High	  Alt	  Med	  Biol	  5(2):	  136-­‐146.	  Hackett,	   P.	   H.,	   R.	   C.	   Roach,	   et	   al.	   (1988).	   "Dexamethasone	   for	   prevention	   and	  treatment	   of	   acute	  mountain	   sickness."	   Aviat	   Space	   Environ	  Med	  59(10):	  950-­‐954.	  Hackett,	  P.	  H.,	  P.	  R.	  Yarnell,	  et	  al.	  (1998).	  "High-­‐altitude	  cerebral	  edema	  evaluated	  with	   magnetic	   resonance	   imaging:	   clinical	   correlation	   and	  pathophysiology."	  Jama	  280(22):	  1920-­‐1925.	  Hadolt,	  I.	  and	  G.	  Litscher	  (2003).	  "Noninvasive	  assessment	  of	  cerebral	  oxygenation	  during	   high	   altitude	   trekking	   in	   the	   Nepal	   Himalayas	   (2850-­‐5600	   m)."	  Neurol	  Res	  25(2):	  183-­‐188.	  Hanlo,	  P.	  W.,	  R.	  H.	  Gooskens,	  et	  al.	  (1995).	  "Value	  of	  transcranial	  Doppler	  indices	  in	  predicting	  raised	  ICP	  in	  infantile	  hydrocephalus.	  A	  study	  with	  review	  of	  the	  literature."	  Childs	  Nerv	  Syst	  11(10):	  595-­‐603.	  Hansen,	   J.	  M.,	  D.	  Pedersen,	  et	  al.	   (2007).	  "Magnetic	  resonance	  angiography	  shows	  dilatation	  of	   the	  middle	  cerebral	  artery	  after	   infusion	  of	  glyceryl	   trinitrate	  in	  healthy	  volunteers."	  Cephalalgia	  27(2):	  118-­‐127.	  Harada,	  K.,	  T.	  Hayashi,	   et	   al.	   (1993).	   "[Transcranial	  Doppler	   sonography	   in	   acute	  intracranial	   hypertension	   model-­‐-­‐usefulness	   of	   pulsatility	   index]."	   No	   To	  Shinkei	  45(9):	  851-­‐856.	  Hartig,	  G.	  and	  P.	  Hackett	  (1992).	  Cerebral	  spinal	  fluid	  pressure	  and	  cerebral	  blood	  velocity	   in	   acute	   mountain	   sickness.	   Hypoxia	   and	   Mountain	   Medicine.	   J.	  Sutton,	  G.	  Coates	  and	  C.	  Houston.	  Oxford,	  Pergamon	  Press:	  260-­‐265.	  Harvey,	   T.	   C.,	   M.	   E.	   Raichle,	   et	   al.	   (1988).	   "Effect	   of	   carbon	   dioxide	   in	   acute	  mountain	  sickness:	  a	  rediscovery."	  Lancet	  2(8612):	  639-­‐641.	  Heine,	   M.,	   A.	   W.	   Subudhi,	   et	   al.	   (2009).	   "Effect	   of	   ventilation	   on	   cerebral	  oxygenation	   during	   exercise:	   insights	   from	   canonical	   correlation."	   Respir	  Physiol	  Neurobiol	  166(2):	  125-­‐128.	  Henson,	  L.	  C.,	  C.	  Calalang,	  et	  al.	  (1998).	  "Accuracy	  of	  a	  cerebral	  oximeter	  in	  healthy	  volunteers	   under	   conditions	   of	   isocapnic	   hypoxia."	   Anesthesiology	  88(1):	  58-­‐65.	  
REFERENCES 262	  
	  Herault,	   S.,	   G.	   Fomina,	   et	   al.	   (2000).	   "Cardiac,	   arterial	   and	   venous	   adaptation	   to	  weightlessness	   during	   6-­‐month	   MIR	   spaceflights	   with	   and	   without	   thigh	  cuffs	  (bracelets)."	  European	  journal	  of	  applied	  physiology	  81(5):	  384-­‐390.	  Higgins,	   J.	   N.,	   C.	   Cousins,	   et	   al.	   (2003).	   "Idiopathic	   intracranial	   hypertension:	   12	  cases	  treated	  by	  venous	  sinus	  stenting."	  Journal	  of	  neurology,	  neurosurgery,	  and	  psychiatry	  74(12):	  1662-­‐1666.	  Hiraoka,	   M.,	   M.	   Firbank,	   et	   al.	   (1993).	   "A	   Monte	   Carlo	   investigation	   of	   optical	  pathlength	   in	   inhomogeneous	   tissue	   and	   its	   application	   to	   near-­‐infrared	  spectroscopy."	  Phys	  Med	  Biol	  38(12):	  1859-­‐1876.	  Hiura,	  M.,	  T.	  Mizuno,	  et	  al.	  "Cerebral	  oxygenation	  in	  the	  frontal	  lobe	  cortex	  during	  incremental	   exercise	   tests:	   the	   regional	   changes	   influenced	   by	   volitional	  exhaustion."	  Adv	  Exp	  Med	  Biol	  662:	  257-­‐263.	  Hochachka,	   P.	   W.,	   C.	   M.	   Clark,	   et	   al.	   (1994).	   "The	   brain	   at	   high	   altitude:	  hypometabolism	  as	  a	  defense	  against	  chronic	  hypoxia?"	  J	  Cereb	  Blood	  Flow	  Metab	  14(4):	  671-­‐679.	  Hochachka,	   P.	   W.	   and	   C.	   Monge	   (2000).	   "Evolution	   of	   human	   hypoxia	   tolerance	  physiology."	  Adv	  Exp	  Med	  Biol	  475:	  25-­‐43.	  Holloway,	   C.	   J.,	   H.	   E.	   Montgomery,	   et	   al.	   (2011).	   "Cardiac	   response	   to	   hypobaric	  hypoxia:	   persistent	   changes	   in	   cardiac	   mass,	   function,	   and	   energy	  metabolism	  after	  a	  trek	  to	  Mt.	  Everest	  Base	  Camp."	  FASEB	  journal	  :	  official	  publication	   of	   the	   Federation	   of	   American	   Societies	   for	   Experimental	  Biology	  25(2):	  792-­‐796.	  Homburg,	   A.	   M.,	   M.	   Jakobsen,	   et	   al.	   (1993).	   "Transcranial	   Doppler	   recordings	   in	  raised	  intracranial	  pressure."	  Acta	  Neurol	  Scand	  87(6):	  488-­‐493.	  Hornbein,	  T.	  F.,	  B.	  D.	  Townes,	  et	  al.	  (1989).	  "The	  cost	  to	  the	  central	  nervous	  system	  of	  climbing	  to	  extremely	  high	  altitude."	  N	  Engl	  J	  Med	  321(25):	  1714-­‐1719.	  Houston,	   C.	   S.	   (1989).	   "Incidence	   of	   acute	   mountain	   sickness	   at	   intermediate	  altitudes."	  Jama	  261(24):	  3551-­‐3552.	  Houston,	   C.	   S.	   and	   J.	   Dickinson	   (1975).	   "Cerebral	   form	   of	   high-­‐altitude	   illness."	  Lancet	  2(7938):	  758-­‐761.	  Hu,	  Y.,	  J.	  Liu,	  et	  al.	  (2013).	  "Recent	  agents	  targeting	  HIF-­‐1alpha	  for	  cancer	  therapy."	  Journal	  of	  cellular	  biochemistry	  114(3):	  498-­‐509.	  Huang,	  S.	  Y.,	  L.	  G.	  Moore,	  et	  al.	  (1987).	  "Internal	  carotid	  and	  vertebral	  arterial	  flow	  velocity	  in	  men	  at	  high	  altitude."	  J	  Appl	  Physiol	  63(1):	  395-­‐400.	  Iacopino,	   D.	   G.,	   C.	   Zaccone,	   et	   al.	   (1995).	   "Intraoperative	   monitoring	   of	   cerebral	  blood	  flow	  during	  ventricular	  shunting	  in	  hydrocephalic	  pediatric	  patients."	  Childs	  Nerv	  Syst	  11(8):	  483-­‐486.	  Imray,	   C.	   H.,	   N.	   J.	   Barnett,	   et	   al.	   (1998).	   "Near-­‐infrared	   spectroscopy	   in	   the	  assessment	   of	   cerebral	   oxygenation	   at	   high	   altitude."	  Wilderness	   Environ	  Med	  9(4):	  198-­‐203.	  Imray,	  C.	  H.,	  S.	  Brearey,	  et	  al.	  (2000).	  "Cerebral	  oxygenation	  at	  high	  altitude	  and	  the	  response	  to	  carbon	  dioxide,	  hyperventilation	  and	  oxygen.	  The	  Birmingham	  Medical	  Research	  Expeditionary	  Society."	  Clin	  Sci	  (Lond)	  98(2):	  159-­‐164.	  Imray,	  C.	  H.,	  T.	  Clarke,	  et	  al.	   (2001).	  "Carbon	  dioxide	  contributes	  to	  the	  beneficial	  effect	  of	  pressurization	  in	  a	  portable	  hyperbaric	  chamber	  at	  high	  altitude."	  Clin	  Sci	  (Lond)	  100(2):	  151-­‐157.	  Imray,	  C.	  H.,	  S.	  D.	  Myers,	  et	  al.	  (2005).	  "Effect	  of	  exercise	  on	  cerebral	  perfusion	  in	  humans	  at	  high	  altitude."	  J	  Appl	  Physiol	  99(2):	  699-­‐706.	  Imray,	   C.	   H.,	   K.	   T.	   Pattinson,	   et	   al.	   (2008).	   "Intrapulmonary	   and	   Intracardiac	  Shunting	  With	  Exercise	   at	  Altitude."	  Wilderness	  Environ	  Med	  19(3):	   199-­‐204.	  
REFERENCES 263	  
	  Imray,	  C.	  H.,	  S.	  Walsh,	  et	  al.	  (2003).	  "Effects	  of	  breathing	  air	  containing	  3%	  carbon	  dioxide,	   35%	   oxygen	   or	   a	  mixture	   of	   3%	   carbon	   dioxide/35%	   oxygen	   on	  cerebral	  and	  peripheral	  oxygenation	  at	  150	  m	  and	  3459	  m."	  Clin	  Sci	  (Lond)	  
104(3):	  203-­‐210.	  Jafarian,	  S.,	  F.	  Gorouhi,	  et	  al.	  (2008).	  "High-­‐altitude	  sleep	  disturbance:	  results	  of	  the	  Groningen	  Sleep	  Quality	  Questionnaire	  survey."	  Sleep	  Med	  9(4):	  446-­‐449.	  James,	   P.	   B.	   (1988).	   "Hyperbaric	   oxygenation,	   carbon	   monoxide,	   and	   cerebral	  edema."	  Br	  Med	  J	  (Clin	  Res	  Ed)	  296(6620):	  500-­‐501.	  Jansen,	  G.	  F.,	  D.	  A.	  Kagenaar,	  et	  al.	   (2002).	  "Basilar	  artery	  blood	  flow	  velocity	  and	  the	  ventilatory	  response	  to	  acute	  hypoxia	  in	  mountaineers."	  Respir	  Physiol	  Neurobiol	  133(1-­‐2):	  65-­‐74.	  Jansen,	  G.	  F.,	  A.	  Krins,	  et	  al.	  (1999).	  "Cerebral	  vasomotor	  reactivity	  at	  high	  altitude	  in	  humans."	  J	  Appl	  Physiol	  86(2):	  681-­‐686.	  Jansen,	  G.	   F.,	  A.	  Krins,	   et	   al.	   (2000).	   "Cerebral	   autoregulation	   in	   subjects	   adapted	  and	  not	  adapted	  to	  high	  altitude."	  Stroke	  31(10):	  2314-­‐2318.	  Jausovec,	  N.	   and	  K.	   Jausovec	   (2010).	   "Resting	  brain	   activity:	   differences	  between	  genders."	  Neuropsychologia	  48(13):	  3918-­‐3925.	  Jensen,	  J.	  B.,	  B.	  Sperling,	  et	  al.	  (1996).	  "Augmented	  hypoxic	  cerebral	  vasodilation	  in	  men	  during	  5	  days	  at	  3,810	  m	  altitude."	  J	  Appl	  Physiol	  80(4):	  1214-­‐1218.	  Jensen,	   J.	   B.,	   A.	   D.	  Wright,	   et	   al.	   (1990).	   "Cerebral	   blood	   flow	   in	   acute	  mountain	  sickness."	  J	  Appl	  Physiol	  69(2):	  430-­‐433.	  Jobsis,	  F.	  F.	  (1977).	  "Noninvasive,	  infrared	  monitoring	  of	  cerebral	  and	  myocardial	  oxygen	  sufficiency	  and	  circulatory	  parameters."	  Science	  198(4323):	  1264-­‐1267.	  Johnson,	  B.	  G.,	  J.	  Simmons,	  et	  al.	  (2005).	  "Ataxia	  at	  altitude	  measured	  on	  a	  wobble	  board."	  Wilderness	  Environ	  Med	  16(1):	  42-­‐46.	  Johnson,	  T.	  S.,	  P.	  B.	  Rock,	  et	  al.	  (1984).	  "Prevention	  of	  acute	  mountain	  sickness	  by	  dexamethasone."	  N	  Engl	  J	  Med	  310(11):	  683-­‐686.	  Kallenberg,	  K.,	  D.	  M.	  Bailey,	  et	  al.	  (2007).	  "Magnetic	  resonance	  imaging	  evidence	  of	  cytotoxic	  cerebral	  edema	   in	  acute	  mountain	  sickness."	   J	  Cereb	  Blood	  Flow	  Metab	  27(5):	  1064-­‐1071.	  Kallenberg,	   K.,	   C.	   Dehnert,	   et	   al.	   (2008).	   "Microhemorrhages	   in	   nonfatal	   high-­‐altitude	  cerebral	  edema."	  J	  Cereb	  Blood	  Flow	  Metab	  28(9):	  1635-­‐1642.	  Kameyama,	  M.,	   M.	   Fukuda,	   et	   al.	   (2004).	   "Sex	   and	   age	   dependencies	   of	   cerebral	  blood	   volume	   changes	   during	   cognitive	   activation:	   a	   multichannel	   near-­‐infrared	  spectroscopy	  study."	  Neuroimage	  22(4):	  1715-­‐1721.	  Kasamo,	  K.,	   Y.	   Okuhata,	   et	   al.	   (1993).	   "Chronological	   changes	   of	  MRI	   findings	   on	  striatal	   damage	   after	   acute	   cyanide	   intoxication:	   pathogenesis	   of	   the	  damage	  and	  its	  selectivity,	  and	  prevention	  for	  neurological	  sequelae:	  a	  case	  report."	  Eur	  Arch	  Psychiatry	  Clin	  Neurosci	  243(2):	  71-­‐74.	  Kellie,	  G.	  (1824).	  "An	  account	  of	  the	  appearances	  observed	  in	  the	  dissection	  of	  two	  of	  the	  three	  individuals	  presumed	  to	  have	  perished	  in	  the	  storm	  of	  the	  3rd,	  and	  whose	  bodie	  were	  discovered	  in	  the	  vicinity	  of	  Leith	  on	  the	  morning	  of	  the	   4th	   November	   1821	   with	   some	   reflections	   on	   the	   pathology	   of	   the	  brain.	  ."	  The	  Transactions	  of	  the	  Medico-­‐Chirurgical	  Society	  of	  Edinburgh	  1:	  84-­‐169.	  Kilic,	   T.	   and	   A.	   Akakin	   (2008).	   "Anatomy	   of	   cerebral	   veins	   and	   sinuses."	   Front	  Neurol	  Neurosci	  23:	  4-­‐15.	  Kim,	  B.	  S.	  D.,	  H.;	  Marks,	  M.	  (2004).	  "Diagnosis	  and	  Managements	  of	  Cerebral	  Veous	  and	   Sinus	  Thrombosis."	   Seminars	   in	  Cerebrovascular	  Diseases	   and	   Stroke	  
4:	  205-­‐216.	  
REFERENCES 264	  
	  Klatzo,	  I.	  (1967).	  "Presidental	  address.	  Neuropathological	  aspects	  of	  brain	  edema."	  J	  Neuropathol	  Exp	  Neurol	  26(1):	  1-­‐14.	  Kobrick,	   J.	   L.	   and	   B.	   Appleton	   (1971).	   "Effects	   of	   extended	   hypoxia	   on	   visual	  performance	  and	  retinal	  vascular	  state."	  J	  Appl	  Physiol	  31(3):	  357-­‐362.	  Koehle,	  M.	  S.,	  P.	  Wang,	  et	  al.	  (2006).	  "No	  association	  between	  variants	   in	  the	  ACE	  and	   angiotensin	   II	   receptor	   1	   genes	   and	   acute	   mountain	   sickness	   in	  Nepalese	  pilgrims	   to	   the	   Janai	  Purnima	  Festival	  at	  4380	  m."	  High	  Alt	  Med	  Biol	  7(4):	  281-­‐289.	  Koyama,	  S.,	  T.	  Kobayashi,	  et	  al.	  (1988).	  "The	  increased	  sympathoadrenal	  activity	  in	  patients	  with	  high	  altitude	  pulmonary	  edema	   is	   centrally	  mediated."	   Jpn	   J	  Med	  27(1):	  10-­‐16.	  Kramer,	  A.	  F.,	   J.	  T.	  Coyne,	  et	  al.	  (1993).	  "Cognitive	  function	  at	  high	  altitude."	  Hum	  Factors	  35(2):	  329-­‐344.	  Krasney,	  J.	  A.	  (1994).	  "A	  neurogenic	  basis	  for	  acute	  altitude	  illness."	  Med	  Sci	  Sports	  Exerc	  26(2):	  195-­‐208.	  Krasney,	  J.	  A.,	  D.	  C.	  Curran-­‐Everett,	  et	  al.	  (1990).	  High	  Altitude	  Cerebral	  Edema:	  an	  animal	  model.	  Hypoxia:	  the	  Adaptations.	  J.	  Sutton,	  G.	  Coates	  and	  J.	  Remmers.	  Ontario,	  Decker:	  200-­‐205.	  Lang,	   G.	   E.	   and	   G.	   B.	   Kuba	   (1997).	   "High-­‐altitude	   retinopathy."	   Am	   J	   Ophthalmol	  
123(3):	  418-­‐420.	  Lawley,	  J.	  S.,	  S.	  J.	  Oliver,	  et	  al.	  (2012).	  "Optic	  nerve	  sheath	  diameter	  is	  not	  related	  to	  high	   altitude	   headache:	   a	   randomized	   controlled	   trial."	   High	   altitude	  medicine	  &	  biology	  13(3):	  193-­‐199.	  Levett,	  D.	  Z.,	  B.	  O.	  Fernandez,	  et	  al.	  (2011).	  "The	  role	  of	  nitrogen	  oxides	  in	  human	  adaptation	  to	  hypoxia."	  Scientific	  reports	  1:	  109.	  Levett,	  D.	   Z.,	  D.	   S.	  Martin,	   et	   al.	   (2010).	   "Design	  and	   conduct	  of	  Caudwell	  Xtreme	  Everest:	  an	  observational	  cohort	  study	  of	  variation	  in	  human	  adaptation	  to	  progressive	  environmental	  hypoxia."	  BMC	  Med	  Res	  Methodol	  10:	  98.	  Levett,	   D.	   Z.,	   E.	   J.	   Radford,	   et	   al.	   (2012).	   "Acclimatization	   of	   skeletal	   muscle	  mitochondria	  to	  high-­‐altitude	  hypoxia	  during	  an	  ascent	  of	  Everest."	  FASEB	  journal	   :	   official	   publication	   of	   the	   Federation	   of	   American	   Societies	   for	  Experimental	  Biology	  26(4):	  1431-­‐1441.	  Lewis,	  M.	  S.,	  P.	  Maruff,	  et	  al.	  (2007).	  "The	  influence	  of	  different	  error	  estimates	  in	  the	  detection	  of	  postoperative	   cognitive	  dysfunction	  using	   reliable	   change	  indices	   with	   correction	   for	   practice	   effects."	   Archives	   of	   clinical	  neuropsychology	   :	   the	   official	   journal	   of	   the	   National	   Academy	   of	  Neuropsychologists	  22(2):	  249-­‐257.	  Luks,	  A.	  M.	  (2008).	  "Which	  medications	  are	  safe	  and	  effective	  for	  improving	  sleep	  at	  high	  altitude?"	  High	  Alt	  Med	  Biol	  9(3):	  195-­‐198.	  Lundqvist,	   C.,	   J.	   S.	   Benth,	   et	   al.	   (2009).	   "A	   vertical	   VAS	   is	   a	   valid	   instrument	   for	  monitoring	  headache	  pain	  intensity."	  Cephalalgia	  29(10):	  1034-­‐1041.	  Lysakowski,	  C.,	  E.	  Von	  Elm,	  et	  al.	   (2004).	   "Effect	  of	  magnesium,	  high	  altitude	  and	  acute	   mountain	   sickness	   on	   blood	   flow	   velocity	   in	   the	   middle	   cerebral	  artery."	  Clin	  Sci	  (Lond)	  106(3):	  279-­‐285.	  Mader,	   T.	   H.,	   C.	   R.	   Gibson,	   et	   al.	   (2011).	   "Optic	   disc	   edema,	   globe	   flattening,	  choroidal	   folds,	   and	   hyperopic	   shifts	   observed	   in	   astronauts	   after	   long-­‐duration	  space	  flight."	  Ophthalmology	  118(10):	  2058-­‐2069.	  Mader,	  T.	  H.	  and	  G.	  Tabin	   (2003).	   "Going	   to	  high	  altitude	  with	  preexisting	  ocular	  conditions."	  High	  Alt	  Med	  Biol	  4(4):	  419-­‐430.	  
REFERENCES 265	  
	  Maggiorini,	   M.,	   H.	   P.	   Brunner-­‐La	   Rocca,	   et	   al.	   (2006).	   "Both	   tadalafil	   and	  dexamethasone	   may	   reduce	   the	   incidence	   of	   high-­‐altitude	   pulmonary	  edema:	  a	  randomized	  trial."	  Ann	  Intern	  Med	  145(7):	  497-­‐506.	  Maher,	   J.	   T.,	   A.	   Cymerman,	   et	   al.	   (1975).	   "Acute	   mountain	   sickness:	   increased	  severity	  in	  eucapnic	  hypoxia."	  Aviat	  Space	  Environ	  Med	  46(6):	  826-­‐829.	  Mairer,	  K.,	  M.	  Gobel,	  et	  al.	  (2012).	  "MRI	  Evidence:	  Acute	  Mountain	  Sickness	  Is	  Not	  Associated	   with	   Cerebral	   Edema	   Formation	   during	   Simulated	   High	  Altitude."	  PloS	  one	  7(11):	  e50334.	  Manjunath,	   K.	   (2002).	   "Estimation	   of	   Cranial	   Volume-­‐an	   overview	   of	  Methodologies."	  J	  Anat	  Soc	  India	  1:	  85-­‐91.	  Martin,	   D.	   S.,	   P.	   Goedhart,	   et	   al.	   (2010).	   "Changes	   in	   sublingual	  microcirculatory	  flow	   index	   and	   vessel	   density	   on	   ascent	   to	   altitude."	   Experimental	  physiology	  95(8):	  880-­‐891.	  Martin,	   D.	   S.,	   C.	   Ince,	   et	   al.	   (2009).	   "Abnormal	   blood	   flow	   in	   the	   sublingual	  microcirculation	   at	   high	   altitude."	   European	   journal	   of	   applied	  physiology	  
106(3):	  473-­‐478.	  Martin,	   D.	   S.,	   D.	   Z.	   Levett,	   et	   al.	   (2009).	   "Changes	   in	   skeletal	  muscle	   oxygenation	  during	   exercise	   measured	   by	   near-­‐infrared	   spectroscopy	   on	   ascent	   to	  altitude."	  Crit	  Care	  13	  Suppl	  5:	  S7.	  Martin,	   D.	   S.,	   D.	   Z.	   Levett,	   et	   al.	   (2009).	   "Changes	   in	   skeletal	  muscle	   oxygenation	  during	   exercise	   measured	   by	   near-­‐infrared	   spectroscopy	   on	   ascent	   to	  altitude."	  Critical	  care	  13	  Suppl	  5:	  S7.	  Martinoli,	  C.	  and	  L.	  E.	  Derchi	  (1997).	  "Gain	  setting	  in	  power	  Doppler	  US."	  Radiology	  
202(1):	  284-­‐285.	  Matsuzawa,	   Y.,	   Kobayashi,	   T.,	   Fujimoto,	   K.	   et	   al	   (1992).	   Cerebral	   edema	   in	   acute	  mountain	   sickness.	   High	   Altitude	   Medicine.	   R.	   J.	   Ueda	   G,	   Sekiguchi	   M.	  Matsumoto,	  Japan,	  Sjinshu	  University	  Press:	  300-­‐304.	  McArdle,	  W.	  D.,	  F.	  I.	  Katch,	  et	  al.	  (2006).	  Exercise	  Physiology,	  Lippincott,	  Williams	  and	  Wilkins:	  357.	  Mills,	  E.	  M.,	  P.	  G.	  Gunasekar,	  et	  al.	  (1999).	  "Differential	  susceptibility	  of	  brain	  areas	  to	  cyanide	  involves	  different	  modes	  of	  cell	  death."	  Toxicol	  Appl	  Pharmacol	  
156(1):	  6-­‐16.	  Miserocchi,	  G.,	  A.	   Passi,	   et	   al.	   (2001).	   "Pulmonary	   interstitial	   pressure	   and	   tissue	  matrix	   structure	   in	   acute	   hypoxia."	   Am	   J	   Physiol	   Lung	   Cell	   Mol	   Physiol	  
280(5):	  L881-­‐887.	  Moller,	   K.,	   O.	   B.	   Paulson,	   et	   al.	   (2002).	   "Unchanged	   cerebral	   blood	   flow	   and	  oxidative	  metabolism	  after	  acclimatization	   to	  high	  altitude."	   J	  Cereb	  Blood	  Flow	  Metab	  22(1):	  118-­‐126.	  Monro,	   A.	   (1823).	   Observations	   on	   the	   structure	   and	   function	   of	   the	   nervous	  system.	  Edinburgh,	  Creech	  &	  Johnson.	  Moreno,	   J.	   A.,	   E.	  Mesalles,	   et	   al.	   (2000).	   "Evaluating	   the	   outcome	   of	   severe	   head	  injury	  with	   transcranial	  Doppler	  ultrasonography."	  Neurosurg	  Focus	  8(1):	  e8.	  Morocz,	   I.	   A.,	   G.	   P.	   Zientara,	   et	   al.	   (2001).	   "Volumetric	   quantification	   of	   brain	  swelling	  after	  hypobaric	  hypoxia	  exposure."	  Exp	  Neurol	  168(1):	  96-­‐104.	  Mosso,	  A.	  (1898).	  Life	  of	  Man	  on	  the	  High	  Alps.	  London,	  Fischer	  Unwin.	  Muller,	  M.,	  K.	  Schwerdtfeger,	  et	  al.	   (2000).	  "Assessment	  of	  middle	  cerebral	  artery	  diameter	  after	  aneurysmal	  subarachnoid	  hemorrhage	  by	  transcranial	  color-­‐coded	  duplex	  sonography."	  Eur	  J	  Ultrasound	  11(1):	  15-­‐19.	  Mullner-­‐Eidenbock,	   A.,	   G.	   Rainer,	   et	   al.	   (2000).	   "High-­‐altitude	   retinopathy	   and	  retinal	  vascular	  dysregulation."	  Eye	  (Lond)	  14	  Pt	  5:	  724-­‐729.	  
REFERENCES 266	  
	  Murkin,	  J.	  M.,	  S.	  J.	  Adams,	  et	  al.	  (2007).	  "Monitoring	  brain	  oxygen	  saturation	  during	  coronary	  bypass	   surgery:	   a	   randomized,	  prospective	   study."	  Anesth	  Analg	  
104(1):	  51-­‐58.	  Murkin,	   J.	  M.	   and	  M.	   Arango	   (2009).	   "Near-­‐infrared	   spectroscopy	   as	   an	   index	   of	  brain	  and	  tissue	  oxygenation."	  Br	  J	  Anaesth	  103	  Suppl	  1:	  i3-­‐13.	  Na,	  S.	  J.,	  J.	  M.	  Hong,	  et	  al.	  (2004).	  "A	  case	  of	  reversible	  postpartum	  cytotoxic	  edema	  in	  preeclampsia."	  J	  Neurol	  Sci	  221(1-­‐2):	  83-­‐87.	  Nadvi,	   S.	   S.,	   M.	   D.	   Du	   Trevou,	   et	   al.	   (1994).	   "The	   use	   of	   transcranial	   Doppler	  ultrasonography	   as	   a	   method	   of	   assessing	   intracranial	   pressure	   in	  hydrocephalic	  children."	  Br	  J	  Neurosurg	  8(5):	  573-­‐577.	  Nair,	  V.,	  A.	  K.	  Mohapatro,	  et	  al.	   (2008).	   "A	  case	  of	  hereditary	  protein	  S	  deficiency	  presenting	   with	   cerebral	   sinus	   venous	   thrombosis	   and	   deep	   vein	  thrombosis	  at	  high	  altitude."	  Acta	  Haematol	  119(3):	  158-­‐161.	  Nelson,	  M.	   (1982).	   "Psychological	   testing	   at	   high	   altitudes."	   Aviat	   Space	   Environ	  Med	  53(2):	  122-­‐126.	  Nelson,	   M.	   T.	   and	   J.	   M.	   Quayle	   (1995).	   "Physiological	   roles	   and	   properties	   of	  potassium	   channels	   in	   arterial	   smooth	   muscle."	   The	   American	   journal	   of	  physiology	  268(4	  Pt	  1):	  C799-­‐822.	  Nelson,	  T.	  O.,	   J.	  Dunlosky,	  et	  al.	   (1990).	   "Cognition	  and	  metacognition	  at	  extreme	  altitudes	  on	  Mount	  Everest."	  J	  Exp	  Psychol	  Gen	  119(4):	  367-­‐374.	  Nicholas,	  R.,	  P.	  D.	  O'Meara,	  et	  al.	   (1992).	  "Is	  syncope	  related	  to	  moderate	  altitude	  exposure?"	  Jama	  268(7):	  904-­‐906.	  Norcliffe,	  L.	   J.,	  M.	  Rivera-­‐Ch,	  et	  al.	   (2005).	   "Cerebrovascular	  responses	   to	  hypoxia	  and	  hypocapnia	  in	  high-­‐altitude	  dwellers."	  J	  Physiol	  566(Pt	  1):	  287-­‐294.	  Norelle,	   A.,	   A.	   Q.	   Fischer,	   et	   al.	   (1989).	   "Transcranial	   Doppler:	   a	   noninvasive	  method	  to	  monitor	  hydrocephalus."	  J	  Child	  Neurol	  4	  Suppl:	  S87-­‐90.	  Nuttall,	   G.	   A.,	   D.	   J.	   Cook,	   et	   al.	   (1996).	   "The	   relationship	   between	   cerebral	   blood	  flow	   and	   transcranial	   Doppler	   blood	   flow	   velocity	   during	   hypothermic	  cardiopulmonary	  bypass	  in	  adults."	  Anesth	  Analg	  82(6):	  1146-­‐1151.	  Oelz,	   O.,	   M.	   Maggiorini,	   et	   al.	   (1989).	   "Nifedipine	   for	   high	   altitude	   pulmonary	  oedema."	  Lancet	  2(8674):	  1241-­‐1244.	  Ogoh,	  S.,	  K.	  Sato,	  et	  al.	  (2012).	  "Effect	  of	  acute	  hypoxia	  on	  blood	  flow	  in	  vertebral	  and	  internal	  carotid	  arteries."	  Experimental	  physiology.	  Ogunshola,	   O.	   O.	   and	   A.	   Al-­‐Ahmad	   (2012).	   "HIF-­‐1	   at	   the	   blood-­‐brain	   barrier:	   a	  mediator	   of	   permeability?"	   High	   altitude	  medicine	   &	   biology	  13(3):	   153-­‐161.	  Ohmae,	   E.,	   Y.	   Ouchi,	   et	   al.	   (2006).	   "Cerebral	   hemodynamics	   evaluation	   by	   near-­‐infrared	   time-­‐resolved	   spectroscopy:	   correlation	   with	   simultaneous	  positron	   emission	   tomography	   measurements."	   Neuroimage	   29(3):	   697-­‐705.	  Ong,	   S.	   G.	   and	  D.	   J.	  Hausenloy	   (2012).	   "Hypoxia-­‐inducible	   factor	   as	   a	   therapeutic	  target	  for	  cardioprotection."	  Pharmacology	  &	  therapeutics	  136(1):	  69-­‐81.	  Otis,	   S.	   M.,	   M.	   E.	   Rossman,	   et	   al.	   (1989).	   "Relationship	   of	   cerebral	   blood	   flow	  regulation	  to	  acute	  mountain	  sickness."	  J	  Ultrasound	  Med	  8(3):	  143-­‐148.	  Owen-­‐Reece,	  H.,	  M.	  Smith,	  et	  al.	  (1999).	  "Near	  infrared	  spectroscopy."	  Br	  J	  Anaesth	  
82(3):	  418-­‐426.	  Owler,	   B.	   K.,	   G.	   Parker,	   et	   al.	   (2005).	   "Cranial	   venous	   outflow	   obstruction	   and	  pseudotumor	  Cerebri	  syndrome."	  Adv	  Tech	  Stand	  Neurosurg	  30:	  107-­‐174.	  Pai,	  S.	  B.,	  R.	  G.	  Varma,	  et	  al.	  (2005).	  "Microsurgical	  anatomy	  of	  the	  middle	  cerebral	  artery."	  Neurol	  India	  53(2):	  186-­‐190.	  
REFERENCES 267	  
	  Palma,	   J.,	   C.	   Macedonia,	   et	   al.	   (2006).	   "Cerebrovascular	   dynamics	   and	   vascular	  endothelial	  growth	  factor	  in	  acute	  mountain	  sickness."	  Wilderness	  Environ	  Med	  17(1):	  1-­‐7.	  Paola,	   M.	   D.,	   M.	   Bozzali,	   et	   al.	   (2008).	   "Reduced	   oxygen	   due	   to	   high-­‐altitude	  exposure	   relates	   to	   atrophy	   in	   motor-­‐function	   brain	   areas."	   Eur	   J	   Neurol	  
15(10):	  1050-­‐1057.	  Patel,	  S.,	  D.	  R.	  Woods,	  et	  al.	  (2003).	  "Angiotensin-­‐converting	  enzyme	  genotype	  and	  the	   ventilatory	   response	   to	   exertional	   hypoxia."	   Eur	   Respir	   J	  22(5):	   755-­‐760.	  Pelamatti,	  G.,	  M.	  Pascotto,	  et	  al.	  (2003).	  "Verbal	  free	  recall	  in	  high	  altitude:	  proper	  names	  vs	  common	  names."	  Cortex	  39(1):	  97-­‐103.	  Peltonen,	   J.	   E.,	   J.	   M.	   Kowalchuk,	   et	   al.	   (2007).	   "Cerebral	   and	   muscle	   tissue	  oxygenation	   in	   acute	   hypoxic	   ventilatory	   response	   test."	   Respir	   Physiol	  Neurobiol	  155(1):	  71-­‐81.	  Pendon,	  J.	  D.	  and	  J.	  A.	  King	  (2003).	  "Brief	  altitude	  exposure	  in	  New	  Zealand	  white	  rabbits	   (Oryctolagus	   cuniculus)	   does	   not	   produce	   elevated	   intracranial	  pressure."	  Wilderness	  Environ	  Med	  14(3):	  183-­‐188.	  Perrey,	  S.	  (2008).	  "Non-­‐invasive	  NIR	  spectroscopy	  of	  human	  brain	  function	  during	  exercise."	  Methods	  45(4):	  289-­‐299.	  Pickard,	   J.	  D.,	   Z.	   Czosnyka,	   et	   al.	   (2008).	   "Coupling	   of	   sagittal	   sinus	  pressure	   and	  cerebrospinal	   fluid	   pressure	   in	   idiopathic	   intracranial	   hypertension-­‐-­‐a	  preliminary	  report."	  Acta	  neurochirurgica.	  Supplement	  102:	  283-­‐285.	  Plutarch	  (1912).	  Alexander	  and	  Caesar.	  London,	  Heinemann.	  Pollard,	  A.	  J.,	  S.	  Niermeyer,	  et	  al.	  (2001).	  "Children	  at	  high	  altitude:	  an	  international	  consensus	   statement	   by	   an	   ad	  hoc	   committee	   of	   the	   International	   Society	  for	  Mountain	  Medicine,	  March	  12,	  2001."	  High	  Alt	  Med	  Biol	  2(3):	  389-­‐403.	  Poulin,	  M.	  J.,	  P.	  J.	  Liang,	  et	  al.	  (1998).	  "Fast	  and	  slow	  components	  of	  cerebral	  blood	  flow	   response	   to	   step	  decreases	   in	   end-­‐tidal	   PCO2	   in	   humans."	   Journal	   of	  applied	  physiology	  85(2):	  388-­‐397.	  Poulin,	  M.	  J.	  and	  P.	  A.	  Robbins	  (1996).	  "Indexes	  of	  flow	  and	  cross-­‐sectional	  area	  of	  the	   middle	   cerebral	   artery	   using	   doppler	   ultrasound	   during	   hypoxia	   and	  hypercapnia	  in	  humans."	  Stroke	  27(12):	  2244-­‐2250.	  Poulin,	   M.	   J.Fatemian,	   et	   al.	   (2002).	   "Changes	   in	   cerebral	   blood	   flow	   during	   and	  after	   48	   h	   of	   both	   isocapnic	   and	   poikilocapnic	   hypoxia	   in	   humans."	  Experimental	  Phyiology	  	  87(5):	  633-­‐642.	  Prior,	   S.	   J.,	   J.	  M.	   Hagberg,	   et	   al.	   (2003).	   "Sequence	   variation	   in	   hypoxia-­‐inducible	  factor	   1alpha	   (HIF1A):	   association	   with	   maximal	   oxygen	   consumption."	  Physiol	  Genomics	  15(1):	  20-­‐26.	  Querfurth,	  H.	  W.,	  S.	  W.	  Arms,	  et	  al.	  (2004).	  "Prediction	  of	  intracranial	  pressure	  from	  noninvasive	  transocular	  venous	  and	  arterial	  hemodynamic	  measurements:	  a	  pilot	  study."	  Neurocritical	  care	  1(2):	  183-­‐194.	  Querfurth,	   H.	   W.,	   P.	   Lieberman,	   et	   al.	   (2010).	   "Ophthalmodynamometry	   for	   ICP	  prediction	  and	  pilot	  test	  on	  Mt.	  Everest."	  BMC	  neurology	  10:	  106.	  Quinn,	  M.	  W.	  and	  I.	  K.	  Pople	  (1992).	  "Middle	  cerebral	  artery	  pulsatility	  in	  children	  with	   blocked	   cerebrospinal	   fluid	   shunts."	   J	   Neurol	   Neurosurg	   Psychiatry	  
55(4):	  325-­‐327.	  Rainov,	  N.	  G.,	  J.	  B.	  Weise,	  et	  al.	  (2000).	  "Transcranial	  Doppler	  sonography	  in	  adult	  hydrocephalic	  patients."	  Neurosurg	  Rev	  23(1):	  34-­‐38.	  Rajput,	   C.,	   E.	   Arif,	   et	   al.	   (2006).	   "Predominance	   of	   interaction	   among	   wild-­‐type	  alleles	   of	   CYP11B2	   in	   Himalayan	   natives	   associates	   with	   high-­‐altitude	  adaptation."	  Biochem	  Biophys	  Res	  Commun	  348(2):	  735-­‐740.	  
REFERENCES 268	  
	  Ravenhill,	   T.	   H.	   (1913).	   "Some	   experiences	   of	   mountain	   sickness	   in	   the	   Andes."	  Journal	  of	  Tropical	  Medicine	  and	  Hygiene	  16:	  313-­‐320.	  Reese,	  T.,	  D.	  Bochelen,	   et	   al.	   (1999).	   "Magnetic	   resonance	   angiography	  of	   the	   rat	  cerebrovascular	   system	  without	   the	  use	  of	   contrast	   agents."	  NMR	  Biomed	  
12(4):	  189-­‐196.	  Reeves,	  J.	  T.,	  L.	  G.	  Moore,	  et	  al.	  (1985).	  "Headache	  at	  high	  altitude	  is	  not	  related	  to	  internal	  carotid	  arterial	  blood	  velocity."	  J	  Appl	  Physiol	  59(3):	  909-­‐915.	  Regard,	  M.,	  O.	  Oelz,	  et	  al.	  (1989).	  "Persistent	  cognitive	  impairment	  in	  climbers	  after	  repeated	  exposure	  to	  extreme	  altitude."	  Neurology	  39(2	  Pt	  1):	  210-­‐213.	  Reite,	   M.,	   D.	   Jackson,	   et	   al.	   (1975).	   "Sleep	   physiology	   at	   high	   altitude."	  Electroencephalogr	  Clin	  Neurophysiol	  38(5):	  463-­‐471.	  Roach,	   R.	   C.,	   P.	   Bartsch,	   et	   al.	   (1993).	   Lake	   Louise	   AMS	   Scoring	   Consensus	  Committee.	   The	   Lake	   Louise	   acute	   mountain	   sickness	   scoring	   system.	  Hypoxia	   and	   Molecular	   Medicine.	   S.	   JR,	   H.	   CS	   and	   C.	   G.	   Burlington,	   Vt,	  CHarles	  S	  Houston:	  272-­‐274.	  Roach,	   R.	   C.	   and	   P.	   H.	   Hackett	   (2001).	   "Frontiers	   of	   hypoxia	   research:	   acute	  mountain	  sickness."	  J	  Exp	  Biol	  204(Pt	  18):	  3161-­‐3170.	  Rodway,	   G.	   W.	   (2007).	   "Limb	   paralysis	   and	   visual	   changes	   during	   Glaisher	   and	  Coxwell's	   1862	   balloon	   ascent	   to	   over	   8800	  m."	   High	   Alt	   Med	   Biol	   8(3):	  256-­‐259.	  Rohr,	  A.,	   J.	  Bindeballe,	  et	  al.	  (2012).	  "The	  entire	  dural	  sinus	  tree	  is	  compressed	  in	  patients	   with	   idiopathic	   intracranial	   hypertension:	   a	   longitudinal,	  volumetric	  magnetic	  resonance	  imaging	  study."	  Neuroradiology	  54(1):	  25-­‐33.	  Rohwer,	  N.,	  C.	  Zasada,	  et	  al.	  (2012).	  "The	  growing	  complexity	  of	  HIF-­‐1alpha's	  role	  in	  tumorigenesis:	  DNA	  repair	  and	  beyond."	  Oncogene.	  Roncin,	   J.	   P.,	   F.	   Schwartz,	   et	   al.	   (1996).	   "EGb	   761	   in	   control	   of	   acute	   mountain	  sickness	  and	  vascular	  reactivity	  to	  cold	  exposure."	  Aviat	  Space	  Environ	  Med	  
67(5):	  445-­‐452.	  Rooks,	  C.	  R.,	  N.	  J.	  Thom,	  et	  al.	  (2010).	  "Effects	  of	  incremental	  exercise	  on	  cerebral	  oxygenation	  measured	  by	  near-­‐infrared	  spectroscopy:	  a	  systematic	  review."	  Prog	  Neurobiol	  92(2):	  134-­‐150.	  Ross,	   R.	   T.	   (1985).	   "The	   random	   nature	   of	   cerebral	   mountain	   sickness."	   Lancet	  
1(8435):	  990-­‐991.	  Rostrup,	   E.,	   I.	   Law,	   et	   al.	   (2002).	   "Cerebral	   hemodynamics	   measured	   with	  simultaneous	   PET	   and	   near-­‐infrared	   spectroscopy	   in	   humans."	   Brain	   Res	  
954(2):	  183-­‐193.	  Rowell,	   L.	   B.	   (1993).	   Control	   of	   regional	   blood	   flow	   during	   dynamic	   exercise.	  Human	  Cardiovascular	   Control.	   L.	   B.	  Rowell.	  New	  York,	  Oxford	  University	  Press:	  204-­‐254.	  Rupert,	   J.	   L.	   and	  M.	   S.	   Koehle	   (2006).	   "Evidence	   for	   a	   genetic	   basis	   for	   altitude-­‐related	  illness."	  High	  Alt	  Med	  Biol	  7(2):	  150-­‐167.	  Rupp,	  T.,	  M.	   Jubeau,	  et	  al.	  (2012).	  "The	  effect	  of	  hypoxemia	  and	  exercise	  on	  acute	  mountain	  sickness	  symptoms."	  Journal	  of	  applied	  physiology.	  Rupp,	  T.	  and	  S.	  Perrey	  (2009).	  "Effect	  of	  severe	  hypoxia	  on	  prefrontal	  cortex	  and	  muscle	  oxygenation	  responses	  at	  rest	  and	  during	  exhaustive	  exercise."	  Adv	  Exp	  Med	  Biol	  645:	  329-­‐334.	  Sahin,	  B.,	  N.	  Acer,	  et	  al.	  (2007).	  "Comparison	  of	  four	  methods	  for	  the	  estimation	  of	  intracranial	  volume:	  a	  gold	  standard	  study."	  Clin	  Anat	  20(7):	  766-­‐773.	  
REFERENCES 269	  
	  Saito,	   S.,	   F.	   Nishihara,	   et	   al.	   (1999).	   "Exercise-­‐induced	   cerebral	   deoxygenation	  among	   untrained	   trekkers	   at	   moderate	   altitudes."	   Arch	   Environ	   Health	  
54(4):	  271-­‐276.	  Sampson,	   J.	   B.,	   A.	   Cymerman,	   et	   al.	   (1983).	   "Procedures	   for	   the	  measurement	   of	  acute	  mountain	  sickness."	  Aviat	  Space	  Environ	  Med	  54(12	  Pt	  1):	  1063-­‐1073.	  Sanchez-­‐Elsner,	  T.,	   J.	  R.	  Ramirez,	  et	  al.	  (2004).	  "A	  cross-­‐talk	  between	  hypoxia	  and	  TGF-­‐beta	   orchestrates	   erythropoietin	   gene	   regulation	   through	   SP1	   and	  Smads."	  J	  Mol	  Biol	  336(1):	  9-­‐24.	  Sander,	  K.,	  H.	  Poppert,	  et	  al.	  (2011).	  "Dynamics	  of	  intracranial	  venous	  flow	  patterns	  in	  patients	  with	  idiopathic	  intracranial	  hypertension."	  European	  neurology	  
66(6):	  334-­‐338.	  Sanders,	  D.	  B.,	  T.	  Kelley,	  et	  al.	  (2000).	  "The	  role	  of	  nitric	  oxide	  synthase/nitric	  oxide	  in	  vascular	  smooth	  muscle	  control."	  Perfusion	  15(2):	  97-­‐104.	  Schoch,	   H.	   J.,	   S.	   Fischer,	   et	   al.	   (2002).	   "Hypoxia-­‐induced	   vascular	   endothelial	  growth	   factor	   expression	   causes	   vascular	   leakage	   in	   the	   brain."	   Brain	  
125(Pt	  11):	  2549-­‐2557.	  Schoonman,	   G.	   G.,	   P.	   S.	   Sandor,	   et	   al.	   (2008).	   "Hypoxia-­‐induced	   acute	   mountain	  sickness	   is	   associated	   with	   intracellular	   cerebral	   edema:	   a	   3	   T	   magnetic	  resonance	  imaging	  study."	  J	  Cereb	  Blood	  Flow	  Metab	  28(1):	  198-­‐206.	  Schrader,	  H.,	  L.	   J.	  Stovner,	  et	  al.	   (2001).	  "Prophylactic	   treatment	  of	  migraine	  with	  angiotensin	   converting	   enzyme	   inhibitor	   (lisinopril):	   randomised,	   placebo	  controlled,	  crossover	  study."	  BMJ	  322(7277):	  19-­‐22.	  Schreiber,	  S.	  J.,	  S.	  Gottschalk,	  et	  al.	  (2000).	  "Assessment	  of	  blood	  flow	  velocity	  and	  diameter	   of	   the	   middle	   cerebral	   artery	   during	   the	   acetazolamide	  provocation	   test	   by	   use	   of	   transcranial	   Doppler	   sonography	   and	   MR	  imaging."	  AJNR	  Am	  J	  Neuroradiol	  21(7):	  1207-­‐1211.	  Schwarz,	   G.,	   G.	   Litscher,	   et	   al.	   (1996).	   "Cerebral	   oximetry	   in	   dead	   subjects."	   J	  Neurosurg	  Anesthesiol	  8(3):	  189-­‐193.	  Scott,	   C.	   J.,	   R.	   H.	   Kardon,	   et	   al.	   (2010).	   "Diagnosis	   and	   grading	   of	   papilledema	   in	  patients	   with	   raised	   intracranial	   pressure	   using	   optical	   coherence	  tomography	   vs	   clinical	   expert	   assessment	   using	   a	   clinical	   staging	   scale."	  Archives	  of	  ophthalmology	  128(6):	  705-­‐711.	  Serrador,	   J.	  M.,	  P.	  A.	  Picot,	  et	  al.	   (2000).	  "MRI	  measures	  of	  middle	  cerebral	  artery	  diameter	  in	  conscious	  humans	  during	  simulated	  orthostasis."	  Stroke	  31(7):	  1672-­‐1678.	  Serrano-­‐Duenas,	  M.	  (2000).	  "[Acute	  mountain	  sickness:	  the	  clinical	  characteristics	  of	  a	  cohort	  of	  615	  patients]."	  Med	  Clin	  (Barc)	  115(12):	  441-­‐445.	  Severinghaus,	   J.	   W.	   (1995).	   "Hypothesis:	   angiogenesis	   cytokines	   in	   high	   altitude	  cerebral	  oedema."	  Acta	  Anaesthesiol	  Scand	  Suppl	  107:	  177-­‐178.	  Severinghaus,	   J.	  W.,	  H.	   Chiodi,	   et	   al.	   (1966).	   "Cerebral	   blood	   flow	   in	  man	   at	   high	  altitude.	  Role	  of	  cerebrospinal	   fluid	  pH	  in	  normalization	  of	   flow	  in	  chronic	  hypocapnia."	  Circ	  Res	  19(2):	  274-­‐282.	  Shibuya,	   K.,	   J.	   Tanaka,	   et	   al.	   (2004).	   "Cerebral	   oxygenation	   during	   intermittent	  supramaximal	  exercise."	  Respir	  Physiol	  Neurobiol	  140(2):	  165-­‐172.	  Silber,	  E.,	  P.	  Sonnenberg,	  et	  al.	  (2003).	  "Clinical	  features	  of	  headache	  at	  altitude:	  a	  prospective	  study."	  Neurology	  60(7):	  1167-­‐1171.	  Singh,	   I.,	   P.	   K.	   Khanna,	   et	   al.	   (1969).	   "Acute	   mountain	   sickness."	   N	   Engl	   J	   Med	  
280(4):	  175-­‐184.	  Smith,	  K.	  J.	  and	  F.	  Billaut	  (2010).	  "Influence	  of	  cerebral	  and	  muscle	  oxygenation	  on	  repeated-­‐sprint	  ability."	  Eur	  J	  Appl	  Physiol	  109(5):	  989-­‐999.	  
REFERENCES 270	  
	  Soehle,	  M.,	  D.	  A.	  Chatfield,	  et	  al.	   (2007).	   "Predictive	  value	  of	   initial	   clinical	   status,	  intracranial	   pressure	   and	   transcranial	   Doppler	   pulsatility	   after	  subarachnoid	  haemorrhage."	  Acta	  Neurochir	  (Wien)	  149(6):	  575-­‐583.	  Song,	  S.	  Y.,	  T.	  Asaji,	  et	  al.	  (1986).	  "Cerebral	  thrombosis	  at	  altitude:	  its	  pathogenesis	  and	   the	  problems	  of	  prevention	  and	   treatment."	  Aviat	  Space	  Environ	  Med	  
57(1):	  71-­‐76.	  Southard,	   A.,	   S.	   Niermeyer,	   et	   al.	   (2007).	   "Language	   used	   in	   Lake	   Louise	   Scoring	  System	  underestimates	  symptoms	  of	  acute	  mountain	  sickness	   in	  4-­‐	   to	  11-­‐year-­‐old	  children."	  High	  Alt	  Med	  Biol	  8(2):	  124-­‐130.	  Stobdan,	  T.,	  J.	  Karar,	  et	  al.	  (2008).	  "High	  altitude	  adaptation:	  genetic	  perspectives."	  High	  Alt	  Med	  Biol	  9(2):	  140-­‐147.	  Subudhi,	  A.	  W.,	  A.	  C.	  Dimmen,	  et	  al.	   (2007).	   "Effects	  of	  acute	  hypoxia	  on	  cerebral	  and	   muscle	   oxygenation	   during	   incremental	   exercise."	   J	   Appl	   Physiol	  
103(1):	  177-­‐183.	  Subudhi,	   A.	   W.,	   M.	   C.	   Lorenz,	   et	   al.	   (2008).	   "Cerebrovascular	   responses	   to	  incremental	   exercise	   during	   hypobaric	   hypoxia:	   effect	   of	   oxygenation	   on	  maximal	  performance."	  Am	  J	  Physiol	  Heart	  Circ	  Physiol	  294(1):	  H164-­‐171.	  Subudhi,	  A.	  W.,	  B.	  R.	  Miramon,	  et	  al.	  (2009).	  "Frontal	  and	  motor	  cortex	  oxygenation	  during	  maximal	  exercise	  in	  normoxia	  and	  hypoxia."	  J	  Appl	  Physiol	  106(4):	  1153-­‐1158.	  Subudhi,	   A.	   W.,	   J.	   T.	   Olin,	   et	   al.	   (2011).	   "Does	   cerebral	   oxygen	   delivery	   limit	  incremental	  exercise	  performance?"	  J	  Appl	  Physiol.	  Sutherland,	   A.	   I.,	   D.	   S.	   Morris,	   et	   al.	   (2008).	   "Optic	   nerve	   sheath	   diameter,	  intracranial	   pressure	   and	   acute	   mountain	   sickness	   on	   Mount	   Everest:	   a	  longitudinal	  cohort	  study."	  Br	  J	  Sports	  Med	  42(3):	  183-­‐188.	  Suzuki,	   K.,	   T.	   Kizaki,	   et	   al.	   (2003).	   "Genetic	   variation	   in	   hypoxia-­‐inducible	   factor	  1alpha	   and	   its	   possible	   association	   with	   high	   altitude	   adaptation	   in	  Sherpas."	  Med	  Hypotheses	  61(3):	  385-­‐389.	  Takenouchi,	   T.,	   L.	   A.	   Heier,	   et	   al.	   (2010).	   "Restricted	   diffusion	   in	   the	   corpus	  callosum	  in	  hypoxic-­‐ischemic	  encephalopathy."	  Pediatr	  Neurol	  43(3):	  190-­‐196.	  Tan,	  H.,	  H.	  Feng,	  et	  al.	  (2001).	  "Outcome	  prediction	  in	  severe	  traumatic	  brain	  injury	  with	   transcranial	   Doppler	   ultrasonography."	   Chin	   J	   Traumatol	   4(3):	   156-­‐160.	  Tarasow,	  E.,	  A.	  Abdulwahed	  Saleh	  Ali,	  et	  al.	  (2007).	  "Measurements	  of	  the	  middle	  cerebral	   artery	   in	   digital	   subtraction	   angiography	   and	   MR	   angiography."	  Med	  Sci	  Monit	  13	  Suppl	  1:	  65-­‐72.	  Ter	  Minassian,	  A.,	  L.	  Beydon,	  et	  al.	  (2001).	  "Doppler	  study	  of	  middle	  cerebral	  artery	  blood	   flow	  velocity	  and	  cerebral	  autoregulation	  during	  a	  simulated	  ascent	  of	  Mount	  Everest."	  Wilderness	  Environ	  Med	  12(3):	  175-­‐183.	  Theis,	  M.	  K.,	   B.	  Honigman,	   et	   al.	   (1993).	   "Acute	  mountain	   sickness	   in	   children	   at	  2835	  meters."	  Am	  J	  Dis	  Child	  147(2):	  143-­‐145.	  Tissot	  van	  Patot,	  M.	  C.,	  G.	  Leadbetter,	  et	  al.	  (2005).	  "Greater	  free	  plasma	  VEGF	  and	  lower	  soluble	  VEGF	  receptor-­‐1	  in	  acute	  mountain	  sickness."	  J	  Appl	  Physiol	  
98(5):	  1626-­‐1629.	  Torikoshi,	  S.,	  M.	  H.	  Wilson,	  et	  al.	  (1995).	  "Ultrasound	  measurement	  of	  transcranial	  distance	  during	  head-­‐down	  tilt."	  J	  Gravit	  Physiol	  2(1):	  P145-­‐146.	  Tsai,	  F.	  Y.,	  A.	  M.	  Wang,	  et	  al.	  (1995).	  "MR	  staging	  of	  acute	  dural	  sinus	  thrombosis:	  correlation	   with	   venous	   pressure	   measurements	   and	   implications	   for	  treatment	  and	  prognosis."	  AJNR	  Am	  J	  Neuroradiol	  16(5):	  1021-­‐1029.	  
REFERENCES 271	  
	  Vajda,	  Z.,	  A.	  Buki,	  et	  al.	  (1999).	  "Transcranial	  Doppler-­‐determined	  pulsatility	  index	  in	   the	  evaluation	  of	  endoscopic	   third	  ventriculostomy	  (preliminary	  data)."	  Acta	  Neurochir	  (Wien)	  141(3):	  247-­‐250.	  Valdueza,	   J.	   M.,	   J.	   O.	   Balzer,	   et	   al.	   (1997).	   "Changes	   in	   blood	   flow	   velocity	   and	  diameter	  of	  the	  middle	  cerebral	  artery	  during	  hyperventilation:	  assessment	  with	   MR	   and	   transcranial	   Doppler	   sonography."	   AJNR	   Am	   J	   Neuroradiol	  
18(10):	  1929-­‐1934.	  Van	   Osta,	   A.,	   J.	   J.	   Moraine,	   et	   al.	   (2005).	   "Effects	   of	   high	   altitude	   exposure	   on	  cerebral	  hemodynamics	  in	  normal	  subjects."	  Stroke	  36(3):	  557-­‐560.	  Vardy,	   J.	   and	   K.	   Judge	   (2006).	   "Acute	   mountain	   sickness	   and	   ascent	   rates	   in	  trekkers	  above	  2500	  m	   in	   the	  Nepali	  Himalaya."	  Aviat	  Space	  Environ	  Med	  
77(7):	  742-­‐744.	  Varnell,	   R.	   M.,	   G.	   K.	   Stimac,	   et	   al.	   (1987).	   "CT	   diagnosis	   of	   toxic	   brain	   injury	   in	  cyanide	   poisoning:	   considerations	   for	   forensic	   medicine."	   AJNR	   Am	   J	  Neuroradiol	  8(6):	  1063-­‐1066.	  Virues-­‐Ortega,	   J.,	   G.	   Buela-­‐Casal,	   et	   al.	   (2004).	   "Neuropsychological	   functioning	  associated	  with	  high-­‐altitude	  exposure."	  Neuropsychol	  Rev	  14(4):	  197-­‐224.	  Voulgaris,	   S.	   G.,	   M.	   Partheni,	   et	   al.	   (2005).	   "Early	   cerebral	   monitoring	   using	   the	  transcranial	  Doppler	  pulsatility	  index	  in	  patients	  with	  severe	  brain	  trauma."	  Med	  Sci	  Monit	  11(2):	  CR49-­‐52.	  Vuyk,	   J.,	   J.	   Van	   Den	   Bos,	   et	   al.	   (2006).	   "Acetazolamide	   improves	   cerebral	  oxygenation	  during	  exercise	  at	  high	  altitude."	  High	  Alt	  Med	  Biol	  7(4):	  290-­‐301.	  Ward,	   M.,	   J.	   S.	   Milledge,	   et	   al.	   (2000).	   High	   Altitude	   Physiology.	   London,	   Arnold	  Publishers.	  Watzman,	  H.	  M.,	   C.	   D.	   Kurth,	   et	   al.	   (2000).	   "Arterial	   and	   venous	   contributions	   to	  near-­‐infrared	  cerebral	  oximetry."	  Anesthesiology	  93(4):	  947-­‐953.	  Wesensten,	   N.	   J.,	   J.	   Crowley,	   et	   al.	   (1993).	   "Effects	   of	   simulated	   high	   altitude	  exposure	  on	  long-­‐latency	  event-­‐related	  brain	  potentials	  and	  performance."	  Aviat	  Space	  Environ	  Med	  64(1):	  30-­‐36.	  West,	   J.	   B.	   (1984).	   "Human	   physiology	   at	   extreme	   altitudes	   on	   Mount	   Everest."	  Science	  223(4638):	  784-­‐788.	  West,	   J.	   B.	   (1996).	   "T.H.	  Ravenhill	   and	  his	   contributions	   to	  mountain	   sickness."	   J	  Appl	  Physiol	  80(3):	  715-­‐724.	  West,	   J.	   B.	   (2004).	   "Paralysis	   and	   blindness	   during	   a	   balloon	   ascent	   to	   high	  altitude."	  High	  Alt	  Med	  Biol	  5(4):	  453-­‐456.	  West,	   J.	   B.,	   R.	   B.	   Schoene,	   et	   al.	   (2007).	   High	   Altitude	   Medicine	   and	   Physiology.	  London,	  Hodder	  Arnold.	  Weyland,	  A.,	  H.	  Stephan,	  et	  al.	  (1994).	  "Flow	  velocity	  measurements	  as	  an	  index	  of	  cerebral	   blood	   flow.	   Validity	   of	   transcranial	   Doppler	   sonographic	  monitoring	  during	  cardiac	  surgery."	  Anesthesiology	  81(6):	  1401-­‐1410.	  Wiedman,	   M.	   and	   G.	   C.	   Tabin	   (1999).	   "High-­‐altitude	   retinopathy	   and	   altitude	  illness."	  Ophthalmology	  106(10):	  1924-­‐1926;	  discussion	  1927.	  Wiener,	   T.	   C.	   (2012).	   "Space	   obstructive	   syndrome:	   intracranial	   hypertension,	  intraocular	   pressure,	   and	   papilledema	   in	   space."	   Aviation,	   space,	   and	  environmental	  medicine	  83(1):	  64-­‐66.	  Williams,	   A.	   G.,	   M.	   P.	   Rayson,	   et	   al.	   (2000).	   "The	   ACE	   gene	   and	   muscle	  performance."	  Nature	  403(6770):	  614.	  Willie,	  C.	  K.,	  D.	  B.	  Macleod,	  et	  al.	  (2012).	  "Regional	  brain	  blood	  flow	  in	  man	  during	  acute	   changes	   in	   arterial	   blood	   gases."	   The	   Journal	   of	   physiology	  590(Pt	  14):	  3261-­‐3275.	  
REFERENCES 272	  
	  Willmann,	  G.,	  M.	  D.	  Fischer,	  et	  al.	  (2011).	  "Quantification	  of	  optic	  disc	  edema	  during	  exposure	  to	  high	  altitude	  shows	  no	  correlation	  to	  acute	  mountain	  sickness."	  PloS	  one	  6(11):	  e27022.	  Wilson,	  M.	  and	  H.	  Montgomery	  (2007).	  "Impact	  of	  genetic	  factors	  on	  outcome	  from	  brain	  injury."	  Br	  J	  Anaesth	  99(1):	  43-­‐48.	  Wilson,	  M.	  E.,	  M.	   Imray,	  C.	  Wright,	  A	   (2008).	   "Changes	   in	  Pupil	  Dynamics	  at	  high	  altitude	   -­‐	   an	   observational	   study	   using	   a	   handheld	   pupillometer."	   High	  Altitude	  Medicine	  and	  Biology	  In	  Press.	  Wilson,	   M.	   H.,	   I.	   Davagnanam,	   et	   al.	   (2013).	   "Cerebral	   venous	   system	   and	  anatomical	  predisposition	   to	  high-­‐altitude	  headache."	  Annals	  of	  neurology	  
73(3):	  381-­‐389.	  Wilson,	   M.	   H.,	   M.	   E.	   Edsell,	   et	   al.	   (2011).	   "Cerebral	   artery	   dilatation	   maintains	  cerebral	   oxygenation	   at	   extreme	   altitude	   and	   in	   acute	   hypoxia-­‐-­‐an	  ultrasound	  and	  MRI	  study."	  J	  Cereb	  Blood	  Flow	  Metab	  31(10):	  2019-­‐2029.	  Wilson,	   M.	   H.,	   C.	   H.	   Imray,	   et	   al.	   (2011).	   "The	   headache	   of	   high	   altitude	   and	  microgravity-­‐-­‐similarities	   with	   clinical	   syndromes	   of	   cerebral	   venous	  hypertension."	  High	  Alt	  Med	  Biol	  12(4):	  379-­‐386.	  Wilson,	   M.	   H.,	   C.	   H.	   Imray,	   et	   al.	   (2011).	   "The	   Headache	   of	   High	   Altitude	   and	  Microgravity?Similarities	   with	   Clinical	   Syndromes	   of	   Cerebral	   Venous	  Hypertension."	  High	  Alt	  Med	  Biol.	  Wilson,	  M.	  H.,	  D.	  Z.	  Levett,	  et	  al.	   (2011).	   "Stroke	  at	  high	  altitude	  diagnosed	   in	   the	  field	  using	  portable	  ultrasound."	  Wilderness	  Environ	  Med	  22(1):	  54-­‐57.	  Wilson,	  M.	  H.	  and	  J.	  Milledge	  (2008).	  "Direct	  measurement	  of	  intracranial	  pressure	  at	   high	   altitude	   and	   correlation	   of	   ventricular	   size	   with	   acute	   mountain	  sickness:	   Brian	   Cummins'	   results	   from	   the	   1985	   Kishtwar	   expedition."	  Neurosurgery	  63(5):	  970-­‐974;	  discussion	  974-­‐975.	  Wilson,	   M.	   H.,	   S.	   Newman,	   et	   al.	   (2009).	   "The	   cerebral	   effects	   of	   ascent	   to	   high	  altitudes."	  Lancet	  Neurology	  8:	  175-­‐191.	  Wilson,	   M.	   H.,	   D.	   Wise,	   et	   al.	   (2012).	   "Emergency	   burr	   holes:	   "How	   to	   do	   it"."	  Scandinavian	  journal	  of	  trauma,	  resuscitation	  and	  emergency	  medicine	  20:	  24.	  Winn,	  H.	  R.,	  R.	  Rubio,	  et	  al.	  (1981).	  "Brain	  adenosine	  concentration	  during	  hypoxia	  in	  rats."	  Am	  J	  Physiol	  241(2):	  H235-­‐242.	  Wolff,	  C.	  B.	  (2000).	  "Cerebral	  blood	  flow	  and	  oxygen	  delivery	  at	  high	  altitude."	  High	  Alt	  Med	  Biol	  1(1):	  33-­‐38.	  Wolff,	  C.	  B.,	  N.	  Richardson,	  et	  al.	  (2007).	  "Near	  infra-­‐red	  spectroscopy	  and	  arterial	  oxygen	  extraction	  at	  altitude."	  Adv	  Exp	  Med	  Biol	  599:	  183-­‐189.	  Wolff,	  H.	  and	  W.	  Lennox	  (1930).	  "Cerebral	  circulation	  XII.	  The	  effect	  on	  pial	  vessels	  of	   variations	   in	   the	   oxygen	   and	   carbon	   dioxide	   content	   of	   blood."	   Arch	  Neurol	  Psychiatry	  23:	  1097-­‐1120.	  Wollman,	   H.,	   T.	   C.	   Smith,	   et	   al.	   (1968).	   "Effects	   of	   extremes	   of	   respiratory	   and	  metabolic	   alkalosis	   on	   cerebral	   blood	   flow	   in	  man."	   J	   Appl	   Physiol	  24(1):	  60-­‐65.	  Woods,	  D.	  R.,	  S.	  Allen,	  et	  al.	  (2008).	  "High	  altitude	  arrhythmias."	  Cardiology	  111(4):	  239-­‐246.	  Woods,	  D.	  R.	  and	  H.	  E.	  Montgomery	  (2001).	  "Angiotensin-­‐converting	  enzyme	  and	  genetics	  at	  high	  altitude."	  High	  Alt	  Med	  Biol	  2(2):	  201-­‐210.	  Woods,	  D.	  R.,	  A.	   J.	  Pollard,	  et	  al.	   (2002).	   "Insertion/deletion	  polymorphism	  of	   the	  angiotensin	   I-­‐converting	   enzyme	   gene	   and	   arterial	   oxygen	   saturation	   at	  high	  altitude."	  Am	  J	  Respir	  Crit	  Care	  Med	  166(3):	  362-­‐366.	  
REFERENCES 273	  
	  Wright,	  A.	  D.,	  C.	  H.	  Imray,	  et	  al.	  (1995).	  "Intracranial	  pressure	  at	  high	  altitude	  and	  acute	  mountain	  sickness."	  Clin	  Sci	  (Lond)	  89(2):	  201-­‐204.	  Wu,	  T.,	   S.	  Ding,	   et	   al.	   (2006).	   "Ataxia:	   an	  early	   indicator	   in	  high	  altitude	   cerebral	  edema."	  High	  Alt	  Med	  Biol	  7(4):	  275-­‐280.	  Wu,	  T.	  Y.,	   S.	  Q.	  Ding,	   et	  al.	   (2007).	   "Who	  should	  not	  go	  high:	   chronic	  disease	  and	  work	  at	  altitude	  during	  construction	  of	  the	  Qinghai-­‐Tibet	  railroad."	  High	  Alt	  Med	  Biol	  8(2):	  88-­‐107.	  Wu,	   X.,	   X.	   Li,	   et	   al.	   (1998).	   "Effects	   of	   acute	   moderate	   hypoxia	   on	   human	  performance	  of	  arithmetic."	  Space	  Med	  Med	  Eng	  (Beijing)	  11(6):	  391-­‐395.	  Yamakawa,	   M.,	   L.	   X.	   Liu,	   et	   al.	   (2003).	   "Hypoxia-­‐inducible	   factor-­‐1	   mediates	  activation	   of	   cultured	   vascular	   endothelial	   cells	   by	   inducing	   multiple	  angiogenic	  factors."	  Circ	  Res	  93(7):	  664-­‐673.	  Yang,	   S.	   P.,	   G.	   W.	   Bergo,	   et	   al.	   (1994).	   "Cerebral	   pressure-­‐flow	   and	   metabolic	  responses	   to	   sustained	  hypoxia:	  effect	  of	  CO2."	   J	  Appl	  Physiol	  76(1):	  303-­‐313.	  Yang,	  Y.	  B.,	  B.	  Sun,	  et	  al.	  (1993).	  "Effects	  of	  acute	  hypoxia	  on	  intracranial	  dynamics	  in	  unanesthetized	  goats."	  J	  Appl	  Physiol	  74(5):	  2067-­‐2071.	  Yaron,	  M.,	  S.	  Niermeyer,	  et	  al.	   (2003).	  "Physiologic	  response	  to	  moderate	  altitude	  exposure	  among	  infants	  and	  young	  children."	  High	  Alt	  Med	  Biol	  4(1):	  53-­‐59.	  Yaron,	  M.,	  N.	  Waldman,	  et	  al.	  (1998).	  "The	  diagnosis	  of	  acute	  mountain	  sickness	  in	  preverbal	  children."	  Arch	  Pediatr	  Adolesc	  Med	  152(7):	  683-­‐687.	  Zhang,	   R.,	   J.	   H.	   Zuckerman,	   et	   al.	   (2002).	   "Autonomic	   neural	   control	   of	   dynamic	  cerebral	  autoregulation	  in	  humans."	  Circulation	  106(14):	  1814-­‐1820.	  Zhou,	   H.,	   G.	   M.	   Saidel,	   et	   al.	   (2008).	   "Cerebral	   blood	   flow	   adaptation	   to	   chronic	  hypoxia."	  Adv	  Exp	  Med	  Biol	  614:	  371-­‐377.	  Zhou,	  X.	  D.	  (1984).	  "Transient	  ischemic	  attack	  in	  young	  people	  at	  high	  altitude."	  Qinghai	  Med.	  J.	  14(2):	  44-­‐45.	  Zrinzo,	   L.	   U.,	   M.	   Crocker,	   et	   al.	   (2006).	   "Commercial	   flight	   and	   patients	   with	  intracranial	   mass	   lesions:	   a	   caveat.	   Report	   of	   two	   cases."	   J	   Neurosurg	  
105(4):	  627-­‐630.	  Zubieta-­‐Calleja,	  G.	  R.,	   Jr.,	  G.	  Zubieta-­‐Castillo,	  Sr.,	  et	  al.	  (1994).	  "Acute	  high	  altitude	  hypoventilation	   that	   resulted	   in	   hyperventilation	   following	   hyperoxic	  tests."	  from	  http://altitudeclinic.com/hyperv.html.	  Zuj,	   K.	   A.,	   D.	   K.	   Greaves,	   et	   al.	   (2007).	   "WISE-­‐2005:	   reduced	   cerebral	   blood	   flow	  velocity	  with	  nitroglycerin-­‐-­‐comparison	  with	  common	  carotid	  artery	  blood	  flow."	  J	  Gravit	  Physiol	  14(1):	  P65-­‐66.	  
 
 
 
 
 
  
APPENDIX	   274	  
	  
12 Appendix 
 
Chapter 2: Methodology Appendix 
2A: Amsler Chart: 
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2B: Neuropsychology: 
 
i) Trail Making: 
 A B  
 
ii) Stroop Color Word Test (SCWT): 
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iii) Letter Cancellation:  
 
 
iv) Digit Symbol Modalities test: 
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v) Rey Auditory Verbal Learning test (RAVLT): 
  
 
vi) Block Design 
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Chapter 4:Brain Oxygenation Appendix: 
 
Table 4A 
 
 
London 
Resting 
SaO2 
Namche 
Resting 
SaO2 
EBC 
Resting 
SaO2 London Resting 
rSO2 
Pearson 
Correlation 
.078 -.040 .012 
Sig. (2-tailed) .317 .611 .890 
N 165 162 139 
London 
Unloaded rSO2 
Pearson 
Correlation 
.084 -.040 .024 
Sig. (2-tailed) .285 .617 .783 
N 165 162 139 
London AT 
rSO2 
Pearson 
Correlation 
.044 -.038 .069 
Sig. (2-tailed) .578 .629 .419 
N 165 162 139 
London 
VO2Max rSO2 
Pearson 
Correlation 
.047 -.049 .050 
Sig. (2-tailed) .549 .534 .557 
N 165 162 139 
London Lowest 
rSO2 
Pearson 
Correlation 
.050 -.044 .046 
Sig. (2-tailed) .521 .577 .594 
N 165 162 139 
Namche 
Resting rSO2 
Pearson 
Correlation 
-.040 -.007 .009 
Sig. (2-tailed) .603 .929 .916 
N 168 167 141 
Namche 
Unloaded rSo2 
Pearson 
Correlation 
-.038 -.017 .003 
Sig. (2-tailed) .621 .829 .971 
N 168 167 141 
Namche AT 
rSO2 
Pearson 
Correlation 
-.020 .081 .055 
Sig. (2-tailed) .798 .300 .515 
N 168 167 141 
Namche 
VO2Max rSO2 
Pearson 
Correlation 
-.034 .088 .116 
Sig. (2-tailed) .664 .256 .170 
N 168 167 141 
Namche 
Lowest rSO2 
Pearson 
Correlation 
-.061 .090 .127 
Sig. (2-tailed) .435 .249 .135 
N 167 166 140 
EBC Resting 
rSO2 
Pearson 
Correlation 
.040 -.014 .204 
Sig. (2-tailed) .637 .874 .016 
N 141 139 140 
EBC Unloaded 
rSO2 
Pearson 
Correlation 
.059 .014 .263 
Sig. (2-tailed) .485 .871 .002 
N 144 142 143 
EBC AT rSO2 Pearson 
Correlation 
.024 .008 .248 
Sig. (2-tailed) .774 .924 .003 
N 141 139 140 
EBC VO2Max 
rSO2 
Pearson 
Correlation 
.029 -.012 .202 
Sig. (2-tailed) .730 .891 .017 
N 141 139 140 
EBC Lowest 
rSO2 
Pearson 
Correlation 
.022 .023 .235 
Sig. (2-tailed) .791 .790 .005 
N 142 140 141 
 
Table 4A: Correlations between resting SaO2 and resting rSO2 at each altitude. 
Only at Everest Base camp does a significant correlation between resting SaO2 
and rSO2 occur.  
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Table 4B 
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%
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ch
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 i
n 
rS
O
2 
at
 V
O
2M
ax
 
E
B
C
 
Ti
m
e 
to
 
V
O
2 
M
ax
 a
t 5
30
0m
 
%age change 
in rSO2 at 
VO2Max 75m 
Pearson 
Correlation 1 .054 .486
** .103 .435** .193* 
Sig. (2-
tailed) 
 .493 .000 .191 .000 .024 
N 165 165 161 163 136 137 
Time to 
VO2Max 
at 75m 
Pearson 
Correlation .054 1 -.263
** -.012 -.193* -.189* 
Sig. (2-
tailed) .493 
 .001 .877 .022 .024 
N 165 171 167 169 141 142 
%age Change 
in rSO2 at 
VO2Max 
Namche 
Pearson 
Correlation .486
** -.263** 1 .178* .604** .102 
Sig. (2-
tailed) .000 .001 
 .022 .000 .235 
N 161 167 167 167 137 138 
Time to 
VO2Max at 
3500m 
Pearson 
Correlation .103 -.012 .178
* 1 .012 .228** 
Sig. (2-
tailed) .191 .877 .022 
 .891 .007 
N 163 169 167 169 139 140 
%age change 
in rSO2 at 
VO2Max EBC 
Pearson 
Correlation .435
** -.193* .604** .012 1 -.140 
Sig. (2-
tailed) .000 .022 .000 .891 
 .098 
N 136 141 137 139 141 141 
Time to VO2 
Max at 5300m 
Pearson 
Correlation .193
* -.189* .102 .228** -.140 1 
Sig. (2-
tailed) .024 .024 .235 .007 .098 
 
N 137 142 138 140 141 142 
Table 4B: Correlation between Time to achieve VO2Max and Percentage 
desaturation of rSO2 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Table 4C  
  Headac
he score 
at 150m 
Headach
e 
present 
at 150m 
(Y/N) 
Headach
e score 
at 
3500m 
Headach
e 
present 
at 
3500m 
(Y/N) 
Headach
e score 
at 
5300m 
Headac
he 
present 
at 
5300m 
(Y/N) 
Resting rSO2 
at 75m 
Pearson 
Corr 
-.155* -.078 -.087 -.045 .075 .062 
Sig. (2-
tailed) 
.047 .321 .271 .566 .380 .466 
Unloaded rSO2 
at 75m 
Pearson 
Corr 
-.180* -.096 -.089 -.043 .056 .040 
Sig. (2-
tailed) 
.020 .219 .256 .588 .513 .638 
AT rSO2 at 
75m 
Pearson 
Corr 
-.196* -.124 -.099 -.046 .066 .057 
Sig. (2-
tailed) 
.011 .114 .208 .563 .440 .506 
VO2Max rSO2 
at 75m 
Pearson 
Corr 
-.129 -.090 -.110 -.037 .081 .043 
Sig. (2-
tailed) 
.098 .251 .162 .641 .340 .618 
Lowest rSO2 at 
75m 
Pearson 
Corr 
-.132 -.091 -.109 -.043 .028 .004 
Sig. (2-
tailed) 
.090 .243 .168 .585 .747 .966 
rSO2 %age 
Change 
Unloaded at 
75m 
Pearson 
Corr 
-.146 -.106 -.002 .018 -.076 -.088 
Sig. (2-
tailed) 
.061 .176 .982 .822 .370 .302 
rSO2 %age 
Change AT at 
75m 
Pearson 
Corr 
-.089 -.109 -.042 -.007 -.031 -.018 
Sig. (2-
tailed) 
.255 .162 .597 .928 .718 .833 
rSO2 %age 
Change 
VO2Max at 
75m 
Pearson 
Corr 
-.003 -.038 -.094 -.020 .036 -.009 
Sig. (2-
tailed) 
.965 .631 .233 .795 .675 .920 
rSO2 %age 
Change lowest 
at 75m 
Pearson 
Corr 
-.002 -.035 -.091 -.028 -.040 -.062 
Sig. (2-
tailed) 
.975 .659 .249 .719 .638 .464 
Resting rSO2 
at 3500m 
Pearson 
Corr 
-.181* -.127 -.060 -.034 .164 .109 
Sig. (2-
tailed) 
.019 .102 .443 .662 .052 .196 
Unloaded rSO2 
at 3500m 
Pearson 
Corr 
-.197* -.138 -.066 -.047 .197* .135 
Sig. (2-
tailed) 
.011 .075 .398 .549 .019 .109 
AT rSO2 at 
3500m 
Pearson 
Corr 
-.189* -.139 -.058 -.045 .169* .147 
Sig. (2-
tailed) 
.014 .073 .455 .566 .044 .080 
VO2Max rSO2 
at 3500m 
Pearson 
Corr 
-.166* -.130 .017 .055 .069 .056 
Sig. (2-
tailed) 
.032 .094 .823 .481 .412 .505 
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Lowest rSO2 at 
3500m 
Pearson 
Corr 
-.156* -.123 .015 .050 .091 .080 
Sig. (2-
tailed) 
.044 .115 .844 .524 .283 .344 
rSO2 %age 
Change 
Unloaded at 
3500m 
Pearson 
Corr 
-.144 -.088 -.040 -.061 .160 .128 
Sig. (2-
tailed) 
.063 .257 .609 .433 .057 .128 
rSO2 %age 
Change ATat 
3500m 
Pearson 
Corr 
-.085 -.069 -.042 -.062 .067 .112 
Sig. (2-
tailed) 
.276 .376 .587 .427 .430 .185 
rSO2 %age 
Change 
VO2Max at 
3500m 
Pearson 
Corr 
-.085 -.076 .055 .090 -.039 -.014 
Sig. (2-
tailed) 
.275 .329 .482 .250 .646 .870 
rSO2 %age 
Change Lowest 
at 3500m 
Pearson 
Corr 
-.082 -.073 .051 .079 -.006 .021 
Sig. (2-
tailed) 
.293 .347 .515 .307 .941 .804 
Resting rSO2 
at 5300m 
Pearson 
Corr 
-.052 -.071 .000 -.068 .020 .003 
Sig. (2-
tailed) 
.542 .405 .999 .424 .811 .973 
Unloaded rSO2 
at 5300m 
Pearson 
Corr 
-.306** -.253** .003 -.058 .058 .042 
Sig. (2-
tailed) 
.000 .002 .968 .489 .489 .615 
AT rSO2 at 
5300m 
Pearson 
Corr 
-.077 -.098 -.024 -.100 .010 .005 
Sig. (2-
tailed) 
.365 .250 .783 .240 .907 .956 
VO2Max rSO2 
at 5300m 
Pearson 
Corr 
-.091 -.116 -.010 -.075 .072 .073 
Sig. (2-
tailed) 
.284 .172 .910 .376 .394 .388 
Lowest rSO2 at 
5300m 
Pearson 
Corr 
-.252** -.220** .008 -.072 .101 .102 
Sig. (2-
tailed) 
.002 .009 .922 .395 .232 .225 
rSO2%age 
change 
Unloaded at 
5300m 
Pearson 
Corr 
-.122 -.139 -.040 -.050 .053 .053 
Sig. (2-
tailed) 
.149 .100 .640 .554 .530 .533 
rSO2%age 
change AT at 
5300m 
Pearson 
Corr 
-.117 -.118 -.060 -.101 -.033 -.008 
Sig. (2-
tailed) 
.167 .161 .481 .232 .700 .921 
rSO2%age 
change 
VO2Max at 
5300m 
Pearson 
Corr 
-.083 -.099 -.011 -.033 .065 .083 
Sig. (2-
tailed) 
.328 .244 .898 .697 .444 .325 
rSO2%age 
change Lowest 
at 5300m 
Pearson 
Corr 
-.080 -.089 -.002 -.053 .094 .113 
Sig. (2-
tailed) 
.350 .298 .986 .538 .267 .184 
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Table 4C: Correlations between headache as recorded at the time of testing 
and rSO2 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
This shows no correlation between rSO2 values and headache score reported 
at the time of exercise testing. 
 
Figures 4A: 
Initial Cluster Analysis.  
This simply split data into right, medium and low rSO2 values, but starting rSO2 
values (which this was mostly being based on) have little meaning between 
individuals. Cerebral oximtery is usually used as a trend monitor hence a cluster 
analysis grouping subjects by their pattern of rSO2 changes is more appropriate.  
Below is the initial cluster. 
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Allgodendrums to create 2 clusters (Figure 4A - i to iv). 
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Table 4D: Descriptives 
  n Mean Std Dev Std 
Error 
95% CI Min Max 
Lower Upper 
Mean 
Resting 
rSO2 
1 48 76.09 3.90 .56 74.96 77.22 67.67 86.67 
2 78 68.91 2.96 .34 68.24 69.57 62.50 78.00 
3 39 60.23 5.00 .80 58.60 61.85 37.67 67.3 
Total 165 68.94 6.88 .54 67.89 70.00 37.67 86.67 
Mean 
Unloaded 
rSO2 
1 48 76.07 3.67 .53 75.00 77.13 68.67 87.83 
2 78 69.53 2.96 .34 68.86 70.19 62.83 82.00 
3 39 60.19 5.03 .80 58.56 61.82 36.00 66.00 
Total 165 69.22 6.85 .53 68.17 70.28 36.00 87.83 
Mean AT 
rSO2 
1 48 78.87 3.73 .54 77.79 79.96 73.17 92.00 
2 78 71.29 2.87 .32 70.64 71.93 64.00 77.83 
3 39 62.18 4.71 .76 60.65 63.71 40.00 70.67 
Total 165 71.34 7.04 .55 70.26 72.42 40.00 92.00 
Mean 
VO2Max 
rSO2 
1 48 77.94 4.26 .61 76.70 79.17 70.33 89.83 
2 78 66.24 4.821 .55 65.15 67.32 53.16 76.50 
3 39 56.76 5.70 .91 54.92 58.61 40.00 66.67 
Total 165 67.40 9.15 .71 66.00 68.81 40.00 89.83 
Mean 
Lowest 
rSO2 
1 48 75.34 5.20 .75 73.83 76.85 67.67 89.83 
2 78 63.58 4.79 .54 62.50 64.66 52.00 73.33 
3 39 54.66 5.59 .89 52.85 56.47 40.00 65.16 
Total 165 64.89 9.13 .71 63.49 66.30 40.00 89.83 
 
Table 4E: 
Clusters actually used: 
Cluster 1: A09 B02 B06 B07 B08 B10 C01 C02 C07 D03 D04 D06 D07 E01 
E02 E05 E06 E07 E16 F01 F03 F07 F08 F09 G04 G06 G08 H01 H05 I02 
I03 I05 I10 J03 J04 K09 L02 L06 L08 M06 M07 A01 A02 B12 B13 B14 C09 
C10 C11 C13 C15 D11 D14 D15 E12 E13 F10 G11 G13 H04 I01 I09 I15 
J11 J13 K12 K13 K14 L10 L12 L13 L15 L16 M01 M02 M11 M15 M16  
Cluster 2: A04 A05 A06 A07 A12 A13 B01 B04 B05 C04 C05 C06 C08 D01 
E08 F04 G02 G05 G07 G12 H06 H07 H08 H15 I04 I06 I07 I16 J01 J02 J05 
J06 J08 K02 K03 K04 K05 K06 L01 L04 L05 L07 M03 M05 M08 A10 A11 
A14 A15 A16 B09 B11 B15 B16 C16 D12 D16 E04 E09 E10 E11 E14 E15 
G09 G10 G14 G16 H03 H10 H11 H12 H13 I08 I12 I13 I14 J09 J10 J14 J15 
J16 K16 L09 L11 L14 M09 M12  
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Table 4F: 
Table demonstrating mean percentage changes in rSO2 values between the 
two clusters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4B: 
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Figure A demonstrates the raw rSO2 readings at each time point during exercise 
at a) 75m, b) 3500m and c) 5300m. From this it can be seen that there is wide 
spread of rSO2 values, but subjects that start with high rSO2 values, tend to 
remain high compared to others when at altitude. 
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ii) rSO2s for the Core team - Namche (3500m) 
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iii) rSO2s for the Core team - EBC (5300m) 
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Chapter 5: Headache and Anthropomorphic Data 
Appendix: 
 
Table 5A: 
Basic Data for Physiological Variables in London (150m): 
 N
 
M
ea
n 
S
td
. 
D
ev
ia
tio
n 
M
in
im
um
 
M
ax
im
um
 
P
er
ce
nt
ile
s 
25
th
 a
nd
 7
5t
h 
H
is
to
gr
am
 
R
es
tin
g 
S
aO
2/
%
 
171 96.9 0.99 93.0 99.00 96.00 98.00 
 
R
es
tin
g 
V
O
2/
K
g 
17 5.08 0.85 2.70 7.40 4.50 5.60 
 
R
es
tin
g 
V
O
2 171 0.38 0.08 0.20 0.56 0.31 0.43 
 
R
es
tin
g 
H
ea
rt 
R
at
e 
171 78.1 12.1 50.0 111.0 70.00 87.00 
 
R
es
tin
g 
E
tO
2/
m
m
H
g 171 108.
30 
3.98 93.0 118.0 106.0 111.0 
 
R
es
tin
g 
E
tC
O
2/
m
m
H
g 
171 33.7
8 
3.06 25.0 40.00 32.00 36.00 
 
A
T 
/ K
g 
171 23.0 5.05 13.2 36.50 19.10 26.30 
 
A
T 
171 1.70 0.46 0.92 3.71 1.39 2.04 
 
A
T 
H
ea
rt 
R
at
e 
171 129.
25 
14.7
8 
93.0 163.0 119.0 141.0 
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A
T 
E
tO
2 
/ 
m
m
H
g 
171
. 
101.
15 
4.87 87.0
0 
113.00 98.00 105.00 
 
A
T 
E
tC
O
2 
/ 
m
m
H
g 
171 42.1
3 
4.26 31.0
0 
52.00 39.00 45.00 
 
A
T 
S
aO
2 
/ %
 
144
. 
96.4
9 
1.01 94.0
0 
99.00 96.00 97.00 
 
A
t T
im
e 
/ h
rs
 171 0.08
85 
0.00
09 
0.00
7 
0.012 0.078 0.009 
 
V
O
2M
ax
 
/ 
lit
re
s 
171 2.85 0.78 1.51 5.16 2.17 3.44 
 
V
O
2M
ax
 
/ 
K
g 
171 38.3
3 
8.53 22.2 63.80 31.40 44.90 
 
V
O
2M
ax
 
he
ar
tR
at
ee
 171 170.
41 
      
V
O
2M
ax
 
E
tO
2/
m
m
H
g 
171 115.
90 
5.14 98.0 127.0 113.0 119.0 
 
V
O
2M
ax
 
E
tC
O
2/
m
m
H
g 
171 36.0
6 
5.18 25.0 56.00 33.00 39.00 
 
V
O
2M
ax
 
S
aO
2/
%
 
129 96.3 1.09 92.0 98.00 96.00 97.00 
 
V
O
2M
ax
 
tim
e 
/ h
rs
 
171 0.01
2 
0.00
13 
0.00
9 
0.017 0.012 0.013 
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R
es
tin
g 
S
ys
 
B
P
/m
m
H
g 
145 125.
18 
20.6
6 
16.0 195.0 111.0 136.0 
 
R
es
tin
g 
D
ia
 
B
P
/ m
m
H
g 
145 81.8
6 
11.6
2 
58.0 128.0 73.00 89.00 
 
R
es
tin
g 
M
A
P
/m
m
H
g 171 96.5
8 
12.3
6 
70.0
0 
134.67 87.00 104.33 
 
H
b 
co
nc
. 
171 144.
78 
12.4
6 
112.
00 
168.00 135.00 155.00 
 
S
ys
 
B
P
 
on
 
sh
ee
ts
 
171 125.
66 
18.9
5 
12.0 180.0 114.0 138.0 
 
D
ia
 
B
P
 
on
 
sh
ee
ts
 
171 80.7
4 
11.3
2 
55.0 128.0 73.00 87.00 
 
R
es
tin
g 
rS
O
2 
%
 
165 68.9
4 
6.88 37.6
7 
86.67 65.08 73.08 
 
R
es
tin
g 
A
O
E
 %
 
165 0.40 0.10 0.15 0.84 0.34 0.45 
 
rS
O
2 
at
 
6m
in
s 
/ %
 
165 69.2
2 
6.85 36.0
0 
88.00 65.17 74.00 
 
A
O
E
 
at
 
6 
m
in
s/
 %
 
165 0.40 0.10 0.13 0.87 0.33 0.46 
 
rS
O
2 
at
 A
T 
/ %
 
165 71.3
4 
7.04 40.0
0 
92.00 66.33 75.83 
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rS
O
2 
at
 
V
O
2M
ax
 / 
%
 165 67.4
0 
9.15 40.0
0 
89.83 61.17 74.67 
 
A
O
E
 
at
 
V
O
2M
ax
 / 
%
 126 0.41 0.13 0.09 0.82 0.32 0.50 
 
rS
O
2%
ch
an
ge
6m
in
s 
165 0.43 2.36 -7.88 6.47 -1.01 1.76 
 
rS
O
2%
ch
an
ge
A
T 
165 3.57 3.92 -5.46 13.80 0.83 6.29 
 
rS
O
2%
ch
ag
ne
V
O
2M
ax
 165 -
2.26 
8.65 -
25.0
7 
16.26 -7.69 4.40 
 
 
 
Table 5B: 
Basic Data for Physiological Variables in Namche(5300m): 
 
 N
 
M
ea
n 
S
td
. 
D
ev
ia
tio
n 
M
in
im
um
 
M
ax
im
um
 
P
er
ce
nt
ile
s 25
th
 
an
d 
75
th
 
H
is
to
gr
am
 
R
es
tin
g 
S
aO
2/
%
 
168 88.3
6 
2.95
3 
80 97 87 90 
 
R
es
tin
g 
V
O
2/
K
g 
169 0.39 0.08 0.19 0.61 0.34 0.45 
 
R
es
tin
g 
V
O
2 169 5.39
8 
0.89
96 
3 8.4 4.8 5.95 
 
R
es
tin
g 
H
ea
rt 
R
at
e 
169 84.1
2 
14.3
75 
29 115 76 93.5 
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R
es
tin
g 
E
tO
2/
m
m
H
g 169 62.3
8 
3.35
1 
54 74 60.5 64 
 
R
es
tin
g 
E
tC
O
2/
m
m
H
g 
169 27.0
2 
2.55
9 
18 34 25 29 
 
A
T 
169 1.46
021 
0.37
1932 
0.81
8 
2.77 1.171 1.701 
 
A
T 
/ K
g 
169 19.8
28 
3.87 13.3 33.5 17 22 
 
A
T 
H
ea
rt 
R
at
e 
168 127.
21 
14.4
29 
83 162 118 136 
 
A
T 
E
tO
2 
/ 
m
m
H
g 
169 62.4
6 
2.86
2 
55 70 61 64 
 
A
T 
E
tC
O
2 
/ 
m
m
H
g 
169 28.7 2.82
8 
22 38 27 30 
 
A
T 
S
aO
2 
/ %
 
153 81.7
3 
3.95
2 
70 89 79.5 85 
 
A
T 
Ti
m
e 
/ 
hr
s 
169 0.00
7784
078 
0.00
0687
408 
0.00
6481
481 
0.0099
53704 
0.0074
07407 
0.0081
01852 
 
V
O
2M
ax
 
/ 
lit
re
s 
168 2.41 0.62 1.34 4.16 1.89 2.88 
 
V
O
2M
ax
 
/ 
K
g 
168 32.7
13 
6.49
98 
20.5 54.2 27.85 37.7 
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V
O
2M
ax
 
H
ea
rtR
at
e 
167 159.
63 
16.7
29 
114 193 148 172 
 
V
O
2M
ax
 
E
tO
2/
m
m
H
g 168 73.1
3 
2.81
6 
63 79 71.25 75 
 
V
O
2M
ax
 
E
tC
O
2/
m
m
H
g 
168 24.1
3 
2.92
9 
17 33 22 26 
 
V
O
2M
ax
 
S
aO
2/
%
 
153 80.0
1 
3.86
2 
72 89 77 83 
 
V
O
2M
ax
 
tim
e 
/ h
rs
 
169 0.01
1024
956 
0.00
1150
96 
0.00
8460
648 
0.0157
40741 
0.0101
90972 
0.0115
74074 
 
R
es
tin
g 
S
ys
 
B
P
/m
m
H
g 
149 125.
93 
15.8
01 
91 175 114 136 
 
R
es
tin
g 
D
ia
 
B
P
/ m
m
H
g 
149 83.6
1 
9.89
2 
63 106 77 91 
 
R
es
tin
g 
M
A
P
/m
m
H
g 171 97.4 10.7
58 
73 128 89.67 104.33 
 
H
b 
co
nc
 
171 147.
23 
13.1
96 
115 188 139 156 
 
N
R
es
tin
g 
S
aO
2 
di
ar
y 
171 88.7
4 
3.66
8 
78 98 87 91 
 
S
ys
 
B
P
 
on
 
sh
ee
ts
 
169 124.
29 
17.9
34 
12 175 114 135.5 
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D
ia
 
B
P
 
on
 
sh
ee
ts
 
169 82.7
5 
10.1
63 
59 107 74.5 89.5 
 
R
es
tin
g 
rS
O
2 
%
 
168 59.1
1 
6.28 34.3
3 
74.50 54.67 63.63 
 
R
es
tin
g 
A
O
E
 %
 
167 0.46 0.10 0.20 0.84 0.39 0.52 
 
S
O
2 
at
 
6m
in
s 
/ %
 
168 58.5
7 
6.50
1 
31 73 54.21 63.5 
 
A
O
E
 
at
 
6 
m
in
s/
 %
 
167 0.47 0.11 0.23 0.90 0.39 0.54 
 
rS
O
2 
at
 A
T 
/ %
 
168 55.0
7 
6.59 30 69 50.21 60.13 
 
A
O
E
 a
t A
T 
152 0.45 0.12 0.21 0.89 0.37 0.52 
 
rS
O
2 
at
 
V
O
2M
ax
 
168 50.1
1 
8.29
56 
25.5 70.3 44.708 56.5 
 
A
O
E
 
at
 
V
O
2M
ax
 
152 0.52 0.14 0.19 0.96 0.41 0.62 
 
rS
O
2%
ch
an
ge
6m
in
s 
168 -
0.94 
2.91 -
11.9
7 
6.33 -2.68 1.03 
 
rS
O
2%
ch
an
ge
A
T 
167 -
6.80 
5.12 -
26.8
9 
3.81 -9.59 -3.19 
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rS
O
2%
ch
ag
ne
V
O
2M
ax
 167 -
15.2
2 
10.6
4 
-
50.7
0 
17.06 -21.58 -7.63 
 
 
 
Table 5C: 
Basic Data for Physiological Variables at Everest Base Camp (5300m): 
 
 N
 
M
ea
n 
S
td
. 
D
ev
ia
tio
n 
M
in
im
um
 
M
ax
im
um
 
P
er
ce
nt
ile
s 25
th
 
an
d 
75
th
 
H
is
to
gr
am
 
R
es
tin
g 
S
aO
2/
%
 144 79.4 4.166 
71 89 76 82 
 
R
es
tin
g 
V
O
2 
145 0.40
381 
0.08
204 
0.24
8 
0.719 0.3355 0.461 
 
R
es
tin
g 
V
O
2/
K
g 
145 5.62
1 
0.88
78 
3.4 9.6 5.1 6.1 
 
R
es
tin
g 
H
ea
rt 
R
at
e 
136 90.9
1 
13.2
14 
43 140 82 99.75 
 
R
es
tin
g 
E
tO
2/
m
m
H
g 
145 48.8
8 
3.05
3 
42 60 47 51 
 
R
es
tin
g 
E
tC
O
2/
m
m
H
g 
144 20.4
6 
2.04
1 
15 26 19 22 
 
A
T 
143 1.20
117 
0.30
45 
0.60
1 
2.289 0.95 1.426 
 
A
T 
/ K
g 
144 16.4
85 
3.55
98 
0 25.9 14.425 18.7 
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A
T 
H
ea
rt 
R
at
e 
133 118.
68 
12.9
66 
82 152 110 128 
 
A
T 
E
tO
2 
/ 
m
m
H
g 
143 50.0
8 
2.45 44 56 48 52 
 
A
T 
E
tC
O
2 
/ m
m
H
g 
143 21.0
4 
2.05
5 
16 27 20 22 
 
A
T 
S
aO
2 
/ %
 
104 72.6 5.34
7 
62 86 68.25 77 
 
A
T 
Ti
m
e 
/ 
hr
s 
143 0.00
7285
92 
0.00
0495
108 
0.00
6018
519 
0.0085
64815 
0.0069
44444 
0.0076
38889 
 
V
O
2M
ax
 /
 
lit
re
s 
142 1.87
502 
0.49
5845 
1.00
5 
3.298 1.4377
5 
2.2815 
 
V
O
2M
ax
 /
 
K
g 
142 25.8
7 
5.51
9 
16 44 21.18 29.83 
 
V
O
2M
ax
 
H
ea
rtR
at
e 130 138.
42 
17.4
95 
94 180 127 149.25 
 
V
O
2M
ax
 
E
tO
2/
m
m
H
g 
142 57.6
3 
2.13
2 
51 62 56 59 
 
V
O
2M
ax
 
E
tC
O
2/
m
m
H
g 
142 17.6
7 
1.92
7 
12 23 16 19 
 
V
O
2M
ax
 
S
aO
2/
%
 101 72.1 4.902 
61 86 68 75.5 
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V
O
2M
ax
 
tim
e 
/ h
rs
 142 0.00
9936
669 
0.00
0776
123 
0.00
8090
278 
0.0117
59259 
0.0092
91088 
0.0105
12153 
 
R
es
tin
g 
S
ys
 
B
P
/m
m
H
g 141 124.
86 
16.2
8 
87 167 113.5 134.5 
 
R
es
tin
g 
D
ia
 
B
P
/ 
m
m
H
g 
141 85.8
2 
10.4
5 
58 109 78.5 93 
 
R
es
tin
g 
M
A
P
/m
m
H
g 
145 98.8
7 
11.3
69 
68 123 91.34 107.33 
 
H
b 
co
nc
. 159 157.67 
13.5
24 
120 191 149 167 
 
S
aO
2r
es
t 
di
ar
y/
%
 
167 77.9
2 
5.31
4 
62 91 74 81 
 
S
aO
2r
es
t 
da
ta
sh
ee
t
s 
145 78.5
5 
4.64
5 
62 89 76.25 81.65 
 
S
ys
 B
P
 o
n 
sh
ee
ts
 
145 124.
3 
16.0
4 
87 167 112.5 134 
 
D
ia
 B
P
 o
n 
sh
ee
ts
 
145 85.7
7 
10.5
17 
58 109 79 93.5 
 
R
es
tin
g 
rS
O
2 
%
 
144 53.6
77 
7.32
91 
22 71.7 49.042 59.125 
 
R
es
tin
g 
A
O
E
 %
 
143 0.45 0.13 0.06 0.97 0.38 0.52 
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rS
O
2 
at
 
6m
in
s 
/ %
 144 52.2
3 
7.57 17.8
3 
70.17 47.17 58.33 
 
A
O
E
 a
t 
6 
m
in
s/
 %
 
143 0.47 0.13 0.09 1.05 0.39 0.55 
 
rS
O
2 
at
 
A
T 
/ %
 
142 48.8
5 
7.41 18.8
3 
65.67 43.33 54.42 
 
A
O
E
 
at
 
V
O
2M
ax
 103 0.42 0.12 0.16 0.73 0.34 0.51 
 
E
_M
ea
nN
IR
S
_V
O
2
M
ax
 
141 45.3
3 
7.46 22.8
3 
61.33 39.83 51.50 
 
A
O
E
 
at
 
V
O
2M
ax
 
100 0.49 0.14 0.17 0.96 0.40 0.57 
 
rS
O
2%
ch
an
ge
6m
in
s 
144 -
2.80 
3.77 -
18.9
4 
6.83 -4.94 -0.56 
 
rS
O
2%
ch
an
ge
A
T 
142 -
9.03 
5.20 -
21.4
9 
3.22 -12.02 -5.82 
 
rS
O
2%
ch
ag
ne
V
O
2
M
ax
 
141 -
15.8
3 
9.49 -
43.1
5 
6.58 -21.59 -8.91 
 
 
 
 
 
 
  
APPENDIX	   300	  
	  
Chapter 7: Retinal Imaging: 
 
Table 7A: Grades of papilloedema: 
Modified Frisén Scale 
 
 
 
Diagnosis and Grading of Papilledema in Patients With Raised Intracranial 
Pressure Using Optical Coherence Tomography vs Clinical Expert 
Assessment Using a Clinical Staging Scale 
 Arch Ophthalmol. 2010;128(6):705-711.  
doi:10.1001/archophthalmol.2010.94 
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Chapter 8: Venous MRI Study: 
 
Figure 8A Calculation of CCS: 
 
 
From Farb RI, Vanek I, Scott JN et al. Idiopathic intracranial hypertension: the 
prevalence and morphology of sinovenous stenosis. Neurology 2003; 60 
(9):141801424 
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